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The use of alcohol, tobacco and other drugs (ATOD) is prevalent in our society.  Nurses, 
midwives and other health care professionals are faced with a diverse group of consumers 
many of whom are affected either temporarily or in the longer term by ATOD related health 
challenges.  These challenges include intoxication, withdrawal, trauma, medical and mental 
health conditions, and social issues. The complexities of providing safe care to consumers 
affected by ATOD are unmistakable and challenging. The provision of safe care is at the core 
of good nursing and midwifery practice.  For nurses and midwives to do this they require 
reliable evidence based clinical guidelines that are accessible and easy to use. 
These guidelines aim to support and provide a benchmark for quality assessment, 
intervention and referral by nurses and midwives in their daily practice. Clinicians should aim 
to use these guidelines within the context of their roles and scopes of practice and, to update 
their knowledge base by accessing current research and clinical guidelines as they emerge.  To 
this end I draw your attention to the information, links to key resources and websites listed at 




Ms Lydia Dennett 
Chief Nurse and Midwifery Officer 
Nursing and Midwifery Office 
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Purpose and Principles 
Statement of purpose 
Alcohol, tobacco and other drug use (ATOD) is prevalent in our society, and associated with 
preventable, yet high levels, of morbidity and mortality.  Nurses and midwives, and other 
health professionals, regularly face the complexities of caring for people and their families 
who are affected by ATOD use. 
These Clinical Guidelines have been developed to support evidence based decision making 
and best practice. They offer a reliable benchmark for quality nursing and midwifery care, 
whether in general hospitals, mental health facilities or community settings. Each clinician 
needs to use and interpret these guidelines according to their role and scope of practice.  
We advise clinicians to regularly update their knowledge through accessing emerging research 
and clinical guidelines.  
Please note there is a list of useful information and links to key resources and websites at the 
beginning of this publication. 
Principles for practice 
These Clinical Guidelines are based on the following principles: 
• Any people affected by ATODs have the right to cultural respect and quality risk 
assessment, intervention and support within any health service.  
• All episodes of care provide an important opportunity - a ‘critical moment’ - for 
people to receive appropriate, understandable health information and education 
related to ATOD use and how to access services and available community resources. 
• All health professionals, including nurses and midwives, must ensure that their own 
attitudes, values and personal experiences do not interfere with all people’s rights to 
respect and quality care. 
• A person-centred approach is needed to effectively care for people with ATOD 
problems, and where appropriate, their families. 
• There is a duty of care for all health professional to attend to the safety and health 
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Abstinence: Refraining from ATOD use at all times. 
Agonist: A psychoactive substance that acts on a neuronal receptor e.g. opioid receptor to 
produce effects similar to those of a reference drug; for example, methadone is a morphine-
like agonist at the opioid receptors. 
Alcoholic hallucinosis: A cluster of psychotic symptoms occurring during or following heavy 
alcohol use not due to acute intoxication alone. Characterised by hallucinations (typically 
auditory), perceptual distortions, paranoid or other delusions, psychomotor disturbances, and 
abnormal affect. Some degree of clouding of consciousness may be present. 
Alcoholic brain syndrome A general term for a range of disorders due to the effects of alcohol 
on the brain-acute intoxication, pathological intoxication, withdrawal syndrome, delirium 
tremens, hallucinosis, amnesic syndrome, dementia, psychotic disorder. More specific terms 
are preferred. 
Alcohol-related brain injury (ARBI): A generic term that encompasses chronic impairment of 
memory and higher mental functions associated with the frontal lobe and limbic system. 
Alcohol-related problem: Any of the range of adverse accompaniments of drinking alcohol. It 
is important to note that "related" does not necessarily imply causality. 
Amphetamine: The group of psycho-stimulant drugs commonly known as speed, uppers, 
whiz, goey, ice, crystal meth. Sold as white or yellow powder, tablets or liquid in capsules. Can 
be swallowed, inhaled (‘snorted’), smoked or injected. Commonly mixed with other 
substances (see psychostimulants). 
Anabolic androgenic steroids (AAS): are drugs that mimic the effects of the male sex 
hormones testosterone and dihydrotestosterone. They are available in oral or parenteral 
form. Anabolic substances have the ability to synthesise body tissue and increase muscle 
mass and/or strength.  
Antagonist A psycho-active substance that blocks the effects of another psycho-active 
substance on the same neural receptor.  
Antidepressant: One of a group of psychoactive drugs prescribed for the treatment of 
depressive disorders. Also used for other conditions such as anxiety disorders including panic 
disorder and PTSD. 
ATOD: Alcohol, tobacco and/or other drugs. 
Benzodiazepine: One of the sedative-hypnotic group of drugs. May be referred to as rowies, 
serries, benzos. A safer alternative to barbiturates, they have a general depressant effect on 
the central nervous system that increases with the dose, from sedation to hypnosis to stupor. 
Benzodiazepines have significant potential for dependence which may occur within two 
weeks of regular use. 
Binge drinking: A pattern of heavy drinking that occurs in an extended period set aside for the 
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purpose. In population surveys, the period is usually defined as more than one day of drinking 
at a time. The terms "bout drinking" and "spree drinking" are also used for the activity, and 
"drinking bout" for the occasion. A binge drinker or bout drinker is one who drinks 
predominantly in this fashion, often with intervening periods of abstinence.  
Blood alcohol level (BAL): The concentration of alcohol (ethanol) present in blood. The legal 
blood alcohol limit for driving in South Australia is 0.05. The BAL is often extrapolated from 
measurements made on breath or urine or other biological fluids in which the alcohol 
concentration bears a known relationship to that in the blood. 
Brief intervention: A strategy in which short (between five minutes and two hours) structured 
therapy is offered on one occasion or spread over several visits. Aimed at helping a person to 
reduce or stop harmful ATOD use. 
Caffeine: A xanthine, which is a mild central nervous system stimulant, vasodilator, and 
diuretic. Caffeine is found in coffee, chocolate, cola and some other soft drinks, and tea, in 
some cases with other xanthines such as theophylline or theobromine. Acute or chronic 
overuse (e.g. a daily intake of 500 mg or more) with resultant toxicity is termed caffeinism. 
Cannabis: The generic name given to the psychoactive substance found in the marijuana plant 
Cannabis sativa, Delta 9-tetra-hydrocannabinol (THC). Street names include dope, grass, pot, 
weed, shit, hash, head, skunk. 
Chroming: A term used for inhalation of aerosol paints. Anecdotally, it derives from chrome 
paint used to inhale. 
Cocaine: A powerful central nervous system stimulant derived from the coca plant, used non-
medically to produce euphoria or wakefulness. Sold as white, translucent, crystalline flakes or 
powder. Street names include coke, snow, C. 
Compulsion: When applied to psychoactive substance use, the term refers to a powerful 
urge-attributed to internal feelings rather than external influences- to take the substance (or 
substances} in question. The substance user may recognize the urge as detrimental to well-
being and may have a conscious intent to refrain. These feelings are less characteristic of 
alcohol and drug dependence than of the psychiatric syndrome of obsessive-compulsive 
disorder. 
Controlled drinking: Alcohol consumption that is moderated to avoid intoxication or 
hazardous use. 
Craving: Strong neurological response resulting in a person experiencing an urge or trigger to 
consider or resume the use of a psychoactive drug for its intoxicating effects. 
Cross-tolerance The development of tolerance to a substance, to which the individual has not 
previously been exposed, as a result of acute or chronic intake of another substance. The two 
substances usually, but not invariably, have similar pharmacological effects. Cross-tolerance is 
apparent when a dose of the novel substance fails to produce the expected effect  
Delirium tremens (DTs): A severe complication of alcohol withdrawal, typically manifesting as 
acute confusion accompanied by rapid pulse, clouding of consciousness, dehydration, 
delirium, elevated body temperature, sweating, extreme fear, hypertension, tachycardia, 
xiv 
 
tremor and hallucinations. It is medical emergency as it carries a high mortality risk. 
Dependence: As a general term, the state of needing or depending on something or someone 
for support or to function or survive. As applied to alcohol and other drugs, the term implies a 
need for repeated doses of the drug to feel good or to avoid feeling bad. Physical dependence 
is a result of neuro-adaptation: a person’s nervous system has adjusted to ATOD to function 
as ‘normal.’ Abstinence may be associated with the onset of withdrawal symptoms and 
discomfort of withdrawal will become a motivator for reinstatement of ATOD use. 
Depressant: Any substance that suppresses, inhibits or decreases some aspects of CNS 
activity. The main classes of central nervous system depressants are sedatives/ hypnotics, 
opioids and neuroleptics. Some antipsychotics and other drugs may have CNS depressant 
effects. 
Designer drug: A novel chemical substance with psychoactive properties, synthesized 
specifically for sale on the illicit market and to circumvent regulations on controlled 
substances. In response, these regulations now commonly cover novel and possible analogues 
of existing psychoactive substances. 
Detoxification: The process by which a person is assisted to withdraw from the ATOD on 
which they are dependent. Usually detoxification refers to medically supervised withdrawal 
that may or may not involve the administration of medication to ease withdrawal symptoms. 
There is an evidence base to support the use of medication for detoxification from alcohol, 
opioids and benzodiazepines. 
Dissociation: a partial or complete disruption of the normal integration of a person’s 
consciousness or psychological functioning.  
Disinhibition: A state of mind where the person feels free from internal constraints on their 
own behaviour—a loss of inhibitions. 
Drug: Any chemical substance used for its effects on bodily processes. 
Drug use patterns:  
 Experimental use: The first few instances of using a particular ATOD. The term 
 sometimes refers to extremely infrequent or non-persistent use.  
 Harmful use: A pattern of ATOD use that is causing damage to mental or 
 physical health (e.g. depressive episodes secondary to heavy alcohol intake; 
 hepatitis infection associated with risky injecting drug use). Harmful use may have 
 a range of adverse social consequences but this is not sufficient to justify a 
 diagnosis of harmful use. 
 Hazardous use: A pattern of ATOD use that increases the risk of harm. In 
 contrast to harmful use, hazardous use refers to patters of use that are of 
 significance despite the absence of any current disorder in the individual. 
 High-risk use: A pattern of harmful ATOD use that is likely to cause damage to 
 health—either physical (e.g. pancreatitis or cirrhosis from heavy drinking or 
 hepatitis from unsafe injecting) or mental (e.g. depressive episodes after 
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 heavy alcohol intake). Harmful use commonly has adverse social, legal or 
 occupational consequences. 
 Risky use: A pattern of substance use that increases the risk of harm. Types of harm 
 may include injuries caused by intoxication such as an occasional binge   the 
 accidental overdose associated with recreational drug use. 
 Symptomatic use: Using ATOD as a means of reducing unpleasant sensations or 
 experiences or to avoid challenging situations or responsibilities. 
Dual diagnosis: Where a person has an ATOD use problem(s) concurrent with a mental health 
problem(s). Also known as ‘comorbidity’. 
Flashbacks: A perception disorder that can follow hallucinogen use. Flashbacks are a 
spontaneous recurrence of the experience that occurred when the person was intoxicated 
with hallucinogens. These feelings include visual distortions, physical symptoms, loss of ego 
boundaries, or intense emotions. Flashbacks can last from a few seconds to a few hours. The 
consensus is that flashbacks are genuine but uncommon disorders that sometimes persist for 
months or years after hallucinogen use and can cause substantial harm.  
Foetal alcohol spectrum disorders (FASD): Refers to a range of behavioural, intellectual and 
developmental problems that range from mild to more severe. 
Foetal alcohol syndrome: The characteristic pattern of retarded growth and development, 
both mental, physical and behavioural, caused by alcohol exposure in utero.  
Gamma hydroxybutyrate (GHB): GHB is a CNS depressant. See the Framework document for 
further information. Common street names include fantasy, grievous bodily harm (GBH), 
liquid E, liquid ecstasy and liquid X. 
Hallucinogen: A mind-altering drug that alters perception, typically by inducing illusions or 
hallucinations. Hallucinogens can include naturally occurring compounds (e.g. magic 
mushrooms) and artificial compounds (e.g. LSD) and are usually taken orally. Some 
psychostimulants may also have hallucinogenic properties (e.g. ecstasy and 
methamphetamine).  
Harm reduction: In the context of alcohol or other drugs, describes policies or programmes 
that focus directly on reducing the harm resulting from the use of alcohol or drugs. The term 
is used particularly of policies or programmes that aim to reduce the harm without 
necessarily affecting the underlying drug use. Harm reduction is the key policy and strategy 
that has enabled Australia to be so effective in preventing and minimising the spread of HIV 
through injecting drug use.  
Heroin: A natural opiate from the opium poppy (as is codeine and morphine) with street 
names such as smack, hammer, H. 
HBV: Hepatitis B virus 
HCV:  Hepatitis C virus 
HIV: Human immuno-deficiency virus. HIV is a retrovirus that causes Acquired 
Immunodeficiency Syndrome (AIDS). 
xvi 
 
IDU: Injecting drug use or in reference to the person who injects drugs. Injections may be 
intramuscular, subcutaneous, intravenous (IV), 
Inhalant: Any of a group of highly volatile compounds or mixtures of compounds that are 
inhaled for the intoxicating effects. Inhalants are also called solvents or volatile substances. 
Inhalant use: Sniffing: inhaling fumes from glue, petrol, paint or other volatile substances 
(also called solvents) for the intoxicating, mind-altering effects. Inhalant use of paints is often 
called ‘chroming’. 
Intoxication: An acute condition of the central nervous system caused by the administration 
of an ATOD that results in dose related disturbances in the level of consciousness, cognition, 
perception, judgment, affect (mood), behaviour and or other psycho-physiological functions 
and responses. These disturbances are related to the pharmacological effects of the ATOD 
which diminish over time according to pharmacological half life and metabolism. 
Kava: A drink prepared from the roots of the shrub Piper methysticum. Acute effects include 
mild euphoria, appetite suppression and sedation.  
Ketamine: A dissociative anaesthetic that has stimulant properties when taken in low doses. 
Khat: The leaves and buds of an East African plant, Catha edulis, which are chewed or brewed 
as a beverage. Khat is a stimulant with effects similar to those of amphetamine. 
Lapse: A brief resumption (e.g. one episode) of ATOD use or increased use where the goal is 
for controlled use or abstinence. 
Loss of control: An inability to modulate the amount and frequency of psycho-active 
substance use: the inability to cease ingesting substances such as alcohol and cocaine once 
their initial effect has been experienced. In recent discussions of the dependence syndrome, 
the term "loss of control" has been replaced by impaired control.  
Maintenance therapy: A form of pharmaco-therapeutic treatment for ATOD dependence to 
prevent the emergence of withdrawal symptoms. It involves the prescription of a substitute 
drug, e.g. methadone or buprenorphine, which may be prescribed for the treatment of heroin 
or other opioid dependence (also OST – opioid substitution treatment). Nicotine patches may 
be prescribed for the treatment of nicotine dependence. 
Marijuana: See cannabis. 
Methadone: A long acting synthetic opioid used in ATOD treatment settings as a maintenance 
pharmacotherapy for people dependent on opioids. It is used to prevent opioid withdrawal 
symptoms and to produce blockade of the opioid receptors to discourage illicit use.  
Naloxone: An opioid antagonist receptor blocker used to reverse opioid overdose. 
Naltrexone:  An opioid antagonist receptor blocker (as well as other receptors, alcohol acts on 
the opioid receptor) predominantly used to assist in preventing relapse through reducing 
cravings in alcohol dependent person seeking abstinence. 
Narcotics Anonymous: A self-help group, based on the 12-step philosophy of Alcoholics 
Anonymous, in which participants support each other in recovering or maintaining recovery 
from opioid dependence. 
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Neuroadaptation: The process by which the function of the brain cells changes in response to 
exposure to drugs. These adaptive changes may include increases in the number of receptor 
sites, alterations in the shape of the receptors, or changes in the chemical functioning of the 
cell.  
Nicotine: The major psychoactive substance in tobacco which has both stimulant and relaxing 
effects. Considerable neurological tolerance and dependence develop to nicotine. 
Opioids: The generic term applied to all psychoactive alkaloids either derived naturally from 
the opium poppy or their synthetic analogues. 
Overdose: The result of a dose of a drug that exceeds the individual’s physical tolerance 
resulting in systems collapse and may be fatal. 
Pharmacotherapy: The use of a suitably prescribed psychoactive drug to manage the 
complications of drug use. This may be for short term relief (e.g. nicotine patches for nicotine 
withdrawal, clonidine or buprenorphine/naloxone for opioid withdrawal management) or 
longer term management (e.g. buprenorphine/naloxone or methadone for opioid substitution 
treatment/maintenance treatment).  The use of acamprosate or naltrexone for the medium – 
long-term management of alcohol cravings after a withdrawal episode is also 
pharmacotherapy. 
Poly drug use: Where a person uses more than one drug, often at the same time or following 
one another, and usually with the intention of enhancing, potentiating, or counteracting the 
effects of another substance. 
Psychostimulant: Any agent that activates, enhances, or increases neural activity of the 
central nervous system. Psychostimulants include the amphetamines, cocaine, caffeine and 
nicotine. This group also includes a range of designer drugs that are amphetamine derivatives 
such as ecstasy. Some amphetamine derivatives may also have hallucinogenic properties. 
Psychoactive substance: A substance that, when ingested inhaled or injected, affects mental 
processes, emotions and behaviour. 
Psychotropic: In its most general sense, a term with the same meaning as ‘psychoactive’ (i.e. 
affecting the mind or mental processes). 
Rehabilitation: The process by which a person experiencing problems related to their use of 
ATOD achieves an optimal state of health, psychological functioning, and wellbeing. 
Reinstatement: Returning to regular ATOD use following a period of abstinence. 
Relapse: In its most general sense, a term with the same meaning as reinstatement.  
The term “lapse” is used to refer to single or occasional return to use without full 
reinstatement of regular ATOD use. 
Sedative/hypnotic: Any of a group of central nervous system depressants that can relieve 
anxiety and induce calmness and sleep. 
STI’s: Sexually transmitted infections 
STD’s: Sexually transmitted diseases 
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THC: Tetrahydrocannabinol is the main psychoactive constituent in cannabis. It has a 
depressant effect and may induce hallucinations. There are also stimulant effects such as 
increased heart rate, and paranoia. 
Tolerance: A decrease in response to a drug dose that occurs with continued use. Increased 
doses of the substances are required to achieve the effect originally produced by lower doses. 
Tranquilliser: General term for several classes of psycho-active drugs employed to treat 
symptoms of various mental disorders. They have an inhibitory effect on psychomotor 
processes without interfering with consciousness and thinking (except at high doses). The 
term ‘tranquilliser’ is often used to refer to any drug that is used for treating anxiety 
disorders. In its most general sense a tranquiliser is a sedative. 
Wernicke’s encephalopathy: An acute, life-threatening, neurological syndrome. It begins 
abruptly, usually with eye movement disorders. These include nystagmus (pupil jerking from 
side to side), gaze palsy (inability of eyes to move in the same direction at the same time) and 
paralysis of the ocular muscles. It is also characterised by confusion, ataxia (movement 
disorder), peripheral neuropathy (damage to nerves of the peripheral nervous system e.g. 
weakness, numbness, pain) and encephalopathy (brain damage).  The most common cause of 
the condition is thiamine deficiency as a consequence of long-term excessive use of alcohol. If 
not treated immediately with Thiamine, person is likely to progress to permanent amnesic 
syndrome (Wernicke-Korsakoff’s psychosis). Fatality can occur.  
Note: Always ensure Thiamine is given before glucose if there is any suspicion or risk of 
Wernicke’s. A large dose of glucose administered to someone with a thiamine deficiency can 
cause an onset of Wernicke’s encephalopathy. 
Withdrawal syndrome: Emerges when a person stops or substantially reduces regular 
excessive drug use that has resulted in neuroadaption of the central nervous system. It is a 
cluster of defined symptoms that are neurologically or physiologically based. The severity of 
the withdrawal syndrome depends on the magnitude of the regular dose, half-life of the drug 
used and time of last dose. The onset of withdrawal syndrome may be delayed in those with 
severe liver disease. Generally withdrawal symptoms are the opposite of the acute effects of 
the drug e.g. hyperactivity of the CNS in alcohol or opioid withdrawal may be due to 
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Useful Resources and Information 
Aboriginal Sobriety Group (ASG) 
ASG is a community-controlled organisation which provides a network of services for 
Aboriginal people who wish to lead an alcohol and drug 'free' lifestyle.  Go to the ASG website 
for information www.aboriginalsobrietygroup.org.au 
ASG Services include: 
• Crisis Intervention – Mobile Assistance Patrol 
• Assessment, referral & counselling 
• Stabilisation –  Cyril Lindsay House – Inner City Adelaide 
• Rehabilitation – Lakalinjeri Tumbetin Waal – (Near Monarto) 
• Outreach Services to Adelaide northern metropolitan and the Riverland. 
ADIS 24 hour - Alcohol & Drug Information Service  
ADIS is a 24-hour confidential telephone information, advice, self-help resources, brief 
counselling and support service that acts as a referral service for the general public, 
concerned family and friends, students and health professionals. ADIS is staffed by 
experienced professionals and offers a range of drug information and self help resources for 
the general public and professionals.  
Nurses, midwives and other health professionals can access clinical advice through the ADIS 
service 24 hrs on 1300 13 1340.  
Up to date evidence based guidelines and other professionals resources can be accessed 
through the DASSA website – go to Professional Resources page for drug information, best 
practice monographs and clinical resources such as these guidelines. 
Drug and Alcohol Day Centres for Aboriginal people 
Pt Augusta DASSA  www.dassa.sa.gov.au  
Ceduna  DASSA  www.dassa.sa.gov.au 




Drug and Alcohol Services SA (DASSA) 
161 Greenhill Road Parkside SA 5063 
Phone (08) 8274 3333 
DASSA has a network of client services in metropolitan and rural SA. 
For up to date information call ADIS on 13 13 1340 or visit the DASSA Website 
www.dassa.sa.gov.au 
DASSA Library & Resource Centre can be accessed by students and health professionals. Call 
DASSA on (08) 8274 3333 for details. 
Mental Health Services [MHS] 
• Child and Adolescent Mental Health Services 
Phone (08) 8161 7198 
• Human Rights and Mental Health  
• Mental Health state-wide 24 hr emergency crisis line  
Phone 131 465 
• Multicultural Mental Health Australia 
Phone 1300 136 289  
• Rural & Remote Mental Health Services 
Phone (08) 8303 1225 or (08) 8303 1355 (Country areas only) 
Mobile Assistance Patrol Services (MAPS) 
• Adelaide – Aboriginal Sobriety Group 
Phone (08) 8223 4204 
• Ceduna – Ceduna Koonibba Aboriginal Health Service  
Phone (08) 8625 3699  
• Coober Pedy – Umoona Community Council  
Phone (08) 8672 5246 
• Pt Augusta MAPS – Pt Augusta Council 
Phone (08) 8641 9100 
• Riverland MAPS 





Self help groups 
• AA 
www.aa.org.au 
• Drug Arm 
www.drugarm.com.au 




South Australian Network of Drug and Alcohol Services (SANDAS) 
(SANDAS) is the peak body for Non-Government Organizations working in the alcohol and 
other drug field in South Australia. For information about how to contact non government 
drug and alcohol services go to www.sandas.org.au 
Alcohol & Drug Information Service (ADIS)  
1300 13 1340 (24 hrs/day) 
Contact DASSA ADIS for information about interstate ADIS drug and alcohol information 
services. 
Sobering Up Units (SUUs) 
• Ceduna SUU Ceduna Koonibba Aboriginal Health Service 
Phone (08) 8625 3699  
• Coober Pedy SUU 
Umoona Community Council  
Phone (08) 8672 5246 
• Mission Australia Youth SUU  
Phone (08) 8346 4015  
• Pt Augusta SUU 
Phone (08) 8641 9171 
• Salvation Army SUU Whitmore Square Adelaide 




Blood Borne Viruses 
Reliable services and community consumer groups concerned with blood borne viruses can be 
found in local service directories, and include the following:  
• Australasian Society for HIV Medicine (ASHM) 
Phone (02) 8204 0700 
• Hepatitis C Council of SA  
Information and Support Line 
Phone (08) 8362 8443 or 1800 021 133 for rural callers 
• MOSAIC 
Free counselling available for people with hepatitis C. Telephone counselling is also 
available for people in rural areas.  
Phone (08) 8223 4566 
• PEACE 
Multicultural HIV & Hepatitis C Services 
Phone (08) 8245 8100  
• The AIDS Council of SA Inc.  
Phone (08) 8334 1611 
Useful Websites 
• Australian Drug Foundation 
Phone 1300 85 85 84 
• Offenders Aid and Rehabilitation Services of SA (OARS) 
Phone (08) 82180700 
• QUIT smoking 
Phone 13 7848 
Peer reviewed journals 
• Drug and Alcohol Review 
• ANZ Journal of Public Health 
• Mental Health and Substance Use: dual diagnosis  
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Professional Resources  
• Alcohol Treatment Guidelines for Indigenous Australians 
www.alcohol.gov.au/internet/alcohol/publishing.nsf/Content/AGI02  
• Australian guidelines to reduce health risks from drinking alcohol 
www.health.gov.au/internet/alcohol/publishing.nsf/Content/guidelines 
• Australasian Society for HIV Medicine HIV, viral hepatitis and STIs - a guide for primary 
care providers 
www.ashm.org.au  
• Guidelines for the treatment of alcohol problems 
www.alcohol.gov.au/internet/alcohol/publishing.nsf/Content/treat  
• Guidelines on the management of co-occurring alcohol and other drug and mental 
health conditions in alcohol and other drug treatment settings 
www.ndarc.med.unsw.edu.au/ 
• National Comorbidity Initiative  
www.health.gov.au/internet/mentalhealth/publishing.nsf/Content/drug-alcohol-
mental-illness-1 
• National Health and Medical Research Council (NHMRC). Consensus-based clinical 
practice guideline for the management of volatile substance use in Australia, 2011.  
www.nhmrc@nhmrc.gov.au 
• National Health and Medical Research Council (NHMRC) Clinical Practice Guidelines 
Portal and Register 
www.clinicalguidelines.gov.au 
• Responding to challenging situations related to the use of psychostimulants: a 
practical guide for frontline workers 
www.nationaldrugstrategy.gov.au/internet/drugstrategy/Publishing.nsf/content/id-
chall 







Relevant services and community groups 
• AIDS Council 
www.acsa.org.au 
• Alcohol and drug information services – SA 
www.wwda.org.au/portalc.htm#sa 
• Alcohol and Drug Information Service (24hr phone line for general public and 
clinicians) 
www.dassa.sa.gov.au  
• Anxiety Support Groups 
www.anxietyaustralia.com.au/support_groups/south_australia.shtml 
• Australian Institute of Health and Welfare (AIHW)  
www.aihw.gov.au 
• Beyond Blue 
www.beyondblue.org.au/index.aspx 
• Blackdog Institute (depression and bi-polar disorder) 
www.blackdoginstitute.org.au 
• Carers Association 
www.carersaustralia.com.au 
• Drug and Alcohol Services SA 
www.dassa.sa.gov.au 
• Family Drug Support SA 
www.fds.org.au/famsupport.html 
• Hepatitis C Council SA  
www.hepccouncilsa.asn.au/ 
• Mental Health Advice Line (national for health professionals- 24hrs) 
www.health.vic.gov.au/mhal/professionals.htm 
• Mental Illness Fellowship of Australia 
www.mifa.org.au/ 






• National Cannabis Prevention and Information Centre (NCPIC) 
www.ncpic.org.au/ 
• National Inhalants information services 
www.inhalantsinfo.org.au 
• Orygen Youth Health (Mental Health)  
www.oyh.org.au 







List your own contact numbers 










1.1 Alcohol, Tobacco and Other Drug use 
Introduction 
This section presents an overview of alcohol, tobacco and other drug (ATOD) use in the 
context of Australian society and how we can assist people whose health is at risk or 
adversely affected. 
Alcohol, tobacco and other drug (ATOD) problems affect individuals from all sections of 
society regardless of their ethnicity, social, cultural and educational background, religion, 
gender or age. It is important to recognise that ATOD use is common and those who use 
may be impacted by the ignorance and prejudice of other people. Assumptions about 
those who use ATOD’s are often founded on myths, stereotypes, media images or 
another’s particular experience. People who use ATOD’s are not a homogeneous group 
and the reasons for commencing ATOD use and continuing to use are varied and for some 
people. 
It is therefore necessary for all nurses and midwives to act to prevent and reduce the 
harms associated with ATOD use resulting from intoxication, withdrawal and dependence, 
and associated physical and mental health issues. 
Poly drug use 
People who use ATODs commonly use more than one type on the same occasion or at 
different times. Reports of single drug use are rare. 
Prescribed and over the counter medicines, as well as alcohol and other psycho-active 
drugs – legal and illegal – all have the potential to interact. Drug interactions can occur in 
two major ways: 
Pharmacokinetic:  when changes take place in the absorption, distribution, metabolism 
 or excretion of the drugs. 
Pharmacodynamic:  changes in the effects of drugs. 
Drug interactions can reduce, increase or alter the effects of drugs and occur through four 
actions. These are: 
Addition:  the effects of two drugs are combined to produce a total effect which 
 is greater than either drug alone. 
Potentiation:  increased activity of the first drug is caused by the second drug which 
 is itself inactive. 
Synergism:  two active drugs have a greater combined effect than simple addition. 
Antagonism:  the second drug cancels some or all of the effects of the first drug so 
 that the overall effect is less than the effect of the first drug alone [7].  
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The dangers of poly drug use include increased risk of: 
• overdose 
• toxicity 
• adverse drug reactions 
• medical conditions not responding to prescribed medications 
• intoxication and subsequent effect on performance being greater than anticipated 
for the amount of ATOD’s used 
• increased or decreased duration of effects due to altered metabolism 
• false sense of competence, e.g. when caffeine and alcohol are used together a 
counteraction of the CNS depressant effects  from the stimulant effects leading to 
impaired performance such as driving safely [7].  
Poly drug use and its risk factors should be considered at all times when assessing and 
responding to a person affected by ATOD’s. 
Patterns of ATOD use 
People who use ATOD’s may have started to use experimentally. Some may continue   
occasionally at levels that may or may not be risky, or more regularly. For example, a 
person may enjoy the effects of a particular drug because it helps them to feel less shy and 
more confident socially or eases their physical or emotional pain. The person may not 
perceive their drug use as risky or harmful to their health or safety. 
There is a spectrum of ATOD problems that are directly related to the pattern of 
consumption. This ranges from ‘once off’ intoxication, to binge drinking/drug use, regular 
high risk use, and dependence (addiction).  
A minority of people who use ATOD’s regularly have an increased risk of psychological and 
physical problems [8]. Most people can identify the positive effects related to their ATOD 
use, as well as any negative effects. Many ‘move in and out’ of their various patterns of 
ATOD use according to their life context, of their use, motivation to use or not, and what 
else is happening in their lives. Their environment and stage of maturation as an adult are 
very influential.  
Clear distinctions between experimental, occasional and dependent use can be difficult to 
define. It is helpful to focus on problem use (including physical, social, psychological and/or 





Some people judge another according to their ATOD use, judging them as ‘bad’ and 
therefore less worthy as another. 
Some common myths are: 
‘Addicts are beyond help’ 
Many people who experience ATOD dependence (addiction) can (and do) modify or cease 
their harmful ATOD use, often without professional help. They may move away from use 
altogether, which may happen over time and as their situation supports this change. They 
may choose to be abstinent or to reduce their ATOD consumption to a safer level which 
they can control. 
‘It is someone else’s problem’ 
Nurses and midwives are in ideal settings across the health system where they can help to 
address ATOD problems, rather than leaving this solely to the ‘specialists’ [9, 10]. 
‘People with ATOD problems are ‘hopeless’ 
Most people with ATOD problems have or want to have jobs, manage their households, 
raise children, and meet a range of responsibilities. 
‘All people who use drugs are dependent’ 
Many people use ATOD’s, at lower risk levels, and while they may experience problems 




1.2 Harm minimisation 
Introduction 
All nurses and midwives are well placed to identify risks or harms associated with people’s 
ATOD use. Their role, knowledge, skills, opportunities, scope of practice and sheer 
numbers enable them to apply a range of harm minimisation strategies and interventions 
that can reduce risk and to enhance safety and wellbeing.  
What is harm minimisation? 
The concept of harm minimisation, and its various practical applications, is based on the 
acceptance that ATOD use exists, is likely to continue despite prohibition, and is 
widespread across all levels of the Australian and international community. This concept 
does not preclude abstinence. 
There are three broad strategies (pillars) of the overarching principle of harm minimisation. 
These are: 
• harm reduction 
• demand reduction 
• supply reduction. 
The harm, demand and supply reduction approaches do not accept or encourage unsafe 
ATOD use or in any way abandon the goal or importance of abstinence. It simply means 
that abstinence is one of a range of strategies and therefore not the only goal a person 
may have in relation to managing their ATOD use. 
Harm reduction 
Harm reduction is aimed at reducing the impact of ATOD-related harm to individuals and 
the community through a range of public health policies, strategies and practices.  
Harm, reduction strategies aim to: 
• address the  harms associated with ATOD use including those related to the drug, 
dose, duration and frequency of use, method of administration, concurrent drug 
use e.g. poly drug use, physical and psychological health, nutrition, hydration and 
sleep status and the persons expectations of effects and the environment in which 
drugs are used [12, 13] 
• recognise that people have different goals and that abstinence is not the only 
option 
• are applicable to all persons presenting to services due to high risk and rates for 
lapses and relapse [14].  
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Harm reduction strategies include: 
• assessing and addressing  people’s ATOD use problems at each possible point of 
contact in the health system (such as in emergency departments, pre-admission 
clinics, other specialist health units such as diabetes clinics, midwifery services, STD 
clinics, heart clinics, adolescent and adult mental health services) 
• providing clean injecting equipment (such as disposal units, needles, syringes, 
alcohol swabs, water) 
• providing information to the community about how to access confidential clean 
needle and syringe programs; and how to safely dispose  of used injecting 
equipment 
Provision of information about ways to: 
• prevent and reduce risk of overdose from the use of opioids and combinations of 
drugs 
• how to use safe, sterile injection techniques to avoid vein damage,  infections that 
can cause abscesses and septicaemia  
• prevent injection of foreign bodies 
• ensure inhalation of fresh air if using inhalants  
• avoid blood borne virus (BBV) infection, by always using new equipment and never 
sharing any injecting equipment including tourniquets and spoons, and choosing 
less risky methods of use. 
Demand reduction  
Demand reduction is aimed at removing the demand for drugs through e.g. education, 
community awareness and media campaigns and prevention programs.  
Demand reduction strategies include: 
• mass media safety campaigns  to raise awareness of risk factors  from drink/ 
driving;  binge drinking, smoking, or injecting drugs 
• educating communities about the risks associated with ATOD use 
• health promotion campaigns to inform and prevent uptake of tobacco smoking by 
children and young people, alcohol use by teenagers, risks from drink spiking, 
• promoting low alcohol drinks  as a safer alternative to drinking full strength drinks 
• providing access to abstinence-based support services (such as therapeutic 
communities or self-help programs like Alcoholics Anonymous - AA, Narcotics 
Anonymous - NA, Marijuana Anonymous – MA and counselling) 




• providing access to specialist  ATOD services for detoxification, therapy and 
rehabilitation. 
Supply reduction 
Supply reduction is aimed at reducing the supply of ATODs through legislation, public 
policy, customs procedures and policing. 
Supply reduction strategies include legislation such as: 
• Laws e.g. The Controlled Substances Act; Tobacco Advertising Act;  Road Traffic Act  
• random breath alcohol and drug testing and criminal penalties to prevent 
dangerous drink and/or drug-driving)  
• prohibition of tobacco advertising 
• prohibition on selling alcohol or tobacco to minors under 18 
• limiting opening hours of hotels and clubs that sell alcohol. 
• restricting  particular types of drugs to prescription only 
• customs and policing to detect and prevent importation, production, availability, 




1.3 Non-judgemental care 
People who use ATOD’s can be stereotyped by others. If clinicians hold such stereotypes, 
they cannot have an accurate picture of the diversity of people who, for a variety of 
reasons, experience problems associated with their ATOD use.  
Incorrect beliefs or information can lead to ongoing stigmatisation of people, resulting in 
them being reluctant to seek help. For clinicians to be effective, ATOD use needs to be 
viewed and responded to as the health issue that it is. 
Barriers to people seeking help 
There are a wide variety of reasons why individuals, families and communities do not or 
cannot seek help for problems associated with their ATOD use.  
Some are: 
• fear of professional judgments (such as being seen as an ‘unfit parent’ or not 
considered as deserving of a hospital bed as another person who has a ‘legitimate’ 
condition)  
• inconvenient opening times of specialist services (such as poor access to care by 
people who work, have children or live far away) 
• money problems  
• culturally unsafe services that have not been designed to meet the needs of 
culturally and linguistically diverse persons and their families (including Aboriginal 
and Torres Strait Islander peoples, migrant groups and ‘same sex’ couples) 
• fear of being labelled a ‘junkie’, ‘ addict’ or ‘alcoholic’ 
• fear of lack of confidentiality (such as their employer, family member/s or 
members of their local community finding out about their ATOD problem) 
• age (most ATOD services are unable to address the needs of people under 16 years 
of age or older people such as those 60 years or more) 
• gender (there are few services designed to meet the needs of women or that 
accommodate children with their parents who are seeking specific ATOD 
treatment) 
• fear professionals including nurses and doctors who have ATOD problems affecting 




Engaging people in treatment and care 
Nurses and midwives can offer effective care by ensuring people at risk of ATOD problems 
understand what treatments are available, the services which can assist them, and how to 
accessing these. People need to know what to expect from services e.g.: 
• type of care/program offered 
o ‘live-in’ or community based rehabilitation 
o ‘abstinence only’ rehabilitation programs  
o community based program  
• where it is situated 
• if family can be involved 
• visiting hours 
• counselling 
• ‘talking therapies’ 
• medically supervised withdrawal (detoxification) 
• pharmacotherapy e.g. methadone or acamprosate  medication  
• comorbidity care. 
To provide this information nurses and midwives need to know about: 
• services provided 
• location and hours of operation 
• eligibility criteria  
• visiting hours 
• access to child care and acceptability of live-in children with parents receiving 
treatment)  
• involvement of family and access to family support whilst in treatment [11, 15-17].  
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1.4 Understanding ATOD problems 
Theories 
Knowledge of the key theories that underpin our current understanding about ATOD 
problems offers a useful basis for determining what may be happening in a person’s life, 
their drug use situation, and why particular clinical interventions and treatment programs 
are likely to be helpful.  
Over the last 50 or so years, varied theories on the nature and aetiology of ATOD problems 
have developed. These were generally culturally-bound and not necessarily evidence-
based. Table 1.3 on the following page describes the main theories.  
The table shows different ways of considering ATOD problems. Current research supports 
the view that ATOD use is common; problems are varied in severity and likely outcomes, 
and may be a one off event, transient, complex or lifelong. We know that ATOD problems 
are influenced by factors relating to the individual person, the pharmacology and 
pharmacokinetics of the drug, cost, availability and legal status of the drug used, and the 
context of their ATOD use. 
The following two models offer ways of understanding the types of problems people 
experience. The first, Thorley’s model, represents the spectrum of alcohol problems. The 
second, Zinberg’s interactive model of the drug use experience. These form the basis of the 
ATOD assessment and interpretation of the key issues that arise from that assessment. 
They can therefore inform the choices of interventions and pathways of care we can offer. 
ATOD use can be relatively safe depending on the age, gender and general health status of 
the person, pattern and context of use, purity and type of drug/s used, frequency, dose, 
route of administration, expected effects and drug use environment. 
ATOD use is not necessarily harmful. It can be non-problematic, e.g. intoxication can occur 
without harm, regular use can occur without being excessive and dependence can occur 
without harm [8].   
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Table 1: Summary of common theories of ATOD use 
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Model 1: Spectrum of alcohol problems (Thorley’s model) 
Thorley developed a system representing the spectrum of alcohol problems based on the 
incidence, magnitude and characteristics of health problems associated with patterns and 
levels of consumption across the UK population [8]. The majority of alcohol related deaths, 
injuries and illnesses were associated with intoxication and regular excessive use (too 
much too often – tolerant but are not psychologically dependent. Only about 10% of 
problem drinkers experience physical and psychological dependence.  









Problems arising from intoxication 
Intoxication can be life threatening. It is associated with ‘once off’ use, binge drinking, 
recreational drug use, injecting drug use, infrequent or sporadic use of combinations of 
drugs including medications. Problems may include: 
• toxicity 
• accidental injury/trauma 
• headaches 
• nausea/vomiting 




• poor problem solving 
• absenteeism 
• choking 
• work problems 
• violence 
• interpersonal problems 
• memory loss 
• unsafe sex 
• unplanned polydrug use 
• legal issues/crime/drink driving. 
Problems arising from regular excessive use 
Regular excessive use is typified by daily or almost daily use where the level of 
consumption is above low risk levels. This pattern related to short and linger term harms to 
safety and health. For example exceeding 20gms of alcohol (two standard drinks) a day for 
healthy adult men and women who are not pregnant [77]. This applies even though the 
person does not exhibit intoxication due to neurological or physical tolerance, in which 
case they would need higher doses to reach the same intoxicating effect they had when 
they first started using the substance.  
Pattern of regular excessive use can be associated with short-term memory problems, 
sleep disturbance, poor work performance, social problems with friends and/or family, 
poor general health including mental health issues and financial problems. Even though 
the person is not psychologically dependent, they may experience the withdrawal 
syndrome if they cease or drastically reduce the amount used due to neuro-adaptation of 
the central nervous system to the dose and frequency of use.  
Withdrawal may occur, possibly for the first time, during an admission to hospital for an 
injury or treatment of a medical condition, and may not be predicted by either the person 
themselves or the medical and nursing team unless the person’s ATOD history is taken.  
14 
 
Regular excessive use can result in: 
• acute and chronic problems such as 
organ damage, heart disease, 
kidney disease, infections, diabetes, 
high blood pressure, stomach 
disorders, liver damage, brain 
damage 
• nutritional/weight problems 
• financial problems 
• memory problems 
• difficulty learning new tasks 
• psychoactive drug tolerance and 
neuro-adaptation 
• poor work 
performance/attendance 
• comorbidities e.g. diabetes, mental 
health disorders 
• sleep disturbances 
• social and relationship problems 
• cognitive difficulties e.g. learning, 
organising and problem solving 
• mood swings 
• psychoactive drug withdrawal. 
Problems arising from dependence (physical tolerance and psychological reliance)  
Dependence (addiction) can range from mild to severe. The more severe the persons level 
of dependence, the greater their risk is of it becoming a chronic relapsing condition. On the 
other hand, despite this complexity, people may and do recover from dependence.  
Dependence is often associated with acute and chronic health and social problems. It is 
almost always associated with the physical withdrawal syndrome when the ATOD is ceased 
or if the reduction in consumption is significant. It is also usually characterised by craving 
and a compulsion to resume use. Resumption of the drug of choice will prevent or 
ameliorate withdrawal and may be the motivation for resumed consumption. 
Dependence therefore involves taking larger doses (amounts) over a longer time to gain 
the same wanted effect  (increased physical tolerance) and withdrawal is induced by 
cessation or reduction of the dose (amount) used.  
Signs of dependent use include: 
• use to avoid withdrawal 
• craving  
• preoccupation (salience) with use 
• lifestyle accommodates and is focused on use 
• narrowed of repertoire of daily activities and social interaction  





The dependent person may continue to use despite problems such as: 
• physical illness (e.g. cancer, heart disease, liver disease, pancreatic or kidney 
disease) 
• mental health problems including depression, anxiety, panic attacks, social and 
interpersonal problems 
• legal issues 
• poor employment opportunities  
• financial and housing problems 
• vocational problems. 
It is important to recognise the person’s current pattern of use and how this relates to the 
situation regarding their health and wellbeing. Interventions should be selected to match 
as best as possible their needs including pattern of use and the nature of their problem.  
For example, it is pointless prescribing a 12-step abstinence program to a young adult 
whose pattern of use is binge drinking occasionally, even if they have just experienced an 
alcohol-related injury. On the other hand, it is equally pointless to advocate a controlled 
drinking program for a person who is drinking at harmful levels and has multiple health 




Model 2: The interactive model of the ATOD use experience 
The interactive model of the drug use experience [1] is useful in understanding the 
aetiology and nature of people’s ATOD problems. This is because the ATOD use 
‘experience’ is influenced by the dynamic interactions between the person, the particular  
ATOD’s they use and the environment (context) in which this occurs. 
This model provides an excellent framework for screening, assessment, interpretation and 
diagnosis of problems, and selection of appropriate interventions for the individual person.  





Integrating the models in practice  
These models are widely accepted in this field as useful and highly relevant. They are used 
to inform Australian government ATOD policies, health promotion strategies, harm 
reduction programs and assessment and interventions for people with ATOD problems. 
Clinicians can benefit greatly from integrating these models into the ATOD clinical 









2.1 Communication and cultural issues 
Introduction 
Effective communication, which is clear and non-judgemental, assists in building rapport 
and developing a sense of trust in people. This is the key to undertaking a quality 
assessment, understanding the person’s major issues, and managing ATOD-related 
problems, including any concurrent physical or mental health problems. 
The Australian community comprises people from diverse cultural and linguistic 
backgrounds. The nursing and midwifery professions have made explicit their ethical views 
regarding the need for non-discriminatory policies and practices in delivering quality care 
to all people. 
Across all Australian state and territory governments, there is the expectation that people 
will be treated with fairness and dignity. Therefore nurses and midwives have the 
responsibility to ensure that people of culturally and linguistically-diverse backgrounds that 
have ATOD problems are shown respect and treated equitably and with dignity.  
As primary service providers, nurses and midwives often provide the link between the 
person, other members of the multidisciplinary team, their person’s family, and other 
service providers, including specialist ATOD services. 
General principles of communication 
ATOD use is a health issue, not a moral issue. Whatever their age or circumstances, a 
person’s recent ATOD use history should be taken as part of the general routine clinical 
assessment - not only if they have been identified as a ‘likely’ or are suspected or known to 
be a person with ATOD problems. 
Cultural and linguistic diversity can make communication difficult. Use of culturally-
appropriate interpreters, including Indigenous interpreters, is essential to overcome 
potential barriers.  
Clinicians need to be clear and straightforward about who they are, their name, their role, 
what they need to know from the person, and why they are asking about ATOD use. 
Clinicians need to attend to the person’s immediate concerns before trying to address 
sensitive issues that may be, at the time, less important to the person themselves. This 
includes their ATOD problem. 
Clinicians need to listen to what the person wants, why they may be worried and what 
they believe will help them. This communication can only happen if rapport and a sense of 
trust have been developed. Clinicians need to show their concern about the person’s ATOD 




Improving cross-cultural communication 
Effective communication with people from diverse cultural groups is crucial in 
understanding and responding to their ATOD issues. 
It is important to note that there can be cultural differences within particular groups in any 
community, including children, young people, old people, women and men. Nurses and 
midwives providing services to diverse groups need to liaise and consult with bona fide 
cultural and bilingual workers, trained interpreters and liaison staff to enhance the 
likelihood of timely and sound assessment, problem identification, intervention and 
appropriate referral. 
People from diverse cultural groups may interpret your requests differently from what you 
expect. Particular words, beliefs and expectations may not reflect that of your particular 
role or service. Their ATOD and other health-related beliefs, experiences, knowledge and 
contexts may also differ from those of other people.  
The following suggestions are helpful when working with people from culturally and 
linguistically diverse communities (CALD): 
Use approved interpreter services 
When there are spoken and/or written language difficulties, it is very important to use a 
professional interpreter service. Relatives, friends or untrained staff may inhibit the 
person’s options of what they can talk about and may raise concerns regarding 
confidentiality. It is best to avoid using family or friends as interpreters wherever possible. 
Emphasise description rather than interpretation or evaluation 
Interpreting or evaluating what someone has said or done—rather than simply describing 
it—is based more on the observer’s own culture and background than on the actual 
observed situation. Suspend judgement so that you have sufficient time to observe and 
interpret the situation from the person’s (and family’s) different cultural perspective. 
Empathy 
Before communicating with the person, put yourself in their ‘shoes’. Ask yourself what 
their experiences and frames of reference might be, and how you might feel if you were 
them. Try to see the other person as they are, not what or whom you think they may 
represent. 
Ongoing evaluation of assessment and care 
Once we have identified and developed an explanation of the ATOD problem/s (such as 
homelessness and alcohol dependence), we need to treat our interpretation as a ‘working’ 
diagnosis that needs to be reviewed effectively in a timely manner, and revised and 
adapted as necessary. Through seeking feedback from the person, and family if 
appropriate, interpreting their responses to our diagnosis, care and interventions, we will 
be better placed in offering effective strategies and assisting them to overcome, or at least 
minimise, their problems.  
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Being clear, concrete and specific 
If culturally appropriate, communicate as directly, clearly and specifically as you can. This 
may be between you and the person or through an interpreter. This approach will aid your 
communication and encourage the person to feel that they will be respected by you. 
Encourage the person to be concrete in their explanations and specific in their responses 
to your efforts. 
Responding with immediacy and timeliness 
When people first meet us they need us to respond directly to them as individuals, to help 
them feel accepted, to listen to their concerns, and give assurance that we will try to meet 
at least some of their immediate needs. Once their confidence is gained and they are 
feeling more at ease, we are in a better position to assess and address any ATOD issues 
they are experiencing. 
Respecting taboo 
ATOD issues may be taboo in particular cultures, families or generations. If so, it is 
important to find ways to raise and address these issues, and find how and when this is 
appropriate. We need to help people to speak about their ATOD use and related issues, if 
at all possible, in ways that they feel most comfortable. The age and gender of the nurse or 
midwife may inhibit or assist in this process, and so it is important to try and ascertain 
whom they would feel most comfortable talking to if this is an option. Seek guidance from 
appropriate cultural and other advisers, trained interpreters, or a suitable family member 
or trusted friend, if available. 
Sensitivity to embarrassment  
Showing other people that things are ‘normal’ when this is not the case is a common way 
for people to deal with their ATOD problems.  
Many people are too embarrassed to report that they or a family member needs help with 
their ATOD-related issue. They feel ashamed and they will be judged by health 
professionals and others. Often the person has had previous experiences that have made 
them feel embarrassed or demeaned or they may know of situations of friends and family 
members that have resulted in shame. 
Parents and close family members may feel that it is only ‘other people’s children’ or those 
from other cultural communities who use ‘drugs’. It is important for nurses and midwives 
to acknowledge that people from all communities use drugs, whether they be medicines, 
tobacco, alcohol or illicit substances, and that young people and adults from any 
community can experience the risks and harms associated with intoxication, regular 
excessive use or dependence. 
Health professionals need to provide an atmosphere in which people can reveal and 
discuss sensitive issues knowing that their experiences will be listened to and validated and 
that their confidentiality will be maintained. 
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Examining one’s own expectations 
It is useful for us to examine and define what we actually expect of the person who has an 
ATOD problem. By honestly clarifying our own feelings, beliefs, attitudes and responses 
towards the other person with ourselves, we can then act to prevent our behaviours 
impacting negatively on them. 
Working effectively with Indigenous People  
Rationale for using the term Indigenous Australians 
For the purposes of this resource, we have chosen the term Indigenous Australians as a 
way of acknowledging all Australian Aboriginal, Torres Strait and Tiwi Islander Peoples. We 
are, however, aware that this terminology has limitations and ask readers to respectfully 
use locally preferred terms in their practice [18]. 
Background 
All groups in the Australian community, including Indigenous Australians, share common 
historical and contemporary issues associated with colonisation and racism, while also 
having diverse cultures, language, practices and beliefs.  
Most Indigenous people live in urban and semi-rural settings, with fewer living in remote 
areas. The reasons and ways in which Indigenous people do or do not use particular 
ATOD’s are affected by their e.g. location, social and economic situations, physical 
environments, living conditions, access to education, training and employment and other 
essential resources, all of which are major social determinants of health and well being.  
Significantly fewer Indigenous people per capita consume alcohol or other drugs compared 
with other Australians. However smoking rates of tobacco are high with about 50% of 
Indigenous people smoking about double the rate of non-Indigenous Australians [19].  
Putting Indigenous ill-health in context 
Indigenous people in Australia have, on average, 17 years less life expectancy than do non- 
Indigenous Australians due to an array of acute and chronic physical diseases, injuries, 
poor mental health and suicide.  
Inquiries into Indigenous Australians’ health have repeatedly recognised the detrimental 
effects of dispossession and alienation on the health and wellbeing of many Indigenous 
Australians. Grief, trauma and loss must therefore be recognised by all health 
professionals, wherever they work, as powerful contributing factors to the much lower 
health and socioeconomic status of Indigenous Australians, including those who use 
alcohol, tobacco and other drugs (ATOD) as they are often using ATOD’s to relieve their 




Indigenous people are commonly affected by co-existing - more than one illness 
(comorbidity) [22]. Compared to the general population, Indigenous people are: 
• at least eight times more likely to develop cardiovascular disease 
• between two and four times more likely to develop diabetes 
• eight times more likely to die from chronic kidney disease [23]. 
Effects of previous contact with health and other institutions 
Many Indigenous people (and/or their loved ones) have had bad experiences in hospitals 
and other institutions when in ‘care’ of doctors and nurses. These experiences include a 
loved one dying away from home (country), having their babies taken away, being kept in 
separate facilities from family members, being segregated from ‘white’ people or being 
given medical treatment without explanation or having given proper informed consent. 
While many incidents such as these have continued to happen over the years since 
colonisation, non-Indigenous people may view them as past history and not relevant 
today. However, distress and the aftermath of incremental trauma, loss and grief are long-
lived across today’s generations. And inappropriate practices still occur resulting in 
enduring trauma and harms.  
Many non-Indigenous health professionals are not aware of how government health, 
social, housing, child protection and other policies have been directed at Indigenous 
people, and may still believe that ‘the past is best forgotten’. However, the history of these 
policies, and their continuing impact, has a very definite bearing on the way Indigenous 
people interpret and respond to their current and future experiences in the health care 
system. There can be a justifiable ‘residue of suspicion’ among Indigenous people towards 
non-Indigenous people who are seen to be ‘in authority’, including nurses, midwives and 
doctors [24]. 
Thus all nurses, midwives and other health professionals need to be aware of how 
institutional racism has impacted, and continues to impact, on Indigenous Australians. 
They need to make sure that they offer services that are accessible, respectful and 
sensitive to all Indigenous people however they present or whatever their health condition 
[25]. 
Continuing ill health and hospitalisation  
Indigenous people have the worst health status of all Australians and most others in the 
world [26]. Their use of hospital outpatient and emergency departments is more frequent 
than that of non-Indigenous people, with Indigenous people being about three times more 
likely to use public or regional hospitals and outpatient services than a family doctor’s 
surgery. This is often because the hospital is the only service available to them, it’s free, or 
there is no general practitioner nearby.  
Indigenous people are admitted to hospital between 1.6 and 3.2 times more often than 
other Australians, meaning that they are more likely to have experienced medical 
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interventions (and therefore have been at high risk of having had bad experiences in 
hospital) than other Australians [24]. The poor levels of social and emotional wellbeing of 
Indigenous people is a direct reflection of their overall status in society, worsening health 
reflected by the highest morbidity and mortality rates and shortened expected life span 
compared with non-Indigenous members of our community [22, 27, 28]. 
How hospitalisation may be understood  
Many Indigenous people experience multiple losses of loved ones and accumulative grief 
throughout their lives, including being seriously ill, being incarcerated in prison or mental 
institutions, or being a member of the ‘stolen generations’. Loss of children to ‘white man’ 
has been devastating and adversely affects how Indigenous people view all institutions, 
including hospitals, other health care and social services, and those who work in them. 
The clinical atmosphere and abrupt interactions of staff in hospitals and other medical 
settings can therefore be strong barriers to Indigenous people trusting and feeling able to 
present for or receive health care [24]. 
Fear as a barrier to effective health care  
Indigenous people commonly fear being in hospital and separated from their families and 
community. Not understanding the medical or English languages influence the way in 
which many Indigenous people perceive and fear hospitals and hospital staff.  They may 
not understand what is happening to them, misinterpret the intensions and practices of 
nurses and others, and have no or little knowledge of their medical problem/s or 
subsequent medical or nursing procedures. 
Because our verbal and non-verbal language is culturally defined, it can be unclear and 
easily misunderstood. Some communication may be perceived as threatening by 
Indigenous people, further exacerbating their anxiety and making them even less able to 
communicate. 
As with anyone, an Indigenous person’s fear can manifest as anger, terror or apparent 
unwillingness to ‘cooperate’ in the situation, leading to further problems and 
misunderstandings. It is therefore doubly important to use effective interpersonal skills 
and to try and offer a culturally-safe environment wherever possible. 
While fewer Indigenous people drink alcohol than non-Indigenous people, those who do 
tend to drink at high risk levels resulting in serious injuries, violence and ill-health. It is also 
linked with mental health problems, including suicide [29, 30]. Indigenous youths are 
nearly 2½ times more likely to die from alcohol-related causes than their non-indigenous 
peers [20]. Co-existing, and multiple, mental and physical health conditions are common 
amongst even young people. All Indigenous people need to be screened and assessed for 
their ATOD use and risk, so that their needs are attended to when they present to hospital 





As with all groups, effective communication between Indigenous and non-Indigenous 
Australians is essential for sound health assessment and care, and this should never be 
disregarded by anyone working within health care services [33]. 
Indigenous Australians are diverse in their cultures, histories and life experiences with each 
person’s experience being unique. Indigenous people hold particular cultural concepts of 
health and illness, and their family structures and gender roles have a strong impact on 
their understanding of what is happening to them, and those who are there to assist in the 
recovery. Also while English is the dominant language in Australian health care services, 
there are significant numbers of Indigenous people for whom English is not their first 
language, and this issue needs to be addressed in any health care encounter.  
As with any acute brain condition, intoxication from alcohol and/or other drugs means that 
the person’s mood, cognition and perception are affected and communication is an even 
greater challenge.  
The basic principles of communicating with Indigenous people should therefore be the 
same as for any cultural group. This means that showing respect and finding ways and 
resources to ensure accurate information sharing and comprehension occur is essential. 
Here are some useful factors to keep in mind: 
• Today’s ATOD problems are directly linked to many Indigenous people’s history 
and ongoing experiences of colonisation; ‘stolen generations’, racism and social, 
cultural and economic disadvantage. 
• A basic understanding of the local culture and community’s expectations of ATOD 
issues and health care is advisable for health professionals. They need to consult 
with and learn from local Indigenous leaders and organisations as a matter of 
practice. 
• Indigenous people’s understanding and experiences of health are holistic, 
therefore holistic health approaches are needed for effective assessment and 
treatments of their ATOD problems.  
• No single approach to alcohol problems is necessarily an appropriate remedy - ‘no 
one size fits all’.   
• Individual and community responses to ATOD problems need be based on 
partnerships between the person, community, health professionals and services. 
• Any individualised therapy or community-based response needs to be conducted 
in the context of each individual’s needs, and where possible, also with their 
chosen family members. 
• Careful use of verbal and non verbal - body language - is a necessary way to show 
respect for an Indigenous person.  
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• Early intervention, treatment, self-management and prevention approaches need 
to take into account that Indigenous people’s drinking may be their way of coping 
with their trauma and suffering, and nurses and other health professionals need to 
avoid blaming and shaming the person for their problems [18]. 
• Health professionals, individuals and their families need to know that of all risky 
drinkers; Indigenous people are more likely to give up ‘the grog’ than non 
Indigenous Australians.  
• Indigenous people need to know that smoking tobacco is a major cause of disease 
and early death of many; that smoking rates are far higher than the non 
Indigenous population; and there needs to be significant reduction in smoking 
rates for Indigenous people’s health to improve.  
• Much can be done to help Indigenous people overcome their drinking, smoking or 
other drug use through pharmacotherapy, counselling, non medical therapies and 




Here are some ways in which to communicate effectively with Indigenous people: 
• Remember that Indigenous people consider themselves to be inseparable from 
their family—this means you are caring for the whole family, not just the 
individual.  
• Enlist the help of an Indigenous liaison officer in the care and discharge planning 
for your person, and seek their advice and assistance wherever possible in regards 
to meeting the person’s needs (providing they have given their informed consent). 
• Be friendly and empathic, and do not call the person by their first/given name 
unless they have requested you to do so or you have specifically sought their 
permission and they have agreed. 
• Ensure confidentiality when talking about ATOD and other sensitive issues. If a 
family member or friend is with the person it is likely that this has been pre-
arranged and culturally suitable.  If unsure ask your client discreetly if they would 
like to be together or alone at this time. 
• Be welcoming to family members. 
• Show respect by treating the person and family as you like to be treated. 
• Smile and present yourself in a confident, friendly and professional manner. 
• Take enough time to introduce yourself, explain the nature of your service and 
your role, and what is likely to happen to them.  
• Show interest in the person and not just their illness or problem. 
• If unsure about how to behave with the person (e.g. you are a woman and he is a 
man) ask them, a family member, friend or cultural interpreter their advice. 
• Spend time talking generally (e.g. try to find some common ground) before asking 
about any personal health or other issues, and explain why you are asking such 
personal questions and what happens with their information. 
• Be aware that the person is most likely to need a relative, friend or other trusted 
person present when you speak with them, and perhaps throughout their 
admission. However, this cannot be assumed and the person’s wishes should be 
ascertained and respected before contacting others. 
• Be careful how your ‘non-verbal signals’ may be interpreted. It may not be 
appropriate, for example, to stand directly in front of the person and look into 
their eyes, or stand over them as they lie in a bed or sit in a chair and look down on 
them. Seek advice if you are unsure how best to present yourself.  
• Avoid using medical terms (jargon) and explain what you mean clearly, in simple 
terms. Always assess if the person understands what you are saying by seeking 
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feedback from them. Re-explain the issue until you are confident that they 
understand what has been said. Drawing pictures can be useful.  
• Where it is necessary to take notes, explain why this is needed and offer the 
person the opportunity to see or read what you have written. Also explain this to 
their trusted companion. 
Some particular issues to think about:  
Gender and age  
Be aware that most Indigenous people whether they are from urban, rural or remote areas 
still value, are in touch with and continue many cultural practices such as;  ‘men’s business’ 
and ‘women’s business’.  Some may be offended and upset by being questioned on 
personal issues or physically examined by a younger clinician or someone of the opposite 
gender. 
Silence 
Listen carefully to the person. Be aware that a silent pause does not necessarily mean the 
person has completed their answer to the question. It may be helpful to ask whether the 
person has anything else to add or needs further clarification before proceeding to the 
next question. If the person does not respond to something you ask, wait and then try 
rephrasing the question. You need to move on if it becomes clear that the issue at hand is 
causing discomfort or embarrassment. 
Hostility and fear 
Be aware that a person may be hostile towards your role based on past experiences, and 
not necessarily towards you personally. Being friendly, non-judgemental and respectful is 
the best way to overcome such difficulties. 
Hope of recovery  
Hope of recovery from ATOD related problems can be realistic for many Indigenous 
people. However, as with many other people in the community, some health professionals 
are pessimistic about the ability of people with ATOD disorders to overcome their 
problems, and this view is also held by many Indigenous people. 
Displaying optimism about the person’s ability to address their ATOD problem is 
important, even if their pathway to recovery may be long or troubled. Offering stories of 
people who have been able to do this can be useful, providing no real names are disclosed. 
For inspiration read Indigenous people’s stories in Giving Away the Grog: Aboriginal 
Accounts of Drinking and not Drinking [34].  
Setting the scene for assessment and intervention  
Nurses and others assisting Indigenous people need to ‘set the scene’ so people feel at 
ease, and encourage them to talk about the issues they face, whether they are those at risk 




Risk assessment for alcohol and other drug use and associated mental health problems 
amongst Aboriginal and Torres Strait Islander people in a culturally appropriate and timely 
manner. This instrument is called the Indigenous risk impact screen (IRIS) and brief 
intervention. 
According to the results (scores) of the IRIS, implement the appropriate 
assessment, nursing care and treatment  plan as discussed in Section 2 and 3. To access 
information about IRIS go to Section 4, Appendix 3.  
Health advice 
Link any of health advice about ATOD use to the person’s own ATOD use, health (and 
other) related problems. This is usually far more effective than giving general health 
information, such as ‘heavy drinking badly affects diabetes’. 
It is helpful to avoid: 
• Assuming anything or base your responses on what you believe might be a 
person’s situation, illness, ATOD problem, cultural background or experiences as 
an Indigenous person. By providing a comfortable atmosphere and undertaking a 
thorough assessment of their general health and ATOD use, you will be able to 
make clearer clinical judgements and provide sound nursing care. 
• Relying on stereotypes such as ‘all Indigenous people drink excessively’. This is not 
only offensive and untrue, but likely to lead to their actual health problems being 
ignored or misdiagnosed. 
• Being confrontational when talking with the person or giving them advice about 
their ATOD use. Confrontation does not change people’s views about how to deal 
with their issues and may further entrench their resistance to reducing or ceasing 
their ATOD use. It is offensive, increases shame and embarrassment, and does not 
encourage openness and information flow about sensitive issues. More than likely 
this may result in your efforts and services being rejected. 
Working with young people and children  
Children and adolescents require particular attention and sensitivity when dealing with 
their alcohol, tobacco and other drug related problems. 
They may be particularly vulnerable due to grief and loss, family conflict or other issues. 
Informed consent for children to be treated for ATOD or any other health problems needs 
to be given by a well-informed, responsible parent or guardian. If this is not possible for a 
young child in your care you need to seek guidance from senior medical and nursing staff, 
and relevant legislation and policy related to this situation. 
In certain circumstances (such as not living at home, being at risk of abuse, not being in 
care of parents, or privacy needs), adolescents can give their own informed consent for 
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treatment. The clinician must follow organisational policy and state laws in this situation 
[35]. Seek advice from the local Child Adolescent Mental Health Team or Youth Health 
Service.  
Please be familiar with:  
National Health and Medical Research Council (NH&MRC) 2009. Australian Guidelines to 





People come to hospital or other health services for a variety of reasons relating to their 
health needs. They may not believe that there is any need to mention their ATOD use to 
the clinical staff. By maintaining an empathic, non-judgemental attitude and explaining 
why all people over the age of 14 years need to have an ATOD assessment as part of their 
general health assessment (based on the age of uptake of ATOD, patterns of ATOD use of 
and related risks to the Australian population), we can encourage them to talk openly 
about their ATOD use and any concerns they may have. 
(For drug-specific assessment guidelines see Section 3; For general guidelines see Section 
2.4: Managing intoxication; Section 2.5: Managing overdose and Section 2.6: Managing 
withdrawal).  
Rationale for assessment  
The importance of the ATOD assessment cannot be overstated. Importantly it is an ideal 
opportunity to deliver brief intervention in a timely manner. Assessment is an intervention 
in itself as it raises the issue of ATOD as a common aspect of many people’s general health 
concerns, alerts the person and their clinicians to any potential risks or actual problems 
that may exist, and provides a timely opportunity for ATOD education, information giving 
and early intervention.  
The ATOD use assessment is necessary to: 
• identify immediate problems 
• treat any emergency or acute problems 
• establish a correct differential diagnosis  
• predict the effects of intoxication, assess its life-threatening potential, and inform 
appropriate intervention 
• identify the purpose or reasons for the person’s ATOD use 
• identify issues related to possible medical complications of ATOD use 
• assess the possibility of any drug interactions (e.g. between medications and other 
drugs the person may have consumed recently and any prescribed medications 
needed at the time for medical treatment) 
• identify the likelihood of dependence, predict the likelihood of withdrawal, assess 
for imminent withdrawal and possible complications 
• identify history of any previous withdrawal syndrome to predict likely severity of 
withdrawal and possible complications such as seizures and hallucinations 
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• assess risk behaviours including self-harm 
• provide education on harm reduction skills (e.g. always using clean injecting 
equipment and knowing where/how to get these, hepatitis B immunisation, daily 
Thiamine for risky and binge drinkers) 
• gain a greater understanding of the person not merely in terms of their current 
ATOD and other symptoms 
• determine the person’s goals related to their ATOD use and if they want any 
assistance to change their use at this time/stage (e.g. start using nicotine patches 
or gum, having a planned/supervised withdrawal and starting counselling) 
• identifying any environmental vulnerabilities related to housing, disaster, weather 
or bushfires 
• select appropriate interventions and service options so that timely and acceptable 
referral can be organised. 
These may include transport to a sobering-up service if medically fit, engaging in 
counselling or pharmacotherapy such as methadone and/or: 
• developing a therapeutic relationship 
• identifying immediate needs and possible complications (such as concurrent health 
problems, psychoactive drug withdrawal, prescribed medication administration 
and pain management needs) 
• understanding the individual, family and/or community 
• identifying the goals of the person and/or their family in relation to their ATOD use 
• offering well-matched intervention/treatment for the individual’s ATOD problems 
• clarifying the reasons for any treatment procedures during the admission or 
episode of care 
• informing care and discharge planning, and any need for ongoing care and referral 
• Providing harm reduction strategies and skills to ensure that further risks can be 
reduced (e.g. provision of clean needles and syringes, swabs and sterile water; 
advice on using low strength alcoholic drinks and where the person engages in 
risky daily drinking or binge drinking to maintain good nutrition and daily Thiamine 
100mgs). 
Try to remember that what appears to be an ATOD presentation may not be. It could be a 
condition that is mimicked or complicated by intoxication or withdrawal. Some diagnoses 
may be confused by the presence of alcohol intoxication or withdrawal. This could lead to 
medical problems being overlooked. Such problems include head injury; cardiovascular 
accident (CVA); infection, hypoxia, hypoglycaemia and other metabolic imbalances, liver 
disease, overdose; adverse drug reaction and psychosis.  
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Assessment should be carried out in a timely manner that is in a safe, confidential 
environment with sensitivity towards the person and their family, and respect for their 
cultural identity and associated needs [11]. 
Using a person-centred approach 
Quality nursing and midwifery ensures that the health needs of individuals are kept to the 
fore and holistic care is provided. 
Nursing care needs to be focused on empowering the person to manage their own lives to 
their full potential. Some people take longer than others to trust health professionals and 
services. People are more likely to enter into a relationship where they are assisted in 
identifying and expressing their own needs and can set goals and objectives to achieve 
them, such as reducing or abstaining from harmful drinking [36-38]. 
Maintaining confidentiality 
Under common law, statutory law and codes of practice, nurses, midwives and allied 
professionals have a professional duty of care relating to honouring and maintaining 
person confidentiality. The person’s right to confidentiality means that all persons must 
have this clearly defined and explained to them before being asked to reveal any personal 
information. Information can be provided to third parties on their behalf only if their 
specific written permission is provided before this occurs.  
They also need to understand any legislation that limits this (such as the requirement for 
mandatory reporting of child abuse or being unfit to possess a firearm) so that they know 
what boundaries exist before they divulge information. People need to know that their 
personal information will be respected and only shared with the clinical team responsible 
for their care. They also need to know that their clinical records can be subpoenaed by 
courts of law. 
Strengthening motivation  
When a person attends a specialist service they will generally have developed at least 
some awareness that an ATOD problem exists. When people are receiving care in a general 
hospital ward, mental health or community health care setting, they may not be aware 
that they have an ATOD problem. The degree to which a person may be aware of their 
ATOD use and their desire and readiness to change and/or seek help is directly related to 
their recognition that a problem exists and that the benefits of use are now outweighed by 
the negative aspects and harms. They may also believe that change is possible, that they 
have (or can develop) coping mechanisms, and that their life can improve [11, 36, 39, 40]. 
Their understanding and willingness to consider the issues and the possibility for change 
can be positively influenced by nursing staff at what may be a ‘critical moment’ in their life 
in contact with health professionals wherever they are receiving health care. In order to 
strengthen people’s motivation to reduce or change their harmful ATOD use, assessment is 
a critical process of information-sharing between person and the nurse, and an important 
trajectory towards engaging in more in-depth care or referral should this be needed.   
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Issues for assessment 
People’s ATOD use can be controversial, particularly if this involves illicit drug use. Some 
nurses and midwives may feel reluctant about discussing drug use with people, particularly 
if it is seen as not affecting the person’s presenting problem. The ability of staff to raise the 
issue of ATOD use is critical to identifying any problems, offering early intervention and 
minimising risks. 
In working with people with explicit ATOD problems, it may be necessary for you to raise 
some rather difficult issues. The skills involved in effectively raising sensitive issues such as 
these are the same skills nurses use to ask about many other personal issues. 
Possible factors that may cause nurses to feel reluctant in raising ATOD use may include: 
• may not be the presenting health problem 
• a reluctance of the nurse to ‘pry’ with the worry that this may jeopardise their 
therapeutic relationship with their person 
• poor knowledge about ATOD use and related issues 
• a belief that only ATOD specialists can address these problems 
• a lack of confidence in responding effectively if an ATOD issue is revealed 
• a belief that if the other presenting problem is ‘fixed’ then underlying ATOD issues 
may go away 
• a belief that only people who are ATOD-addicted require assistance for their ATOD 
problem 
• a degree of comfort/discomfort with one’s own ATOD use such as smoking or 
binge drinking or one’s own experience of a difficult family issue 
• a belief that ATOD problems are too difficult to fix and therefore there is no point 
in asking about them.  
Misconceptions may exist regarding the most effective way to raise the issue of ATOD use. 
Traditionally the focus has been on people who appear to be or have been diagnosed as 
‘chronic’ or ‘dependent’ users, with a strong belief that ‘denial’ is an integral component of 
their personalities and that confrontation will break down denial.  
However, it is precisely the techniques of confrontation and labelling people ‘alcoholics’ or 
‘addicts’ that produces denial, particularly among people who do not perceive themselves 
in this stereotypical way. This judgemental approach is unhelpful as it does not promote a 
safe therapeutic environment that facilitates trust, or foster rational discussion about the 
reasons for person’s ATOD use and any positive and negative consequences associated 
with their use. Zinberg [1] stated, all ATOD use is functional in that it serves a purpose for 




How to raise the issue of ATOD use 
Routine questioning acknowledges that ATOD use is widespread in the community. ATODs 
may be used to have fun, cope with stress, deal with pain, stay awake, go to sleep or 
improve performance. ATOD use issues may occur for anyone and affect people in 
different ways. 
It is therefore very useful to incorporate ATOD use within your general assessment routine, 
even if problems are not suspected. If your person knows that you do this with all persons, 
it normalises the issue. The advantage of this approach is that it allows for a range of 
problems associated with ATOD use to be recognised, and not just the more obvious 
difficulties such as dependence (that is, problems associated with regular excessive use 
and intoxication). Once assessed, ATOD problems and concerns can be identified, choices 
for treatment offered and a management plan negotiated with the person. 
Routine questioning of all persons also decreases the responsibility on nurses and 
midwives to work out when to raise the issue and with whom. It diminishes the probability 
that people will feel singled out if you explain that you ask everyone these questions [41]. 
Importantly, it provides a unique opportunity to educate and clarify the questions the 
person may have about ATOD use, and in fact saves time by alerting to you to any potential 
complications that may develop during the admission such as acute withdrawal. 
Hints to assist communication 
If you feel uncomfortable discussing ATOD use with your persons, these points may be 
useful: 
• Ascertain if an interpreter is needed and if so, ensure this occurs. 
• Tell the person that you ask all persons over the age of 14 years about their ATOD 
use because it is common and may affect diagnosis and treatment of their 
problem. 
• Link the person’s current ATOD use with their presenting condition (if appropriate) 
such as chest infection, liver disease, injuries. 
• Use non-threatening verbal and body language. 
• Use ‘open-ended’ questions such as, ‘Can you describe a typical drinking or drug 
use occasion for you?’ 
• Use a comfortable environment (quiet, private, adequate lighting). If privacy is 
impossible, draw the screen or curtain and speak quietly to ensure others do not 
hear personal details. 
• Display a caring attitude (non-judgemental approach). 
• Ensure that the person knows they have the right to refuse to answer any 
questions and that confidentiality is assured. 
• Note any inconsistencies in what the person tells you about their ATOD use (such 
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as their physical condition not being consistent with being a light drinker) and 
explore these if possible to ascertain their own understanding of what is being 
asked/said. 
• If a question angers the person, leave it until later when it can be rephrased or do 
not ask again. 
• Take account of their ‘whole’ health profile. If there is a discrepancy between what 
the person tells you about their ATOD use and what you see (ascites, spider naevi 
on face, chronic cough, muscle wasting of legs, needle marks), record this. 
Combine the information you draw from the person’s own ATOD history and your 
clinical observations. 
• Phrase questions that give the person permission to talk about their ATOD use, and 
if appropriate, ask questions that display an assumption that the person uses some 
form of ATOD such as medicines or alcohol. This gives the person permission to 
talk about their use. 
• A history of the person’s ATOD use may be elicited (where possible with consent) 
from their partner, friends or family. 
• Be sensitive to the person’s ability to respond to your inquiries. 
Factors that will influence responses to you include the person’s: 
• age 
• culture 
• personal history 
• level of pain 
• fear of your judgement and 
reprisal 
• fear of a breach of their 
confidentiality 
• fear of losing their job  
• need for more privacy 
• level of English comprehension  
• legal status of their ATOD use 
• past negative experiences with 
health professionals 
• fear that parents or other family 
members will find out 
• fear of any other health problems 
they may have developed (e.g. HIV 
or hepatitis). 
Do not be distracted from important points 
Always make sure phones are silenced and other people including staff do not interrupt 
you.  
Allow for minor diversions by the person during their assessment, but try to help them to 
return to the point of discussion. If they seem to be avoiding answering your questions or 
become hostile, reassure them, and if necessary, do not proceed. Make an objective note 
in their case notes or assessment form about what was happening and continue to monitor 
the person. Return to the assessment later when they have settled and/or had pain relief.  
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You may need to suggest that another clinician undertakes assessment if this seems 
appropriate. It may be that the person would prefer a clinician of his or her own gender. 
Do not allow your personal attitudes to affect the assessment. 
The person’s way of life and behaviours may not conform to your own personal standards 
of what is acceptable behaviour. Such considerations should be put aside and not affect 
the therapeutic process. 
Be sensitive to the person’s cultural background and language 
(See Section 2.1: Communication and cultural issues). 
Do not assume that the person perceives their ATOD use as a problem 
Even though people may be drinking over the recommended low-risk level [42] or using 
other drugs at harmful levels, we should not assume that the person believes that this is a 
problem. Many people do not know that their ATOD use is risky or harmful [43]. 
A person may refuse to engage in ATOD assessment 
People are unlikely to object to their ATOD assessment if they know why it is happening 
(that all persons of the service are offered ATOD assessment and therefore not only for 
them specifically), and that questions are asked in a matter-of-fact manner as part of 
routine history taking.  
However, people do have a right to refuse ATOD assessment, and if this happens, 
discontinue discussion in a way that can allow them to return to the topic at another time 
should they wish. Make a note of their refusal in their clinical record. 
A person may not want ATOD treatment 
If a person is intoxicated or withdrawing when in your care, wants to leave the 
hospital/service and has been assessed as unsafe to leave, the nurse or midwife (and 
doctor) must exercise their duty of care to ensure the person’s safety and wellbeing. Refer 
to the team leader and relevant policies to determine the appropriate course of action. 
Always document the situation and action taken. Best practice has been shown to include 
detaining the person who is delirious, dangerously intoxicated, is at risk of harming others 





Nursing guidelines—general assessment 
Systematic assessment of all people over 14 years of age should include: 
• pattern and recent history of ATOD use 
• physical assessment 
• mental health history 
• history of any injecting and other risk factors 
• psychosocial issues 
• environmental and other vulnerabilities related to housing, disaster, weather or 
bushfires 
• other needs. 
Pattern and recent history of ATOD use 
The following should be covered as part of every ATOD use assessment: 
• type of drug (note that polydrug use is common and the assessment should include 
all drugs—prescribed and over-the-counter medicines, herbal remedies, tobacco, 
alcohol, illicit) 
• route of administration (oral, inhalation, injecting, suppository—rectal) 
• frequency of use (e.g. very occasional, less than weekly, once a week, more than 
once a week, daily, more than once a day) 
• amount used in grams/doses or daily cost (for illicit drugs such as 
psychostimulants, cannabis, heroin) 
• duration of use at current level, any changes in pattern over time (age commenced 
use; recent typical pattern) 
• time and amount of the last dose (where possible, clarify in exact terms, such as 
grams of alcohol, milligrams of methadone, grams of cannabis, points of 
amphetamine etc.) 
• with whom is the drug typically used (e.g. friends at the pub, at work, at 
rave/dance parties, with family and friends at home, alone)  
• past/present contact with alcohol and other drug treatment services 
• any periods of abstinence and when were these 
• what influenced a resumption of harmful ATOD use 
• history of withdrawal symptoms on cessation or reduction of use 
• history of complications of withdrawal such as seizures. 
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Note: Always consider the likelihood of poly drug use amongst people of all ages. It is 
vitally important that you assess for poly drug use and any immediate and longer term 
potential for drug interactions e.g. drugs the person may have recently used and are 
possibly still affected by, during admission, and any additional medications given for acute 
illness. 
In addition people who use more than one drug at a time need to be educated about the 
potential for accidental overdose, unwanted effects, and toxicity due to differing drug 
actions and half lives e.g. additive effects, synergistic effects, potentiation, or antagonism. 
Validated screening instruments are essential for accurately identifying the pattern of 
drinking, and level and nature of problem (see Appendices 1 and 2a, b & c). Also see 
Appendices 3 - 7 for alcohol, drug and tobacco assessment tools. 
Examples of useful lead-in statements and questions: 
• Do you have any cigarettes or cigars with you? 
• How many cigarettes or cigars do you have with you? 
• How often do you smoke cigarettes or cigars? 
• How many cigarettes or cigars do you smoke each day? 
• Do you ever drink alcohol? 
• How often do you have a drink? 
• On a typical day, how much alcohol would do you have? What size container is 
your drink in (e.g. a stubby, small vegemite glass, cask)?  
• Do you use any medicines, powders, creams or tablets other than those your 
doctor has prescribed for you (for example to help you relax, sleep, cope with pain, 
block out bad thoughts, deal with stress, feel good, have fun or excitement)? 
• Do you ever need to use more of your medicine(s) than the doctor prescribed? 
• Do you ever use other people’s medicines (sleeping pills, antibiotics, heart pills, 
laxatives, and pain killers like codeine)? 
• Do you use other medicines from the chemist or supermarket? If so, what, why 
and how often? 
• Do you use any other drugs such as cannabis (marijuana), amphetamines (speed), 
heroin, nitrous oxide (laughing gas), GBH, ketamine, steroids, solvents (aerosol 
paint, glue, petrol, cooking spray) or hallucinogens (LSD, magic mushrooms, 
Datura)? 
• Do you ever take more than one drug at a time (e.g. alcohol and cannabis, sleeping 
pills and heroin, amphetamines and alcohol, sleeping pills and alcohol, ecstasy and 
cannabis)? If so what happens? 
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• What benefits do ATOD’s give you? 
• Have you ever had a problem from using a drug? 




Table 2: Drug use questions & their purposes 
Question Purpose 
When did you last use? (Specify 
date and time plus name of drug, 
quantity, route of administration) 
Identifying the type, likely pharmacological actions, possible side 
effects, half-life and range of ATODs used. The dose/quantity and 
route of administration should indicate pattern and extent of use 
and associated risks such as imminent overdose, withdrawal, drug 
interactions, risk of emergencies, infection. 
What age were you when you first 
used this drug? 
Establishing the onset, pattern/s and length of use. The lower the 
age of initiation the greater potential for subsequent harm. 
Has there been any recent change 
in the amount and way you use 
(e.g. less or more)?  
Ascertaining whether the use is/has previously been experimental, 
recreational or at dependent levels and any changes in pattern 
(e.g. reduction, increase). 
Starting with today, then yesterday, 
then the day before yesterday etc. 
… which days did you use (this 
drug/s) over the last week? (use 2, 
3 or 4 weeks if use infrequent) 
Ascertaining whether the use is/has been occasional, recreational, 
binge, regular excessive or at dependent levels [42]. 
What times of the day do you 
usually use the drug/s? 
Establishing pattern, quantity and severity of use. 
Where do you usually use the 
drug/s? 
Identifying the environment/s where use is likely to occur to 
ascertain external influences, potential risks, contexts that affect 
decision to use. 
Do you typically use the drug/s 
alone, or with others? Who with? 
Establishing whether use is typically a solo or group activity. 
Whether partner is involved. 
What mood might you be in when 
you typically use the drug/s? 
Identifying any specific events or mood states which can trigger 
use of ATOD’s (e.g. happy, sad, ‘party mood’, depressed, in pain, 
argumentative, preparation to go out, being at parties/raves, 
response to pressures, family occasions). 
How does your ATOD use generally 
make you feel? 
Identifying the reasons for use, likely outcomes of use, identifying 
any risks, identifying risk for continued problem use. 
Have you ever experienced any bad 
effects from your ATOD use? 
Identifying physical illnesses (e.g. overdoses, gastritis, pancreatitis, 
accidents, hepatitis, septicaemia), psychological (e.g. moody 
swings or depression, anxiety, paranoia, hallucinations, suicidal 
ideation), social (e.g. loss of friends/employment, family conflict), 
legal (e.g. loss of drivers licence, arrests, gaol). 
Has anyone ever told you they are 
worried about your ATOD use? 
Identifying whether use has come to the attention of, or is a 
concern for others such as friends, partner and/or family. 
Have you previously tried to 
reduce, stop or change your 
alcohol, tobacco and other drug 
use? 
Identifying periods of abstinence, reductions in use, change in 
pattern to control use, any personal strengths or weaknesses in 
being successful in making change. What strategies did they use 
that worked? 
Are you worried about your ATOD 
use? 
Elicit the person’s perspective of how serious they consider their 
use of ATOD’s is. 
Would you like to do anything 
about your current ATOD use? 
Eliciting from the person their perceived need and/or likely 





Nurses and midwives should carry out relevant observations as appropriate. These include 
vital signs, neurological observations, nutritional status, fluid balance, level of 
consciousness and signs of ATOD intoxication or withdrawal. Examples of physical signs 
arising from ATOD use are listed below, many being due to the pharmacological effects, 
half-life of the drug or drugs used, the route of administration, accidental injury or illness 
arising from concurrent use. 
Signs of harmful ATOD use 
• flushed or ashen face 
• jaundice 
• puncture marks 
• phlebitis 
• erosion or irritation around 
nostrils/septum 
• conjunctival irritation 
• unstable or abnormal gait 
• swollen abdomen, ascites 
• spider naevi on face 
• cellulitis 
• skin abscesses 
• irritation or rash around nose and 
mouth 
• odour—breath, skin 
• distended blood vessels along side of 
neck. 
Specific signs of intoxication 





• pressured or rapid speech 
• decreased concentration or erratic 
ability to concentrate  
• opioid intoxication—pinpoint pupils 
• drowsiness/decreasing alertness  
• slurred speech 
• mood swings 
• poor or inability to manage normal 
tasks (e.g. lacing-up shoes, writing 
clearly). 
Specific signs of withdrawal 
(See Section 3 for specific drugs and withdrawal management). 
Symptoms of the various withdrawal syndromes (e.g. alcohol withdrawal, opiate 
withdrawal, benzodiazepine withdrawal, amphetamine withdrawal, cannabis withdrawal, 
nicotine withdrawal) are due to the particular pharmacology of the drug (CNS depressant 
or stimulant), and its half-life.  
Symptoms emerge with a significant drop in blood concentration or abrupt cessation of 
ATOD use. This occurs in someone whose central nervous system has neuro-adapted to 
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maintain normal body function in response to his or her excessive and frequent (daily) use. 
A general guide is that the withdrawal syndrome will usually exhibit opposite signs to the 
acute drug affects (such as, a CNS depressant alcohol withdrawal can produce increasing 
irritability, acute agitation, anxiety, tremor, sweating, nausea, headache, general physical 
and psychological discomfort). It can also progress to severe complications known as 
delirium tremens (DTs) and possibly death if not managed effectively. 
Signs and symptoms of intoxication and withdrawal for specific drugs are detailed in 
Section 3: Drug-specific information. 
Past medical history 
Other health conditions may exist (e.g. diabetes, heart disease, liver disease, accidents, 
head injuries, abnormal menstrual pattern, menopause, poor nutrition or hydration status, 
or mental health problems). All concurrent health issues need to be assessed and attended 
to. 
Ask about: 
• any recent or concerning unintended weight loss or gain 
• possible injuries—recent and not so recent 
• general health problems (e.g. diabetes, renal disease, cancer, stroke, infections 
including septicaemia, human immunodeficiency virus (HIV), hepatitis A, B and C, 
liver or pancreatic problems, chronic gastritis, high blood pressure, heart disease, 
breathing problems).  
Note: These are only some examples of problems that may be relevant to the person’s 
pattern of ATOD use and their drug administration methods. 
Mental health history 
Alcohol and other psychoactive drugs all affect cognition, emotions, moods and 
behaviours. They can, for instance, temporarily induce over confidence, mania or 
depression, confusion, disorientation, perceptual disturbances, euphoria, agitation, panic 
attacks, emotional lability, pressured, rapid or slurred speech, repetitious behaviours, fear 
or aggression. It is therefore important to include a mental health assessment as part of 
the overall ATOD assessment. 
Ask about: 
• any previous psychiatric/mental health problems such as depression, panic attacks, 
anxiety disorder, bi-polar disorder, schizophrenia 
• related admissions or medical treatment 
• any medications prescribed for the disorder—past and present 




A mental status examination includes observing and asking questions relevant to: 
• Current level of consciousness  
• Quality of memory - recent and past 
recall. 
• Affect - does the person seem unduly 
anxious, depressed, flat, blunted, 
inconsistent with person’s expressed 
mood etc.? Do the person’s emotions, 
posture, facial expression etc. Seem 
natural for their present situation? 
• Behaviour - approach/reaction to you 
and their assessment interview. Does 
the person maintain normal eye 
contact if this is appropriate for their 
culture? What is the person doing 
during their assessment interview? 
What is their behaviour like 
(restlessness, hand wringing, pacing, 
lethargic and sleepy) Illusions (e.g. 
Misinterpretation of visual stimuli in 
the environment such as a wavy 
pattern on a curtain perceived as a 
snake moving). 
• Level of orientation  
• Level of logic in expressed ideas – 
are they rational? And in context? 
 
• Speech - manner of speech, speech 
pattern, possible disorders, aphasia, 
dysarthria, incoherent, disjointed, 
preservation, flight of ideas, how 
(e.g. Loud, soft, fast, pressured) form 
- the thoughts relate to each other, 
logical. 
• Comprehension - understanding 
simple instructions. 
• Abnormality of perception - visual, 
auditory, tactile, olfactory 
hallucinations. Are any auditory 
hallucinations threatening, accusing 
or commanding?  
• Also ask about appetite and sleep 
issues as well as any delusions 
occurring.  
People with complex ATOD problems are likely to need a psychiatric assessment. 
History of injecting and/or other risk factors 
The following should be explored if the person has indicated a past history of injected 
drugs. Ask if they: 
• use clean needles and syringes and other injecting equipment (‘gear’) 
• ever share, needles, syringes and other injecting equipment including swabs, 
spoons, water for dilution, tourniquets—such as a piece of cloth or a belt 
• can access supplies, clean needles and syringes 
• know how to inject safely to protect veins and tissues 
• know how to safely dispose of used injecting equipment 
• have adequate knowledge of HIV/hepatitis B and C issues including routes and risk 
of transmission, immunisation drug use 
• have had any health complications from injecting (e.g. abscesses, thrombosis, viral 
illness, and heart or chest problems) 
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• have a good understanding about safe sex, the need for condoms to protect 
against infections and how to use condoms. 
This is the ideal time to provide the person with clear information. 
Psychosocial issues 
Ask about the following: 
• Family (any problems or special circumstances?) 
• Housing; risk of homelessness (any urgent needs?) 
• Children (any urgent issues, current need for care or assistance?) 
• Employment (is this satisfactory? Any immediate worries?) 
• Legal (any immediate worries?) 
• Financial (any immediate worries?) 
• Vulnerability from harsh weather or disaster e.g. exposure to extreme cold, 
heatwave or bushfire. Consider issues such as lack of or poor access to; a safe 
place, appropriate clothing for weather conditions, fresh water, shade, air 
conditioning or heating 
• Other agencies involved - may already have a plan, undertake follow-up of 
vulnerable person or develop collaborative plans with local emergency services  
• Possible family history of ATOD use issues 
• Any negative social consequences of the person’s ATOD use and related situations. 
It is important to consider the above issues pertinent to the person you are caring for. Try 
to ensure these are considered in the person’s care and after care plan as early as 
practicable prior to discharge to maximise engagement and continuity of care; and thus 
avoid unnecessary re-admissions and distress. 
Planning care 
The aim of any clinical intervention is to undertake quality care. The types of interventions 
chosen will vary depending on the type of ATOD problem and the particular needs of the 
person. Sharing the care through multidisciplinary teamwork and inter-agency 
collaboration is essential. All nurses and midwives have a key role in shared care. There are 
excellent models of shared care in general health services and these are applicable for care 
of people with ATOD issues. Relevant policies and available resources in the health care 
setting will influence what type of interventions and outcomes occur. 
During the care planning process, nurses and midwives need to assist the person to clarify 
their own needs and goals, taking into account priorities of clinical issues and immediate 
concerns, the person’s motivation to address their ATOD problem and what outcomes they 
want, other needs and concerns including family and housing issues. At all times harm 
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reduction processes need to be put in place to minimise any further risks and/or harms, 
whatever the person’s longer-term actions may be. 
It is important that the nurse or midwife, and the person themselves, have a common 
understanding about what interventions are possible. For example: 
• being cared for in a primary health care setting 
• being referred to a specialist 
• having useful information 
• having the choice of self-help strategies 
• learning new strategies to change harmful ATOD use 
• learning how to attain and maintain change—relapse prevention 
Linkages are essential in building local disaster plans for, and follow-up of, vulnerable 
people. Building strong local networks of local collaborative partnerships help to support 
vulnerable people. This may include sharing referral and communication strategies, 
common emergency and intervention plans for times of high risk and day to day support. 
Partnerships can include health, police, ambulance and fire services, shelters and 
community centres, managers of shopping centres and bus/railway stations, 
neighbourhood houses or other safe places. 
Networks of services can devise effective ways of supporting vulnerable  people at times of 
risk or disaster with e.g. prepaid mobile phone with essential numbers to call for 
assistance;  emergency lighting, water and food supplies; transport, addresses of known 
safe places; essential medication and first aid kits. 
Following assessment the nurse or midwife should also identify whether the person can be 
assisted in the primary health care setting or needs referral, and assistance from e.g. GP, 
social worker, Aboriginal health service, specialists or other relevant services. This should 
then be built into the treatment plan. 
Knowing when to refer on 
There are no hard and fast rules about whether people with ATOD problems should be 
cared for in the primary health care setting or within specialist services. The decision to 
refer on to other services/agencies will depend on the outcome of ATOD assessment, the 
person’s own preference, the severity of their problems, actual location, accessibility and 
availability of services, and family needs etc. The following table provides a broad 
framework of some factors that may assist in deciding what may be the most appropriate 




Referral options may include: 
• Sobering-up unit (may be referred to as a non-medical detoxification centre) 
where following careful assessment intoxication is considered as the presenting 
factor (no risk of injury or potential medical crises). This is voluntary and does not 
include medically supervised care. 
• Withdrawal (detoxification) services. Some provide non-medical supervision and 
others medical supervision. The person’s needs must be ascertained. The person is 
referred according to their medical condition, intoxicated state or likely severity of 
withdrawal.  
• Pharmacotherapy services such as methadone or buprenorphine maintenance 
programs for opioid-dependent people. 
• Residential programs (such as a therapeutic community), usually accessed by 
people who have undergone a withdrawal (detoxification) program and aim to be 
alcohol or drug free. They may require psychiatric medications for comorbidity 
such as depression. This needs to be negotiated before transfer or referral. 
• Community-based services for counselling, home detoxification, self-help groups 




Table 3: Factors assisting decisions about appropriate venue for care/treatment 




Recreational drug/alcohol users 
Lower levels of hazardous drug/alcohol 
consumption 
Less severe dependence   
Chaotic, poly drug/alcohol use 
Dependence > than one year 
Methadone or buprenorphine 
assessment and therapy 
Person’s request/choice 
Complications Stable psychiatric conditions 
Co-existing medical problems (e.g. 
diabetes, hypertension, infection, 
injury, HIV, HBV, HCV, acute illness, 
injury) 
Unstable psychiatric condition 
Pregnant women at special risk 
History of chronic ATOD relapse or 
unsuccessful ATOD treatment episodes 
History of recent self harm 
HIV or hepatitis C  
Previous ATOD 
treatment 
No previous attempts to cease or 
reduce ATOD use 
Strong motivation to undergo 
intervention including withdrawal 
management 
Willingness to access other appropriate 
services, e.g. social worker 
Drug use already stabilised by specialist 
services or GP 
Family/support network 
History of poor ATOD treatment 
outcomes 
Poor home or family support system 
Multiple agency involvement 
Undertaking current ATOD treatment, 
e.g. methadone, chronic pain 
management, co-management for 
mental health disorder 
Social Employment/study commitments 
Financial resources 
Family responsibilities 
Family/social and effective supports in 
place 
Being a volunteer, carer, parent 
Not acceptable to go to specialist 
inpatient service for cultural/gender 
reasons 
Child care and safety concerns 
Homeless/unstable social 
circumstances 
Poverty, unemployment, poor supports 
Must be acceptable to culture and 
gender 
[45] 
Note: Where the person has an ATOD problem and unstable psychiatric illness, immediate 
referral with assistance should be made for combined (collaborative) mental health and 
alcohol/drug specialist services.  
Contact your local alcohol and drug information service for advice and information on the 
range services available near you (See Section 5).  
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2.3 Early and brief intervention 
Introduction 
The terms ‘brief intervention’ and ‘early intervention’ are often used interchangeably. 
However there are two definitions that we use.  
Early intervention (EI) is designed to intervene as early as possible in the history of a 
person’s risky or harmful ATOD use. It aims to prevent further risks, avoid or ameliorate 
any existing complications, and reduce any harm associated with that use. 
Studies have shown that talking with people at a ‘critical moment’, such as when in 
hospital and at an early stage in their ATOD use, can be very effective in educating and 
preventing further problems and complications [46]. Most importantly, early intervention 
is known to be effective when people understand that they can moderate their ATOD use 
rather than abstain, making the required behaviour change more acceptable and easier. 
Brief intervention (BI) is defined by the short period of time needed to deliver the 
intervention and the context in which it is offered. BI can be applied in a variety of settings 
and provided by a range of health professionals (e.g. hospital and community based nurses 
and midwives, general practitioners, social workers, counsellors). BI includes strategies to 
inform and educate the person about their ATOD use and related risks.  
BI employs techniques such as motivational interviewing in order to motivate the person 
to identify any ATOD problems, move towards change, set goals and undertake changes in 
their ATOD use. BI can be undertaken in as little as a few minutes for small problems to the 
provision of several planned sessions to assist the person through the process of change. BI 
can be supported by written information and self-help strategies.  
Rationale for early intervention 
Early intervention focuses on the early stages of harmful ATOD use when there is a risk of 
physical and psychosocial problems. The person may have been using ATOD in this way for 
a short length of time or a few years, but may not yet experience obvious health or social 
problems.  
Rationale for brief intervention 
Brief intervention can be very effective when applied at ‘critical moments’ in the person’s 
life, such as being admitted to hospital, possibly for an ATOD-related injury or illness, or 
another event that heightens their awareness and need for help—such as a family crisis or 
employment problem.  
More intensive treatment for ATOD problems is still needed for individuals experiencing 
complex ATOD problems (e.g. heavy drinkers or drug users with a history of relapse 




Brief intervention can be applied at any stage in the person’s ATOD-using career (not just 
in early stages of use), but is not as likely to be effective for those who experience chronic 
relapsing dependence or psychiatric comorbidity. This group usually requires supportive 
care and longer-term expert treatment. 
BI may not be appropriate for: 
• People showing signs and symptoms of serious physical illness arising from their 
ATOD use. In this instance, people need to be assessed by a physician. 
• People who are dependent on ATOD and need comprehensive general health and 
mental health screening and specialist assessment and treatment. 
• People who feel powerless over their situation or have concurrent health and 
social problems that require more intensive counselling, intervention and support 
than is possible in a brief intervention. 
General principles of early and brief intervention 
Early and brief interventions can be undertaken at any time during the nurse’s/midwife’s 
contact with the person. 
Miller and Sanchez [47] described a number of factors that can make brief intervention 
effective, and these apply to early intervention as well. These are grouped under the 
acronym ‘FRAMES’: 
FEEDBACK: Providing honest information with the person regarding the results of 
the ATOD assessment. 
RESPONSIBILITY:  Promoting the notion that the person has responsibility for their own 
actions and has the ability to change their ATOD behaviour. Self-help 
manuals can assist in the process. 
ADVICE: Giving clear advice on the nature of the ATOD problem encouraging 
the person to think about change and, if necessary, to seek further 
treatment that is appropriate to them. 
MENU: Providing the person with a menu of choices that will help them to 
resolve ATOD problem. 
EMPATHY: Being aware of the situation from the person’s perspective, ‘being in 
their shoes’. 
SELF-EFFICACY:   Emphasising that the person has strengths and abilities to achieve 





Guidelines for brief intervention  
Brief intervention (BI) can differ in the mode of delivery, amount of time required e.g. can 
be delivered in  5 minutes, and the  range of resources provided. BI generally involves: 
• identifying risk through ATOD assessment/screening with feedback of outcomes 
• assessing  the person’s capacity and readiness to change 
• applying motivational interviewing—to assess stage of change, create recognition 
of the need for change, and support the willingness to change 
• matching the BI strategy to the person’s needs and circumstances (e.g. provision of 
relevant, easy-to-understand information, self-help materials, pamphlets, video or 
audiotape, discussion) 
• staying relevant and helping the person to identify achievable goals (small steps) 
• offering skills development and strategies for the person to meet their goals and 
improving self-efficacy (e.g. dealing with craving, building self-esteem to support 
new skills like controlled drinking or relapse prevention to maintain abstinence) 
• offering follow- up/monitoring referral [48]. 
Assessment/Screening 
(See Section 2.2: Assessment). 
Screening is allows for quick assessment of risk and offers an indication of likely level of 
risk. It is not full assessment or diagnosis. 
Validated tools for screening and brief intervention for ATOD problems include: 
• AUDIT (Alcohol Use Disorders Test) – see Appendix 1. 
• ASSIST (the Alcohol Smoking and Substance Involvement Screening Test) see 
Appendix 2a, b & c. 
• IRIS (Indigenous Risk Impact Screen) – see Appendix 3 
Alcohol Use Disorders Test – AUDIT (See Appendix 1) 
The AUDIT screening tool was developed and validated by the World Health Organisation 
(WHO) in 1989. AUDIT is not a diagnostic tool, but rather an interpretive and indicative 
tool. Although the global score itself is useful, AUDIT considers three main areas to elicit 
specific information about patterns of use that indicate harmful or hazardous use and the 
potential for dependence. The three main areas assessed are: 
Questions 1-3: Quantity and frequency of use 
Questions 4-6: Possible dependence on alcohol [49].  
The AUDIT will elicit a score of between 0 and 40. Although a score of 8 or more indicates 
risky e.g. binge drinking or regular excessive drinking requiring brief intervention, scores of 
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13 or more are indicative of dependence and possible physical and/or mental health 
problems and therefore requires in-depth assessment and treatment [49].  
Figure 3: Flow Chart 
 
     [18] 
The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) and linked 
Brief Intervention (See Appendix 2a, b & c)  
The ASSIST screening questionnaire and Brief Intervention was developed by the World 
Health Organisation (WHO) and specialist addiction researchers and clinicians in response 
to the overwhelming public health burden associated with problematic substance use 
worldwide.  The ASSIST was developed principally for use in primary health care settings 
where harmful substance use among clients may go undetected, or become worse.  Many 
primary and community health care workers can identify dependence (or addiction) among 
clients, but may not be able to identify substance use that is not dependent, but still 
causing harms.  Ten years of international research has shown that the ASSIST is valid and 
reliable and able to be linked into an effective brief intervention. 
The ASSIST is a health worker-administered pencil and paper questionnaire and screens for 
all levels of problem or risky substance use.  It consists of eight questions covering tobacco, 
alcohol, cannabis, cocaine, amphetamine-type stimulants (including ecstasy) inhalants, 
sedatives, hallucinogens, opiates and ‘other drugs’, that can be answered by most clients in 
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around ten minutes.  A risk score is provided for each substance, and scores are grouped 
into low, moderate or high risk.  The scores are recorded on a custom-designed Feedback 
Report Card and are used to provide feedback to clients about their substance use and 
associated risks as part of the Brief Intervention.   
The risk score determines the level of intervention (treatment as usual, brief intervention 
or referral to specialist treatment).  A self-help manual for clients is available to help 
consolidate the brief intervention “Self-help Strategies for cutting down or stopping 
substance use: A guide”. 
Some level of training is required before use. Please visit www.dassa.sa.gov.au 
The manuals are entitled: 
• The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): A 
manual for use in Primary Care. 
• The ASSIST-lined Brief Intervention for Problematic substance Use: A manual for 
use in primary Care. 
Training workshops conducted by DASSA are available.  These are approximately six hours 
and interest can be registered by contacting DASSA on 8274 3333.  
A demonstration of the ASSIST and linked brief intervention can be viewed by following the 
links on www.dassa.sa.gov.au 
Identification of the person at risk 
(See Section 2.2: Assessment). 
Assessment of readiness to change 
The person’s responses to the issues will give an indication of the stage they are at in terms 
of wanting, and being able, to change their ATOD use. (See Table 2.3: ‘Matching stage of 
change to intervention strategy’ later in this section). 
It is useful to identify the person’s: 
• concerns about their alcohol and other drug use 
• their pattern of use (see Section 2.2: Assessment) 
• influences on their use 
• reasons for changing 
• likes/dislikes about their ATOD use 
• consequences of ATOD use 
• risk factors of ATOD use 
• supports for change, barriers to change, e.g. partner uses ATOD too 




Assisting clients to be motivated in changing their risky ATOD use is a powerful element 
that nurses and other clinicians can use with many of their clients, particularly those with 
less serious or complex ATOD related problems. It is however useful to understand that 
anyone’s motivation and capacity to change a harmful behaviour is not necessarily a 
constant emotion or intent.  
Motivation varies according to how they feel and what is impacting on their life at the 
time. Capacity can be reduced or adversely affected by cognitive problems or intellectual 
disability, poor physical or mental health, adverse living situations or experience of sexual 
abuse or other trauma.  
Therefore just because a person appears not to be motivated to change their risky drinking 
today it does not mean that at another time they will not respond positively to a nurse’s 
use of motivational interviewing and offer of support for them to change at another time. 
This may be because they are feeling well, their life situation is better or their mental 
capacity has improved. 
Motivational interviewing is suitable for people who have the capacity to change (physical, 
emotional and cognitive). It is particularly useful when the person is becoming ambivalent 
about their ATOD problems i.e. they have started to weigh up and consider what benefits 
there are as opposed to the problems they are experiencing. In other words they are 
reaching a stage whereby they are contemplating change – either giving up or cutting 
down on their drinking, smoking or other drug use. 
This interviewing technique can help to ‘move’ the person further towards their willingness 
and commitment to change. It incorporates strategies that acknowledge the good aspects 
of their ATOD use (from their perspective), as well as enhancing their ability to weigh up 
the risks and benefits, thus creating discomfort and a growing desire to commit to change. 
Getting ready to change is all part of this preparatory process.  
When motivational interviewing is helping the person to consider change they will indicate 
to the other person (e.g. nurse) that they feel they might be ready for change, and will 
start to plan how they can stop or reduce their ATOD use. During this next stage they will 
need information about, and support in, setting realistic goals and strategies (baby steps) 
and time frames for change that they can reasonably manage. They will also need to 
develop the actual skills to that will enable them to make such change, and they will need 
support from others to do this. They therefore need advice and encouragement in deciding 
who can best help them, and what community supports there are to assist. The nurse is 





Five principles of motivational interviewing 
Motivational interviewing rests upon five basic principles: 
Expression of empathy  
1. Use skilful active and reflective listening. 
• Know that ambivalence is normal—acceptance of this may facilitate change. 
• Do not label the person (e.g. ‘alcoholic’, ‘drug addict’). 
2. Deployment of discrepancy 
• Build on the person’s self-awareness of the consequences of their ATOD use. By 
• giving factual information when client raises their own concern about the 
consequences of their ATOD use (e.g. injury, arguments, lost money, ill-health, 
hangovers at work) can be powerful. 
• Consequences that conflict with their other important and desired goals favour 
willingness for change. 
• Offer advice and feedback in a way that expresses concern for their wishes and 
wellbeing can encourage a desire for change. 
3. Avoiding arguing 
• Arguments are counter-productive and will not help. 
• Focusing on the person’s own concerns and perceptions is helpful. 
• Resistance by the person is a signal to change your interview strategies. 
• The person, not the counsellor, should present any arguments for change and 
identify the actions needed to solve issues or problems (see ‘Sample questions to 
encourage self motivational statements’ below). 
4. Rolling with resistance 
• Momentum (‘going with the conversation’) can be used to good advantage 
•  The person’s perspectives can be shifted. 
• New perspectives can be invited but not imposed. 
• The clinician should not seek to ‘correct’ the person’s views. 
• The person is the most valuable resource in finding solutions to their own 
problems. 
5. Supporting self-efficacy 
• A person’s own belief and hope in the possibility of change is important in 
developing and maintaining the motivation to change. 
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• Self-efficacy is not the same as self-esteem—it impacts on the person’s beliefs 
about their ability and potential to change. 
• The person is responsible for choosing their own goals and carrying out their 
personal change. 
There is hope for people with ATOD problems to be helped through by the range of 
alternative options now available [36, 38, 50]. 
Building on the person’s self-awareness of the consequences of their ATOD use is helpful. 
Providing factual information when the person raises their concerns about their ATOD use 
(e.g. injury, arguments, lost money, ill-health, and hangovers at work) can be powerful. 
Below are two statements that reflect back to the person about their own concerns and 
perceptions: 
1. You are worried that your husband is going to leave this time you if you 
keep taking amphetamines. 
2. You said you are scared that the doctor has told you that your lung disease 
is due to your smoking. 
Finding out from the person the consequences of how their ATOD use may be conflicting 
with other important life goals (such as being fit, a good parent or worker) can help them 
to consider change. Offering advice and feedback in ways that show your concern for their 
wellbeing can encourage their desire for change. 
Avoid arguing as this is inevitably counter -productive and builds resistance. Resistance 
shown by the person is a signal that they are not yet ready to consider change (pre-
contemplative) and/or you need to change your interview strategies.  
Importantly always leave them with the belief that change is possible and help is available. 
Rolling with resistance: 
• ‘Going with the conversation’ can be helpful. 
• The person’s perspectives can be shifted. 
• New perspectives can be invited but not imposed. 
• The person, not the nurse/counsellor, needs to be able to identify and decide for 
themselves their reason for positive change; and find the actions they need to 
solve their problems. 
Supporting self-efficacy: 
• A person’s own belief and hope in the possibility of change is important in 
developing and maintaining the motivation to change. 
• Self-efficacy is not the same as self-esteem—it impacts on the person’s beliefs 
about their ability and potential to change. 
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• The person is responsible for carrying out their personal change. 
• Many people with ATOD problems want to be helped [36, 38, 51]. 
 
Sample questions to evoke self-motivational statements 
Questions for problem recognition: 
• What are the benefits of ATOD use for you (e.g. what is good about drinking)? 
• What makes you think there might be an ATOD-related problem? 
• In what ways has this actually been a problem for you? 
• What difficulties have you had in relation to your ATOD use? 
• How do you think other people might have been harmed by your use of ATOD? 
• Has your use of ATOD ever stopped you from doing something you wanted to do? 
Questions according to level of person’s concern: 
• What is there about your ATOD use that you or other people feel is concerning? 
• What worries you about your ATOD use? What might happen to you? 
• How do you feel about your current ATOD use? 
• What are the good things about it? 
• Does anything concern you? 
• How does this concern you? 
• What do you think will happen if you keep using the ATOD as you are? 
Questions regarding their intention to change: 
• Are you thinking about changing your ATOD use at the moment? 
• Why might your change your ATOD use? 
• What benefits can there be from changing your ATOD use? 
• How do you feel about this now? 
• What else could we do to help you with this problem? 
• Identifying stages of change—matching brief intervention strategy  
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Table 4: Matching stages of change to intervention strategy 
Stage Matching intervention strategy 
Pre-contemplation  
‘Happy user’, does not see 
any need for change 
Harm reduction—e.g. Thiamine for risky and binge drinkers, low alcohol 
beer when possible, provision of free condoms, provision of clean 
needles/syringes, swabs, water etc. 
Advice/information and education 
Invitation to return for further assistance 
Contemplation 
Thinking about change, 
‘unhappy user, might want 
to change but not sure 
Problem assessment 
Education/information re risks and harms 
Motivational interviewing 
Reinforcing concerns and need for change 
Harm reduction—e.g. Thiamine for risky and binge drinkers, low alcohol 
beer when possible, provision of free condoms, provision of clean 
needles/syringes, swabs, water etc. 
Advice/information 
Invitation to return for further assistance 
Determination to change 
Ready to make decisions 
Motivational interviewing  
Decision making 
Support for this decision to change 
Time and invitation to return for further assistance 
Action 
Ready to take action to 
change or has commenced 
action 
Develop an action plan 
Problem solving/goal setting—practical and achievable 
Skills identification, development and practice 
Self-help manuals 
Feedback/support 
Practicing how to manage barriers to change 
Maintenance 




Building self efficacy 
Skills rehearsal 
Support 
Information about dealing with risky situations 
Lapse and relapse 
Recommenced risky use—
once off, or more sustained 
ATOD use following making 
changes 
Support to return to goals if things go wrong 
Chance to debrief 
Problem solving 
Normalising lapse and relapse 
Information sharing 
Goal setting again 




Setting goals  
• empower the person to set their own goals/choose from their options (e.g. 
reduction in use or cessation of ATOD use) 
• provide support and encouragement for them to achieve goals 
• facilitate their action plan (e.g. follow-up appointment, referral). 
Developing skills and strategies for self-efficacy 
• Empower the person to achieve their goals through provision of: 
• support and encouragement, articulating their strengths to build self-efficacy 
• culturally appropriate and easy-to-understand information/self-help materials 
• skills and strategies for preventing and managing relapse, identifying and dealing 
with at-risk situations. 
Providing information 
Education can be offered at various levels ranging from brief easy to understand 
information to more in-depth education sessions. It is important to offer people general 
and specific health information such as good nutrition and safe medication use, as well as 
the effects and risks from ATOD use. It is also important to tailor this with a discussion 
about the person’s particular options for better health and well being. 
Providing ATOD information and other resources and facilitating the person’s access to 
more intensive support if needed, are essential aspects of helping people to reduce their 
risks from ATOD use. Naturally our nursing interventions need to reflect each person’s 
particular needs and their capacity for change. The bottom line is ensuring that a harm 
reduction strategy is in place, even if change is not at the time possible or relapse is likely 
to occur (see section on next page). 
There is a wide range of web-based and printed information and self-help booklets 
available to assist people to understand and make decisions about their managing their 
ATOD related problem.  There are also resources specifically aimed at assisting women, 
youth, Indigenous people, and other groups. Call the 24 hours ADIS advisory service on 
1300 13 13 40. 
Handy hints in suggesting resources 
Preface suggestions with phrases such as: 
• ‘This is what other people have found helpful …’ 
• ‘You are the best judge about what will assist you’. 
• ‘What do you think?’ 





The offer of follow-up indicates your concern for the person’s welfare and provides them 
with an opportunity for further support and skills development. There is evidence 
suggesting that regular medical check-ups and feedback improve the effectiveness of brief 
intervention. 
Refer when needed 
Assist or facilitate the person to self-refer to the selected service for follow-up. Provide 
resources and practical help if needed, including offering a bridge by putting them in touch 
by telephone to talk to the receiving agency while they are still with you. 
Harm reduction strategies 
Nurses and midwives can advise people about using harm reduction strategies as part of 
the delivery of early or brief intervention. This is critical where the person does not wish to 
change their ATOD use and is still using in hazardous ways.  
Some strategies include advising them to: 
• drink alcohol within low-risk levels 
• drink low alcohol drinks when possible 
• drink water or soft drinks in between drinks if bingeing 
• use alcohol or drugs in a safe place with trusted people 
• have a test dose (small amount) of illicit drugs to gauge the strength and likely 
effect before using the whole amount to avoid accidental overdose or a ‘dirty deal’ 
where the drug is contaminated with other chemicals of substances 
• ask friends or partner to always call an ambulance if you become ill or overdose 
• not mix different drugs as this increases the risk of overdose and death e.g. alcohol 
and opiates or benzodiazepines. This places them at risk of severe/adverse effects 
• maintain an otherwise healthy lifestyle—good diet, exercise, sleep etc. 
• not drive a car or boat or operate machinery, including household machines, when 
affected by ATOD 
• not get into a car or boat with a driver who has been using alcohol or other drugs 
• be informed about ATOD use by getting accurate information and accessing health 
education resources 
• use safest possible route of administration—e.g. avoid injecting but if injecting, do 
not use other people’s needles/syringes, swabs, tourniquets/belts or any other 
injecting equipment 
• use a condom when having sex. 
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(For more harm reduction strategies, see Section 3: Drug-specific information). 
Relapse prevention strategies 
• raise the person’s awareness of positives and negatives about the relapse event 
and strategies to manage next time and reinforcement of reasons for wanting 
change 
• help the person to identify  triggers for relapse and how they can manage these 
• help the person to find their coping skills to manage threats to change  
• help the person to plan how best to avoid risky situations that may trigger relapse  
• suggest that they receive alcohol/drug refusal skills training from their counsellor  
• talk to them about how they can manage cravings to avoid relapse 
• inform the person about  psycho-therapies such as cognitive restructuring (e.g. 
positive thinking; thinking ahead) that can be developed with a trained therapist  
• discuss behavioural self-management  
• help them to consider how best to preparing for lapse and relapse 
• inform the person about (if medically appropriate) pharmacotherapies e.g. 
Naltrexone, Acamprosate. 
Brief intervention and relapse prevention 
(See Section 2.3: Early and brief intervention & Appendices 4, 5, 6 and 7: ATOD use 
assessment forms, for quantification of ATOD use and definitions of hazardous and harmful 











2.4 Managing intoxication 
Introduction 
Recognising the signs of intoxication and any risk of impending overdose from 
psychoactive drugs is essential in ensuring the immediate resolution of risks to the person. 
Once the immediate problems have resolved, there may be the opportunity to provide 
them with important information about safe ATOD use and harm reduction in the future 
through early intervention. 
The use of more than one drug (poly-drug use) is common. It is therefore important to 
identify and observe for the effects of more than one drug in the intoxicated person. 
Rationale for intoxication management 
Intoxication occurs from the direct pharmacological effect of the drug on the CNS.  
Intoxication is dose-related and becomes more obvious as consumption and the blood 
level increases. Observable intoxication is mediated by the person’s neurologic tolerance 
whereby they will need a larger dose or quantity to feel (and show that they are) 
intoxicated. Nurses and midwives need to be able to correctly estimate and manage 
intoxication as it complicates general health problems and the safety and management of 
people, even when their intoxication is not life-threatening. Intoxication can be extremely 
dangerous: 
• it can mimic or mask serious illness and injuries 
• it can complicate other health problems. 
Psychoactive drugs affect mood, cognition, behaviour and physiological functioning. 
Alcohol and opioids for example are central nervous system depressants that suppress 
respiration, coughing reflex, gag reflex and cardiovascular function, thus inducing a variety 
of arrhythmias. 
Severe intoxication causes: 
• altered physical functions (e.g. depressed respiration, altered temperature 
regulation) 
• altered mental function (e.g. panic or paranoia resulting in accidental injuries or 
self-destructive behaviour) 
• acute poisoning 
• accidental overdose 
• death. 
It is essential to pay attention to a person’s complaints of e.g. a sore head, blurred vision, 
or reports of a fall or injury no matter how intoxicated they seem. People who are 
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aggressive or disruptive because they are intoxicated can risk their own safety and/or the 
safety of other people, staff, and visitors. They may also have a head injury or metabolic 
dysfunction and must still receive appropriate medical and nursing assessment and 
treatment.  
Thiamine deficiency  
Note: (See Section 3.1.1 Alcohol - Critical Situations).   
Thiamine is always administered parentally to people with a history of risky alcohol 
consumption as a prophylaxis against Wernicke’s encephalopathy.  This is best considered 
as a standing order for all risky drinkers. (See Section 3 Alcohol for Thiamine regime). 
• Any healthy adult male who drinks as a daily average, 8 or more standard drinks a 
day (e.g. 5 stubbies of full strength beer), or healthy adult female who drinks as a 
daily average, 6 or more standard drinks a day (e.g. 4 stubbies of full strength 
beer).  
• This daily average may be even less for people with nutritional deficits, young or 
older people or those with health problems such as heart disease, liver disease or 
diabetes. Intramuscular injection of thiamine can be painful, particularly if the 
person has muscle wasting. Parenteral thiamine may be preferable due to gastric 
inflammation and poor absorption from excessive drinking, it may however be 
necessary to give orally providing the person can swallow safely. 
Intravenous thiamine can be given simultaneously with glucose products – only if 
anaphylactic shock can be managed – even though risk is slight this still needs to be 
anticipated. 
For more information on thiamine and Wernicke’s encephalopathy see Section 3: Drug-
specific information – Alcohol. 
When someone is overly intoxicated with an Opioid such as morphine, codeine or heroin 
they may require Narcan to reverse the effects and prevent overdose. This can be given 
even when other drugs have been consumed.  
General principles of intoxication management 
• Any intoxicated person is at risk of aspiration and asphyxiation due to vomiting at a 
time of diminishing consciousness, whether or not there are overt signs of injury. 
• All intoxicated people are at risk of and should be monitored for poisoning and 
overdose. 
• All intoxicated people must be kept under observation until their intoxication 
diminishes and they can safely manage their environment. 
• All intoxicated people with a low blood alcohol/breath alcohol reading but whom 
appear grossly intoxicated must be assumed to have either consumed other drugs, 
sustained a head injury or have another severe illness. 
64 
 
• Thorough physical and mental status examinations need to be conducted to reveal 
the level of intoxication. 
• If the intoxication does not diminish with falling serum alcohol/drug levels, the 
person must be assessed for other possible causes of their condition. People who 
appear intoxicated may be suffering other conditions. 
 
• Maintenance of the airway is of paramount importance to the semi-conscious or 
fully comatose person. 
• People who have stabilised after being intoxicated should be further assessed for 
any possibility of withdrawal—early identification and intervention of withdrawal 
can prevent complications which may be life threatening (see withdrawal sections 
appropriate to the specific drug). 
• Alcohol withdrawal can occur before a zero blood alcohol reading. 
• Any person presenting with seizures should be assessed for alcohol withdrawal, 
benzodiazepine withdrawal or stimulant intoxication, as well as other possible 
causes. Withdrawal seizures must be treated according to best practice, with the 
person observed for at least four hours post seizure, using the Glasgow coma scale 
score (See Appendix 3). 
Identification of hazardous drug use 
A person’s physiological and behavioural reaction to a drug depends on the: 
• characteristics of the individual 
(e.g. age, size, gender, health 
state, mood etc.) 
• pharmacokinetics of drug/s used 
• side effects or unwanted effects 
of the drug/s used 
• one drug is used in combination 
with other substances including 
medicines, inhalants, herbal 
preparations 
• pharmacology of the drug/s used 
• how much (dose) of the drug/s 
taken 
• the setting in which the drug/s 
used 





Table 5: Symptoms & effects of drugs 





























tins, cans, bottles, 
flasks nearby 
smell of alcohol 
vomit on 
shoes/clothes 
alcohol-related injuries (e.g. 
falls, fights, pedestrian 
injuries) 
drink-driving 





risks increase if used with 






































and other spray 
paint 
smell of solvent 
used 
 
long-term damage to health 
(liver, kidney, brain 
damage) 
sudden sniffing death 
syndrome 
asphyxiation (swelling of 
throat) 
risks increase if used with 
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syrup and vials  
overdose 
withdrawal (nausea, pain 
cramps, diarrhoea, 
irritability, dilated pupils) 
impact of unsafe injecting, 
e.g: HIV, hepatitis B/C 
pericarditis 
abscesses 




































evidence of lack 
of sleep 
poor nutrition 
loss of weight  
hallucinations 
drug induced psychosis 
depression and suicidal 
ideation following 
withdrawal 
exacerbation of mental 
illness 
withdrawal (excessive sleep, 
irritability) 
impact of unsafe injecting: 




























be kept away 
from light and 
wrapped in foil 
risk of self-harm 
injuries/falls 
unpredictable behaviour 
may predispose mental 
illness 
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be sold as 
ecstasy but 
contains speed, 
PMA or GBH  
increased 
energy 






























white, but may 
be coloured with 
motif stamped 
onto one side of 
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all adverse effects and 
negative consequences as yet 
unknown. 
can occur with short term use 
Ketamine 
Common street 


















flashbacks similar to those 










































delusions and violent 
behaviour 
can lead to collapsed veins or 
skin ulcers at the injection 
site 
ulceration and permanent 
damage to mucosa of nasal 
passage if snorted 
[15, 52]  
68 
 
Screening for alcohol and other drug use 
The presence of a drug or its metabolites in a person’s blood or urine helps to corroborate 
the ATOD assessment findings and clinical symptoms. This is especially important in the 
following situations: 
• people who are unable to give a coherent history 
• people who cannot or do not wish to reveal their drug use 
• people with atypical reaction to drugs 
• people whose absorption, metabolic or excretory functions have been impaired by 
drug use or other diseases 
• people who have consumed unknown drugs and quantities of drugs (e.g. with 
drink-spiking). 
Alcohol levels are measured by breath analysis or blood sample. Other drugs are usually 
measured by urine sample. Timeliness of urine sampling is important due to the short 
duration of possible detect ability of some drugs. It is important to note: 
• Drug concentrations in urine do not accurately reflect drug concentrations in 
blood. 
• Only drug concentrations in blood provide an accurate measure of drug effect. 
• Positive urine results indicate recent drug use [53].  
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Table 6: Duration of detectable drugs in urine  
Substance Duration of detect ability 
Alcohol 12-24 hrs  
Amphetamines 48-72 hrs 
Methamphetamine 48 hrs 
Barbiturates 
  short-acting 




Benzodiazepines Up to 1-2 weeks 
Cocaine 48-72 hrs 
Chronic use— up to 4 weeks 
Lysergicacid di-ethylamide (LSD) Up to one week 
Methadone 3-5 days 
Opioids (codeine/morphine/heroin) 2-4 days 
Cannabis (marijuana) Infrequent user— up to 10 days 
Chronic user 7-30 days or more 
Propoxyphene 2-3 days 
Phencyclidine (PCP) Up to 2 weeks 
[15, 54] 
Nursing guidelines—intoxication assessment 
• Take an ATOD use history on admission (see Appendix 3, 4, 5 and 6: Taking a 
drinking history). Ask about today’s use and time of last drink or drug dose. This 
must be recorded and reported to MO. 
• Measure breath alcohol concentration (BAC) if appropriate and record. 
• Observe vital signs (temperature, pulse, blood pressure, respiration). 
• Refer to the physical examination by the medical officer  
o including pupils; widely dilated or pinpointed, ataxia/gait, coordination, 
impaired reflexes, collapsed and unable to walk, etc. 
• If an alcohol and other drug use history cannot be obtained from the person, try to 
determine the type of drug/s used, how much was used and when last used by 
asking another person accompanying the person. Always observe for signs of 
impending overdose or poisoning (see Section 2.5: Managing overdose). 
• Observe for signs of drug use such as puncture marks, cellulitis, phlebitis, skin 
abscesses, nasal erosion, irritation or rash around nostrils, septum or mouth, 
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evidence of rectal damage, dehydration, rapid weight loss. 
• Consider conditions other than intoxication  
o e.g. head injury, acute infection, electrolyte imbalance, CVA, 
hypoglycaemia, psychosis, severe liver disease etc, vomiting, incontinence. 
• Skin colour and condition  
o e.g. pale, sweaty, flushed. 
• Speech—faster, slower, slurred, unintelligible. 
• Record observations. 
Refer to the mental status examination which should assess the following: 
• any confusion  
• attention span  
• memory – short and long term 
• mood (e.g. any sudden changes) 
• speech (e.g. audibility pace is calm 
or rapid) 
• paranoia (e.g. uncalled for 
suspicion) 
• capacity for appropriate decision 
making 
• level of consciousness 
• orientation 
• judgement—accurate or poor 
• behaviour (e.g. sudden changes e.g. 
happy to very sad or angry) 
• comprehension (e.g. understanding 
conversation and situation 
• abnormality of perception (e.g. 
hallucinations). 
The initial assessment of an intoxicated person who may be at risk of overdose needs to 
take into account any factors that may lead to suspicion of head injury: 
• person (or companion) tells you they are injured or in pain 
• history of a fall, no matter how long ago or how minor (there may be no obvious 
signs of injury) 
• visual disturbances 
• headache 
• irritability 
• limb weakness 
• personality change 
• aggression 
• moods swings 
• failing responses to external stimuli.  
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If assessment indicates intoxication: 
• Maintain airway and monitor signs frequently. 
• Continue monitoring the person’s physical and mental state. 
• Ensure the medical officer is aware of the person’s status. 
Note: vomiting is likely to occur in the grossly intoxicated person. This can present a major 
problem in semiconscious or unconscious people. 
Checking for causes other than intoxication 
People who appear to be intoxicated may be experiencing conditions due to other causes. 
Intoxicated people often present with additional problems such as fractures, trauma, 
lacerations, other illnesses etc. 
Nurses and midwives need to always consider and investigate the possibility of an 
underlying illness. If an apparently intoxicated person cannot easily walk, stand or get up 
from a chair, you must keep them for observation, regardless of the lack of obvious injury. 
Any person who presents as incoherent, disoriented or drowsy should be treated as having 
a head injury until proven otherwise.  
The following conditions can mask or mimic signs of intoxication: 
• infection 
• respiratory disease, hypoxia 
• acute psychotic state (e.g. 
schizophrenia) 
• epilepsy (temporal lobe), postictal 
• alcohol/drug withdrawal 
• shock due to injuries 
• hyperthermia (e.g. risk of 
rhabdomyolosis)  
• early signs of cerebral vascular 
accident (CVA) or transient 
ischaemic attack (TIA) 
• semi-consciousness or coma 
• head injury, subdural haematoma 
• diabetes (e.g. confusion due to 
hypoglycaemia or ketoacidosis) 
• drug toxicity (Dilantin, Digoxin) 
and/or side effects of other 
prescribed drugs 
• meningitis - encephalopathy 







Supportive care will most often prevent an intoxicated person from becoming upset or 
frightened and/or disrupting other people, staff and visitors. 
Supportive care also plays a major role in the safe and effective management of people 
who are intoxicated, and their environment to prevent accidents and trauma while in your 
care. 
What to do 
• Approach the person in a quiet, consistent, friendly and respectful manner. 
Patronising and authoritarian attitudes may evoke anger and result in an 
aggressive response—this is a common response to threats to dignity and self-
respect. 
• If the person is accompanied by friends who are also intoxicated, ask them to wait 
outside the room. 
• Provide the person with a seat in an uncluttered, quiet part of the room. 
• The nurse must introduce him/herself, giving their name and role. 
• Ask the client’s name. Orient the person and establish rapport, inform the person 
where they are and what is happening. 
• Only ask specific questions about the presenting illness or injury. 
• Elicit information—do not rely on the person to volunteer it. Ask sober family 
member or friend if available.  
• When possible, postpone questions or procedures that antagonise the person. 
• Give simple information/messages as required taking care to avoid information 
overload. 
• Repeat information if necessary. 
• When instructing the person or seeking their cooperation, give clear, concrete 
instructions. If necessary, repeat slowly. Also guide them to and from their 
destination, hand them things, etc. 
• Reduce the possibility of accidents. 
When talking to the person: 
• use slow, distinct speech if English is not their first language they may revert to 
their first language while intoxicated—they may need an interpreter  
• use short, simple sentences 
• avoid emotional topics and involved discussions 
• maintain eye contact if appropriate 
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• use the person’s name, e.g. Mr …  
• adjust pace of talking to match the person’s. 
The nurse needs to notify other staff that he/she is dealing with an intoxicated person and 
ensure safe procedures for managing any challenging behaviours that may develop. Work 
with other staff to manage verbal or physical aggression; ask other staff for their support at 
the time and opportunity for debriefing immediately after any incident. Seek further 
counselling if needed. 
Managing unwanted behaviours 
Some specific ATOD-induced behavioural problems stem from CNS confusion and other 
drug induced effects, much like any other acute brain condition where a person’s 
perception, cognition, communication abilities and impulse control are diminished. Many 
such situations can be prevented and managed well by nurses who use particular 
approaches as listed below.  
Anxiety/agitation/panic 
• approach the person in a quiet, calm and confident manner 
• stand beside them rather than front on and do not appear aggressive 
• move and speak in an unhurried way 
• minimise the number of staff attending to the person 
• always explain who you are and what you are doing 
• provide a quiet environment to reduce unnecessary CNS stimulation 
• reassure the person frequently (e.g. ‘it won’t take much longer,’ ‘I am just going to 
do … because ...’) 
• remain with the person to calm him or her down 
• explain any actions or interventions needed no matter how simple (e.g. moving the 
pillow; taking TPR) 
• protect the person from accidental harm (e.g. do not leave them unattended on a 
barouche or bed without safeguards. lower the bed as close to the floor as 
possible) 






• provide frequent reality orientation 
• reduce amount of unnecessary equipment nearby 
• reduce amount of unnecessary noise 
• use/display some object familiar to the person (e.g. dressing gown, slippers) 
• ensure frequent supervision 
• accompany the person to and from places (e.g. bathroom, lounge) 
• explain in simple terms what is happening. 
• explain altered perception/hallucinations 
• explain their perceptual errors; tell them what is real (e.g. that the curtain does not 
have snakes on it) 
• reassure that this will pass 
• create a simple, uncluttered environment 
• provide care in well-lit surroundings to avoid perceptual ambiguities from poor 
light 
• protect person from harm. 
Anger/aggression 
• use space for self-protection (e.g. ensure you have easy access to the open door; 
do not crowd the person; keep furniture between yourself and the person if 
feeling unsafe etc.) 
• keep own emotions in check 
• speak in a calm, reassuring way and do not raise your voice 
• use the person’s proper name when speaking to them 
• do not challenge or threaten the person by tone of voice, eyes or body language 
• let the person air their feelings and acknowledge them 
• work in pairs if you feel at risk 
• determine the source of the person’s anger and if possible, remove it 
• be flexible within reason 
• be aware of workplace policies on managing aggression 
• work in pairs where at all possible and keep yourself safe at all times  




• At times staff may feel stressed dealing with people with ATOD problems and 
whose behaviour is difficult or threatening. Staff debriefing on the ward—either 
formal or informal—should be available as part of day to day practice. Referral to 
an employee assistance program (EAP) may be needed for those who need 
support away from the workplace. 
If a person refuses treatment 
• If a person who is intoxicated or withdrawing from ATOD wants to leave the 
hospital and they are assessed medical to be unsafe to leave, you need to exercise 
your duty of care to ensure their safety and wellbeing, and that of other people.  
• Refer to and be familiar with the relevant legislation as well as organisational 
policy and procedures manual of your health facility to determine the appropriate 
course of action.  
• Consult MO and senior staff.  
• Record all actions and note times.  
• The person may need to be admitted or detained under the Mental Health Act or 
other legislation in your state or territory, until they are deemed medically safe 
and able to care for themselves safely and not cause harm to other people. 
For further information on intoxication, refer to Section 3: Drug-specific information. 
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2.5 Managing overdose 
Introduction 
Overdose can be by accident or as a result of deliberate self-harm.  
Any person who presents as incoherent, disoriented or drowsy should be treated as having 
a cerebral event (head injury) until proven otherwise. Overdoses should be managed 
according to the individual policy of each hospital. (For information on overdose please go 
to individual drugs in Section 3: Drug-specific information). 
Note:  Acute poisoning and acute withdrawal can have common features. 
• Those with a high alcohol tolerance may experience withdrawal while their blood 
alcohol concentration is still positive and above zero. 
• Accidental overdose is a high risk when a person has used more than one 
depressant drug. 
• Risky of binge drinkers may overdose from high intake of alcohol or having used 
other drugs in combination with alcohol. 
• Inexperienced drinkers or drug users (e.g. children and adolescents) can overdose 
from excessive doses of alcohol or another drug due to low tolerance. 
Rationale for overdose management 
• Overdose occurs when a person has consumed a dose of a drug that alters the 
ability of the central nervous system to maintain respiration and other vital bodily 
functions. This can occur when more of the drug has been used in one dose than 
would usually be recommended as a safe therapeutic dose or as a high dose 
exceeding the person’s acquired CNS tolerance. 
• All people who present with decreasing or diminished level of consciousness must 
have careful and appropriate monitoring of all vital signs and neurological function. 
The Glasgow coma scale (see Appendix 6) and vital signs provide the best method 
of assessment. These observations must be done on arrival, after checking airway, 
breathing and circulation, and should be continued at a maximum of 15-minute 
intervals for at least four hours. 
• With the use of the Glasgow coma scale (GCS) and monitoring of vital signs, the 
nurse can quickly recognise any deterioration in the person’s condition and 
intervene at the earliest possible time. 
• If the condition rapidly deteriorates, which is always a risk, usual nursing 
intervention is followed. 
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Nursing guidelines—overdose assessment 
(See Section 3: Drug-specific information). 
Monitoring possible progression of intoxication to overdose 
Careful monitoring of the person enables early identification and intervention at risk of 
impending overdose. To observe for progression to an overdose state, monitor the 
following: 
• increasing agitation or sedation 
• changing mental state—hallucinations, panic or deep depression 
• abnormal pulse (irregular, below 60 or above 120 per minute) 
• breathing difficulties 
• decreasing levels of consciousness 
• seizures 
• increasing disorientation 
• diminished response to stimuli. 
Please note the need to: 
• evaluate risk of self-harm 
• remove any medicines, alcohol, other drugs or substances (e.g. solvents) that could 
be ingested by the person. 
Identify type of drug and dose 
If the person has a sample of the drug recently used with them this can greatly assist with 
correct identification of the drug. 
Note: For assistance with identification of the drug, check The Australian Drug 
Compendium or Poisons Information Service, or ask the nearest medical staff, general 
practitioner or pharmacist. If a non-pharmaceutical drug has been used: 
• check the label on container (e.g. aerosol can) 
• ask the poisons information service in your state  
• ask any relevant government agency (e.g. agriculture, mining)  
• ask the manufacturer. 
Collect urine sample (as soon as possible) to: 
• identify type of drug/s used and confirm actual ingestion of that drug/s 




Collect blood sample for: 
• presence of drug/s 
• blood alcohol level  
• serum drug levels. 
Other concerns: 
• history of ingestion of foreign substance 
• medical history (e.g. epilepsy, diabetes). 
Identifying people at risk of overdose 
People in this category must be identified and assessed for need for: 
• urgent urine screening 
• specific antidotes 
• haemodialysis. 
Guide for ‘dangerous’ classification: 
• unusual overdoses 
• paracetamol 
• unusual drug combinations 
• overwhelming overdoses. 
Significant overdoses of the following: 
• ethyl or methyl alcohol 
• opiates/opioids  
• sedatives 





• quinine and quinidine 
• iron salts 
• heavy metals 
• cyanide.  
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Nursing management of overdose 
A standard approach should be used for management of all overdose situations.  
Alcohol intoxicated people may have ingested other substances that may complicate and 
compromise their condition further. There may also be underlying pathology. All these 
factors must be considered. 
Signs  
Measure and observe the following and manage according to best practice: 
• hypotension 
• bradycardia/tachycardia/arrhythmias 




To be initiated with the following guidelines as routine practice: 
• do not give food or fluids 
• keep the person calm, if awake, and quiet as excessive movement may enhance 
rapid absorption of alcohol and other drugs. 
Be alert and manage the following conditions according to best practice: 
• slowing respiration  
• respiratory depression or failure 
• airway obstruction 
• bronchospasm 
• acidosis 
• aspiration   
• pulmonary or cerebral oedema  
• haemorrhagic conditions  
• hypoglycaemia  
• hyper/hypokalaemia  




Potentially lethal overdoses 
People who have had a potentially lethal overdose must be identified and assessed as early 
as possible for any need for: 
• urgent urine screening if and where possible 
• specific antidotes 
• haemodialysis. 
Any person presenting with seizures should be assessed for alcohol withdrawal as well as 
other causes. The seizures must be investigated and treated according to best practice. The 
person must be observed and monitored for at least four hours after seizure, incorporating 
Glasgow coma scale (GCS) score. 
Unconscious people 
Head injuries, CVA, overdose and intoxication must all be taken into consideration when 
assessing all unconscious people. Thorough assessment, early recognition and intervention 
are vitally important. Remember that treating people with respect is a priority and that 
seemingly unconscious people may be aware of what is being said. 
Poisoning must be suspected in all people who present unconscious or with decreasing 
level of consciousness. The priority of care is as follows: 
Airway management: clear airway e.g. vomit, mucous and remove ill fitting dentures. 
Position head (head tilt/jaw thrust position). Have suction available. In trauma, be aware of 
possible spinal injury. 
Breathing: if clearing airway does not stimulate spontaneous respiration, commence 
manual ventilation with high flow oxygen and air viva with Guedel’s airway in situ.  
Circulation: cannulation for blood sampling, drug access and fluid replacement may be 
required. 
Medical management 
(For medical management see Section 3). 
All people with a depressed or altered level of consciousness must have frequent regular 
monitoring of vital signs. This is best achieved by using the Glasgow coma scale in 
conjunction with vital signs including respirations, temperature, blood pressure and pulse. 
In the unconscious person axillary temperature should be taken. An indwelling catheter 
should be inserted to monitor urine output. Collect urine for drug screen. 
Presume that any person who is unresponsive has a full stomach. Therefore suction should 
always be available; if not, place in coma position and monitor closely.  
• Electro-cardiograph, x-rays, etc. can be done after basic observations and 




Brief Intervention and relapse prevention for people recovering from overdose 
Once recovered and when appropriate consider offering Brief intervention and relapse 
prevention advice and information on services.  
Brief intervention may be undertaken once the acute overdose episode has resolved and 
the person is willing and able to discuss and understand the information they are given. 
The focus should be on preventing any reoccurrence of an overdose situation and 
strategies for harm reduction if drug use is likely to continue. 
(See Section 1.2 Harm reduction – 2.3: Early and brief intervention and the section(s) 
related to the specific drug for further harm reduction strategies). 
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2.6 Managing withdrawal 
Introduction 
The severity of withdrawal symptoms is not clearly or directly related to the quantity of 
drugs previously consumed and where physical tolerance has occurred. When assessing for 
withdrawal and for the purpose of dose titration for clinical management, it is necessary to 
estimate the time of last drink or dose, as well as placing clinical judgement on the likely 
onset and severity of withdrawal based on previous history and/or observable clinical 
signs. It is not useful to rely on the subjective symptoms reported by the person or 
family/friend present. 
Effective clinical monitoring and management of withdrawal in its early stages can greatly 
reduce or prevent the progression to complicated withdrawal that may be life-threatening 
due to accidental injury, dehydration, electrolyte imbalance, seizures, delirium tremens or 
the negative impact on other concurrent disorders including acute infection, renal disease 
or diabetes. 
In the management of withdrawal, it is crucial to select the appropriate withdrawal 
symptoms monitoring scale as indicated by the person’s recent ATOD use history. 
The management of particular withdrawal syndromes associated with specific ATOD’s is 
detailed in Section 3: Drug-specific information. Relevant ‘gold standard’ tools are included 
and available as Appendices.  
Rationale for withdrawal management 
Withdrawal symptoms can range in severity from mildly uncomfortable to life-threatening. 
Some people withdraw from ATOD without the aid of medication and may only need 
support and encouragement. Others, especially those with a history of long-term harmful 
alcohol or benzodiazepine use, can experience serious withdrawal complications (e.g. 
benzodiazepine or alcohol withdrawal-induced seizures) and will require appropriate 
medication and nursing supervision. 
It is best to assume that any person who has consumed alcohol and other drugs excessively 
on a daily basis over a significant period of time (weeks) can experience some withdrawal 
symptoms on ceasing or reducing their intake. Severity of withdrawal symptoms can differ 
depending on the person, the drug(s) used, duration of use, past experience of withdrawal, 
other psychological and physical conditions (e.g. nutrition, hydration) and acute or chronic 
illness.  
Drugs with short half-lives, such as alcohol or heroin, will give rise to withdrawal symptoms 
at an earlier phase after the last dose, and the symptoms will peak and fade faster than 




General principles of withdrawal management 
The approach taken to managing withdrawal will depend on whether the person is 
specifically admitted to hospital or the clinic for their withdrawal management, or they 
incidentally experience withdrawal as a result of admission for another illness or injury. In 
either situation, it is always important to know if the person has a history of severe 
withdrawal, such as seizures or delirium tremens (DTs). 
Managing anxiety is essential to the effective management of any withdrawal state. The 
basis of all successful withdrawal management is a clear and accurate ATOD use 
assessment with immediate attention to last dose and time taken.  
Nursing management of withdrawal focuses on these main areas: 
• assessment and early recognition 
• monitoring, documenting and reporting  
• preventing withdrawal complications where possible 
• minimising progression to severe withdrawal 
• decreasing risks of any injury to self/others 
• eliminating any risk of dehydration, electrolyte or nutritional imbalance 
• reducing any risk of seizures 
• identifying concurrent illness that masks/mimic or complicate withdrawal 
• providing supportive care 




Nursing guidelines—withdrawal management 
Assessment and early recognition of withdrawal 
A withdrawal syndrome always develops progressively after cessation or rapid reduction in 
alcohol or other drug use. Therefore, history taking and assessment, ongoing monitoring, 
early recognition and prompt management of the initial (and milder) withdrawal state can 
prevent progression to more severe stages and complications. See Appendices 9 – 13 for 
withdrawal observation tools and Appendix 14 for the neonatal abstinence syndrome tool. 
The basis of all successful withdrawal management is a clear and accurate alcohol and 
other drug use assessment. If the assessment (see Section 2.2 Assessment) has not been 
completed accurately, withdrawal may not be anticipated and therefore managed 
effectively. A clear assessment will point to the possibility of withdrawal, allowing the 
nurse to plan the person’s care. For each of the following potential problem areas there 
are specific management goals and actions nurses need to take to achieve the goal. A 
consistent approach is very important. The following is a suggested nursing care plan for 
managing withdrawal. 
Nursing care plan—minimising risk of severe withdrawal 
Nursing management goals: 
• prevent withdrawal complications 
• identify any change in the persons clinical condition early 
• if change occurs provide rapid, appropriate interventions. 
Nursing actions: 
• assess, monitor and predict  
• reassure and take a supportive approach 
• monitor withdrawal symptoms, document observations based on validated 
withdrawal scale 
• intervene during mild state of withdrawal (e.g. relaxation, reassurance, 
medications as prescribed) 
• explain effects of withdrawal medication (e.g. diazepam) to the person 
• administer medication strictly as prescribed and assess effectiveness (do not 
withhold medication unless complications arise) 
• monitor and evaluate effectiveness of nursing interventions 
• document and report outcomes 
• provide self-help information for withdrawal period 
• maintain hydration, nutrition, hygiene, physical safety. 
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Decreasing risk of injury or self-destructive behaviour 
Nursing management goals: 
• allow the person to move freely if safe and able to do so 
• maintain safety at all times 
• maintain privacy and dignity. 
Nursing actions: 
• assess fine and gross motor coordination, stability and orientation 
• assist with daily tasks for self-care where necessary 
• help person to express his or her feelings, allow them to talk about their emotional 
experiences, concerns and issues 
• maintain a well-lit, uncluttered environment 
• ensure safety by removing dangerous objects (e.g. chairs, vases, heavy objects, 
razor blades, knives etc.) and assess for suicidal ideation—if this is indicated, 
facilitate a quick referral to the psychiatric team 
• supervise closely—the person may need to be restricted to a supervised area. 
Eliminate risk of dehydration, electrolyte and nutritional imbalance 
Nursing management goals: 
• maintain adequate hydration 
• maintain Thiamine and essential nutritional intake 
• maintain body weight. 
Note: Thiamine (Vit B1) should be given to all at risk drinkers (See Section 3.1.1 – Alcohol – 
Critical situations). 
Nursing actions: 
Thiamine (Vit B1) should be given prior to glucose loading (See section 3.1.1 – Alcohol – 
Critical situations).  Coagulopathy may render intramuscular injection unsafe. Resuscitation 
equipment should be immediately available when Thiamine is given IV, in the unlikely 
event of anaphylaxis [55]. 
• assess and record nutritional intake, fluid intake and output 
• encourage and assist adequate fluid intake and nutrition 
• administer other vitamins and fluids as ordered 
• monitor blood pressure, temperature, pulse and respirations 
• monitor any nausea or vomiting and administer anti-emetics as ordered 
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• monitor any tremor of hands, limbs, tongue. 
• Reduce potential for seizure 
Nursing management goals: 
• prevent seizures 
• maintain safety. 
Nursing actions: 
• assess and monitor withdrawal status regularly  
• observe best practice guidelines for seizure prophylaxis 
• administer medication as ordered. 
Identify presence of concurrent illness that mask or mimic withdrawal 
Nursing management goals: 
• exclude conditions that may mimic/mask withdrawal (e.g. hypoglycaemia) 
• treat concurrent medical and psychological conditions as required. 
Nursing actions: 
• take adequate history 
• monitor and respond to withdrawal state and concurrent condition 
• follow procedures relating to other conditions including those detailed in section 
2.4 Managing intoxication. 
• administer medications as ordered. 
Provide supportive care 
Nursing management: 
• explain to the person what is happening and that you are there to look after them 
• allay and lessen anxiety, agitation, confusion, disorientation, hallucinations, anger 
or fears of not having needs met, and maintain personal comfort 
• encourage and support the person to complete their withdrawal episode. 
Nursing actions: 
If showing signs of anxiety, agitation, panic: 
• approach in a calm, friendly and open manner 
• always introduce self 
• always explain any nursing actions required 
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• spend time with the person to establish rapport 
• move and speak in unhurried way 
• provide support and encouragement 
• minimise the number of staff attending to the person 
• reinforce goals related to the admission 
• decrease stimulation by providing quiet and uncluttered environment 
• give the person the opportunity to discuss feelings/concerns 
• provide frequent reassurance 
• show interest/empathy in person’s welfare and health 
• remain with the person to calm him/her down 
• seek input regarding their comfort level and needs 
• explain any medical or nursing interventions 
• provide information on self-help strategies 
• protect from accidental harm (e.g. do not leave unattended on a trolley or bed 
without safeguards) 
• offer activities such as relaxation, warm bath, soft music. 
If showing signs of anger or aggression: 
• determine the source of anger 
• defuse the situation 
• let the person air their feelings, acknowledge them 
• address the person by their proper name 
• keep your own emotions in check, speak in a calm, reassuring way 
• use space to protect yourself 
• do not challenge or threaten by the tone of your voice, eyes or posture 
• be reasonably flexible, keep in mind own safety and that of others. 
Signs of confusion or disorientation: 
• confusion, disorientation, altered perception or hallucinations may indicate 
progression to severe withdrawal (associated particularly with alcohol withdrawal) 




If there is an emergence or exacerbation of these symptoms in a person who is not 
intoxicated, an urgent medical review is warranted:  
• provide information on place, time and day regularly to the person 
• offer reassurance 
• remove any unnecessary equipment, restrictive clothing, bed linen 
• use/display object(s) familiar to the person (e.g. their own slippers, dressing gown) 
• ensure safety by frequent supervision and safeguards such as padded cot sides, 
lower bed as far as possible 
• walk with the person to and from the bathroom, lounge, etc. 
With altered perception/hallucinations: 
• explain perceptual errors and provide reassurance 
• create a simple and uncluttered environment 
• nurse in well-lit/evenly lit surroundings to avoid perceptual ambiguities, and take 
care with night lighting to avoid shadows 
• explain any procedures you need to do  
• protect from harm. 
More detailed information about nursing management of withdrawal from ATOD may be 
obtained by phoning the local alcohol and drug information service (ADIS) in your state. 
Brief intervention and relapse prevention 
(See Section 2.3: Early and brief intervention). 
Preparation for discharge follow-up and referral 
Nursing management: 
• plan for discharge and ensure the person is aware of, and can choose from, the 
range of services/support available 
• where appropriate involve the person’s family in their after care plan and 
discharge  
Nursing actions: 
• effective management and support may influence a person’s successful 
completion of withdrawal and their decisions to engage in further interventions or 
activities to cease or reduce their ATOD use, and any harms associated with their 
use 
• advise the person that withdrawal may be an initial ‘milestone’ in encouraging the 
person to change their harmful ATOD use 
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• education about harmful ATOD use and withdrawal can support this change 
• person needs to be encouraged to use self-management strategies (e.g. relaxation, 
sleep management, defocusing from craving to other activity) that were 
introduced in the acute phase of withdrawal. These may assist in alleviating any 
ongoing withdrawal symptoms and craving that can persist for weeks or months 
• determining the person’s longer-term goals will guide the clinicians caring for them 
in what information might assist the person to make their choices relating to any 
future goals in reducing or ceasing their ATOD use. Their goal may be abstinence, 
methadone maintenance or controlled use 
• providing the person with information about the services available to them 
following discharge, such as methadone (pharmacotherapy) maintenance, can 
assist them in achieving their goal, such as future abstinence through 
pharmacotherapy  
• providing access to supportive counselling can assist the person with achieving 
their short and long-term goals  
• assisting the person to engage in self-help and community groups, such as Alcohol 
Anonymous (AA) or Narcotics Anonymous (NA), who can provide free and 
accessible support for the person to achieve their goals and re-integrate into the 
community. ALANON and ALATEEN are available for family members and young 
people. 
• providing referral to residential rehabilitation programs that can assist the person 
to achieve abstinence  
• providing the person with information and assistance to make follow-up 
appointments will help them to engage with services that can help them resolve 
their problems and achieve their goals for change. 
Maternal and neonatal care 
Midwives and nurses can be challenged at times in how best to care for pregnant women 
who use alcohol, tobacco and other drugs such as heroin or other opioids (for specific drug 
information (see Section 3). 
Attracting and maintaining pregnant women in drug treatment and maternity services is 
vital for them and their babies.  Being non-judgemental and offering reassurance and 
support is always the best approach. This will help the midwife and other staff to develop 
rapport and trust and optimise the health and well being of the woman and her baby. We 
know that: 
• Drugs and pregnancy outcomes of women engaged with a specialist perinatal 
outreach addictions service have better general health themselves as well as 
healthier babies, even if they are still using illicit drugs [56-58]. 
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• Engaging the woman’s partner/family is a very important aspect of enabling the 
woman to manage her ATOD use issues and general health and achieve optimal 
progress at the earliest possible stage in her pregnancy. 
The key aims in caring for the woman and her baby are to: 
• ensure that she and her family feel welcome and not judged by nurses, midwives 
and other staff, and that she knows her antenatal care and drug use will be 
managed effectively  
• encourage her to cease ATOD use with guidance, and if necessary specialist 
support/treatment such as methadone for opioid dependence, so as to achieve 
maximum health and wellbeing for her and her developing baby  
• ensure effective coordination of  maternal and family care between all relevant 
services (midwife /doctor and specialist A&OD team) and other parties  
• care planning meeting (with consent) with the woman (and partner/family if 
appropriate) as early as possible in her pregnancy  
• ensure contingency plans and strategies are in place to prevent and intervene early 
in any health or social ‘crises’ along the way.  
The woman, (and if she wishes her partner/family) should be informed about all clinical 
meetings and invited to attend. 
These meetings should include: 
• the woman (and partner /family as appropriate)   
• relevant case worker, medical, maternity, neonatal, ATOD, MH and social work 
staff. 
The case worker or team should help the woman to: 
• identify problems, educate and help her to set goals 
• receive psychosocial support and access to community resources and network. 
Assessing ATOD use in pregnancy (see Section 3 for specific drug assessment)  
It is essential to know the woman’s: 
• pattern of ATOD use  (include tobacco, over-the-counter (OTC) and other 
pharmaceuticals, herbals, inhalants etc)  
• current and recent past e.g. last 12 months 
• frequency of use e.g. multiple times/day, daily, every two or three days, weekly, 
monthly, occasional, binges  
• quantify doses or $ amount used  
• time & date of last use/dose/s 
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• route/s of administration (swallowed liquid or tablet; topical gel or patch; sniffed; 
smoked/inhaled; injected)  
• risks e.g. sharing injecting equipment, unsafe sex, driving vehicle when intoxicated 
• any known allergies and medical conditions. 
Possible complications during pregnancy  
(See Section 3 for specific drug information). 
Uncontrolled use of ATODs in pregnancy can lead to complications such as: 
• Low birth weight and premature labour.  
• Abrupto placentae, spontaneous abortion, intrauterine death, intrauterine growth 
retardation, foetal distress, meconium aspiration and neonatal jaundice.  
• Blood-borne viral infection from unsafe injecting can result in maternal infection 
and vertical transmission to her baby (see Section 1). 
• ATOD withdrawal during pregnancy carrying serious risk of miscarriage or stillbirth, 
particularly if withdrawal is sudden.  
• Importantly alcohol withdrawal carries significant risk for the woman as well as 
foetus. Any pregnant woman at risk of withdrawal needs to be cared for in hospital 
to ensure her withdrawal is managed safely and that any obstetric complications 
are prevented and treated (see Section 3).  
General health 
Health problems can occur during pregnancy, and need to be discussed as early as possible 
with the woman. Her physical and mental health should be monitored and reviewed 
throughout her pregnancy, and include: 
• injury (e.g. from domestic violence, episodes of intoxication, falls etc.) 
• dental problems (e.g. caries and oral infections) 
• poor nutrition e.g. Thiamine deficiency, anaemia, malnutrition, gestational 
diabetes etc. 
• acute and chronic bacterial or viral infections including those acquired through 
unsafe injecting  
• depression, anxiety including Post Traumatic Stress Disorder (PTSD). 
Any of the above and other health issues can increase the risk of obstetric complications 
and premature delivery.  
It is important that the woman’s general health is therefore regularly checked and in 
addition to usual monitoring should include a review of general nutrition, any risk of 
anaemia, dental hygiene and complications from acute or chronic infections such as 
bacterial and blood borne viruses. 
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Pregnant women with ATOD problems should be advised of the benefits of well 
coordinated care between their GP or drug treatment and maternity service as this will 
offer them best possible outcomes. 
In a ‘nutshell’: 
• Pregnant women who use ATOD’s can do well given effective clinical, social and 
emotional support. 
• Women need non judgemental, well coordinated care from their midwife, nurse, 
treating doctor (GP or drug treatment service) and obstetric staff. 
• Partners and trusted family members should be included according to a woman’s 
needs and wishes. 
• A sound care plan needs to be developed by the treating teams in collaboration 
with the woman (and parent/family) at the earliest possible time in the pregnancy. 
• Consideration of the woman’s changing needs and possible crises ‘along the way’ 
along with regular monitoring, re-assessment, early intervention and social 
support will be critical throughout the pregnancy, labour and postnatal periods. 
Education and quality information should be provided to women and their partners and 
families about: 
• general, dental and mental health during pregnancy, labour and the neonatal 
period  
• caring for a newborn at risk of withdrawal and during the withdrawal stage (See 
below and Section 3)  
• ATOD effects and how to get help 
• harm reduction information (See Section 1)  





2.7 Alcohol, Tobacco, Other drugs & 
Pregnancy 
This section provides general information about ATODs and pregnancy. 
This information has largely been drawn from the following document: 
Ministerial Council on Drug Strategy 2006, National Clinical Guidelines for the management 
of drug use during pregnancy, birth and the early developmental years of the newborn, 
Commonwealth of Australia, March. 
This document is available at the following website:  
www.health.nsw.gov.au/pubs/2006/pdf/ncg_druguse.pdf 
Specific information on the management of particular ATODs and pregnancy, as well as the 
neonate, are presented in Section 3 of this document.  
Section 3 is focused on the specific management of intoxication, overdose and toxicity in 
relation to a number of drugs of dependence. Subsections entitled ‘Maternal and Neonatal 
Care’ are incorporated which address the appropriate management of particular drugs, 
including the impact of the drug on pregnancy and its outcomes. Section 3 also contains (as 
appropriate for different drugs), the management of withdrawal, pharmacotherapy 
programs in pregnancy, and management of labour and the newborn including neonatal 




Harm and risk for withdrawal from drug use during pregnancy  
Table 7: Summary of harm and withdrawal potential from drug use during pregnancy 
Chemical 
Class 




Risk for foetus – IUGR, lower birth weight, 
increase in infections and breathing 
complications in first weeks of life. 
Risk for pregnancy – increased risk of placental 
problems, bleeding, miscarriage, premature 
birth and stillbirth. 
Yes 
Caffeine Risk for foetus – if daily consumption over 
600mg per day – increased risk of miscarriage, 
difficult birth and low birth weight. 
Risk for pregnancy – crosses placental barrier 
similar to that of mother, may experience 
withdrawal symptoms such as rapid, irregular 
pulse, rapid breathing and tremors. 
Yes 
Amphetamine Risk for foetus – reduced blood flow and 
oxygen to foetus from vasoconstriction. Linked 
to increased risk of e.g. smaller head size, eye 
problems, cleft lip and palate, delayed motor 
development. 
Risk for pregnancy – increased risk for 
miscarriage, premature birth, placental 





Risk for foetus – has been associated with 
delayed development and subtle abnormalities 
in newborn. 
Risk for pregnancy – limited research and 
specific effects on pregnancy. 
 
Cocaine Risk for foetus – IUGR, small birth weight 
And birth defects e.g. defects of genitor-urinary 
tract, heart, limbs. 
Risk for pregnancy – may cause bleeding, 









Drug Potential Harm Withdrawal 
potential 
Depressant Alcohol Risk for foetus – risk of foetal alcohol spectrum 
disorder, foetal alcohol syndrome, IUGR. 
Risk for pregnancy – miscarriage, bleeding, 











Barbiturates Risk for foetus  







Risk for foetus – smaller baby and prone to 
illness, increased risk for BBV, 
Risk for pregnancy - increased risk of 





Marijuana Risk for foetus – reduced growth and increased 
risk of illness. 












Risk for pregnancy – LSD and other 
hallucinogens appear to be linked to increased 




 Risk for foetus – increased risk of birth defects, 
(similar to those for alcohol if use toluene). 
Risk for pregnancy – increased risk of 
miscarriage, early labour/premature birth with 








Good antenatal care is critical for early identification and amelioration or risks to the 
woman and her baby and is aimed at optimizing pregnancy outcomes through reducing the 
risks to the mother and her baby [60]. 
Continuity of care  
Continuity of ante and post natal care is important for all pregnant women and their 
babies, especially young first time mothers.   
This is especially important for pregnant women, who have problems related to their use 
of ATOD’s where collaboration of multidisciplinary teams including obstetric medical 
specialist, midwives and ATOD specialist medical and nursing personnel can optimize the 
outcomes for the woman and her baby [60]. Continuity of care is established by: 
• effective engagement skills, including cultural awareness  
• effective systems including clear identification of an ongoing main case worker and 
assertive follow-up of non attendances 
• individualised care planning in consultation with the woman 
• timely and accurate documentation and multidisciplinary team communication 
• seamless referral systems and service delivery [60]. 
Engaging with pregnant women 
The aim of engagement is to establish a professional, trusting and empathetic relationship 
in which the woman is and feels welcome, supported and encouraged to continue to 
attend [60]. 
Successful engagement relies on the quality of the relationship established with the 
woman by the health care team. Failure of engagement may result in loss of the woman to 
follow-up, which increases the risk of less than optimal pregnancy outcomes for the 
woman and her baby [60]. 
Pregnant women with problems related to their use of ATOD’s may be reluctant to engage 
with mainstream services for antenatal care for a range of reasons. Some reasons may 
include; being fearful of notification to child welfare services, past history of negative, 
judgmental or punitive responses from health service providers or feeling unwelcome [60]. 
Pregnant teenagers and young women are particularly at risk of having poor antenatal care 
due to non-engagement with service providers, continuing drug use and late pregnancy 
presentation.  
Each presentation of a drug dependent pregnant woman at any service needs to be 
identified as an opportunity to engage or encourage the woman to remain engaged in 




Engagement is enhanced when: 
• the team ensures a non-judgemental attitude and aproach  
• there is a commitment to providing optimal and timely health care for all women 
regardless of race or diagnosis - dependence is seen as a health issue -  not an issue 
for moral, social or other judgments 
• a safe, supportive therapeutic milieu and an environment that ensures dignity, 
privacy and confidentiality is created by the team 
• there is an understanding of the potential barriers to the woman accepting 
antenatal care, and strategies are in place to overcome them 
• the woman’s feelings and perceptions are acknowledged and the woman is 
reassured to address fears  
• the team understands that disclosing ATOD use in pregnancy is difficult 
• the team establishes and sustains a sound and trusting professional relationship 
with pregnant women who have ATOD issues, whereby importance is given to 
creating a therapeutic partnership in which the woman makes decision based on 
the selection of safe interventions from the range of options discussed and 
available to her 
• there is an awareness that women with drug and alcohol issues often have a 
number of service providers involved in their lives 
• an understanding and acknowledgment that regardless of drug use, the woman 
will want what is best for her baby 
• pregnancy provides an excellent opportunity to engage the woman in drug and 
alcohol treatment and change [60]. 
Client Education 
In the health sector, the education approach can commonly involve “telling someone what 
to do and they will do it” model which assumes that if you tell someone about what is 
good for them they will act in accordance with the advice given. This approach does not 
work and is not useful in encouraging behavioral change. This model will not be productive 
in supporting a drug-dependent pregnant woman.  
Client education during pregnancy is a critical component of antenatal care for all women. 
For pregnant women who use drugs it is particularly important. Women need to be 
empowered to make decisions to protect and enhance the health and wellbeing of 
themselves and their baby and to choose from among the safe options available to them in 
the context of full information provision (including risks) and need to be supported in the 
decisions they make. 
Information must be relevant and meaningful (i.e. fits with the information they need 
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based on what will assist in implementing thier decisions). In this, client education is 
undertaken in the context of a partnership with the woman and aims at meeting their 
needs and expectations. The woman feels her wishes are considered in the content of the 
education program and education strategy selection process.  
The program development process should include undertaking a needs assessment with 
the woman which may include asking about or consideration of some the following as 
relevant: 
• stage of change 
• motivation for change 
• literacy levels 
• beliefs regarding susceptibility and seriousness of threat or risk to herself and her 
baby 
• need for information related to intervention choices 
• barriers to learning or change e.g. learning difficulties 
• benefits of change 
• beliefs in self efficacy - belief that she can succeed and that strategies are likely to 
be successful 
• current  beliefs, skills and knowledge i.e. what does the woman know about? 
• needs and expectations for the program, what the woman wants to learn about 
and wants as an outcome of the educaiton porgram i.e. What do they want to 
know and/or be able to do? 
• type of intervention required - if it is for prevention or intervention purposes, does 
it involve behavioral change e.g. stopping, substituting or learning a behavior or 
about pregnancy or child care 
• how the person learns (we all learn differently); using strategies that fit with the 
invidual’s learning style will positively effect their capacity to understand the 
information e.g. seeing, doing, reading, audiovisiuals such as film or notes,  as 
reminders or pictures or story boards 
• client competency to carry out identified actions or new behaviours – what could 
get in the way, what could help 
• relapse prevention - lapse factor assessment and strategy development for how to 
get back on track 
• level of personal responsiblity 
• rapport developed  
• personal characteristisc - e.g. personal space, past behavioral change adherence to 
99 
 
strategies and family influence. 
• Negotiation of program content [61-64]. 
Throughout the client intervention process, the impact and outcomes of each component 
needs to be undertaken with the woman. This focuses on success and addressing barriers 
or problems for adherence as they arise. The evaluation discussion should also seek to: 
• identify any changes woman wants to make to their care and or education plan 
• answer any questions 
• problem solve 
• negotiate any changes to the the education program 
• short-term goal setting to address problems and actions to meet them 
• time for ongoing education contact and follow-up antenatal care visit.  
Screening 
Drug and alcohol use 
Screening for alcohol, tobacco and other drug use should be included all antenatal initial 
assessments. There is some recent evidence yet to be published that has identified one 
screening question that will give an indication of other drug use. The question is, “Do you 
smoke?” 
Where women do not smoke during pregnancy, the incidence of using other drugs is 
almost nonexistent [65]. 
Further screening where the woman uses tobacco can also include asking about: 
• current and previous use of ATOD’s e.g. alcohol, tobacco, cannabis, stimulants 
(amphetamine), ecstasy, opioids, inhalants 
• drugs used from the time of conception (or earlier if possible)  
• prescribed medications including e.g. opioid pharmacotherapy, benzodiazepines 
• over the counter medications e.g. paracetamol. 
It is important to identify the amount, dose, pattern, route of administration and 
frequency of use, in order to identify risks for the mother and her baby arising from high 
doses, regular or daily use and dependence and/or the method of use. 
Alcohol Screening 
All pregnant women should be screened about their consumption of alcohol. Where 
women are drinking a full assessment of alcohol intake should be undertaken and 
appropriate referrals should be made. A validated tool for use in pregnancy such as T-ACE, 
TWEAK can be used to assist assessment. AUDIT can also be used but is not specifically 
validated for use in pregnancy. 
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Urine drug screening for illicit drugs 
Pregnant women should have urine drug screens no less often than other women in similar 
circumstances (e.g. when in an opioid treatment program). 
Screening for blood-borne viruses 
It is cost effective to screen all drug-dependent pregnant women for blood-borne viral 
infections early in pregnancy, particularly where evidence supports the benefits of 
interventions to reduce the risk of vertical transmission to the newborn. All screening for 
blood-borne viruses must be conducted with the informed consent of the woman, and 
with appropriate pre-test and post-test counseling. 
Screening for other critical and associated potential risks 
All pregnant women should be screened for risk of mental health issues and social issues 
that may place then at risk such as family or relationship violence and homelessness. 
Managing withdrawal during pregnancy 
See specific drug sections in Section 3 for management of drug use and withdrawal in 
pregnancy. 
Women who are pregnant and present with alcohol or other drug use may have tolerance 
and may choose withdrawal as a part of treatment strategies. Pregnant women need 
appropriate, safe clinical management based on the most current best evidence available.  
This involves a careful assessment of their needs (including antenatal care, mental health 
and drug issues) and consideration of available options that may include Opioid 
maintenance pharmacotherapy, psycho-social care and referral to high risk obstetric 
services.   
Women who are >28 weeks pregnant should be managed in a specialist inpatient obstetric 
service by where management of their health and pregnancy, along with appropriate drug 
withdrawal treatment, can occur. Planned withdrawal aims to provide a safe and effective 
clinical response to women who are pregnant and seeking alcohol or other drug 
withdrawal.  
Possible hazards 
There is a risk of precipitation of complications of pregnancy if the relevant withdrawal 
syndrome is not adequately treated. 
There may be consequences of the use of medication that is contraindicated (or relatively 
contraindicated) in pregnancy (ADEC categories B, C ,D & X). See information regarding 
these categories below. 
Principles for Management 




Women known to be pregnant and wanting inpatient withdrawal management should be 
admitted as a matter of some urgency and where possible their admission should be 
expedited. 
Pregnant women requesting outpatient withdrawal management should be advised of any 
relevant risks involved and encouraged to consider inpatient management.  
All other women of reproductive age presenting for inpatient withdrawal management are 
required to provide a urine sample for pregnancy testing prior to the administration of 
medications (unless to do so would result in serious medical complications). 
Attention should also be given to any antenatal care needs throughout withdrawal 
management. This may include needs for: 
• transferring the woman to a specialist antenatal care service  
• an ultrasound scan if there are concerns about her pregnancy, and 
• referral to a specific antenatal clinic e.g. High Risk Pregnancy Clinic if the woman is 
not already engaged in antenatal care. 
Note: It is advisable to check with the relevant obstetric service whether the woman is 
already known to them and for further information and advice. 
A number of medications routinely prescribed in drug withdrawal are not ADEC Category A 
(no evidence of harmful drug effects) – see listing below of categories for medications 
commonly used in withdrawal. 
Categorisation of drugs commonly administered in medical withdrawal setting, with 
category explanations: 
A:  Drugs which have been taken by large numbers of pregnant women and women of 
 childbearing age without any proven increase in the frequency of malformations or 
 other direct or indirect harmful effects on the foetus having been observed. 
B1:  Drugs which have been taken but only by a limited number of pregnant  women 
 and women of childbearing age, without an increase in the frequency of 
 malformation or other direct or indirect harmful effects on the human foetus 
 having been observed. Studies in animals have not shown evidence of an increased 
 occurrence of foetal damage. 
B2:  Drugs which have been taken by only a limited number of pregnant women and 
 women of childbearing age, without an increase in the frequency of malformation 
 or other direct or indirect harmful effects on the human foetus having been 
 observed. Studies in animals are inadequate or may be lacking but available data 
 show no evidence of an increased occurrence of foetal damage. 
B3: Drugs which have been taken by only a limited number of pregnant women and 
 women of childbearing age, without an increase in the frequency of malformation 
 or other direct or indirect harmful effects on the human foetus having been 
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 observed. Studies in animals have shown evidence of an increased 
 occurrence of foetal damage, the significance of which is considered uncertain in 
 humans. 
C:  Drugs which, owing to their pharmacological effects, have caused or may be 
 suspected of causing, harmful effects on the human foetus or neonate without 
 causing malformations. These effects may be reversible. Appropriate texts should 
 be consulted for further details. 
D:  Drugs which have caused or are suspected to have caused, or may be expected to 
 cause an increased incidence of human foetal malformations or irreversible 
 damage. These drugs may also have adverse pharmacological effects.
 Appropriate texts should be consulted for further details. 
X:  Drugs which have such a high risk of causing permanent damage to the foetus that 



















Diazepam (oxazepam, temazepam, nitrazepam) – hypotonia, respiratory depression and 
hypothermia in the newborn; prolonged use causes withdrawal in the neonate. 
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Pericyazine – high doses in late pregnancy have caused prolonged neurological 
disturbances in the newborn infant. 
Naproxen – inhibits prostaglandin synthesis, when given in the last trimester may cause 
closure of the foetal ductus arteriosus, foetal renal impairment, inhibition of platelet 
aggregation and delay labour and birth. 
Methadone – may cause respiratory depression in the newborn infant.  Withdrawal 
symptoms in newborn infants have been reported with prolonged use of the drug. 
Suboxone and Subutex. 
Category D 
Quinine. 
Discharge planning  
Discharge planning for the pregnant woman is an extremely important part of her 
withdrawal management, ongoing treatment, relapse prevention, general health and 
mental health and antenatal care. 
Therefore careful liaison with relevant antenatal services and  regular follow-up with her 
midwife/caseworker are necessary. If she does relapse, opioid maintenance treatment 
should be urged and supported, as appropriate, or readmission facilitated. 
Neonatal Abstinence Syndrome (NAS)  
(See Section 3 for specific drug information) 
The mother and her baby require non-judgemental support, regular observation and close 
monitoring so that withdrawal symptoms can be detected and treated early. 
• like any other mother she will be very concerned about the wellbeing of her baby – 
and needs to be involved and supported in caring for her baby  
• the mother may feel ashamed and therefore afraid to ask for help 
• she may fear her baby will be very sick or die, or taken from her because of her 
ATOD problems (she may have already lost a baby to miscarriage, prematurity, or 
other reasons).  
Assessment of the mother’s ATOD use history and most recent use is necessary to guide 
clinical decisions about the possibility of NAS in the neonate. 
• NAS symptoms generally begin 24 to 48 hours after delivery 
• withdrawal symptoms need to be regularly monitored and treated as early as 
possible (See Section 3) 
• both mother and baby will require extended admission of about 8 days and close 




• mother may also undergo ATOD withdrawal and she too needs to be carefully 
monitored and treated according to her history and symptoms 
• a history of previous withdrawal indicates caution being required as it is likely to 
recur this time 
• any suspected previous complications must be noted, prevented or treated 
effectively e.g. alcohol, benzodiazepine withdrawal (see Section 3)  
• if the mother is undergoing methadone or buprenorphine treatment for opioid 
dependence she will require her usual daily doses AS WELL as additional pain relief 
and symptomatic medications (See Section 3 for Opioid Withdrawal and Pain 
Management). 
Care of neonate with NAS  
(See Section 3 for specific drug NAS). 
The mother, father and other concerned family members need to be educated, shown, 
supported and enabled to be fully involved in establishing their baby’s feeding and general 
care routine. This includes NAS observations and treatment as required.  
The baby requires supportive care including: 
• low stimulus (and if possible private) environment preferably rooming with mother 
• demand feeding – breastfeeding if possible and/or formula - small frequent feeds 
(sucking can be ineffective) as this encourages bonding, optimal nutrition, soothing 
and settling and has the bonus effect of reducing the severity of withdrawal 
symptoms 
• regular monitoring of how the baby suckles, intake and weight 
• pacifier 
• cuddling, swaddling, close skin contact 
• careful and frequent observation and monitoring for onset, progression, severity 
and lessening of withdrawal symptoms. Observe between observation regime e.g. 
NAS observation regime (See Section 3 for specific drug and Section 4 Appendix 16 
for NAS - Finnegan Observation Chart).  
Medical treatment of significant NAS 
Morphine and phenobarb are used to treat NAS. The baby will need to be transferred to 




Nursing care of mother and baby  
• Mother (and partner/family) need be educated about her baby’s condition, what 
to expect, the nature of and reasons for treatment 
• Mother needs to feel included and welcome and supported to be with her baby as 
much as possible – this will help her baby to recover, and is good for her 
• Mother’s ability to provide demand feeding needs to be encouraged, guided and 
maintained. 
Going home 
Preparation for going home needs to be carefully prepared for and managed, and based on 
the particular health, social and other needs of the mother, baby and her family unit. 
• Daily midwifery visits will be required as well as regular contact and support from 
her drug treatment and maternity care units. 
• The mother’s ATOD treatment regime needs to be supported and maintained  
• Various social issues may arise such as e.g. housing or financial support needs 
• The baby may require medication for three weeks after going home.  
The women’s drug treatment doctor and team need to be notified of her and her baby’s 
discharge so that arrangements are in place to continue her pharmacotherapy e.g. 
methadone without interruption. This can prevent relapse and other problems arising 
unnecessarily. 
Home visiting social services need to be included (if possible) in discharge planning, and 
notified when this occurs. This can enable regular support that can assist mother and baby 
to progress well. 
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2.8 Blood Borne Viruses  
The most common blood borne viruses associated with injecting drug use are: 
• Hepatitis B, C  
• HIV [66] 
The following website has additional information visit www.ashm.org.au 
This website has accurate information related to current evidence based management of 
HIV, Hepatitis B & C  
Testing  
Informed consent is required before HIV, Hepatitis B and C testing. To enable a person to 
make an informed decision and give consent they require adequate information around 
testing and the implication of results for them. 
Discussion of issues related to hepatitis B, C and HIV should be undertaken for all people 
who are or have been injecting drugs. 
Hepatitis C infection is common among people who inject drugs. It may be diagnosed some 
years after injecting has ceased. Transmission can occur with any unsafe injecting drug use 
even in a once off situation.  
Testing (with effective pre-test education and post-test counselling) should be offered to 
any person considering being tested for a blood-borne infection or disease. They should be 
offered hepatitis B vaccination if found to be not immune. 
The person should be provided with relevant literature to read prior to pre-test 
counselling.  
Pre-test Counselling 
Pre-test counselling aims to:  
• provide the person with the opportunity to understand the implications of testing 
(both a negative and positive result)  
• give an opportunity to discuss risk factors for transmission  
• educate people about transmission risk reduction  
• enable the person to make an informed choice about undertaking testing. 
Pre-test education should be adapted to the person’s knowledge and cultural 
understanding as appropriate. 
Pre-test counselling should involve the following: 
• explanation of blood borne viruses 
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• assessment of risk behaviours and education on risk reduction measures 
• information on transmission and how to prevent transmission of BBV’s 
• description of the relevant tests and possible results 
• discussion around fears and concerns 
• information on confidentiality and privacy 
• explanation of the logistics of testing (including how results are provided, and the 
window period) 
• information about the implications of a negative or positive result including re-
testing and sero-conversion 
• notification requirements and contact tracing 
• treatment options and support services 
• exploration of psychosocial issues and support.  
A person should be given the time to think about the issues before making a decision on 
whether to proceed with testing. 
Procedure for BBV Testing 
• undertake pre test counselling and negotiate for post test counselling 
• obtain written consent 
• ensure blood is collected for testing and sent to pathology. 
Post-test Counselling 
All HIV, Hepatitis B and C test results should be given in person (face to face) and 
preferably by the same person who undertook the pre-test counselling. The education and 
counselling should be adapted to the person’s individual needs and cultural understanding 
as appropriate. 
Nurses are well placed to provide follow-up, counselling and support, to reinforce the 
information provided and link the person with available community services. 
There are two main aims of post-test counselling. These are to: 
• address the immediate concerns of the person receiving a positive test result  
• provide necessary information and follow up support. 
If the result is positive 
Allow for discussion of the following issues as appropriate e.g.: 
• support needs during the initial period following receipt of a positive test result 
and the immediate emotions, feelings and reaction to the result. 
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• provision of factual information relevant to the test results 
• likely changes for themselves and their family  
• ways to deal with loss, grief, depression, anger and anxiety  
• reinforce transmission information, prevention strategies and pre test education 
provided. Also provide and teach relevant harm reduction and transmission 
prevention practices e.g. for safe sex, safe use of injecting equipment, low risk drug 
use and promotion of abstinence 
• any difficulties or issues that may prevent the person from engaging in safe 
practices 
• co-infection or re-infection 
• who to tell, why and how 
• options for drug treatment and medical management 
• positive news e.g. the percentage of people who will clear the virus or respond 
well to treatment 
• complementary management options 
• ongoing counselling  
• legislative requirements (notification, contact tracing, clinical records storage and 
coding). 
What a positive result means in regard to: 
• medical aspects/prognosis 
• psychological aspects 
• notification requirement 
• social aspects (supports etc) 
• insurance aspects 
• personal perception of risk 
• confidentiality 
Provide prevention information/education in relation to: 
• self management and infection with new genotypes 
• harm reduction. 
Post-test counselling may require more than one session and the time taken to provide this 
will vary according to the individual persons needs. As there may be an emotional reaction 
to a positive test result, it may be necessary to repeat information provided on more than 
one occasion, to allow the information to be absorbed.  
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If the result is negative: 
Allow for discussion of the following issues as appropriate e.g.: 
• discuss what a negative results means (i.e. 3 month period before sero-conversion) 
and need for retesting 
• reinforce transmission information, prevention strategies and pre test education 
provided. Also provide and teach relevant harm reduction and transmission 
prevention practices e.g. for safe sex, safe use of injecting equipment, low risk drug 
use and promotion of abstinence 
• any difficulties or issues that may prevent the person from engaging in safe 
practices 
• discuss future testing following any practices placing them at risk of infection  
• provide further information and support as requested. 
Hepatitis B 
Hepatitis B infection is preventable. Hepatitis B vaccine should be offered to all people who 
inject drugs who upon testing for the virus are shown to have no immunity. Immunity is 
life-long but co-infection can occur. 
Transmission 
Hepatitis B is a virus transmitted through any body fluid. Co or re-infection can occur due 
to different mutants of the virus. 
Progression to chronic infection or carrier 
5% of people who have acute hepatitis B infection progress to chronic infection. This 
increases to around 80% in children affected at birth. Neonatal infection usually results in 
asymptomatic carrier state. Some may progress to cirrhosis. 
Persons with chronic HBV infection might be asymptomatic, have no evidence of liver 
disease, or have a spectrum of disease ranging from chronic hepatitis to cirrhosis or 
hepatocellular carcinoma (a type of liver cancer). 
Signs and Symptoms of Acute Hepatitis B  
The presence of signs and symptoms of hepatitis B varies by age and depend on whether a 
person has acute or chronic hepatitis B infection.  
Acute hepatitis B infection 
Many adults and children with acute hepatitis B are asymptomatic and unaware that they 
have the infection. A very small percentage with acute hepatitis B develop ‘fulminating 
hepatitis’ within a short period of time.[67]. 




• jaundice occurring approximately 12 weeks after initial infection with yellow eye 
sclera, skin, dark urine and pale faeces 
• loss of appetite 
• nausea and vomiting 
• lethargy 
• abdominal pain 
• muscle and joint pain. 
Chronic hepatitis B 
Most people with chronic hepatitis B are asymptomatic, feel healthy and are unaware they 
are infected. Others may experience symptoms similar to those of other forms of viral 
hepatitis.  
Symptoms of chronic hepatitis B include: 
• lethargy 
• depression and irritability 
• liver pain  
• nausea and vomiting  
• loss of appetite   
• muscle and joint pain  
Current treatments for Hepatitis B 
Lamivudine is a 12 month treatment for people whose biopsy shows chronic active 
hepatitis.   
If awaiting transplant this treatment is not commenced without discussion with the 
transplant unit.  
Interferon monotherapy may be used with 5 – 7 % people clearing the virus. 
For up to date comprehensive information about Hepatitis B treatment please refer to the 
following website: www.hepatitisaustralia.com/about-hepatitis/hepatitis-b 
Hepatitis C 
In South Australia, it is estimated that there are over 17,000 people who have been 
exposed to the hepatitis C virus, with around 150 new infections each year. 
The majority of people who contract the virus are asymptomatic and unaware that they 
have the infection. Thus diagnosis does not usually occur around the time of exposure. 
The diagnosis of hepatitis C can result in shock and confusion.   
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Respectfully engaging with people, providing accurate information and allowing time to 
answer their questions can assist them to understand the: 
• diagnosis and its meaning 
• transmission and the nature of the  infection 
• potential for clearance of the virus 
• possible progression to chronic disease and time frames 
• treatment options and outcomes.  
The following topics need to be discussed with the person newly diagnosed: 
• the screening test and what it means 
• natural history of hepatitis C   
• physical impacts  
• lifestyle recommendations 
• treatment options 
• social impacts  
• disclosure 
• notification requirements 
• risk factors for transmission /prevention for self and others 
• Hep B vaccination 
• referral options  
• resources available. 
What is the screening test and what does it mean? 
A hepatitis C antibody test (HCV Ab+) is the initial blood test to screen for hepatitis C.  
A positive result to the hepatitis C antibody test means that a person has been exposed to 
the hepatitis C virus. It does not necessarily mean the person has the virus, though an 
antibody positive test together with an abnormal liver function test (LFT) gives greater 
than 80% likelihood that the person has the virus. 
Antibodies to hepatitis C remain in the body over many years, even when people have 
cleared the virus naturally or through pharmaceutical treatment. Antibodies do not protect 
against re-infection with other strains of the hepatitis C virus. 
A PCR (polymerase chain reaction) qualitative test is used to detect the actual virus (HCV 
RNA). This test is free for people who have tested HCVAb positive. 
The ‘window period’ for hepatitis C sero-conversion ranges between 2-26 weeks, and 90% 
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of people have detectable antibodies after three months. Indeterminate test results can 
occur. PCR testing will confirm infection. 
Two other PCR tests are used in the work up for treatment to measure viral load and 
identify genotype. 
Natural History of Hepatitis C   
Individual health outcomes of hepatitis C infection vary markedly, so it is usually impossible 
to give any accurate prognosis at the time of diagnosis. People need to be reassured that 
being infected with hepatitis C is serious but treatable. Hepatitis C related liver disease is 
generally slowly progressive, and the majority of people infected will not progress to 
serious liver disease. 
Information on the natural history of hepatitis C, observed at a population level, gives 
people some understanding of long term outcomes of hepatitis C infection. 
Natural History 
Of 100 people infected with the hepatitis C virus: 
On average 25% clear the virus naturally 
within 12 months 
On average 75% will have chronic infection 
A person is considered to have chronic hepatitis C, if they have not cleared the virus 
naturally within the first 6 months after exposure. 
Of 100 people with chronic hepatitis C infection who remain untreated after 20 years: 
45% may never 
develop serious liver 
disease 
47% develop mild to 
moderate liver 
damage 
7% may develop 
cirrhosis 
1% of those with 
cirrhosis may 
develop liver failure 
or liver cancer 
Of 100 people with chronic hepatitis C infection who remain untreated after 40 years: 
45% may never 
develop serious liver 
disease 
30% develop mild to 
moderate liver 
damage 
20% may develop 
cirrhosis 
5% of those with 
cirrhosis may 
develop liver failure 
or liver cancer 
[68] 
Duration of infection  
The duration of infection is a critical factor in the ongoing management of hepatitis C. It is 
important to assist the person to identify as closely as possible when they may have been 
exposed to the virus. This may be aided by explaining the risk factors for infection: 
• sharing injecting equipment 
• unsterile tattooing 
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• blood transfusion or use of blood products prior to 1990 
• born in a country with high prevalence of hepatitis C 
• unsterile medical or dental procedures in countries of high prevalence 
• incarceration in a correctional facility or their partner. 
This process touches on sensitive issues for some people, and the emphasis should be on 
when rather than how someone was exposed to the virus. 
Some people have various risk factors; it is useful to measure duration of infection from 
the earliest possible exposure. Some people may not be able to identify their risk factors. 
Physical Impact 
The hepatitis C virus affects various people in different ways. There is a lack of correlation 
between the symptoms experienced and liver disease. That is, experiencing symptoms 
does not necessarily mean there is liver disease, and some people may experience no 
symptoms but still have liver disease. 
Symptoms of Hepatitis C  
People can experience symptoms ranging from mild to severe. Symptoms include:  
• lethargy, fatigue, general malaise lack of energy 
• headaches 
• nausea and vomiting 
• diarrhoea 
• muscle and joint pain  
• skin irritation and rashes 
• depression and anxiety 
• discomfort in the upper abdomen area near the liver. 
Hepatitis C - Liver Disease 
Liver disease is measured by a fibrosis score on liver biopsy. Factors identified that result in 
more rapid progression of liver disease include: 
• aged over 40 at time of infection 
• heavy alcohol intake, both current and past 
• obesity 
• fatty liver 
• Type 2 diabetes 




• abstaining or at least minimising alcohol intake and other drug use  
• achieving and maintaining healthy weight through exercise  
• healthy diet  
• rest and relaxation  
• managing depression and anxiety– referral to GP, counsellor, psychiatrist if 
required. 
Many people with liver disease manage symptoms with the use of complementary 
therapies. They should be encouraged to discuss their use of complementary therapies 
with their GP. 
Treatment Options 
The newly diagnosed person should be told there is treatment available for hepatitis C for 
the ‘acute’ phase which may result in a good prognosis.  
Treatment has improved markedly over the past few years with overall viral clearance at 
around 60%. A sustained viral response (SVR) or viral clearance is defined as the absence of 
hepatitis C RNA in serum, six months after cessation of treatment.  
Treatment outcomes vary according to genotype. While viral clearance is around 60% 
across all genotypes, for people with genotype 1and 4 there is 40%-50% expected viral 
clearance, and for people with genotype 2 and 3, expected viral clearance is in the range of 
70%-90%. 
Outcomes of Combination Therapy 
Treatment Duration 6 months 12 months 
Genotype 2 & 3 1 & 4 
Expected SVR 70% - 90% 40% - 50% 
 
Treatment is usually combination therapy of pegylated interferon (self – administered by 
injection weekly) and ribavirin (tablets taken daily), over a period of 6 – 12 months, 
depending on the genotype of the virus present.  
In Australia, 55% of people have genotype 1, requiring 12 months treatment. 35% have 
genotype 3, requiring 6 months treatment. People with cirrhosis, no matter what their 
genotype, may have 12 months of treatment. 
Side effects of treatment vary for individuals. Management of side effects has improved 




S100 Criteria – free access to prescribed medications 
Criteria apply to access hepatitis C treatment under the Pharmaceutical Benefits Scheme: 
• no prior interferon treatment 
• over 18 years of age 
• hepatitis C virus detected by PCR 
• women must not be pregnant or breastfeeding 
• a woman and her partner must use effective contraception during and for 6 
months after treatment. 
Note: Liver biopsy was removed from the S100 criteria in April 2006. 
Treatment may be available to those with prior non-pegylated interferon therapy under 
certain circumstances through specialist centres.  
 
  
Treatment Update March 2012. 
The treatment for Hepatitis C Genotype 1 is about to change significantly (as of March 2012).  
Currently standard of care with 48 weeks of pegylated interferon and Ribavirin treatment 
cure rates are between 45-50%. With the advent of new therapies the expected cure rates 
will increase by up to 70%, and perhaps higher depending on treatment history and fibrosis 
level.  
There are currently 2 new protease inhibitors which are added to the background therapy of 
pegylated interferon and ribavirin, making the new standard of care for Genotype 1 
Hepatitis C a triple therapy regime. Currently Boceprevir and Telaprevir are available in 
Australia through patient familiarisation programs; both medications have TGA approval but 
are not currently available through the national Pharmaceutical Benefits Scheme.  
There will be the benefit for some people for shortened duration of therapy. For individuals 
with Genotype 1 Hepatitis C there will be many considerations in choosing a regimen that 
will suit them and provide the best chance for a sustained virologic response (cure).  
The background therapy of pegylated interferon and Ribavirin is required for either of the 
protease inhibitors. In choosing either Boceprevir or Telaprevir as the protease inhibitor for 
a particular individual, the side effect profile duration of therapy, past treatment history and 





It is often difficult for people with hepatitis C to tell others of their status due to the 
associated stigma and fear of judgemental reactions.  
Discussion with the person about the people they ‘trust’ to tell can be useful. It is usually 
best to limit this to those closest to them, until they have had the opportunity to ‘come to 
terms’ with their diagnosis, and feel well informed about what the diagnosis means for 
them. 
Legal requirements regarding disclosure 
People with hepatitis C are not legally bound to disclose their health status. There are a 
few exceptions to this: 
• healthcare workers who perform exposure prone procedures 
• blood donors 
• people in the armed forces 
• disclosure requirement on insurance forms. 
Disclosure of hepatitis C status is not required for infection control purposes. All blood 
should be viewed as potentially infectious and standard precautions should be used. 
Notification Requirements 
Mandatory notification of hepatitis C is a requirement of the Environmental and Public 
Health Act, South Australia. The Act allows for surveillance and to detect and follow up 
different modes of infection. People often need to be reassured that this information is 
confidential, and that only de-identified data is released publicly. 
Risk Factors  
People newly diagnosed with hepatitis C can be very concerned about passing the infection 
on to their partners and families – particularly children. Reassure the person that this risk is 
low. 
• Sexual transmission is rare – hepatitis C is not classified as an STI. There needs to 
be blood present during sex for infection to occur. There may be an increased risk 
of transmission for example with anal intercourse, during a woman’s menstrual 
period, or when STD infections are present.  
• Household transmission is a very low risk – it is recommend to avoid sharing 
personal grooming aids (e.g. toothbrushes, razors) as these items may have small 
amounts of blood present, invisible to the eye.   
• Hepatitis C is not transmitted via kissing, hugging, sharing cups, plates, cutlery. 
• Vertical transmission – around 3%-5%, largely dependent on whether mother has 
high viral load during pregnancy. Viral load is high during the acute phase of 
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hepatitis C infection. 
• Women with hepatitis C can breastfeed. Breastfeeding is not recommended if 
nipples are  cracked and bleeding 
• Tattooing or body piercing by family or friends can pose a high risk for infection 
transmission. These should be undertaken by accredited professionals. 
For people who are still injecting drugs, advise that: 
• There is a high risk of transmission from sharing unsterile injecting equipment e.g. 
tourniquets, mixing items, swabs, surfaces, blood on hands, as well as needles and 
syringes. 
• They can be reinfected with another strain of the hepatitis C virus. Antibodies do 
not protect against other strains of the virus.  
• Hepatitis B vaccination should be recommended for people with hepatitis C who 
may still be engaging in high risk behaviours – injecting drug use or unsafe sex, 
multiple sexual partners.  
• Hepatitis B vaccination is free for people with hepatitis C, and can be accessed via 
their GP. 
Transmission during pregnancy 
Screening test for vertical transmission. There is some risk of vertical transmission of HCV 
to her baby if the mother is: 
HCV Ab +ve  
• risk is less than (<) 1%  
RNA positive (+ve) 
• risk is 4-5%  [69]. 
All babies born to HCV positive mothers need to be Ab tested at 18 months of age.  
Where a mother is HCV RNA +ve and testing is requested, an HCV PCR can be undertaken 
when the baby reaches 6-12 weeks of age. 
If results show the baby is: 
RNA positive (+ve) 
• risk of HCV infection is 73%  
RNA negative (- ve)  
• risk of HCV infection is very unlikely. 
Babies with confirmed HCV infection [HCV Ab and RNA positive] need to be referred to a 
paediatric gastroenterologist. Quality information and support including counselling need 
to be offered to the mother, father and family. 
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Clinical assessment and investigation of chronic hepatitis C 
This section has been adapted from [70]. 
Physical Examination 
A physical examination should be undertaken to identify any evidence of liver disease. 
Although the majority of people have no signs of chronic liver disease, a significant 
minority will. 
Signs of liver disease in chronic hepatitis C 
Common signs: 
• spider naevi 
• hepatomegaly 
• firm liver edge 
• palmar erythema (liver palms). 
Less common signs- usually indicate severe liver disease (60% of people have no signs of 
chronic liver disease): 
• jaundice 
• loss of body hair 
• hirsutism in females 
• splenomegaly (usually an indication 
of portal hypertension) 
• ascites 
• encephalopathy 
• asterixis  (hepatic flap) 
• gynaecomastia 
• hepatomegaly or shrunken liver 
from cirrhosis 
• dilated veins on abdominal wall 
• peripheral oedema 
• hepatic bruitis (a sign of liver cell 
cancer).  
Table 8: Initial Testing for Hepatitis C 
Initial testing after 
positive antibody 
 
HCV RNA PCR Detects presence of HCV  
HAV, HBV, HIV serology Exclude other BBV’s 
Blood biochemistry & LFT’s ALT’s, Albumin, Bilirubin, Glucose 
CBE Platelets 
INR  INR 
Alpha-fetoprotein (AFP)   
(6 monthly in cirrhosis) 
Baseline investigation for HCC 
 
Serum alanine aminotransferase (ALT) levels are not reliable indicators of severity of liver 
disease or degree of inflammatory change.  
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ALT elevations indicate ongoing hepatic inflammation but a proportion (up to 30%) of 
those with normal liver enzymes may have hepatitis on biopsy.  
A review of ALT levels cannot therefore be used to predict severity of disease.  
Severity of liver disease is best assessed by hepatic synthetic function – measured by 
serum albumin and International Normalised Ratio (INR) or prothrombin time.  
By paying attention to albumin, bilirubin and prothrombin time (which are true liver 
function tests) a more accurate assessment of severity & progression of disease can be 
gained. 
 Table 9: Further Testing for Hepatitis C   
Testing once (within 
12 months post 
diagnosis to exclude 
other liver disease) 
Thyroid function  (TSH) Keep check for symptoms; re-
test if symptoms present 
Serum transferrin saturation and 
ferritin 
To exclude haemochromatosis 
Nuclear, mitochondrial and smooth 
muscle antibodies 
For other causes of liver 
disease 
Caeruloplasmin and Copper To exclude Wilson’s disease 
Alpha-1-antitrypsin To exclude deficiency  
ANA, SMA, LKM To exclude auto immune 
disease 
Ultrasound If cirrhosis is suspected or 
considering liver biopsy 
Consider  Liver biopsy Staging and grading liver 
disease 
6 monthly LFT, CBE, INR. 
Ultrasound and AFP (if cirrhotic) 
Monitoring liver function and 
screening for HCC if cirrhotic 
 
• Serial platelet counts are of unusual value in chronic HCV. A progressive fall 
indicates progression of hepatic fibrosis, usually with cirrhosis and increasing 
portal hypertension. Platelet count has become close to a surrogate indicator of 
cirrhosis in chronic hepatitis C. 
• Liver biopsy remains the only reliable test to diagnose disease severity. 
• Complications of liver disease include liver cell cancer (hepatocellular carcinoma 
HCC), which may be identified on ultrasound investigation.  
• People with stage 3 fibrosis or cirrhosis on liver biopsy, should have 6 monthly 
ultrasound and 3 - 6 monthly alpha fetoprotein as part of early screening program 




• Tests for evidence of cryoglobulinaemia, renal disease and porphyria may be 
indicated if clinical signs and symptoms indicate the presence of these rarer 
complications of chronic HCV infection. 
Clinical evidence of cirrhosis 
Although many people with cirrhosis may be asymptomatic, profound lethargy and 
significant right upper quadrant discomfort are frequent symptoms. Physical examination 
may reveal a hard liver edge and splenomegaly. 
There may be indicators from biochemical and haematological parameters that cirrhosis is 
present: 
• slightly low serum albumin 
• slightly prolonged international normalised prothrombin ratio (INR) 
• aspartate aminotransferase (AST) level greater than ALT level and 
thrombocytopenia. 
Signs and symptoms of mixed cryoglobulinaemia (skin rash – palpable purpura on lower 
limbs, proteinuria) are more frequent in presence of cirrhosis. 
In people with HCV related cirrhosis, the annual risk of developing HCC is 1-6%.  
Thirty percent (30%) of all adult liver transplants are for HCV associated cirrhosis. It is the 
most common reason for liver transplants in Australia.  
Referral Options  
People with hepatitis C should have regular monitoring by their general practitioner, on a 
6-12 monthly basis (depending on duration of infection and liver disease progression 
factors). This check up should include liver function tests and other blood tests, associated 
with a long term management plan.  Regular monitoring without a long term plan is 




Referral to specialist hepatologists should be considered for ALL people with hepatitis C, 
but particularly when they: 
• request a referral 
• are newly infected 
• are interested in treatment options 
• have abnormal liver function tests 
• may be cirrhotic 
• have been infected for 10 years or more. 
SA Liver Clinics and Treatment Centres 
Flinders Medical Centre   (08) 8204 5511 
Lyell McEwen Hospital  (08) 8182 9000 
Queen Elizabeth Hospital  (08) 8222 6000  
Royal Adelaide Hospital  (08) 8222 4000 
There are three Liver Clinics in non-tertiary settings: at Northern Service DASSA in 
Elizabeth; Eastern Service DASSA (Warinilla Clinic) in Norwood and Nunkuwarrin Yunti 
Aboriginal Medical Service in Adelaide. 
Hepatitis Australia 
People diagnosed as having hepatitis C infection should be encouraged to make contact 
with the Hepatitis Australia ongoing support and information to people living with the 
virus. For information, advice about where to obtain assistance call: 
Hepatitis Helpline  - available 9am to 5pm week days (national) 1300 437 222 – callers will 
be connected to their local area  
Hepatitis SA  - 1800 021 133 - available 9am to 5pm weekdays for rural callers  
Hepatitis SA Office - 8362 8443  - available 9am to 5pm weekdays 
Other supports include:  
MOSAIC: Ph (08) 8223 4566 
Free counselling is available for people with hepatitis C.  
PEACE: Ph (08) 8245 8100 
Multicultural HIV & Hepatitis C Services 
SAVIVE: Ph (08) 8334 1699 
Education on hepatitis C for people who inject drugs. 
Resources: The Hepatitis C Council of SA has a wide range of written resources on hepatitis 
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C. Healthcare workers can order resources on line. Nurses can access on line education 
resources on the Hep C Council website www.hepccouncilsa.asn.au or by phoning (08) 
8362 8443. 
For additional information visit: www.ashm.org.au. This website has accurate information 
related to current evidence based management of HIV, Hepatitis B & C  
Human Immuno-deficiency Virus (HIV) 
The HIV infection rates among the Australian injecting drug use population remains low at 
around 1-2%. Signs of acute infection:  
• glandular fever type symptoms 
• flu like symptoms out of season 
• fever for more than 3 days 
• maculo-papular rash 
• recent high risk exposure 
• recent evidence of sexually transmitted infections (STI’s). 
Testing 
Tests can be positive after three weeks. All people at risk are advised to be screened for 
HIV exposure with the appropriate pre-test and post-test counselling. 
Evidence based treatment for HIV 
For additional information visit: www.ashm.org.au. This website has accurate information 
related to current evidence based management of HIV [71]. 
Post Exposure Prophylaxis (PEP)  
PEP is a course of anti-HIV drugs that is taken shortly after possible exposure to HIV 
infection. It is thought that the drugs may help reduce the risk of acquiring HIV after 
unprotected sex, sharing needles or a needle-stick injury. 
Note: Safe injecting and safe sexual practices have been important in keeping Australia's 
HIV infection rate low. Post Exposure Prophylaxis is not intended to replace these safe 
practices. 
Who should take PEP? 
Anyone who has had risky contact with a person who has HIV or who may have HIV should 
consider taking PEP. This risky contact may include: 
• having unsafe sex 
• sharing a needle 
• sustaining a needle-stick injury. 
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It is important for people with high risk exposure to discuss the need for PEP with a doctor 
trained in using anti-HIV drugs, or with emergency health services in order to determine 
the risk of acquiring HIV and whether PEP is indicated. 
The medical officer will need to consider details of the exposure, how much time has 
passed since the event and what is known about the HIV status of the other person or 
people involved. 
How persons can access PEP? 
If a person thinks they might need PEP, they should contact: 
During business hours:  GP who is trained and licensed to prescribe HIV    
   medications.  
After hours:   The Accident and Emergency Department of a public   
   hospital. 
To talk to someone about PEP  
AIDS Council in SA  (08) 8334 1611 
SHINE SA    (08) 8300 5300 
When should PEP be initiated? 
Ideally, PEP should be started within hours of exposure, but may be offered up to 72 hours 
after the exposure. It is likely that PEP will work most effectively if it is started as soon as 
possible after the exposure to HIV - preferably within one or two hours. This gives the 
drugs the best chance to work against HIV before it becomes established in the immune 
system. 
If the person thinks they may be pregnant, they will need to discuss this with their doctor 
prior to commencement of the PEP regime. 
Treatment Regime 
PEP involves taking a 2 or 3 medication combination once or twice daily for four weeks. 
The drugs need to be taken at certain times of the day and may need to be taken with or 
without food.  
It is very important not to miss any doses of PEP. Full adherence to medication can 
maximize the benefits from PEP. 
If seen at an Emergency Department the person may be given a starter pack to enable 
them to commence PEP immediately. This pack only has enough pills for a few days. To 
continue PEP, the person will need to be referred to a doctor or sexual health centre. 
Side effects 
PEP drugs can cause side effects such as nausea, diarrhoea, headaches, tiredness and a 
rash in 2/3 of those who take the medication.  
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The person should be advised to discuss possible side effects and how to manage them 
with their doctor. 
HIV blood test screening 
If the person and their doctor decide to use PEP, "baseline" blood tests will be done to 
check current HIV, hepatitis B and hepatitis C status. 
Tests for other sexually transmitted infections (STIs) may also be recommended. 
PEP Action 
At this stage no studies have been done to test whether the likelihood of getting HIV after 
unprotected sex or unsafe injecting is reduced by taking PEP. 
There are, however, some encouraging signs from studies done with health care workers 
that show that their risk of becoming HIV positive after a needle stick injury is significantly 
reduced by using PEP. 
These studies suggest that it may be possible to reduce the risk of HIV transmission by 
prompt use of PEP after possible exposure to HIV, sexually or through injecting equipment. 
It must be stressed, however, that PEP will not eliminate the risk of HIV transmission. 
Follow-up after completing PEP 
People should be advised that follow-up with their doctor is extremely important. For all 
people who take PEP, blood tests for HIV are repeated at these times after the exposure: 
• at 6 weeks, then 
• at 3 months, and 
• at 6 months 
This is longer than the usual 3-month 'window period' for HIV testing because PEP may 
prolong the time to detect HIV infection. 
Contraception 
Women commencing PEP should be advised to use effective methods of birth control to 
avoid pregnancy whilst on PEP. 
Safe sex 
All people, whose HIV status is being monitored over the six months, are advised to 




Critical nursing advice 
All persons commencing PEP should be advised: 
• to protect themselves and any partner by safer sex and/or injecting practices 
• that PEP is not guaranteed to stop people from being infected with HIV (taking PEP 
will not make a person immune to further exposures - it is not a replacement for 
safe sex and safe injecting practices) 
• against donating blood, organ or tissue, and sperm while taking PEP and being 
monitored for HIV infection 




2.9 Comorbidity: Co-existing ATOD and 
Mental Health Problems 
Background 
The prevalence and nature of comorbidity (co-existing mental health [MH] and alcohol, 
tobacco and other drug [ATOD] problems) are seriously impacting on individuals, 
communities, health services and professionals across Australia.  
Many people with comorbidity come into contact with a general hospital, emergency 
department, GP, community health agency or non government organisation (NGO), at 
some time. An example is when an adult is admitted to a medical/surgical ward or other 
specialist unit. Likewise, children and young people at risk of developing MH and ATOD 
problems are often in contact with child/youth services, school nurses, youth mental 
health services, and hospital units. 
Nurses and midwives who work in primary health care settings are in a very favourable 
position to identify people at risk from ATOD use and mental health problems. This is an 
opportunity to support and refer them to an appropriate service depending on the nature, 
impact, complexity and severity of the issues they are experiencing.  
While not expected to have specialist skills, primary health nurses and midwives do need 
to recognize when a person is at risk of comorbidity and be able to refer to the specialist 
team that can assist in offering the best care. This will ideally involve coordinated care 
between the treating teams depending on the nature, complexity and severity of the 
person’s needs and circumstances.  
People with comorbidity may present for help when their problem has become severe, 
acute or significantly advanced. This means that wherever they present, medical and 
nursing staff need to recognise that this is common and does not mean they cannot be 
helped. Even though their treatment may be more intensive and can be potentially less 
effective, there are interventions that can help. Clearly the first priority is to attend to their 
immediate needs, and as their condition settles then work together to devise the best 
possible care plan.  
Recovery from comorbidity 
People with comorbidity may present for help when their problem has become severe, 
acute or significantly advanced. This means that wherever they present, medical and 
nursing staff need to recognise that this is common and does not mean they cannot be 
helped. Even though their treatment may be more intensive and can be potentially less 
effective, there are interventions that can help. Clearly the first priority is to attend to their 
immediate needs, and as their condition settles then work together to devise the best 
possible care plan.  
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Whilst comorbidity can be a chronic condition, (much like other chronic illnesses) recovery 
is possible for many. Recovery to the level of function a person is likely to achieve typically 
involves multiple episodes of treatment before progress can be made.  A person’s capacity 
to recover will be influenced by the complexity of their conditions, and their mental, 
emotional and physical capacity to change. As well, their family and social situations 
including their living environment will play a large influence on whether or not change 
possible. The complexity of comorbidity and the losses and challenges of daily living cannot 
be underestimated. Compassion is the essence of caring for this group of people 
Relapse and/or the need for re-admission should not be viewed as a sign of the person’s 
lack of commitment but rather of the nature, severity and complexity of the condition. 
Relapse of mental health and ATOD conditions is common and should be viewed as an 
opportunity for learning, as either a part of the recovery process or in regaining stability for 
optimum level of functioning. . It is important to offer treatment, support and 
encouragement to realise that this is common for anyone with a complex health problem, 
and there is hope that they can recover.  
Physical conditions 
People who are admitted to hospital for various different physical conditions may also 
have comorbidity. It is necessary to consult and work closely with the specialist teams best 
able to guide how best to manage this person’s conditions at this time. Clearly this needs 
to occur early on in the admission e.g. current ATOD use and/or MH treatment may involve 
daily medication regimes. In other words seek guidance from and ensure that appropriate 
referral is built into the care plan, discharge and ongoing care plans. 
Role of early identification and intervention  
Early identification and intervention (EI&I) for a person with their first episode of mental 
illness is extremely important. This will assist in preventing their risk of also developing 
ATOD problems secondary to their MH condition. The reverse is also true where a person 
with early onset of ATOD problems receives EI&I and quality interventions [73]. 
In children and young people, offering EI&I to reduce their risk factors for ATOD and MH 
problems can help prevent social alienation from peers and others. This can play a large 
part in whether or not they remain at school or in work. EI&I can also assist them and their 
family in avoiding or reducing experimentation with alcohol or drugs, and thus any 
potential complications that ATOD use may have on the onset of mental illness as a 
secondary disorder for those pre-disposed. This means that all nurses working with 
children and young people have a critical role in the engagement with this client group, 
and the timely identification of any risk factors and provision of early intervention and 




Screening for comorbidity  
Where possible, screening for risk should be undertaken routinely with all people aged 14 
years and over (or younger if particularly vulnerable). This will help to determine whether 
they are experiencing co-morbidity, or independent MH or ATOD problems.  
Nurses working in emergency departments or hospital wards are ideally placed to offer 
routine screening of their clients and thus identify risk, facilitate further assessment and 
early intervention. This will serve to prevent complications from other comorbidities such 
as acute physical illness linked to or separate from their MH and ATOD condition. It is 
known that this client group comprises a significant percentage of people in hospitals as 
they are more likely to present to general hospitals and primary health care agencies than 
specialist MH and ATOD services. 
Validated Tools for Screening  
Screening for ATOD problems: 
• AUDIT (Alcohol Use Disorders Test) - See Appendix 1 
• ASSIST (Alcohol Smoking And Substance Involvement Screening Test) – See 
Appendix 2 
• IRIS 
Screening for MH problems: 
There are various screening tools for MH problems including e.g. suicide risk, mental health 
problems and specific disorders e.g. anxiety, depression. 
Screening for comorbidity in Indigenous Australians: 
IRIS (Indigenous Risk Impact Screen) – See Appendix 3 or go to  
www.clinicalguidelines.gov.au/browse.php?treePath=&pageType=2&fldglrID=722& 
Services to people with comorbidity 
As with other health conditions, not every person experiencing ATOD or MH problems 
need specialist treatment. Indeed, appropriate providers of early intervention are in the 
primary health care and other service delivery sectors. This can be best explained in the 
following model which explains the spectrum of risk according to presence or not of 








Common comorbidity presentations 
People may present with a range of co-existing ATOD and MH comorbidity problems 
including:  
• alcohol or drug dependence, depression and acute withdrawal  
• alcohol dependence, psychosis and intellectual disability 
• benzodiazepine dependence and anxiety  
• heavy drinking and bi-polar disorder 
• amphetamine induced psychosis (short lived with abstinence) 
• cannabis induced psychosis (short lived with abstinence)  
• heroin dependence and PTSD    
• nicotine (smoking) and schizophrenia 
• codeine tolerance and acute pain 





Multiple comorbidities   
People with ATOD and mental health comorbidity can also experience serious physical 
illnesses e.g. injury; infections; diabetes, hypertension; cardiovascular disease; renal and 
gastrointestinal diseases; lowered immunity, blood dyscrasias. People may also present 
with intellectual or physical disability) congenital or acquired; and various social, financial, 
family and other relationship problems.  
Negative stereotyping and labelling  
Care is needed to engage people with multiple comorbidities. Many have been negatively 
stereotyped (labelled as “too hard” or “difficult”) by service providers and community 
members. Client thus labelled are often reluctant to seek help resulting in a further 
deterioration of their situation. It is important therefore to maintain respectful interactions 
with the person and communications with the treating team.  
It is equally important to promote hope of recovery to the person i.e. that their needs and 
problems are understood, they can be helped and that their health and situation can 
improve. 
It is necessary when considering a person’s care needs and when making referrals to other 
services that all agencies involved are kept well informed of the person’s range of 
problems and needs that require realistic interventions as well as support for them and 
their family and carers. 
Challenging behaviours 
All too often, people with ATOD and mental health comorbidity who display challenging 
behaviours are labelled as having “personality disorder (PD)” without proper psychiatric 
assessment and diagnosis. This labelling practice is unacceptable, and has potentially 
dangerous sequelae for the person including self harm and suicide.  
People’s behaviour is often a sign of unmet need and fear. Asking about what the person 
would like or what is needed can often reduce anxiety and assist in gaining cooperation.  
There are useful strategies that can be used to assist in reducing mutual frustration and 
unnecessary sanctions against people at risk. 
It is necessary to challenge directly or indirectly any colleague who does not meet their 





In a ‘nutshell’: 
• understand the person’s behaviours as unmet needs, fear, anxiety, concerns  
• engage them by assuring them you are there to help  
• ask what is concerning them and what their immediate needs are (people 
commonly report negative experiences in health services due to staff attitudes to 
them or under-medication for their illness or post surgery;  or poorly managed 
ATOD withdrawal) 
• develop rapport so that a therapeutic relationship can be established and thus 
assist in setting behavioural expectations and effective health care delivery  
• respectfully discuss concerns and behavioural expectations with the person 
• negotiate appropriate strategies to alleviate the person’s concerns and assist them 
to  manage their feelings and responses better   
• involve them in developing their care plan wherever possible including: 
• maintain respectful nurse-client behaviours (two way) 
• prevent and manage challenging behaviours in ways that support the person but 
not their behaviour 
• implement nursing actions that aim to stop unacceptable behaviours in ways that 
are fair and safe for the person, staff and others. 
Principles for intervention in an Acute setting 
The key principles that guide care and treatment of people with comorbidity in the general 
hospital include: 
• safe stabilisation and monitoring of ATOD, MH and physical health conditions 
• assessment and intervention and/or treatment planning 
• integrated care within and across teams and services including crisis intervention, 
withdrawal management and after care 
• advocacy and family support [74, 75]. 
It is important to remember that in the initial stages of a person’s presentation to the 
emergency department, the consideration of the underlying nature of the symptoms is less 
important that its management [73].   
The aim of the initial assessment in the acute or primary health care setting is to identify 
any immediate or potentially life threatening medical or psychiatric problem/s in order to 
implement appropriate interventions.  
As soon as practicable, a risk assessment and provisional diagnosis based on MH/ATOD 
symptoms, and planning for safe medical and nursing care needs to be undertaken.  
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Further in-depth assessment and differential diagnosis is required once the emergency has 
passed, and the person is stable and able to participate and contribute to identification of 
issues and planning for ongoing intervention following discharge.  
Engagement 
People with comorbidity often have low self esteem and feelings of shame and stigma due 
to attitudes and behaviours of other people. Because of this they may be less willing to 
relax with you and offer a reasonable account of their MH and ATOD issues. This will be 
even less likely if they feel you might be judgemental or dismissive.  
At times, people with ATOD problems can feel an enormous sense of guilt and shame at 
some of the things they have done, or anger they feel about what happened to them e.g. 
being abused  and its sequelae e.g. feelings of hopelessness, helplessness, guilt and 
unworthiness 
• Engagement is the major priority with any person experiencing comorbidity. 
• Engagement can be facilitated by the nurse or midwife taking a supportive 
approach by encouraging the person within their capacity to consider change and 
take responsibility to address their issues. 
• This can promote the person’s consideration and acceptance of the services 
offered and willingness to adhere to their treatment. 
• It can also provide the opportunity for the nurse to discuss with the person their 
concerns about their needs, treatment options and preferences. 
Developing, trust, hope, motivation and self efficacy 
Providing a friendly and safe environment for assessment requires the nurse to actively 
aim at developing rapport and trust with the client. This is the most important precursor to 
effective assessment, diagnosis and treatment. Demonstrating acceptance and empathy, 
using active listening, explaining why they are being assessed and using open-ended 
questions about any difficulties they may be having are essential. 
Normalising a person’s feelings of guilt and shame and placing their experiences in context 
is important. Acknowledging the person’s worth and responses aimed at externalising the 
issue and not making judgements can be helpful. E.g. ATOD use often causes people to do 
things they would never normally do. Informing the person that help is available and 
offering referral to someone they can talk to demonstrates that their problems are 




Comorbidity Assessment in Acute Emergency Setting 
Note: For further information regarding specific ATOD assessment, please refer to Section 
2.2, and Section 3.  
This section provides a summary of the evidence based parameters of comorbidity 
assessment. These include: 
• effective communication 
• using a person centred approach 
• confidentiality 
• raising the issue 
• identifying factors that will assist in building motivation for change 
• holistic care planning, and referral. 
Assessment should be inclusive of all of the issues relevant to the person’s presenting 
situation, including mental health, ATOD use, physical health, cultural and social issues. 
Assessment of a person experiencing an acute episode of a mental illness may be difficult 
due to the symptoms experienced e.g. the person may be overly suspicious, anxious, 
frightened, misperceive the questions or provide incoherent answers.   
Depending on the severity of the person’s acute illness, assessment data required to 
identify immediate needs may need to be obtained from a trusted family member, carer or 
friend depending on who is with the person or can be contacted. 
Risk Assessment 
Safety is paramount and needs to be assessed and monitored throughout the person’s 
assessment and treatment. Health services need to have effective policies, protocols and 
procedures to help staff in assisting and managing people at risk of accidents e.g. falls, as 
well as harming self or others. These should include the need for: 
• additional assessment by specialist clinician 
• close supervision [specialling] until risk to self or others no longer exists, or 
• the person has been transferred to an acute MH service [74]. 
Once the person is mentally and physically stable and able to be involved, a comprehensive 
comorbidity assessment should be undertaken. It is important to involve family or carers as 
appropriate. The aim of comorbidity assessment is to identify the person’s:  
• immediate risk factors e.g. suicidal ideation or self harm; withdrawal; delirium 
tremens, withdrawal seizures, intoxication; overdose or toxicity; self harm; acute 




ATOD history, pattern of use, problems; and their severity (see section 2)  
• MH history, onset of current problem and its severity  
• current physical illness/es and previous history  
• any disability (physical or intellectual including alcohol or drug related brain injury)  
• immediate and future needs from the person’s perspective  
• potential and capacity to make changes  
• goals and readiness for change - motivation may be stronger or weaker in relation 
to changing ATOD  use versus their MH problems [76] 
• current medications [prescribed and OTC] 
• date, time and dose of last prescribed medication/s use 
• recent history of ATOD use (dose, quantity. method of use and risky behaviours) 
• date, time and dose of last ATOD use 
• recent or current ATOD or MH treatments. 
Acute ATOD conditions 
For detailed information regarding acute ATOD conditions and assessment please refer to 
sections 2 and 3.  
Acute MH conditions 
As with serious physical conditions e.g. hypoxia, head injury, meningitis or delirium, 
assessment of someone’s acute MH condition may be impeded due to their symptoms and 
behaviours: 
• difficulty in concentrating 
• poor memory 
• agitation 
• rapid mood swings 
• suspicious thoughts 
• acute anxiety 
• fear 
• misperceptions of communication and actions  












monitor and record: 
Identify: 
 
Physical Signs and symptoms of 




other serious injury or 
illness 
evidence of self harm 
medications side effects 




level of consciousness 
symptoms  
experienced 
risk for self harm 
Current medications 
(prescribed, OTC, herbal, 
complementary) 
Any alcohol or other drugs 
including solvents 
Time of last prescribed and 
non prescribed medication/s 
dose, ATOD’s used 
ATOD Immediate risk of: 
acute intoxication 
acute withdrawal (in 
particular alcohol) 
overdose or toxicity 
recent history of all 
types of ATOD used. 
ATOD effects and 
interactions with any 
medications 
Onset and severity of: 
withdrawal symptoms 
and/or signs of 
withdrawal 
complications 
Onset or progression 
to overdose 
 
Collateral information from 
family/friends:  
dose, quantity, method of 
use (swallow, inject etc.) and 
associated risks 
time and dose/amount and 
method of last ATOD use any 
recent or current ATOD or 
MH problems and 
treatments 
risk of withdrawal – known 
history of withdrawal and 
complications of withdrawal 
e.g. alcohol withdrawal 
seizures or delirium tremens 
(see Section 3) 
history of past ATOD 
problems and treatments 
Mental Health 
(MH) 






anxiety e.g. panic attack 
medication side effects 
and interactions 
medications 
Risk for suicide, other 
self harm or harm to 
others 
Evidence of recent or 
current self harm e.g. 













People experiencing mental illness may also have a range of social and other issues related 
to their illness that may impact on their presentation and presenting issues.  
These may include: 
• violence (not common)  
• family, relationship and employment difficulties   
• high risk social conditions e.g. homelessness, high risk tenancy tenure, vulnerability 
from the actions of others particularly financial 
• inability to manage finances and activities of daily living 
• inappropriate or unsafe housing e.g. young person staying in adult shelter, unsafe 
electrical wiring, not power or water. 
It is important to ask about and document these issues. No person should be discharged to 
homelessness or to an unsafe home environment. Where there is known extreme family 
violence considerations should be given for referral to the area family safety committee. 
Principles of care  
Care of the person with comorbidity in the emergency setting may need to be 
opportunistic but should always be, timely and aimed at: 
• the person’s condition and response to interventions  
• promoting the person's awareness of any interaction between ATOD use, mental 
health problem and any prescribed medication  
• involving and educating family or carers where appropriate. 
Principles include: 
• prioritising the person’s immediate and devising an integrated plan. 
• identifying and noting longer term needs which form the basis of referrals in pre 
discharge planning 
• timely monitoring and review of all conditions to recognise early signs of 
deterioration, relapse  or improvements and amend care plans accordingly 
• timely monitoring and review of social and cultural situation to identify situations 
which may negatively impact on post discharge progress and recovery  
• stabilising and initiating treatment for all conditions as the primary intervention 
goal  
• facilitating a trusting therapeutic relationship with the person will help form a 
treatment alliance which promotes the person’s participation in their intervention 
process and encourages them to engage with ATOD and/or MH services and other 
services as needed [74]. 
137 
 
Treatment planning  
Planning is based on client needs and the required clinical responses – including the client’s 
preferred treatment options; provision of various services and resources that are available 
and acceptable to the person.  
The treatment plan aims to meet the person’s needs as best as possible e.g.: 
• safe medication use 
• safe housing 
• induction and stabilization of medical therapies e.g. methadone for opioid 
dependence or acamprosate for alcohol dependence)  
• talking therapies such as cognitive behavioural therapy (CBT), narrative therapy 
and counselling  
• comorbidity treatment 
• treatment of any physical health conditions  
• support for disability. 
Collaboration and coordination of the care plan between clinical teams and services are 
necessary to ensure delivery of comprehensive care.  
Nursing Management in the Acute Emergency Setting 
The appropriate interventions to manage presenting issues are implemented based on the 
care plan developed by the treating team. This would be amended as required according to 
any changes in the person’s condition and treatment responses.  
Acute nursing management aims to: 
• implement the nursing care plan 
• address and stabilise co-existing health problems as per nursing assessment and  
diagnoses  
• monitor regularly for  early signs and symptoms and early intervention for acute 
conditions  as these emerge e.g. withdrawal, Wernicke’s Encephalopathy, 
septicaemia,  overdose, psychosis, hypoglaecemia etc. 
• initiate and administrate  all ordered prescription and non prescription 
medications and prophylactic medication regimes 
• observe for any adverse side effects or drug  interactions – particularly important  
for multiple prescribed medications and complex pharmacy regimes.  
o safe management of their medicines needs to be addressed for the person 




• predict and manage specific concurrent conditions or injury e.g.:  hypertension, 
electrolyte imbalance,  dehydration; diabetes, cardiac or other physical conditions; 
as well as acute intoxication, withdrawal, overdose; drug interactions; acute or 
underlying mental illness 
• attend to the person’s immediate social needs and include these as core  
components of their care and discharge plans. 
General Care 
Family and Social Interventions 
It is important to encourage, educate, support and include the person’s preferred family 
members, carers and significant others in their care. They are critical in ensuring the 
person can be supported during admission and after discharge.  They need to be involved 
as appropriate and provided with information about: 
• the person’s main problems (depending on their need to know and patient 
confidentiality) - what these mean for the person and treatment and supports 
required 
• comorbidity problems and the person’s behaviours which they may have found 
disturbing – these may be  sign s of the mental illness  and not just ‘bad behaviour’  
• the care plan needs to include the prescribed medications, possible side effects 
and their safe management  
• How they can help the person manage their medications and treatment, attend 
appointment 
• how to  recognise early signs of relapse and when and how to seek help 
• how to access social supports, recreation or activity groups 
• how to look after themselves  and seeking help when needed. 
Where a person is socially isolated or does not have family or other suitable social 
supports, special consideration needs to be given when devising appropriate ways to help 
them engage with others, build social skills and networks e.g. linking with community self-
help and support groups which  are accessible through  the  24 hour phone service 1300 13 
1340. Many have members who can visit people in hospital. 
Education of the person and their family 
People with comorbidity often need information about the: 
• nature and prognosis of their problems, likely symptoms, and  longer term 
consequences 
• likelihood of recovery and/or amelioration of symptoms 
• available treatments and how effective they may be 
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• range of non prescribed and prescribed medications that may be useful, and their 
possible side effects  
• risks from not receiving treatment in time 
• emerging signs of relapse, what strategies to use and when to seek help 
• strategies and skills  to self manage symptoms and medications, including building 
confidence and self esteem   
• need to ask questions and receive answers  to the same questions more than once 
– their retention of information may be impaired at times   
• need for any information or advice provided to be documented in their case notes 
and care plan. 
Self Help Groups 
Becoming involved with a suitable community self help group is known to have better 
outcomes for people with ATOD dependence and mental illness.  It is an important adjunct 
to the person’s plan for treatment and ongoing support. These groups may focus on MH 
and/or ATOD problems and   social issues of their members. These include AA, ALANON, 
NarAnon, Beyond Blue, MIND, SANE, Gamblers Anonymous and GROW (see Resources 
Section 4). 
Encouraging people  to join a self help group can provide them with new friends  with 
similar issues and positive, social contact, and help them to build their confidence and skills  
in managing their comorbidity [74]. 
Safe Medication Management 
A major concern regarding comorbidity relapse is if the person forgets to take their 
medications or stops their medications, e.g. they feel better or have side effects.   Each 
person’s reasons for this vary and can be complex. The nurse or midwife needs to explore 
these, work with the treating team to find ways that can better help the person to 
managing better, maintain recovery, and avoid relapse and exacerbation of their 
symptoms. 
When a person is admitted to hospital and had erratic medication use or recently ceased 
use, it is important to quickly build rapport so that the reason for this can be understood.  
Their reasons may be due to having no money or easy access to a pharmacy or their doctor 
due to transport problems; It may be due to the side effects of their medications such as 
weight gain, loss of libido, blunting or numbing of emotions “feeling like a zombie” or 
having “no feelings of happiness”.  
For the person with psychosis, it is important to engage with them and explore the effects 
of their medications on their comorbidity symptoms, including the effects of ATODs they 
may be using. Understanding the wanted and unwanted effects is important in estimating 
why this is occurring and deciding what mediation adjustments may be required to reduce 
the unwanted effects and optimise the wanted effects. For example, were the medications 
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are  stopping or reducing their positive symptoms such as having more energy  and losing 
weight the person may resist the risk of losing these benefits.   
If person decides not to use their medications and/or use other ATODs such as cannabis, 
providing them with education and goof information about their need for the prescribed 
medications is necessary. Their situation also needs to be communicated to their treating 
GP and specialist so that their situation can be monitored and prescribed medications 
resumed as the opportunity arises. Good communications can also stimulate other services 
to engage with the person and support them prevent and manage any relapse (see Section 
2.3). 
Assessment and re-assessment are key opportunities to educate the person and their 
family or carer about their risks from using ATODs. In particular the relationship this may 
have with interfering with the stability of their comorbidity conditions, and impact on likely 
progression and severity of their conditions. 
Nurses and midwives can assist in a person’s longer term medication management and 
relapse prevention by: 
• Providing all medicines on time and doses as prescribed throughout the admission.  
• Monitoring for side effects and report and record these to the prescribing medical 
officer. 
• Informing the person and their family about how particular medications can assist 
their treatment and recovery. 
 The importance of presenting easy to understand information to the person cannot be 
overstated. They may have limited understanding of the words used, difficulties in reading 
or be confused, unaware or concerned about their medications and why and how they are 
to be taken. 
Information should include mental illnesses, ATOD problems, comorbidity and safe 
medication use (see Resource and Contacts Section). 
Safe medication use  
The person and their family need information about: 
• How their medicines work (pharmacology)  
• Wanted effects and how long these take to start working from first dose  
• Possible side effects and what to do  
• Possible other drug interactions including medicines, alcohol, other drugs 
• Toxic effects (poisoning)  
• Overdose 
• When and how to seek assistance. 
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Building the person’s confidence and skills in managing their medications is important. This 
needs to involve teaching them the skills to manage, educating them about their options 
and decisions about their medications and treatment plan, and what supports there are 
nearby to help them when they go home. 
In a ‘nutshell’: 
• Ensure their needs and choices, are considered in care plan and medication 
reviews. 
• Advocate for them to ensure their involvement in their above, and any other 
important decisions affecting them. 
• Advise them to continue their prescribed medications even when they feel better. 
• Help them to understand that their medications are chosen to relieve their 
symptoms and maintain stability.  
o Ask them on what they understand about their medications, how they feel 
about taking them and any concerns they may have.  
o Be prepared to answer her questions and seek advice from their 
prescribing doctor as needed.  
• Inform their GP and specialist if they (or family) are concerned about possible 
problems from taking their medications so that this can be reviewed as soon as 
possible.  
• Help the person to understand, whether or not their comorbidity conditions are  
likely to endure, and how best to manage this e.g. 
o Their alcohol dependence may respond well to treatment while their 
mood disorder may endure and require long term medication and other 
treatment. 
• Communicate with the person’s family or carer to help them understand why the 
person needs their prescribed medicines. 
o  Discuss with them what may occur if the medications are not taken as 
prescribed or are ceased without medical supervision. 
• Handover to your team any issues that arise from these actions and record in the 
person’s case notes.  
Medication Regimes 
Assist the person to find ways that they can use to ensure they can take their medications 
safely by: 
• helping them, to identify and solve problems that prevent them from taking their 




• ensuring they know how to get the right bus/train to attend their appointment for 
e.g. medication and treatment reviews 
• providing information that does not rely on good literacy and numeracy skills – 
such as pictures and easy symbols that represent the information required.  
Educate them with reliable internet resources such as Beyond Blue and the 
Australian Drug Foundation (See Section 4 Resources). 
Teaching them easy practical ways to manage medications safely: 
• teach how to fill their medication dosette for  a week or asking the pharmacist to 
regularly prepare Webster packs from the pharmacist 
• teach how to store medications safely 
• inform them, about their local bus or train outs, and how to use the  community 
bus that can take them to their local pharmacy and GP 
• teach the person about what to do if they lose their prescriptions or medications  
• advise them and their family or carer about what arrangements can be made with 
their local pharmacy for them to leave their prescriptions and medication stores 
there for safe keeping and easy access.  
Encourage the person to talk about their medications or other concerns they have about 
their treatment after their discharge: 
• early  in their admission (as appropriate) and as problems arise rather than waiting 
till discharge is imminent 
• reassure them that they can talk to their doctor and treating team at any time 
about their medications and any problems they may be having, and that this is 
important. 
Engaging the family or carer so that they understand the issues and can support the person 
within their capacity is very useful. This means informing and involving them in the long 
term treatment planning, including:  
• Addressing any practical and cultural barriers to treatment such as transport; poor 
English or cultural support; limited hours of operation of services (e.g.  weekday 
business hours only).  
• Educating family or carers about what to do if the person becomes distressed 
about their medications (See Resource Section).  
• Call  the Alcohol and Drug Information Service (ADIS) 24 hour phone support 




Medication regime – patient refusal of medications while in hospital  
If the person absolutely refuses to take their medications:  
• Let them know you are there to help. 
• Acknowledge concerns and show 
empathy.  
• Ask them what they would prefer to 
happen and what they think might 
happen if they do not have these 
medications.  
• Relate this to their particular 
comorbidity conditions and their need 
for medications. 
• Ask the person to share reasons and 
concerns.  
• Do not argue with them.  
• Educate them and provide quality 
information to assist them in making 
an informed choice.  
• Ensure they know what other services 
can be provided such as psychological 
therapies, counselling and social 
support (see Section 2). 
Other Nursing Management 
Maintaining boundaries of behaviour  
Setting and maintaining safe behavioural boundaries between yourself and the person 
with comorbidity, particularly when acute, is essential. This will help them to have positive 
treatment experience and outcomes. It is especially important in assisting them to take 
control over possible harmful behaviour. Some people have diminished capacity to control 
their behaviour due to their MH condition e.g. they may have a personality disorder that 
interferes with their capacity to interact positively with others, and can interfere with them 
receiving the treatment they require. Importantly we need to remember that their 
behaviour is often their coping strategy having been developed from a past history of 
trauma such as child sexual abuse and other trauma. 
Examples of setting boundaries include: 
• Maintaining your professional relationship at all times while still being friendly and 
communicative. 
• Having consistent, fair and firm boundaries (not rigid or punitive).  
• Developing a behavioural management plan for all staff.  
• Establishing acceptable rules about contacting another worker or service external 
to their current care team. 
• Make sure the person understands the boundaries, why they are in place and how 
they will be used – to keep them safe and enable their treatment and support to 
be optimised – we want to help. 
• Work flexibly within the set boundaries, and monitor and review the person’s 
response and progress regularly [74].  
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Developing behaviour management plans 
Developing a behaviour management plan with the person needs to include: 
• Identifying and setting limits regarding unacceptable behaviours that may arise 
according to currently or very recent presentation.   
• Identify clearly the consequences of particular unacceptable behaviour - relevant 
to the nature and severity of the behaviour e.g. Terminate admission if medically 
safe to do so. 
• Ensure familiarity of Mental Health Act, and how this may need to be applied.  
It is important to be supportive and inform the person about: 
• what is acceptable and expected 
• what is unacceptable in relation to their behaviour e.g. trying to be intimate with a 
staff or other people; requesting  illegal medication provision; using  alcohol or 
drugs on the premises, being verbally or physically aggressive; intimidating or 
threatening staff or other people; possessing a weapon 
• the goal is to work with them not against them  
• any consequences respond to the actual behaviours – not excessively punitive 
• seeking the person’s concerns (and fears) about their comorbidity and treatment  
• how their  unmet needs can be  addressed and therefore reduce their concerns 
during their treatment plan 
• keeping their confidentiality may need to be breached e.g. if they threaten others 
or harm themselves due to impulsive behaviour. 
Referral to specialist ATOD and Mental Health services 
Not all people with ATOD or MH symptoms require specialist referral. If their condition/s 
are stable and not greatly impacting on general function and daily life, they are likely to 
respond well to general nursing and medical care while in hospital. Their after care plan 
should ensure they will be monitored regularly by their GP and supported by other 
relevant health and social services depending on their situation. If the hospital team is 
unsure it is wise to consult a specialist clinician/service for further assessment and 
guidance in managing their comorbidity during their admission.  
If screening and assessment reveals more serious ATOD and/or MH comorbidity, the 
person’s symptoms are unstable and their health, well being and capacity to manage are 
compromised, they require immediate referral to a specialist consultant/service. It is 
important that this referral happens early in the admission to ensure that the specialist 
service can assess them prior to discharge and put in place their after care plan.  This will 
include clinical management as well as then community supports and services required by 
the person and their family. 
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In a ‘nutshell’:  
Referral to specialist ATOD/MH services should be considered when the person’s: 
• ATOD use places them at high risk of 
injury, dependence, poor general and 
mental health and issues such as; 
poor medication management, 
needle/syringe sharing, unsafe sex, 
drink or drug driving 
• MH issues interfere with daily life and 
capacity to function 
 
• presentation is due to inability to 
maintain their existing ATOD and MH 
treatment regimes 
• condition indicates they are at risk of 
harm to self or others  
• condition has resulted in multiple 
presentations 
• condition indicates ATOD 
dependence.  
For those in rural/remote areas there is a 24 hour clinical consultation service through 
ADIS (See Resources Section) Call 1300 13 1340. 
Referral may be required if the nurse and medical team do not feel comfortable in treating 
the person’s condition during admission and in their after-care planning. If the person is 
being admitted or leaving another service such as hospital, their care coordinator or 
caseworker needs to be notified. This is especially important if the person is receiving 
treatment from ATOD or MH services. 
Whilst a person is in hospital referral to a specialist consultant/service needs to be 
discussed with the care team. Referral should occur with the person’s consent (or their 
legal guardian) unless there is MH legislation (detention) in place to protect the person’s 
safety or that of the community. 
If a person refuses to consent to the nursing and medical team can consult the clinical 




When referring a person to ATOD services, certain information will need to be provided, 
such as: 
• copies of any screening results  
(AUDIT, ASSIST, IRIS) 
• information about the person’s 
current  condition/s  
• expectations of the specialist service 
• current ATOD treatment   
• MH History and current MH 
treatment 
• known diagnosis of mental illness 
• person’s insight into their ATOD /MH 
issues 
• any challenging behaviours – current 
and recent past 
• reason for referral  
• level of urgency  
• ATOD history (see Section 2) 
• MH risk assessment result  
• MH symptoms and severity 
• persons’ concerns regarding their 
ATOD and MH problems  
• what the person needs from their 
service e.g. in-depth assessment, early 
admission, medical and psychological 
treatment, medication review, 
coordinated care, specialist nursing 
care. 
Relevant referral information allows the specialist nurse or other professional to identify 
any resources needed to be taken to the hospital when coming to assess the person before 
discharge. For example if the person is undergoing alcohol withdrawal the specialist ATOD 
nurse could educate the other staff as well as the person about this, and provide a self help 
booklet to assist them through withdrawal. 
What to expect from specialist services 
In responding to people with comorbidity, there should be ‘no wrong door’ in MH and 
ATOD services  - there needs to be an integrated approach and willingness from both 
specialties to accept comorbidity referrals and work together to support and treat the 
person’s conditions simultaneously. 
Every person with comorbidity conditions require comprehensive assessment and tailored 
care plan. They require a designated case manager or key worker whose role is to 
coordinate their care, and ensure effective collaboration between the relevant services, for 
support, treatment, monitoring and assertive follow up for all of their health and related 
issues.  No person with comorbidity or their family or carer should be left without 
adequate comorbidity sand general health care or community supports. 
It is important therefore that the general health care team know what to expect regarding 




The person affected by comorbidity, and their family or carer need to be well informed 
about what they should expect  in this regard  such as concurrent (holistic) assessment and 
treatment planning, coordination between relevant teams and services. Whether they 
attend a mental health or drug and alcohol specialist services their comorbidity should be 
diagnosed and treated. Therefore these services should be asked about what they provide 
in regards to comorbidity care so that your team and the person and their family or carer 
are well aware of what they offer and how they can assist. This can ensure people with 
comorbidity are referred effectively and not ‘bounced’ between’ services which has 
happened.  
Knowing about the admission/intake criteria of the various specialist services enables 
nurses and their team to be selective in their comorbidity referrals, and advocate on behalf 
of the people in their care. 
Best practice in comorbidity care 
It must be recognised that there can be barriers to people affected by comorbidity 
receiving the specialist care they require from some mental health or drug and alcohol 
services. This is particularly relevant for outer city and rural/remote areas, where support 
from telemedicine (psychiatry), ATOD telephone clinical advice (1300 13 1340) and local 
hospital and community health services are required.  
People affected by comorbidity who are receiving treatment from specialist services 
require regular monitoring and re-assessment as their needs change, and support in 
accessing other essential services such as housing and social connect ion programs.   
Their physical health issues, including dental problems are also important considerations.  
People affected with comorbidity may only present for care when their condition /s are 
acute or significantly advanced and complex. This means that nurses and the team within 
the emergency department of other areas of the general hospital are commonly caring for 
people when they are most vulnerable. This makes assessment and treatment challenging 
but even more critical so as to adapt their treatment and discharge plans in ways that can 
maximise monitoring and stability of their conditions, and minimise their risk of relapse 
and crisis episodes. This issue needs careful consideration for each person so affected, with 
collaboration between the key treating clinicians and services, so that discharge planning 
includes close monitoring and support with regular follow-up and coordinated community 
care.  
People affected by comorbidity are diverse, can be young or older. Their experience of 
comorbidity may be influenced by their development stage of life, living situations and 
individual experiences and characteristics. People affected by comorbidity can  have  ‘once 
off’  or occasional episodes that resolve,  while others have longer term or lifelong 
comorbidity that is complex and commonly erodes their well being and life opportunities.  
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Stabilisation, recovery and ‘moving on’ from any of their conditions (e.g. anxiety or alcohol 
dependence) are challenging.  Many do succeed having had multiple attempts before 
reaching their goal.  
This is why a ‘client centred’ tailored approach to assessment, treatment and after care for 
each person presenting with comorbidity is required. This can start when they are a patient 
in the general hospital or community setting.  
Features of client centred comorbidity treatment/care include: 
• Comprehensive physical, ATOD and 
MH assessment. 
• Risk reduction and relapse plan for 
early identification and intervention. 
Includes ATOD, MH and physical 
conditions. 
• Long term safe housing with 
supported accommodation if 
required. 
• Regular case-conferencing between 
all services to review person’s 
progress, identify additional needs, 
amend care plan. 
• Treatment/care plan  
• Assertive outreach, monitoring and 
follow-up. 
• Collaboration between all services 
involved, with clearly defined roles 
and agreed communications. 
• Provision of consultation and support 
for collaborating services and 
professional groups on client 
management e.g. clinical team in the 
hospital or mental health unit and 











The section presents four categories of psycho-active drugs affecting the central nervous 
system (CNS). According to the particular category, particular drugs of concern are 
presented with the necessary clinical guidance for assessment and safe management in the 
general health care setting. 
The categories are:  
3.1 Depressants  
• 3.1.1  Alcohol 
• 3.1.2 Opioids (opiates) 
• 3.1.3 Pain and analgesia 
• 3.1.4 Benzodiazepines  
• 3.1.5 Gamma hydroxybutyrate (GHB)  
3.2 Cannabis 
3.3 Psycho-stimulants 
• 3.3.1  Nicotine 
• 3.3.2 Amphetamines  
• 3.3.3 Cocaine 
3.4 Hallucinogens 
• 3.4.1  Hallucinogens 
3.5 Other  
• 3.5.1 Ketamine 
• 3.5.2 Inhalants (solvents) 




In this chapter: 
• 3.1.1  Alcohol 
• 3.1.2 Opioids (opiates) 
• 3.1.3 Pain and analgesia 
• 3.1.4 Benzodiazepines  





Alcohol is a major central nervous system depressant. Alcohol is consumed by about 84% 
of Australians, the majority of whom drink at low risk levels [79]. However there are 
significant groups of people, many from a young age, whose short or longer term health is 
at risk due to drinking.  
Here is some essential information taken from the national alcohol guidelines for 
Australians [80]. 
Key terms: 
• Standard drink – the Australian standard drink contains 10g of pure alcohol (e.g. 
100ml wine; 285 mls of full strength beer; 60 mls fortified wine such as port; 30mls 
of any spirit). 
• Drinking occasion/single occasion – a sequence of drinks taken without the blood 
alcohol concentration reaching zero in between.  
• Regular drinking – repeated drinking occasions over a period of time – e.g. drinking 
daily, or every weekend, over many years. This is not necessarily dependent 
drinking.  
• Harmful drinking – drinking at levels that are likely to cause significant injury or 
short or long term ill health.  
• Harm – adverse health outcomes; in this context harm includes disease and/or 
injury resulting from consumption of alcohol.  
• Immediate effects – the acute effects of during or after an occasion of drinking, 
lasting until the blood alcohol concentration returns to zero.  
• Cumulative effects – the effects of many drinking occasions.  
• Risk – a person’s risk of experiencing an adverse health outcome is the probability 
of the person developing that outcome in a specified time period.  
• Absolute risk – the actual risk of injury or disease from drinking.  
• Lifetime risk – the accumulated risk from drinking either on many drinking 
occasions, or on a regular (e.g. daily) basis over a lifetime.  
• Relative risk – the risk of harm in drinkers relative to the risk of harm in non-
drinkers.  
Note: that the relative risk on its own does not give any information about the absolute 
risk of harm.  
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Short or long-term risk to health from any alcohol consumption 
Short term or immediate effects (such as once off or occasional risky drinking) can include: 
• Intoxication 





• delayed reaction time 
• impaired balance 
• co-ordination and loss of fine 
motor skills 
• impaired respiration at high BAC 
with the possibility of 
unconsciousness and death. 
Long term or cumulative effects include:  
• Cardiovascular disease  
• cancers (various) 
• diabetes 
• nutrition-related conditions 
• risks to the unborn child 
• liver disease 
• cognitive impairment (incl. brain 
damage)  
• premature disability or death 
[81]. 
Alcohol consumption at even low-risk levels is not recommended for people who are: 
• experiencing a health condition made worse by drinking 
• taking particular medications  
• children and adolescents under 18 years of age 
• pregnant or breastfeeding 
• about to engage in activities involving risk or a degree of skill (e.g. driving, flying, 
water sports, skiing, operating machinery  
• using other drugs or substances that adversely interact with alcohol [81].  
The National Health & Medical Research Council (NH&MRC) [80] has developed guidelines 
for people considering alcohol consumption, based on the latest best evidence. These are: 
Guideline 1 - Reducing the risk of alcohol-related harm over a lifetime  
For healthy men and women, drinking no more than 2 standard drinks on any day reduces 
the lifetime risk of harm from alcohol-related disease or injury.  
Guideline 2 - Reducing the risk of injury on a single occasion of drinking  
For healthy men and women, drinking no more than 4 standard drinks on a single occasion 
reduces the risk of alcohol-related injury arising from that occasion. 
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Guideline 3 - Children and young people under 18 years of age  
For children and young people less than 18 years of age, not drinking is the safest option. 
Parents and carers should be advised that children under 15 years of age are at the 
greatest risk of harm from drinking and that for this age group, not drinking is especially 
important. For young people aged 15-17 years, the safest option is to delay the initiation of 
drinking for as long as possible.  
Guideline 4 - Pregnancy and breastfeeding  
Maternal alcohol consumption can harm the developing foetus or breastfeeding baby.  
For women who are pregnant or planning a pregnancy, not drinking is the safest option. 
For women who are breastfeeding, not drinking is the safest option. 
In addition to the above it is important to note: 
• Mental health problems– people who have, or are prone to, mental health 
conditions (e.g. anxiety and depression, schizophrenia) may have worse symptoms 
after drinking. Alcohol can also trigger a variety of mental health conditions in 
people who are already prone to these conditions. 
• Other health conditions that are made worse by alcohol – people who already 
have physical health conditions caused or exacerbated by alcohol, such as epilepsy, 
alcohol dependence, cirrhosis of the liver, alcoholic hepatitis or pancreatitis, other 
acute or chronic diseases are at risk of the condition becoming worse if they drink 
[80]. 
To access the 2009 Australian Guidelines to Reduce Health Risks from Drinking Alcohol go 
to: www.nhmrc.gov.au/publications/synopses/ds10syn.htm 
Alcohol and clinical intervention 
The following mechanisms are important to understand in relation to alcohol withdrawal 
and therefore how best to determine if a person is at risk. 
Tolerance – the immediate effects of alcohol on the brain are often less apparent in people 
who drink regularly, as they acquire a degree of tolerance. Tolerance occurs in part 
because the liver becomes more efficient at breaking down alcohol. The person learns to 
cope with, and compensate for, the deficits induced by alcohol. Despite this tolerance, the 
long-term effects remain damaging, particularly as the drinkers who have greater tolerance 
for alcohol are likely to be those who experience higher blood alcohol levels more 
frequently [80]. 
Dependence – alcohol is an addictive drug and regular use can result in alcohol 
dependence. Alcohol dependence is a complex phenomenon. In brief, it refers to situations 
where a person feels a strong need to drink so that drinking is given priority over other 
behaviours that the person had previously found much more important.  
Dependence ranges from mild to severe. People with severe dependence drink regularly at 
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high-risk levels, often find it hard to limit how much they drink, and generally have marked 
tolerance to the effects of alcohol. If they stop drinking for a few hours, they experience 
tremulousness and anxiety. Alcohol is strongly linked with anxiety and depression in those 
with alcohol dependence, and this increases the risks of violence and self-harm. Alcohol 
dependence is a major risk factor for suicide [80]. 
Alcohol tolerance and dependence can be missed, particularly if a person is admitted to 
hospital for surgery or unexpected illness or injury. Alcohol withdrawal can be very serious 
leading to seizures, hallucinations and delirium tremens (DTs), which can be life-
threatening.  
Alcohol withdrawal symptoms can frequently be predicted if the risk of tolerance and 
possible past history have been identified. It is therefore extremely important that all 
nurses undertake a drinking history to assess risk, and are ready and can recognise and 
manage the symptoms of withdrawal and possible complications.  
For additional information refer to [82].  
To access this document go to:  
http://www.health.gov.au/internet/alcohol/publishing.nsf/Content/treat-guide 
Critical situations 
Thiamine, other vitamins and mineral supplements 
Thiamine (Vitamin B1) is administered to people drinking the daily equivalent to 8 standard 
drinks or more (men) and 6 standard drinks or more (women) to treat or prevent Wernicke 
– Korsakoff’s syndrome. The need for Thiamine treatment may be determined by blood 
test results that indicate Thiamine deficiency. 
Thiamine deficiency—Wernicke’s encephalopathy  
Thiamine deficiency is common in people who drink heavily and is a major cause of 
Wernicke’s encephalopathy. This is an acute condition associated with high-risk levels of 
alcohol use, or any condition that has caused poor nutritional status and its sequelae (e.g. 
malnutrition, anorexia or bowel disease). If the condition is not treated effectively and 
early, it can lead to permanent brain damage and memory loss. It can occur in heavy 
drinkers (60gms a day or almost daily for adults). 
Preventing Wernicke’s encephalopathy in people at risk but not withdrawing 
• In people who are nutritionally compromised and therefore at serious risk of 
Wernicke’s encephalopathy, parenteral thiamine should be given prior to any 
glucose loading.  
• IV thiamine can be administered concurrently with a glucose infusion   
• People at risk of alcohol withdrawal should be administered at least 100mg TDS 
IMI or IV particularly if there is evidence of Coagulopathy.  
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• Coagulopathy may render intramuscular injection unsafe. 
• If withdrawal occurs the person should be administered 100mg TDS IM or IV for 
three days followed by oral thiamine 100mg TDS for the remainder of the 
admission.  
o A B Forte formulation containing 250 mgs thiamine may be available and 
used in some settings.   
• Correct any electrolyte` disturbances including hypomagnesaemia 
• Daily oral multivitamins should also be administered.  
• Resuscitation equipment should be immediately available when thiamine is given 
IV, in the unlikely event of anaphylaxis [50]. The risk of this is extremely low [83]. 
Treating Wernicke’s encephalopathy  
Signs and symptoms of Wernicke’s encephalopathy: 
• ophthalmoplegia (reduced eye movements or nystagmus) 
• neuropathy – pins and needles or loss of feeling in extremities 
• ataxia – unsteady gait 
• confusion – people may also have impairment of memory, concentration and 
judgement, confabulation and labile mood. These problems may coexist with both 
intoxication and withdrawal 
• acute disorientation. 
This condition is preventable and can be reversible if recognised and treated with 
parenteral Thiamine.  
Because a high carbohydrate load exacerbates Thiamine deficiency, any carbohydrate 
loading e.g. glucose or dextrose must be accompanied by parenteral thiamine. This can be 
given simultaneously if given IV. 
Thiamine treatment is based on the person’s drinking history and changes in clinical signs. 
With signs of Wernicke’s encephalopathy, treatment of presumed Wernicke’s should be 
commenced. 
• Parenteral doses of at least 500mg thiamine every 24 hours IM or IV diluted in 
saline over 30 minutes should be given for at least 3 – 5 days. The intramuscular 
route should not be used for people who have Coagulopathy. This is followed by 
300mg per day oral or parenteral for 1 – 2 weeks.   
• Always check magnesium status since deficiency can impair Thiamine utilisation 
[84]. 
• Oral multivitamin and mineral supplement are also needed. 
• Any person who has alcohol related brain damage or an episode of Wernicke’s 
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encephalopathy or continues to drink should be maintained on oral thiamine 
supplements on a continuing basis. 
Alcoholic hallucinosis 
Alcohol hallucinosis is a cluster of psychotic symptoms that appear during or following a 
period of heavy alcohol use. It can co-exist during acute intoxication or withdrawal but is 
apparently not caused by these conditions.  
This disorder is characterised by hallucinations (typically auditory, but often involving other 
senses), perceptual distortions (usually visual tactile, auditory), paranoid or other 
delusions, psychomotor disturbances, and abnormal affect (ranging from intense fear to 
ecstasy). The sensorium is usually clear although some degree of clouding of consciousness 
may be present. 
Supportive care is the major focus of intervention and includes withdrawal observations in 
order to identify and manage symptoms of the withdrawal syndrome that may emerge. 
Assessment and quantification 
The level of alcohol intake is an important determinant of: 
• the likelihood of alcohol withdrawal and its subsequent severity  
• whether the person may be using alcohol at a level known to cause long-term 
harm  
• early identification of likely problems will influence choices and effectiveness of 
nursing interventions. 
Screening, assessment and monitoring tools 
(See Section 2.2: Assessment and Section 4: Appendices).   
A complete ATOD use history should reveal the following – go to Section 4, Appendix 4: 
• type of alcohol e.g. beer, wine, spirits  (and any other drug) 
• how much has been consumed in the last 24 hours  
• e.g. 10 schooners of regular beer = 10 standard drinks 
• e.g. 3  stubbies of regular beer = 5 standard drinks  
• how much is consumed - average daily intake (measured in number of standard 
drinks/grams per day) 
• frequency of drinking  (and  any other drug) e.g. once a week, daily, less than 
monthly  
• duration of use – when started drinking (be specific) , last few weeks, yesterday 
was first time etc.  
• nutritional status 
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• time and amount of last dose of any other drug/s used  
• route of administration for other drugs (e.g. sedatives, analgesics , heroin, ecstasy, 
amphetamines) e.g. oral, injecting (IV or IM), snorting, inhalation 
• concerns about drinking and/or any other drug use 
• benefits of drinking  and/or  any other drug use. 
It is important to have exact information on the amount and frequency of use and to 
document this clearly in the case notes. 
If the person does not give exact amounts initially, ask in a non-judgemental manner 
questions such as: 
• How many, how much, what is the size of the glass/bottle/cask? 
• How often would you have that amount? 
• How long have you been drinking at this level? 
• Do you do this every day? 
Note: When taking a drinking history do not accept phrases such as ‘social drinker’ or 
‘occasional drinker’. This does not convey an accurate clinical picture of what has been 
happening or what implications consumption level and pattern may have on the person’s 
current medical and psychological condition.  
Indicators of harmful alcohol use and risk of withdrawal 
Intoxication 
Any person presenting with clinical signs suggesting harmful alcohol and other drug use 
needs to be fully assessed by nursing and medical staff to identify any co-existing injury or 
illness, and that there is no risk of toxicity or overdose. 
Recent high level of alcohol consumption is generally demonstrated by:  
• level of alcohol consumption according to blood alcohol or breath alcohol 
concentration (BAC)  
• decreased level of consciousness 
• unsteady gait 
• slurred speech 
• physical trauma possibly attributable to alcohol and other drug use (e.g. fractures, 
head injuries, other injuries resulting from violence, pedestrian or motor vehicle 
and boating accidents).  
People who present intoxicated or seemingly intoxicated may be at risk from any of the 
following; alcohol dependence, withdrawal, liver disease, pancreatitis, oesophageal 
varices, hypertension, cancer, other conditions. 
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Alcohol dependence and withdrawal  
The Alcohol Use Disorders Identification Test (AUDIT) that shows a score of 13 or more 
indicates definite risk of alcohol dependence and withdrawal (see Appendix 1). 
Index of suspicion for withdrawal: 
• An alcohol intake of 80gms or more per day (such as 5 stubbies/cans of full 
strength beer) for a healthy adult man, or 60gms or more per day (3 stubbies/cans 
of full strength beer) for a healthy adult woman on a regular basis. 
• Debilitated, young, frail or elderly people may experience withdrawal at 
consumption levels less than 80gms/day for men and 60gms/day for women. 
• Some people who have been abstinent can develop tolerance and experience 
withdrawal after only two or three weeks of resuming heavy drinking. 
Brief and early intervention – harm reduction  
(See Section 2.3: Early and brief intervention). 
In this context, harm reduction uses strategies of brief intervention in helping someone 
who is drinking at risky levels to avoid short term and longer term harm. For example 
encouraging them to: 
• avoid risks associated with intoxication or overdose 
• reduce drinking levels in any session  
• understand alcohol and its effects, and harms to health 
• learn practical ways to reduce their risks.  
Strategies in reducing long-term harm from regular intake (i.e. damage to physical and 
mental health):  
• consider not drinking (abstinence) or at least drink below low-risk drinking 
guidelines [80] go to: www.nhmrc.gov.au/your-health/alcohol-guidelines  
• ensure good nutrition and healthy lifestyle 
• take Thiamine 100mg orally daily.  
Strategies in reducing short term harm from intoxication: 
• eat and drink water before drinking alcohol 
• set a drinking limit (and stick to it) and count drinks 
• try to have drinks in standard size glasses 
• have a non-alcohol spacer (e.g. water or soft drink) between alcoholic drinks  
• don’t drink and drive or use machinery  
• plan ahead—catch a taxi, stay overnight, arrange a non-drinking driver,  
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• try low alcohol alternatives such as light beers and wines  
• quench thirst on water or soft drinks – never with alcohol  
• avoid top-up drinking—keep your own glass  
• avoid drinking in rounds 
• avoid salty snacks 
• take small sips and put the container (e.g. can; cup; glass; pannikin; jar; bottle)  
down in-between each sip. 
Alcohol intoxication 
Alcohol is a central nervous system depressant. It works on all areas of the brain. In high 
doses alcohol depresses respiration, cough reflex, gag reflex and cardiovascular function 
causing various arrhythmias. Intoxication is a potentially lethal condition - as with other 
drugs, people can overdose on alcohol.  
(See Section 2.4: Managing intoxication and Section 2.5: Managing overdose). 
Signs of intoxication  
• strong smell of alcohol on their 
breath  
• analgesic and anaesthetic effects—
no/minimal pain despite obvious 
injury or illness  
• ataxia 
• increasing stupor or coma 
• cold and clammy skin 
• lowered blood pressure 
• accelerated heart rate or 
bradycardia 
• positive breath/blood alcohol 
reading 
• altered mood and/or cognition (e.g. 
mood swings, loss of inhibition, 
disorientation, confusion) 
• inappropriate behaviour/emotive 
responses to what is happening 
• altered consciousness  
• slurred or incoherent speech 
• lowered body temperature 
• slow and noisy respiration. 
Note: the person may also have consumed other depressant drugs. 
(See Section 2.4: Managing intoxication and Section 2.5: Managing overdose). 
Alcohol withdrawal syndrome 
Alcohol withdrawal syndrome can occur in someone whose body has become tolerant to 
alcohol. It is caused by the brain reacting to the fall in the blood alcohol concentration (not 
absence of alcohol), with onset occurring before the blood alcohol concentration is zero. 
Alcohol withdrawal can be mild, moderate or severe. It is a medical syndrome with a set of 




Early recognition and correct management of the initial, milder stages of withdrawal is 
crucial in preventing progression to the severe, life-threatening stages. 
• Alcohol withdrawal can start 6 to 12 hours after the last drink and is not reliant on 
a zero blood alcohol reading. 
• It is most important to suspect and anticipate withdrawal in a person whose 
drinking history or physical symptoms are indicative. 
• Suspect possibility of withdrawal in a person with an unexplained acute organic 
brain syndrome. 
• Seizures can occur at any time during withdrawal, but usually within the first 48 
hours. Any seizure must be reported and investigated. 
• Hallucinations occur in approximately 25% of people experiencing withdrawal. 
They are usually visual or tactile (typically insects crawling over the body) and 
occasionally auditory. They can be unpleasant, frightening and cause severe 
anxiety. They can be associated with complications. 
• Delirium tremens (DTs) is a medical emergency. It is an acute complication of 
alcohol withdrawal (20% death rate if untreated).   
• Symptoms include profound disorientation, confusion and hallucinations, 
electrolyte imbalance and eventual system breakdown. 
• Onset is likely to occur between 24 and 36 hours after the last drink but may vary 
from person to person. 
• Needless to say anyone at risk of or diagnosed with Delirium tremens must receive 
close medical and nursing monitoring and treatment  in a well equipped intensive 
care setting [75]. 
Alcohol withdrawal, observation and monitoring 
Please see Appendix 10 for exemplars of an alcohol withdrawal observation scale, based 
on the CIWA-Ar. These are useful as monitoring tools only—they do not diagnose alcohol 
withdrawal. 
Alcohol withdrawal—Index for suspicion 
So as to judge the potential for alcohol withdrawal the following Index of Suspicion 
provides a guide. If the person has: 
• a history of heavy drinking or alcohol dependence and it is  less than 10 days since 
they last consumed alcohol 
• had a regular daily intake of 80 grams or more of alcohol (eight drinks for men) or 




• regularly taken smaller amounts of alcohol in conjunction with other central 
nervous system (CNS) depressants, e.g. Benzodiazepines 
• had previous episodes of alcohol withdrawal 
• experienced previous alcohol withdrawal seizures or other serious symptoms 
• a current admission for an alcohol-related reason 
• a previous history of an alcohol-related condition (e.g. alcoholic hepatitis, alcoholic 
cardiomyopathy, pancreatitis, oesophageal varices, liver disease) 
• a physical appearance indicating harmful alcohol use, e.g. facial vascularisation, 
reddened eyes, signs of liver disease (e.g. ascites, jaundice), muscle wasting, spider 
naevi, palmar erythema, previous injuries 
• recent pathology results showing raised serum Gamma Glutamyl Transpeptidase 
(GGT) and/or raised mean cell volume (MCV) 
• displayed or reported symptoms such as hypertension, anxiety, sleep disturbance, 
agitation, tremor, sweatiness, nausea/vomiting or early morning retching. 
Onset of withdrawal 
Due to falling blood alcohol levels the early signs of withdrawal usually appear between 6-
24 hours after the last intake/drink of alcohol. Symptoms may emerge before the breath 
alcohol reading reaches zero, e.g. at 0.1 Blood Alcohol Level (BAL). 
Features of mild withdrawal 
Signs and symptoms may occur within 24 hours and subside 48 hours after stopping or 
substantially reducing alcohol intake. These include: 
• mild rise in temperature, e.g. 37°C 
• slight tremor 
• nausea 
• mild dehydration 
• mild hypertension 
• dyspepsia 
• insomnia 
• mild anxiety 








Features of moderate withdrawal 
Signs and symptoms may occur within 24 hours and subside 72 hours after stopping or 
substantially reducing alcohol intake.  
These include: 
• mild rise in temperature, e.g. 
37°C 
• hyperventilation and panic 
attacks 
• moderate sweating 
• diarrhoea 
• anorexia 
• mild to moderate hypertension 
(diastolic reading of 100-
110mmHg) 
• nausea and vomiting 
• weakness 







• mild tremor. 
Features of severe withdrawal 
Signs and symptoms may occur within 24 hours or may be delayed until 48 hours or more 
after stopping or substantially reducing alcohol intake. Further delays in onset may be 
caused by administration of other central nervous system (CNS) depressants, e.g. opioid 
analgesia or anaesthetics. The usual course of withdrawal is five days, but can be up to 14 
days.  
The features include: 
• acute anxiety (may or may not 






• hypersensitivity to stimulation 
• tachycardia 
• withdrawal seizures, any seizure 
can be life threatening and are 
• hyperventilation and panic 
• convulsions/seizures 
• excessive sweating 
• vomiting 
• disorientation/confusion (for time 
and place) 
• hallucinations (auditory, tactile or 
visual) 
• moderate to severe hypertension 
(danger sign is a diastolic pressure 




preventable in people with a 
known history through a diazepam-
loading regime 
• marked tremor. 





Features of Complicated Alcohol Withdrawal 
• onset seizures (6-48 hours +) 
• onset disorientation (48 + hours) 
• onset confusion (48 + hours) 
• onset hallucinations (48 + hours) 
• onset delirium tremors (2-6 days after last drink). 
The presence and severity of each of these symptoms varies with the level of severity of 
withdrawal. Presence of concomitant illness, infection, injury or other physical trauma, and 
recent surgery increases the likelihood of complicated alcohol withdrawal. 
Delirium tremens (DTs) 
Delirium tremens (‘the DTs’) is the most severe complication of alcohol withdrawal 
syndrome, and is a medical emergency. It usually develops two to five days after cessation 
or significantly reducing alcohol consumption, but may take seven days to appear [75]. The 
usual course is three days, but can be up to 14 days. 
Symptoms 
• exaggerated features of simple alcohol withdrawal, e.g. CIWA-Ar [85] Alcohol 
Withdrawal Score (CIWAR-AR) score increases later in withdrawal syndrome (See 
appendix 10) 
• autonomic instability (e.g. fluctuations in blood pressure or pulse may be 
hypertensive and tachycardic), disturbance of fluid balance and electrolytes, 
hyperthermia and sweating 
• extreme agitation restlessness or disturbed behaviour – this may be to the extent 
where the person needs restraint or to be detained under the Mental Health Act 
for their protection 
• gross tremor 
• confusion and disorientation 
• paranoid ideation, typically of delusional intensity 
• hallucinations affecting any of the senses, but typically visual (highly coloured, 
animal form). 
A mild alcohol withdrawal syndrome may not precede delirium tremens. Dehydration, 
infection, arrhythmias, hypotension, renal failure and pneumonia may be precipitating 
factors. Delirium tremens may result in death in 20% of cases. If treated, the mortality rate 




Effective management is likely to include: 
• effective sedation 
• intravenous fluids to correct or avoid dehydration and electrolyte imbalance 
• treatment of any concurrent conditions 
• symptomatic treatment of nausea, diarrhoea, headache 
• prophylactic thiamine replacement during alcohol withdrawal  
• all risky or binge drinkers should be considered to be at risk of Wernicke’s 
encephalopathy 
• chronic drinkers with poor dietary intake and nutritional status should be 
administered parenteral thiamine [83]. Thiamine should be given prior to glucose 
loading. See section on thiamine below. 
Some people can have lingering cognitive dysfunction (may recover in 4-12 weeks) 
following withdrawal. If this is accompanied by Wernicke’s encephalopathy, higher daily 
doses of Thiamine may be required. Cognitive dysfunction may be permanent. 
See Thiamine regime for prevention and treatment of Wernicke’s encephalopathy in this 
section. 
Monitoring alcohol withdrawal 
Always record the time of the last alcoholic drink, and the blood or breath alcohol 
concentration at time of admission. This will optimise accurate diagnosis of risk of 
withdrawal, likely time of onset and whether there is also risk of other overdose, 
concurrent illness or injury. 
The most systematic and useful way to measure the severity of withdrawal is to use a 
reliable alcohol withdrawal scale which, if implemented early, can provide baseline data 
and any subsequent deterioration (or improvement) of symptoms. The changes in signs 
and symptoms are observed and documented regularly in order to discern, measure and 
treat increasing severity over time. This ensures that not only is treatment timely but also 
reduces the likelihood of unintended under dosing or over dosing with benzodiazepines 
(generally diazepam) and any symptomatic medications used to manage the alcohol 
withdrawal syndrome.  
The Clinical Institute Withdrawal Assessment for Alcohol—Revised Version (CIWA-Ar) is 
recommended for best practice and provided in this document in two exemplars (See 
Appendix 10) and as a standalone withdrawal observation recording form. 
Note: The CIWAR-Ar is merely a monitoring tool to detect symptoms and is NOT a 
diagnostic instrument. It guides the identification of symptoms indicative of severity of an 
already diagnosed withdrawal syndrome.  
Re-evaluate the person’s symptoms regularly to ensure that it is not another condition 
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being observed, particularly if the person may also have a concurrent condition and/or 
does not respond well to standard alcohol withdrawal treatment. 
Clinical Institute Withdrawal Assessment for Alcohol—revised version (CIWA-Ar) 
The CIWA-Ar (see Appendix 9) is a 10-item scale that several studies have shown is a valid, 
reliable and sensitive instrument for assessing the clinical course of alcohol withdrawal. 
This scale allows a quantitative rating (from 0-7 with a maximum possible score of 67) of 
the following components of withdrawal: 
• nausea and vomiting 
• tremor 
• paroxysmal sweats 
• anxiety 
• agitation 
• tactile disturbances 
• auditory disturbances 
• visual disturbances 
• headache and fullness in head 
• disorientation and clouding of sensorium. 
Early onset of alcohol withdrawal may be indicated by a slight rise in temperature (37°C) in 
a person who does not have an infection. 
It is very useful to include TPR and BP assessment on the same form as the CIWA-Ar in the 
hospital setting. This enables concurrent monitoring of the person’s general health status, 
identifying other problems through objective clinical signs, and/or early signs of the onset 
of alcohol withdrawal.  
Use of CIWA-Ar in the Emergency Department 
Monitor the person hourly for at least four hours using the CIWA-Ar. Contact the medical 
officer for re-assessment if: 
• CIWA-Ar total score reaches 8 
• alcohol score increases by at least 5 points over this four hour period, or 
• you are at all concerned 
Use of CIWA-Ar for hospitalised people e.g. surgical or medical unit: 
• monitor hourly if the alcohol withdrawal score is greater than 20 
• 2 hourly if score is 8-20 
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• 4 hourly if score is less than 8, for a further three days. 
Note: If score fails to settle with prescribed diazepam or rises above 15, the medical officer 
must be notified immediately. Specialist medical advice is needed if the withdrawal score is 
greater than 25. 
Pharmacological treatment 
The medical officer may prescribe pharmacological treatment to prevent and combat acute 
withdrawal symptoms, without over-sedating the person.  
The most commonly prescribed pharmacological treatment for alcohol withdrawal is 
diazepam due to its cross tolerance with alcohol, long half life and anti-convulsant 
properties. 
Further clinical advice about alcohol withdrawal and recommended medication regimes 
can be obtained from Alcohol and Drug Information Service 24 hour telephone information 
and Clinical Advisory Service – call 1300 13 1340. (See section 5). 
In general it is advised that unless otherwise prescribed by an experienced medical officer, 
the alcohol withdrawal diazepam regimes should not commence until: 
• medical assessment is made to diagnose alcohol withdrawal as the cause  of the 
person’s presentation or symptoms 
• other potential organic exacerbating factors have been assessed e.g. sepsis, 
cardiovascular event, metabolic problem such as diabetes  
• breath/blood alcohol level (BAL) reading 0.1% or less.  
Potential hazards 
• benzodiazepine over sedation 
• dose of diazepam is inadequate to control withdrawal symptoms. 
• misdiagnosis of alcohol withdrawal when other serious medical problems exist that 
either accounts for or exacerbates the alcohol withdrawal score. 
Alcohol withdrawal regimes 
Mild withdrawal predicted  
• no other likely medical condition that may complicate or mimic withdrawal 
• no history of withdrawal seizure 
• daily alcohol intake less than 80 grams (60 grams in women)  
• daily alcohol intake greater than 80 grams (60 grams in women) and the person is 
under 30 years old 
• history of previous mild withdrawal syndrome.  
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Who is at risk of alcohol withdrawal? 
Any person admitted is at risk of experiencing alcohol withdrawal syndrome when: 
• Alcohol consumption >80g per day and less than 10 days since last drink  
• Previous history of alcohol withdrawal 
• History of alcohol dependence and less than 10 days since last drink 
• AUDIT questionnaire score >12 on admission  
• Admitted with breath or blood alcohol >0.15g/dl.  
How to initially manage? 
• commence alcohol withdrawal observations 2-4 hourly and continued for 72 
hours.  
• if alcohol withdrawal symptoms develop then people should be nursed in a low 
stimulus environment, provide reassurance, reorientation, even lighting, continuity 
of care throughout the shift  
• if alcohol withdrawal symptoms develop then assume that withdrawal is 
complicated by medical problems. E.g. sepsis, CCF, metabolic problems such as 
diabetes, inadequate postoperative analgesia, urine retention. The person in this 
situation  requires a medical assessment.   
Which regime?  
There are four benzodiazepine regimes depending on the clinical circumstances.  
• Mild alcohol withdrawal regime  
• Symptom triggered regime 
• Loading regime 
• Seizure prophylaxis regime 
Note: Any person undergoing alcohol withdrawal requires a Thiamine regime.   
1.  Mild withdrawal predicted when  
• there is no other likely medical condition that may complicate or mimic withdrawal 
• there is no history of withdrawal seizure 
• daily alcohol intake has been less than 80 grams (60 grams in women)  
• daily alcohol intake has been greater than 80 grams (60 grams in women but the 
person is  under 30 years old 
• there is a recent history of previous mild withdrawal syndrome.  
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If circumstances match the above then: 
• Protocol for mild alcohol withdrawal may be suitable in the general hospital setting 
or where alcohol withdrawal is complicating another condition, e.g. surgical 
procedures (and where concurrent illness does not preclude diazepam). 
• Diazepam 5-10 milligrams (mg) orally, four times a day as necessary (qid) (prn) 
should be prescribed to cover mild agitation in the event of a low alcohol 
withdrawal score. 
• In addition the patient should also be given Regime 2 [ie Symptom triggered 
regime] to cover the emergence of more severe withdrawal.  
2.  Symptom triggered regime  
Where a person is admitted for a purpose other than alcohol withdrawal management, e.g. 
surgery, injury, medical condition and their management does not preclude the use of 
sedation with diazepam. In this instance the protocol based on withdrawal symptom 
severity may be the preferred regime. This could be due to a number of factors, e.g. also 
receiving opioid pain relief, minor head injury and neurological observations are required 
during early phase of admission. 
If this is the case then:  
• Prescribe diazepam 20 milligrams (mg) 2 hourly to commence if alcohol withdrawal 
score (AWS) rises to 8 or more and continue until it falls to <8. Maximum dose 
120mg over 24 hours.  
• If more is required a medical officer should first review the person. 
• Diazepam may be recommenced if AWS score rises to >8. Diazepam should be 
withheld if person shows signs of benzodiazepine toxicity. 
• More intensive nursing care will be required for a person whose AWS >20. 
3.  Loading regime  
Use when:  
• main reason for admission is to manage alcohol withdrawal syndrome  
• no history of withdrawal seizures 
• daily drinking more than 80gms for men and 60 grams women 
• past history of severe withdrawal 
• person under the age of 30 years or drinking less than 80gms (60 grams  
• women) per day with a past history of severe withdrawal 
• person is not debilitated, elderly and/or frail 
• person does not have a concurrent acute medical condition, e.g. diabetes, renal or 
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liver disease, serious injury or infection. 
If this is the case then:  
Loading with diazepam is commenced according to weight: 
Less than (<) 75kg 20mg 2 hourly for 3 doses 
(i.e. 60mg total) 
75-90kg 20mg 2 hourly for 4 doses 
(i.e. 80mg total) 
More than (>) 90kg 20mg 2 hourly for 5 doses 
(i.e. 100mg total) 
• Diazepam should also be administered as per the AWS score to commence if the 
AWS score is greater than (>) 10 after loading dose is completed. 
• Diazepam 5-10mg orally, four times a day as necessary (qid) (prn) may also be 
prescribed to cover mild agitation in the event of a low AWS score. This 
commences the day after diazepam loading. 
• Temazepam 10-20mg at night (nocte) as necessary (prn) may also be prescribed 
for night sedation for three nights (not to commence until the day after diazepam 
loading). 
4.  History of alcohol withdrawal seizures 
• Any seizure must be taken seriously and investigated for causes. 
• People with a past history of alcohol withdrawal seizures should receive diazepam 
loading (as in 2. above).  
• If person’s weight is more than 75kg an additional 15mg dose may be needed for 
the first day.  
• If the AWS score is greater than 10 after the loading dose is completed, the dosing 
regimen (as in 3. above) should be instituted. Thereafter all people requiring 
seizure prophylaxis should receive 10mg diazepam twice a day for two days, 
followed by 5mg twice a day (BD) for one day. 
Note: Seizure prophylaxis should not be withheld because a person is asleep. The dose 
may be delayed slightly if this is clinically appropriate, but it is important to ensure that the 
full amount is given. 
Note: In either seizure prophylaxis or weight related loading, diazepam should only be 
withheld if signs of benzodiazepine intoxication are present; short periods of sleep are 
allowable. As long as the patient is easily rousable, the regime should continue.  
Thiamine regime – for all people at risk of alcohol withdrawal or who are withdrawing 
• 100mgs Thiamine IM or IV as TDS for three days    
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• 100mgs Thiamine oral TDS for remainder of the admission.  
• Oral multivitamin and mineral supplement daily.  
• On discharge advise oral 100mg thiamine daily and recommend periodic review 
with person’s general practitioner or health services. 
Symptomatic medications 
• Symptomatic medication relief may be needed for nausea/vomiting, headache or 
gastrointestinal upset. 
• Any symptomatic medications should be prescribed as usual, e.g. paracetamol: 
500mg-1 gram oral 4-6 hourly as necessary. 
• Metoclopramide: 10mg oral/or intramuscular, three times a day as necessary. 
Clinical judgement 
Clinical judgment will be required when there is combined alcohol and benzodiazepine 
withdrawal. A benzodiazepine reduction regime is often more appropriate (with 
superimposed alcohol withdrawal regime in the event of a withdrawal scale score rising to 
more than 15 using CIWA-Ar Score). 
Alcohol withdrawal management - diazepam sedation contra-indicated 
A Diazepam regime may be contraindicated in the following: 
Acute or chronic liver disease  
• The advice of a specialist physician is necessary. 
• It is essential to determine that the person is in withdrawal and not hepatic 
Encephalopathy as injudicious sedation is dangerous. 
• The dose of the sedative needs to be lower than for people who have normal liver 
function. 
• Lorazepam may be preferable to diazepam because it has a shorter half life and it 
has no active metabolites (1-2mg Lorazepam = 5mg diazepam). 
• Consider seeking specialist dietary advice. 
Chronic airflow limitation 
• Advice of a specialist physician is necessary. 
• Respiratory failure. Sedating benzodiazepines are not the drug of choice for 
Chronic Obstructive Airway Disease (COAD). In acute deterioration of COAD, HDU 
(high dependency unit) monitoring may be indicated. 
• An oxazepam regime may be the choice in this instance due to short duration of 




No oral intake 
• Consult specialist physician. 
• Give 5mg diazepam intravenously (IV), repeated up to half hourly. If more frequent 
doses are required, this is a medical emergency and specialist advice should be 
sought. 
Use of Haloperidol  
Haloperidol may be required in addition to diazepam to control symptoms of alcohol 
withdrawal, especially when psychotic symptoms such as hallucinations or paranoid 
ideation (particularly if acted upon with aggression) are pronounced 
Advice should be sought from intensive care registrar or medical specialist.  
• Doses of 0.25mg 1-2 hourly orally or parenteral, and as required.  Doses up to a 
total of 10mg/day may be required. 
• Benztropine should be prescribed at doses of 0.5-2 mg as necessary prn to a 
maximum of 6mg daily for dystonic reactions, which are characterised by 
opisthotonos (usually extension of the neck), oculogyric crisis (eyes upward) or 
other unusual dystonia including abnormal tongue movements. 
People receiving other CNS depressants (e.g. Opioid) 
Monitor oxygen saturation 1-2 hourly. Dose of diazepam may need to be reduced. 
Situations requiring specialist consultation 
As a general guide, refer to Intensive Care Unit (ICU) Registrar if: 
• oxygen saturation is being checked and is ≤ 94% on room air 
• respiratory rate less than 8 or more than 25 breaths per minute 
• person not easily rousable to other’s speech 
• the person has delirium tremens 
• person has other medical problems that may cloud conscious state, e.g. 
neurosurgical condition 
• other medical conditions that make administration of sedatives dangerous, e.g. 
chronic obstructive airways disease, hepatic failure, receiving opioids. 
Note: If a person’s withdrawal syndrome is difficult to manage and they need higher doses 
than the usual diazepam regime for their situation, management in a high 
dependency/intensive care unit is preferable. Some people in this situation may require 




Nursing management of alcohol withdrawal  
(See Section 2.6: Managing withdrawal). 
Note: There is no place for prescribing or giving alcoholic beverages for treatment of 
alcohol withdrawal. 
Always nurse in a safe low stimulus environment. 
Nutrition and hydration 
• Monitor and maintain fluid balance. Electrolytes may be monitored as a 
component of medical management including magnesium. Fluids need to be 
encouraged as dehydration from sweating, nausea, vomiting and diarrhoea may 
cause an exacerbation of the withdrawal syndrome 
• Appetite may vary—encourage healthy diet where there is loss of appetite due to 
nausea or vomiting and encourage regular light food intake. When persons are 
likely to be nutritionally compromised or have liver disease, specialist dietary 
advice may be required. Nutritional planning needs to include consideration of 
special sensitivity to avoid iatrogenic complications, to treat deficiencies, prevent 
illnesses caused by the long-term effects of alcohol and/or to treat the 
complications of alcohol dependence [86]. 
Concurrent illness 
People with concurrent illness may score high on the CIWAR-AR for reasons other than 
alcohol withdrawal. Sedative medication should not be given until a diagnosis of alcohol 
withdrawal is confirmed and the effects of concurrent illness have been assessed. 
Pharmacotherapy for Alcohol Dependence  
Pharmacotherapy for people with alcohol dependence with the goal of abstinence can be 
very effective. They may require regular support to manage their daily medication. They 
are more likely to benefit if receiving non medical therapy e.g. structured rehabilitation, 
general counselling, cognitive behavioural therapy (CBT), narrative therapy or other 
supportive programs. Alcohol pharmacotherapy includes: 
Acamprosate (Campral™) 
Prescribed Acamprosate is a pharmacotherapy used to prevent alcohol relapse post-
withdrawal. The effect, while not well understood as yet, seems to prohibit or lessen 
craving for alcohol. It may have various CNS actions. 
• recommended length of treatment is one year 
• should be initiated as soon as possible following withdrawal 
• daily dose is calculated according to body weight with average daily dose between 
1.3-2 grams per day for a person weighing greater than 60kgs 
• dosage is usually two tablets three times per day (333mg in each tablet) 
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• does not interact with alcohol, and does not have hypnotic, anxiolitic or 
antidepressant effects 
• considered safe in the absence of liver disease or renal insufficiency 
• can be given concomitantly with disulfiram, and interactions with other drugs have 
not been.  
Note: Acamprosate has been shown to be effective by increasing non-drinking days and 
nearly doubling abstinence rates in study populations. It is yet unknown which particular 
groups will particularly benefit from this therapy. 
Safety 
Acamprosate is well-tolerated—no adverse effect if alcohol is consumed. Acute overdose is 
usually benign with diarrhoea being the major symptom. No withdrawal syndrome occurs 
on cessation of Acamprosate. 
Side effects (usually mild and transient) 
• diarrhoea 
• vomiting 
• itching skin rash 
• nausea 
• dyspepsia 




• kidney disease (renal insufficiency 
where serum creatinine is more 
than 120 micromol/L) 




Naltrexone can be prescribed to assist the person to remain abstinent from alcohol 
following withdrawal. Naltrexone does not influence intoxication or the withdrawal effects 
of alcohol (may reduce craving, aid reduction of drinking and associated problems, and 
assist abstinence); it produces modest improvements in the outcome of conventional 
treatment when starting treatment, if you need to confirm an individual is drug-free (some 
alcoholics also use opioids), give a Naloxone challenge or test urine for presence of opioid 
metabolites. This is to assess the likely benefit of treatment for alcohol dependence. For 
up-to-date clinical guidance please refer to Australian Medicines Handbook.    
• Naltrexone suppresses the priming effect of alcohol (blunts the euphoric effects of 
alcohol and reduces the positive reinforcement of alcohol use) and can assist in 
achieving goals of reduction in consumption and/or abstinence 
• monitoring the liver profile is recommended during the course of naltrexone 
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treatment, which is usually three to six months 
• a dose of 50mg daily has shown positive outcomes with relapse rates, craving and 
number of non-drinking days 
• Naltrexone is effective, safe and well tolerated. Naltrexone is best commenced 
following alcohol withdrawal; however, there are no contraindications in 
commencing naltrexone while the person is still drinking. In this situation efficacy 
in assisting someone to reduce or cease his or her use is not known. 
Safety 
• Naltrexone can cause hepato-cellular injury when given in excessive doses. 
Note: Caution is required if transaminases are above three times the normal range. 
Side effects 
Side effects are generally dose-dependent and include: 









The principal contraindication for naltrexone use is when there is coexisting use and 
dependence on opioids as a withdrawal episode may be induced. Other contraindications 
include: 
• oral hypoglycaemic medication 
• acute hepatitis or liver failure 
• concomitant therapy with thioridazine 
• opioid analgesic use. 
Caution should be exercised when combining naltrexone with other drugs associated with 
potential liver toxicity. 
Disulfiram (Antabuse®) 
The goal in prescribing disulfiram is to provide a powerful disincentive to drink. It is usually 
prescribed for three to six months following withdrawal and is provided in combination 
with monitoring, support, and psychosocial interventions. 
It is dispensed in 200mg dispersible tablets, with the usual dose being 200mg daily. The 
usual recommended length of treatment is six weeks to six months. 
Disulfiram inhibits the ALDH in the liver, and if the person drinks alcohol, causes an 
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accumulation of acetaldehyde. Within 15 minutes of drinking the person may experience 
the following: 
• flushing  
• feeling heat and sweating 
• nausea 
• vomiting 
• palpitations and rapid pulse 
• headache 
• difficulty breathing 
• blood pressure may rise steeply initially followed by a drop in blood pressure 
resulting in pallor, weakness, dizziness, nausea and vomiting. 
Ideally it is commenced post-withdrawal or at least 48 hours after the last drink (with 
evidence of zero blood alcohol level). Alcohol should not be consumed for one week 
following the last dose. 
Indications for use are for a person who is alcohol dependent, wishes to achieve 
immediate abstinence, and who clearly understands the nature of the drug and its effects. 
To be successful this therapy requires a method of supervision of daily doses. 
Safety 
• Liver function tests are needed fortnightly for two months, then monthly 
• People with major co-existing psychiatric disorders such as bipolar, depression and 
psychotic illness need close supervision as disulfiram may worsen these disorders 
by affecting the brain dopamine systems. However 200mg daily is generally 
considered safe for these people. 
People commencing on disulfiram should be advised of the following: 
• do not consume or use any alcohol or alcohol containing products or food 
including medicines, cough mixtures, marinated meat, wine trifle and food 
essences 
• after shave, mouthwashes, alcohol rubs and perfumes are safe unless swallowed 
• always read labels on all food and medicines to ensure they don’t contain alcohol. 
Side effects 
Short term effects which may occur in the first two weeks include: 
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• initial drowsiness 
• metallic taste 
• headache 
• stomach upset 
• fatigue 
• rash/acne 
• sexual dysfunction 
These side effects usually disappear by themselves. Other side effects or adverse reactions 
include: 
• peripheral neuropathy 
• changes in vision, eye tenderness/pain 
• mood changes 
• yellowing of the skin/eyes 
• abdominal pain. 
Contraindications 
• The reaction caused by consumption of alcohol whilst taking disulfiram may cause 
tachycardia and hypotension, and precipitate a coronary event or serious 
arrhythmia 
• older people need a cardiac history (an electrocardiogram) prior to commencing 
disulfiram. 
• Disulfiram has not been used widely in pregnancy but does not appear to be 
teratogenic. It should only be prescribed in pregnancy under care of a high risk 
pregnancy team. (ref. MIMS category B2) Lactation is a precaution for prescription. 
Complications may result if the person has a history of: 
• coronary artery disease 
• history of arrhythmias 
• heart failure 
• severe liver disease (disulfiram can cause toxic hepatitis although this is rare).  
Drug interactions  




• anti-tuberculosis medication [87]. 
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Maternal and neonatal care 
These guidelines are based on an assessment of current evidence concerning risk of harm 
from alcohol to the developing foetus and young babies during their breastfeeding period.  
Pregnancy and alcohol  
Maternal alcohol consumption can result in a spectrum of harms to the foetus.  
Risk of birth defects is greatest with high, frequent maternal alcohol intake during the first 
trimester. However exposure to alcohol during pregnancy (including before pregnancy is 
confirmed) can have adverse effects on foetal brain development. It remains unclear 
whether alcohol effects are dose related or if there is a threshold above which adverse 
effects occur. Variation in effects can be due to the stage of development of the foetus at 
the time of exposure and the individual characteristics of the mother. This uncertainty is 
reflected in reports on alcohol use in pregnancy in Australia and overseas [88]. 
Alcohol Intoxication in pregnancy  
Intoxication can lead to injury, alcohol toxicity, overdose or exacerbation of illness for 
pregnant women. This also places their foetus at serious risk. 
 In particular:  
• intoxication, where there are high peak levels of alcohol in the blood stream may 
adversely affect the central nervous system of the foetus 
• possible complications including miscarriage, stillbirth and premature birth 
• ‘an average of two or more standard drinks (20 grams or more) a day has been 
linked with low birth weight, behavioural and learning difficulties, and an increased 
risk of spontaneous abortion’ [89]. 
The national alcohol guidelines for pregnant and breastfeeding women advise  that no 
alcohol is the safest option in both cases [80]. The risks of drinking during pregnancy and 
breastfeeding differ as noted separately below. Expert opinion cautions that currently 
there is no safe level or period of drinking during pregnancy established thus strongly 
advise that no drinking is the safest option.  
In addition: 
• Women who drank alcohol before knowing they were pregnant or during 
pregnancy need to be reassured risks to their foetus is likely to be low if they had 
consumed alcohol at low risk levels. Efforts should be made not cause them to 
become anxious if there had been isolated episodes of drinking. 
• Women who remain concerned should seek specialist medical advice. Health 
professionals who are uncertain how to advise pregnant women seeking 
information concerning the potential for alcohol-related harm should seek expert 
advice from specialist drug and alcohol/ obstetric services. 
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• Women who find it difficult to decrease their alcohol intake will require support 
and treatment and it is very important that they are referred to the appropriate 
services as early into their pregnancy as possible. 
Foetal Alcohol Spectrum Disorder (FASD) and Foetal Alcohol Syndrome (FAS) 
The harmful effects of alcohol on the foetus are dose related [80] and termed foetal 
alcohol spectrum disorder. The term Foetal Alcohol Syndrome refers to the more severe 
effects characterised by brain damage, facial deformities and growth defects.  
Foetal Alcohol Spectrum Disorder (FASD) – identification 
• diagnosis is difficult  
• infant should be reassessed at 6 months 
• babies with signs of FASD need to be followed up regularly over their early years 
• signs include learning difficulties, behaviour problems 
• where any child is diagnosed with attention deficit disorder there should be a 
history taken of mothers alcohol use in pregnancy [60]. 
Foetal Alcohol Syndrome (FAS) – identification  
Characteristic features include: 
• Failure to thrive  
• Microcephaly 
• Characteristic facial features  
• Developmental delay 
• Background of heavy alcohol consumption by mother during pregnancy 
Other signs may include: 
• generalised hypo-tonicity 
• poor coordination & motor skills 
• intellectual disability 
• growth deficits e.g. head, & bones [60].  
Diagnosis of FAS at birth can be difficult. Where the neonate’s mother has previously given 
birth to a baby with FAS, the following should be incorporated into care plans: 
• infants should be assessed at birth and followed up to at least 6 months with 
reassessment at 6 months where FAS is suspected 
• children with signs of FAS should have regular community follow up by 
appropriately trained health professional during pre-school and early school life 
(up to at least 7 years of age) [60].   
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Assessment of women 
Assessment of women who have consumed alcohol before knowing that they were 
pregnant should include appraisal of how much alcohol was consumed and at what stage 
in the pregnancy. 
Practical advice for women who are pregnant or may soon become pregnant 
• no drinking alcohol is the safest option 
• alcohol cessation at any point during the pregnancy is worthwhile as the risk to the 
infant continues until delivery. “it is never too late” 
• risk of harm to the foetus seems to be greatest with high, frequent, maternal 
alcohol intake 
• risk of harm to the foetus is likely to be low if a woman consumed small amounts 
of alcohol before becoming aware of being pregnant or during her pregnancy 
• level of risk to an individual foetus is influenced by maternal and foetal 
characteristics that are hard to predict at this point in time. 
Practical advice on drinking during pregnancy 
It is important that all women of child-bearing age, as well as the general public,  are aware 
that there is uncertainty about the pattern of alcohol consumption, and gestation period/s 
in which drinking occurs, that places the developing foetus at risk. This is in order for 
informed decision making to occur regarding alcohol use in pregnancy. Nurses and 
midwives need to highlight that: 
• risks are higher with high alcohol intake, including episodic intoxication 
• risks appear to be low with low level intake 
• it is impossible to determine how maternal and foetal factors will alter risk in the 
individual. 
Breastfeeding 
Alcohol use while breastfeeding is not recommended [60, 80]. As for pregnancy, it is not 
yet possible to set a ‘safe’ or ‘no-risk’ drinking level for breastfeeding women and their 
babies. We know that: 
• alcohol enters the breast milk and may persist in the milk for several hours after 
alcohol consumption [90, 91] 
• blood alcohol level in breast milk is the same as the mother’s blood alcohol level 
and is transferred to the infant as it suckles 
• alcohol adversely affects lactation, infant behaviour (e.g. feeding, arousal) and 




Giglia  and  Binns [90] found that consumption of two standard drinks (20 grams pure 
alcohol) or more per day during lactation is  associated with: 
• decreased lactation in terms of the milk ejection reflex, milk production of mother 
and milk consumption by the baby 
• earlier cessation of breastfeeding 
• deficits in infant psychomotor development 
• disrupted sleep-wake pattern in the infant. 
Education and support of breastfeeding women is very important. 
• Qualitative research has shown that breastfeeding mothers are generally unaware 
of the effects of alcohol on breastfeeding performance and development of the 
infant 
• Women who consumed alcohol at levels of more than two standard drinks per day 
were almost twice as likely to discontinue breastfeeding before the infant was 6 
months old than women who drank below this level [90]. 




Australian standard drinks 
1 2 3 4 5 6 7 
50 1:51 3:43 5:35 7:27 9:18 11:11 13: 03 
59 1:42 3:26 5:09 6:52 8:36 10:19 12:02 
66 1:37 3:15 4:53 6:31 8:10 9:48 11:26 
70 1:33 3: 07 4:41 6:15 7:50 9:24 10:57 
 
Note: Time is calculated from the onset of drinking. Assumptions made are that: alcohol 
metabolism is constant at 15 mg/dL and that the height of the woman is 162.56 
centimetres.  
Example 1: For a 40.8 kg woman who consumed three standard drinks in 1 hour, it would 
take approximately 8 hours 30 minutes for there to be no alcohol in her breast milk, but for 
a 95.3 kg woman drinking the same amount, it would take approximately 5 hours 33 
minutes. 
Example 2: For a 63.5 kg woman drinking four standard drinks starting at 8:00pm, there 
would be a zero level of alcohol in her breast milk approximately 9 hours 17 minutes later 
(i.e. at 5:17am) [90, 91]. 
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Note: It can only be estimated as to how long alcohol takes to disappear from breast milk 
as this varies for each individual woman [91]. 
Practical advice for mothers who are breastfeeding and choose to drink 
It is acknowledged that an abstinence message may discourage breastfeeding. For this 
reason, although women who are breastfeeding are advised that ‘not drinking alcohol is 
the safest option’, practical guidance regarding minimising the risk to lactation and to the 
breastfed infant is also provided for mothers who choose to drink. 
Internationally and in Australia it is recommended that infants are exclusively breastfed for 
the first six months of life and that breastfeeding (in addition to complementary foods) is 
extended into the second year of life [80, 92]. Although 75.6 per cent of Australian infants 
are exclusively breastfed following birth, only 12 per cent are exclusively breastfed at 6 
months of age, and only 19 per cent of infants are receiving any breast milk at 12 months 
of age [88, 90, 91]. 
It is important not to discourage women from breastfeeding. Advise mother to: 
• avoid drinking until breastfeeding is well established 
• limit their drinking to no more than two standard drinks a day 
• avoid drinking immediately before breastfeeding 
• express breast milk and refrigerate in advance if planning to drink, and ensure 
baby is in the care of a safe, sober adult. 
Women should be advised on the length of time that alcohol is secreted from their breast 
milk and their optimal timing for subsequent breastfeeding in relation to how much 
alcohol over time they have consumed [90]. 
Beyond breastfeeding 
Abstaining from drinking is always the safest option when supervising babies and other 
children. Mothers, fathers, family members and other carers of babies need to be 
informed about how the acute affect of alcohol can alter their capacity to anticipate and 
minimise risks, and safely undertake tasks including: 
• lifting a baby or child 
• cycling 
• driving 
• managing household or other equipment. 
This is due to the acute effects of alcohol on eye hand coordination, reaction time and 
problem solving - even at low levels of consumption. It is very important to inform mothers 
and others that intoxication can lead to injury while holding a baby [60]. 
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Alcohol withdrawal during pregnancy 
Any pregnant woman who at risk of spontaneous, unplanned or planned alcohol 
withdrawal must be hospitalized and receive close monitoring and expert medical and 
nursing care. Care should include: 
• reassurance and being informed about what is happening and why 
• personalised medication management, including seizure prophylaxis, may be 
required 
• frequent foetal & maternal monitoring for signs of distress or illness 
• CIWA-Ar monitoring and symptom management 
• effective nutritional support, including vitamin & mineral supplements 
• safe and non-judgemental care sensitive to their situation, gender and culture. 
Note: Refer to Thiamine regime. 
Neonatal withdrawal 
A neonate assessed to be at risk of withdrawal due to the mother’s level and pattern of 
alcohol use during pregnancy is monitored closely for withdrawal symptoms over the first 
few days of life.  
• Neonatal withdrawal will start 24 – 48 hours after birth – according to date and 
time of the mother’s last drink.  
• This time difference (mother may start withdrawal 6 to 12 hours after last drink) is 
due to the neonate’s immature liver.  
• A neonate experiencing alcohol withdrawal can usually be managed well with 
supportive care and medications [60].  
• Importantly the mother’s withdrawal requires careful monitoring and 
management. 
• The mother, whether or not she is undergoing withdrawal, needs support, to know 
what is happening with her baby, and be encouraged and shown how to bond to 
her baby by taking part in any decisions and special care that her baby requires.  
Assistance and support 
Specialists can advise how best to care for women and their babies who are at risk from 
alcohol, during pregnancy, delivery and early stages after delivery when mothers and 
babies can be physically and emotionally vulnerable.  
Partners/fathers and other family members need to be well informed and encouraged to 
be non–judgemental and helpful. They need to understand what will be needed in the 
months to come and how best to support the new mother and baby in relation to alcohol 
and related health and psycho-social issues. 
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3.1.2 Opioids (opiates) 
Introduction  
Opioids (opiates) are a class of substances with morphine-like effects that can be reversed 
by the specific antagonist naloxone. Some opioids are semi-synthetic chemical derivatives 
of morphine (such as heroin) and others are fully synthetic (such as pethidine and 
methadone). They share a common core structure that allows them to interact with opioid 
receptors [93]. 
Opioids have a depressant effect on the central nervous system. They decrease the 
spontaneous activity of neurones, producing drowsiness, mood changes and mental 
clouding. However, they also have features quite distinct from the sedative-hypnotics. 
They are powerful analgesics and suppress reflex cough and diarrhoea. 
Prolonged opioid use results in tolerance and lowering of pain threshold, therefore 
apparently mild pain may be perceived as more severe. This may be inadvertently 
interpreted as drug-seeking behaviour rather than inadequately relieved pain. 
Prescribing opioids for opioid dependence  
Most potent opioids are Schedule 8 medications and hence regulated by law in all 
Australian jurisdictions. Medical practitioners and other prescribers must be aware of their 
local jurisdictional legislation regarding prescribing opioids. In most jurisdictions specific 
authority is required from the relevant government agency, [in South Australia the Drugs 
of Dependence Unit] in order to prescribe opioids for the purpose of managing a 
dependent person, e.g. for withdrawal or maintenance treatment.  
Unlike alcohol withdrawal, the syndrome associated with the cessation of opioid use is not 
likely to be life-threatening. However, the symptoms can cause the person undergoing 
withdrawal considerable discomfort and may lead to resumption of use to avoid or abate 
the symptoms, early discharge and thus poor intervention outcomes. 
A person’s ability to make clear, responsible decisions may be markedly affected. This 
needs to be taken into account in terms of management decisions and further referrals. 
The major focus of intervention is to minimise the risks (e.g. overdose and other harms 
including blood-borne viruses such as hepatitis B and C or HIV) that are associated with 
injecting drug use. 
Equally important is to provide support and encourage the person to accept a referral for 
ongoing interventions whether this is aimed at abstinence or pharmacotherapy 
maintenance (e.g. buprenorphine, methadone). 
Injecting drug use carries the greatest risk of infection, particularly when equipment is 
shared. Dirty and unhygienic injecting habits can result in local or systemic infections and 
poor injecting technique can cause venous or arterial thrombosis. Some drug users inject 
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subcutaneously (‘skin-popping’) and some intramuscularly, but the most favoured route is 
intravenous with the associated increased risk of overdose [94]. 
Assessment and quantification 
(See Section 2.2: Assessment). 
Taking the drug history 
When taking the person’s drug use history, including illicit drug use, it is important not to 
portray judgement or criticism as this will result in the person feeling ashamed and less 
likely reveal essential details about their drug use. This is a critical moment for engagement 
and developing rapport, which will then increase the likelihood of the person’s acceptance 
of intervention now and in the future.   
Drug use is a legitimate health issue, not a moral issue. When taking the history: 
• be clear about who you are, your role, what you need to know and why 
• explain that you are concerned for the person’s wellbeing and are there to help 
• show concern about their drug-use without judgement 
• acknowledge their concerns 
• if history is unclear seek clarification 
• be aware if the person becomes uncomfortable about further disclosure do not 
persist—acknowledge that they may prefer to not discuss this. 
The drug history should record: 
• type of opioid used e.g. heroin, morphine, codeine, other 
• pattern of use  
• how long ago did this start (e.g. days, weeks, months, years) 
• how often is it used e.g. daily, occasionally, weekly,  once a month etc. 
• how is it used – injected, swallowed, snorted -  route of administration 
• frequency, amount and time of last use. 
Estimating likely dose of illicit drugs 
The quantity of illicit drug doses is difficult to assess as each ‘deal’ varies and may also 
contain other drugs and ‘fillers’ e.g. battery acid or talcum powder.  We estimate ‘the dose’ 
by its current street price or weight in street grams. Asking how much the person spends 
each day on their drug of choice can assist in estimating their level of tolerance.  How long 
they have been using the drug, and   route of administration (e.g. swallowing, snorting or 
injecting) are also important to know. 
For information on current illicit drug prices and likely ‘doses’ call: 




• record daily pattern and quantify (as above)  
• record risk-taking behaviours (e.g. needle or equipment sharing, unsafe sex, 
driving under the influence) 
• other medical problems or hepatitis/liver disease, head injury, mental health 
problems, systemic disease 
• other drug use including tobacco, alcohol, medicines. 
Note: Ask about and record any observations the woman has made about her pregnancy 
related to her drug use e.g. when is the baby most/least active, if/when 
contractions/tightenings have been noted and how this relates to intoxication and 
withdrawal and bleeding, previous use in pregnancy. 
Information about a person’s drug use may also be gathered from the following sources: 
• history (interviewing the person or accompanying persons if the person is unable 
to answer questions) 
• data obtained through inspection/assessment of physical and mental status 
• blood test results (liver function tests, hepatitis B screening, hepatitis C and HIV 
screening) with informed consent along with pre- and post-test counselling 
• presence of a drug or its metabolites in urine or blood 
• Recognise the psychosocial aspects. Many heroin users participate in a social group 
with distinctive norms and beliefs leading to discomfort in many conventional 
settings and wariness of stigmatisation. They may have difficulty adjusting to a 
drug-free lifestyle. 
Physical status 
Examples of harms arising from drug use are listed below. Many of them are due to the 
route of administration or accidental injuries during intoxication. It is important to record 
the following: 
• past overdose 
• cellulitis 
• skin abscesses 
• septicaemia  
• hepatitis B or C 
• drug side effects (e.g. constipation) 
• puncture marks 
• phlebitis 
• bacterial endocarditis 
• HIV infection 
• dental disease 





Early and brief intervention  
(See Section 2.3: Early and brief intervention). 
Risk reduction  
Abstinence is the first principle of harm reduction as it is the only way of preventing and 
removing risk.  However, not everyone is abstinent and  it is therefore important to 
provide sound advice and strategies to reduce their drug use risks.  
Note: Accurate information is also needed to reduce risk. This can be obtained from the 24 
hr phone service - contact ADIS on 1300 13 1340  
Advice should include:  
1. Considering abstinence 
o socialise with people who do not use drugs 
o find alternative non-drug-orientated activities   
o seek information about options  
o seek professional support and counselling 
o explore treatment options  
2. Preventing infections from injecting   
o seek information about safer injecting practices 
o  always wash hands before and after injecting and when handling injecting 
equipment including tourniquets, swabs 
o avoid injecting into infected or inflamed tissue  
o mix powders with sterile water and filtering solution before injecting 
3. Vein care 
o use safer and hygienic injecting practices to prevent vein damage, arterial 
thrombosis and local or systemic infections 
o always use new needles and syringes with small bore to protect skin and 
vein integrity 
o take care to rotate injecting sites to avoid tissue and vein damage 
o always inject into a vein 
o avoid injecting into neck, groin, breast, feet and hand veins 
o do not inject into swollen limbs even if veins appear to be distended 
4. Safer routes of administration 
o consider alternative routes of use (e.g. snorting, swallowing or smoking) 
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5. Preventing blood borne virus infections  
o do not share injecting equipment (i.e. needles, tourniquets, syringes, 
spoons, filters or water for mixing drugs) due to the risks of blood-borne 
viruses infection 
o safely disposal of all used injecting equipment 
6. Avoiding overdose  
o Not using previous dose having been abstinent (tolerance drops)  
o not using opioids (e.g. Heroin and morphine) combined with other drugs -
especially CNS  depressants e.g. benzodiazepines and/or alcohol 
o never use drugs alone 
o acquire some basic training in resuscitation methods in the event of a 
drug-using friend collapsing 
o obtain opioid (e.g. heroin or pharmaceutical morphine of codeine)  from a 
reliable dealer in order to be more certain of its strength – try a small ‘test’ 
dose before using 
o if using after a break from opioid use physical  tolerance will be lower. Use 
less than that previously used to test tolerance and reduce  risk of 
overdose. 
Opioid intoxication 
(See Section 2.4: Managing intoxication). 
Acute effects of opioids: 
• drowsiness ‘nodding off’ 
• euphoria 
• miosis 
• orthostatic hypotension 




• respiratory depression 
• in rare cases, delirium. 
Caution: Monitor the person closely as intoxication can rapidly progress to overdose 
depending on the type of opioid and route of administration. Other drugs may also 
increase the risk of overdose e.g. alcohol or benzodiazepines and any medicines which 





Accidental overdose is not uncommon and may be due to: 
• varying dose and increased purity of illicit supplies 
• reduction in tolerance after period of abstinence (e.g. release from prison, 
discharge from rehabilitation or hospital) 
• mixing drugs (particularly injecting benzodiazepine, cocaine) and/or alcohol 
• leakage from poorly wrapped drugs that have been ingested (body ‘stuffers’ and 
packers) 
• being a novice opioid-injecting drug user. 
It is important to remember that there are significant risks of overdose from opioids in 
people with particular physical conditions. These include: 
• sleep apnoea 
• chronic airways disease 
• cardiac conditions 
 
Signs of overdose: 
• slow respiration 
• miosis 
• weak pulse 
• bradycardia 
• possible pulmonary oedema 
• subnormal temperature 
• cyanosis 
• difficult to rouse, decreased level of 
consciousness 
• muscle twitching. 
Pharmacological/medical management of general opioid overdose 
• Maintenance of airway and breathing are most important in overdose 
management – follow cardiopulmonary resuscitation (CPR) protocol. 
• Narcan (naloxone), an opioid antagonist, is used as a reversal agent and will 
reverse the effect of opioid overdoses. People who were previously sedated may 
become agitated, aggressive and difficult to manage due to sudden precipitated 
withdrawal syndrome 
• Naloxone is shorter-acting than opioids. Repeat doses may be required until the 
opioid effect is resolved e.g.  methadone has a long half life (approx. 24 hours), and 
so the effect of a single dose of naloxone  is obviously insufficient 
• Naloxone should always be given in the case of respiratory depression even if the 
person is conscious [95] 
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• Naloxone hydrochloride (naloxone) is available as 1 millilitre (ml) ampoules of 400 
micrograms and as Min-I-Jet containing 2mg in 5ml. 
A dose at 0.8-2mg by intravenous injection should be administered, repeated at intervals 
of two to three minutes to a maximum of 10mg. If respiratory function does not improve, 
other diagnostic options such as other drug intoxication or other organic causes of loss of 
consciousness, including hypoglycaemia, should be considered. 
The subcutaneous or intramuscular injection route should be used if an intravenous route 
is not accessible. The same regime should be employed as for intravenous use, but the 
clinician should expect a slower response. 
Because naloxone is short-acting, and repeated injections or intravenous infusion may be 
needed if a longer-acting opiate such as methadone or buprenorphine has been taken. 
Naloxone can be given as a continuous intravenous infusion of 2mg diluted in a 500ml 
intravenous solution titrated at a rate determined by the clinical response. 
Effects of methadone or buprenorphine overdose 
• Can persist for up to 72 hours, even in circumstances where people have been 
resuscitated. Depending on the magnitude of the overdose, they should be 
observed for a period of up to 72 hours. For high dose intoxication, naloxone 
infusion should be considered [94]. 
• Because of the longer half-life of methadone compared with heroin or morphine 
(methadone = 24-48 hours), people who overdose from methadone and who are 
subsequently treated with naloxone, may seem to recover initially but can relapse 
into respiratory depression and coma if not adequately monitored and treated 
with additional naloxone.  
Management of overdose of buprenorphine (Subutex®) and buprenorphine and 
naloxone (Suboxone®)  
Overdose [i.e. opioid toxicity] due solely to buprenorphine in an opioid tolerant person is 
unusual. If the person appears to be intoxicated and is known to be opioid tolerant, then 
poly drug toxicity [buprenorphine plus combination with alcohol, benzodiazepines or other 
CNS depressant drugs] may be the issue. Most overdoses involve combined use of more 
than one central nervous system depressant.  
On the other hand buprenorphine in moderate or high doses in an opioid-naïve person 
[and especially in children] may result in opioid toxicity. It is important to remember that if 
swallowed, buprenorphine absorption will be poor due to first pass metabolism. However 
the person should generally be monitored for 24 hours even if there has been a good initial 
response to treatment. [see below]  
The major aim of managing a Buprenorphine overdose is to recognise and respond early 




Possible complications of Buprenorphine overdose include:  
• respiratory and cardiovascular depression, aspiration, hypoxia 
• precipitation of withdrawal 
• inadequate response leading to non-reversal (or temporary reversal then relapse) 
of respiratory depression 
• physical /verbal assault from individual with precipitated withdrawal (rapid 
reversal of opioid overdose with naloxone) 
• needle-stick injury. 
 
General Principles for Medical Management of Buprenorphine Overdose 
Naloxone (naloxone hydrochloride) in standard doses of 0.4-0.8 mg, will readily reverse 
most overdoses of heroin, morphine or methadone, but this may not be the case for 
buprenorphine.  Much higher doses may be required than for reversal of other opiate 
overdose and even these may not be fully effective in reversing buprenorphine overdose.   
Initial management of overdose should include respiratory support, the establishment of 
IV access and administration of large doses of naloxone.   
Once reversal is achieved, repeat administration of Naloxone will be necessary to prevent 
respiratory depression due to the short half-life of Naloxone. 
High doses of antagonist are needed for overdose reversal: Buprenorphine has a high 
affinity for μ opioid receptors, and is not easily displaced by the antagonist, naloxone. In 
some cases doses of 10 to 30 times the normal naloxone doses (up to 10 to 35 mg/70 kg) 
may be required to partially reverse the effects of buprenorphine toxicity [96-101]. 
However, cases have also been reported where much smaller doses (2 to 4mg) of naloxone 
have been effective in reversing the effects of buprenorphine [102]. 
A continuous infusion of naloxone may be employed in these circumstances and may be 
required for over 24 hours due to the long half-life of buprenorphine.  A guide is to use 
two-thirds of the initial reversal dose on an hourly basis.  Ten times this dose could be 
added to a litre of Normal Saline or D5W and infused at 100ml/hour.  The infusion rate and 
concentration may be adjusted to achieve the desired antagonistic effect without fluid 
overload.  
Naloxone requirements may vary during the infusion period necessitating close monitoring 
of vital signs and increasing or decreasing the dose as required. 
Medical regime may include: 
• 2mg of naloxone IV immediately 
• if no response within two minutes, repeat the dose of naloxone 
• repeat the process up to 10 mg of naloxone 
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• monitoring of respiratory and cardiac status.  check blood pressure - if shocked, 
commence intravenous fluids may be prescribed 
• oxygen, intravenous fluids and assisted ventilation as indicated 
• continual monitoring and administration of high dose naloxone hourly. 
Nursing Management 
• undertake usual overdose procedures related to maintenance of airway, cardiac 
status and monitoring of state of consciousness 
• if in full cardio-respiratory arrest commence CPR. Give 2mg of naloxone iv 
immediately or other dose as per ordered medically prescribed regime 
• undertake usual nursing observations including observing for other signs of 
external injury or for other possible causes of altered conscious state, e.g. 
hypoglycaemia, head injury. If no response within two minutes, repeat the dose of 
naloxone 
• avoid assumptions that the presentation is solely due to overdose especially for 
people well known to participate in drug use as something else may be happening 
• attempt to get as much history as possible about the overdose from other sources 
[103]. 
Opioid withdrawal 
Overdose following opioid withdrawal 
A person who has undergone opioid withdrawal during hospitalisation or in a medically 
supervised detoxification clinic will have significantly lowered tolerance to all opioids.  
To avoid the risk of accidental overdose from using an opioid now tolerance has reduced 
the person needs to be informed about why this can occur – even with significantly smaller 
doses/amounts than they were using previously.  
Opioid withdrawal precipitated by buprenorphine or naltrexone  
Naltrexone is an antagonist that blocks the effects of opioids on the central nervous 
system, including heroin. Buprenorphine is a partial agonist which at normal doses will 
displace other opioids from mu receptors. Administration of buprenorphine or naltrexone 
to an opioid dependent person who has a significant amount of opioid still in their system, 
is likely to result in a severe withdrawal reaction requiring hospital treatment. 
• onset of buprenorphine or naltrexone-precipitated withdrawal occurs 20-60 
minutes following oral ingestion of naltrexone, or within seconds with IV 
administration 
• gastrointestinal symptoms are usually predominant 
• severe vomiting and diarrhoea may occur 
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• agitation, distress and delirium with confusion are common 
• signs of sympathetic overactivity, particularly profuse sweating and piloerection 
can occur.  
Assessment 
If at all possible the person’s history of opioid dependence should be obtained from them 
or from: 
• an accompanying partner or friend  
• by examining any likely injection sites for recent injection ‘ track’ marks, 
inflammation or bruising. An absence of track marks should not exclude this 
diagnosis. 
The ATOD and general history is however often difficult to obtain from the person who is 
confused. Clinicians need to consider naltrexone-precipitated withdrawal where a person 
presents with signs of opioid withdrawal and delirium or intractable vomiting. 
Note: Extra care is necessary to assess: 
• depth of sedation using the Glasgow Coma Scale (See Appendix 8)  
• capacity to protect their airway 
• any other serious symptoms.  
• people who are deeply sedated or vomiting are highly likely to require intubation 
and intensive care.  
• electrolytes and arterial blood gases will need to be checked and monitored 
closely. 
Note: In this instance, the use of flumazenil (benzodiazepine antagonist) to reverse 
sedation is not recommended due to risk of: 
• concurrent benzodiazepine dependence 
• inducing life-threatening seizures. 
Clinical management 
It is essential that supportive and symptomatic treatment for at least four hours is 
provided due to risk of delirium and agitation. In addition attend to:  
• ensuring fluid and electrolyte replacement in a person who is vomiting  
• inserting intravenous cannulae and administration of fluids as required 
• a person is likely to tolerate oral fluids within 12 hours of oral ingestion of 
naltrexone 
• reassuring the person that their symptoms, although severe, will be short-lived 
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• antagonist-induced withdrawal syndrome such as this is extremely traumatic with 
people expressing fear of death 
• they need repeated reassurance to feel safe and recover  
• educating the person that taking heroin or another opioid will not alleviate their 
symptoms as administration of opioid agonists does not help  
• relieving vomiting and diarrhoea -  conventional anti-emetics provides little relief  
• Octreotide (Sandostatin®) 100mg is the drug of choice in this instance 
• treating agitation and sympathetic over-activity with clonidine (150mcg orally or 
100mcg intramuscular 
• repeated after two hours if agitation persists and hypotension is not a problem) 
• urgent sedation that is imperative (where people are violent and confused) 
• midazolam 5-10mg intramuscular may be helpful 
• abdominal cramps may be relieved by a single dose of 20mg hyoscine-
butylbromide (Buscopan®) reorientating the person who has experienced 
naltrexone-induced withdrawal delirium. This is critical in both obtaining a history 
and in clinical management. 
The person should be informed that some residual withdrawal symptoms may persist for 
up to seven days.  
Note: The person needs to be warned of the high risk of overdose if they use heroin or 
other opioids following naltrexone-induced withdrawal. 
Onset and duration of withdrawal syndrome 
Knowledge of the half-life of each opioid drug (e.g. heroin vs. methadone) and the likely 
time of onset of withdrawal symptoms following the last dose assists in predicting, 
identifying and effectively managing withdrawal symptoms. 
Objective and subjective symptoms of opioid withdrawal: 
• lacrimation 
• rhinorrhoea 
• yawning  
• sweating  
• piloerection  
• hot and cold flushes  




• muscle twitches 
• nausea and vomiting 
• abdominal cramps 





Table 12: Times of onset of withdrawal syndrome in dependent opioid users 
Opioid Time after last dose 
symptoms appear (hours) 
Duration of withdrawal syndrome 
(days) 
Heroin/morphine 6-12 hours 5-7 days 
Pethidine 3-4 hours 4-5 days 
Methadone 24-48 hours 10-21 days 
Kapanol/MS 
MS Contin (if intravenous) 
8-24 hours 7-10 days 
Codeine orally 8-24 hours 5-10 days 
Buprenorphine/ 
Buprenorphine/Naloxone 
Variable but generally around 
48 hours 
Can be prolonged as Methadone 
generally 10 – 14 days 
Tramadol Variable 12 – 20 hours 7 days can be longer 
[Adapted from 3] 
Opioid withdrawal syndrome can start as soon as four (4) hours after the last dose and is 
manifested as a marked drive to use the drug [93]. 
Opioid withdrawal is the characteristic group of symptoms (syndrome) that occurs due to 
recent cessation or reduction in daily prolonged use of an opioid drug. 
People who use opioids continuously can experience a moderate to severe but not life-
threatening withdrawal syndrome. Withdrawal from heroin can begin 6 to 12 hours after 
the last dose and lasts for about four to 10 days. Methadone has a longer half-life than 
heroin. Withdrawal from methadone has a later onset, starting 24 to 48 hours after the 
last dose and lasting from 10 to 20 or more days. Moderate to severe withdrawal can occur 
after doses of more than 100mg morphine per day for 30 days; mild withdrawal can occur 
after even shorter periods of administration. 
Heroin (diacetylmorphine) is rapidly metabolised to morphine. Pharmaceutical heroin is 
equipotent with morphine but street heroin is of variable purity (current information from 
seizures suggests up to 70%) with additives (adulterants) making up the weight. Onset of 
withdrawal is 6-12 hours after the last dose and usual duration is five to seven days. 
Methadone has a much longer half-life than morphine (24-48 or more hours with chronic 





Figure 7: Progress of the acute phase of opioid withdrawal last dose 
 [Adapted from 3] 
Special considerations 
Polydrug dependence: Withdrawal from each drug group may need to be addressed and 
consideration should be given to admission and management. It may be necessary to 
institute a benzodiazepine reduction regime in addition to the symptomatic medications. 
In these circumstances advice should be sought from a specialist ATOD medical officer or 
an alcohol and drug information service. 
Pre-existing medical condition: If this is likely to be exacerbated by withdrawal, admission 
and management is indicated.  
Pregnancy: Opioid withdrawal should not be undertaken during pregnancy due to the high 
risk to the viability of the foetus. Methadone maintenance followed by gradual 
withdrawal/reduction may be a more appropriate option. Advice should be sought from a 
specialist ATOD medical officer regarding the best management options for pregnant 
women. Increasing evidence is accumulating in the literature regarding the safety of 
buprenorphine maintenance in pregnancy.  
Post- acute withdrawal phase: May last two weeks to three months, characterised by 
cravings for the drug, low frustration tolerance and mood swings. The person is likely to 
experience ongoing symptoms over this timeframe. Assist the person by focussing on 




relapse management plan and encourage participation in exercise (acupuncture may have 
a role through similar effects on endorphins). A supportive, positive and understanding 
home environment is very helpful in assisting people through this phase. Provide 
reassurance that symptoms will lessen over time. 
Signs and symptoms of opiate withdrawal: 
• drug-seeking behaviour 
• joint pain 
• anorexia 
• restlessness 
• disturbed dreams/nightmares 
• diarrhoea 




• muscle twitches 
• hot and cold flushes 
• abdominal cramps 
• muscle and joint aches 
• insomnia 
• anxiety 






This withdrawal syndrome can be very uncomfortable and distressing, but not life-
threatening unless there is a severe underlying disease. People may have a low tolerance 
to pain due to the effect of long-term opiate use and these needs to be acknowledged and 
treated effectively.  
Major complications 
• anxiety and agitation 
• low tolerance to discomfort and dysphoria 
• dehydration and electrolyte imbalance (arising from severe vomiting and 
diarrhoea) 
• drug-seeking behaviour (through requests for medication or attempts to self-
medicate) 
• muscle cramps 





Opioid withdrawal precipitated by buprenorphine or naltrexone  
Naltrexone is an antagonist that blocks the effects of opioids on the central nervous 
system, including heroin. Buprenorphine is a partial agonist which at normal doses will 
displace other opioids from mu receptors. Administration of buprenorphine or naltrexone 
to an opioid dependent person who has a significant amount of opioid still in their system, 
is likely to result in a severe withdrawal reaction requiring hospital treatment. 
• onset of buprenorphine or naltrexone-precipitated withdrawal occurs 20-60 
minutes following oral ingestion of naltrexone, or within seconds with IV 
administration 
• gastrointestinal symptoms are usually predominant 
• severe vomiting and diarrhoea may occur 
• agitation, distress and delirium with confusion are common 
• signs of sympathetic overactivity, particularly profuse sweating and piloerection 
can occur.  
Nursing management 
(See Section 2.6: Managing withdrawal). 
Nursing observations 
(See Appendix 10: Clinical Objective Opiate Withdrawal Scale (COWS)  
The clinical objective opiate withdrawal scale (COWS) is a validated clinician-administered, 
tool which rates eleven common opiate withdrawal signs or symptoms. The added score of 
the eleven items can assess the severity of opiate withdrawal and to make inferences 
about a person’s level of physical dependence on opioids. Nursing observations should be 
undertaken four hourly or more frequently if required. 
• create a supportive environment – provide reassurance and encouragement. 
• provide information to counter negative expectations (e.g. around stigma and fear 
withdrawal symptoms). 
• provide the prescribed medications and explain their effects and expected impact 
on withdrawal. 
• provide self-help information [104]. 
Drug-seeking behaviour can be a consequence of anxiety and/or inadequate 
pharmacological and nursing management of withdrawal symptoms. Ensuring adequate 
assessment of withdrawal symptoms, timely administration of medication and the offer of 
alternatives to medication such as hot baths and massage for muscle cramps, teach and 
encourage relaxation activities (e.g. reading, watching television, playing cards) to direct 
attention from withdrawal symptoms. 
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It is important to involve the person in their assessment of the severity of their withdrawal 
symptoms by administering the Clinical Objective Opiate Withdrawal Scale (COWS). (See 
Appendix 10). 
Considering the person’s report on the efficacy of their symptom relief can assist in 
reducing anxiety regarding being under-medicated  
Requests for medication may be dismissed inappropriately as ‘drug-seeking’.  It is 
important and more helpful to identify this as the person having a need that is not being 
met. Asking about their concerns and how you can be of help. If the person is making 
unreasonable or illegal requests for additional drugs, talk with them to find out what is 
happening and their concerns. As appropriate explain why such requests cannot be met 
and offer reasonable options for them, taking a supportive respectful approach. 
In some instances a contract management plan between the person and the clinical team 
helps to define the boundaries and set behavioural limits while in the treatment setting. 
This can result in positive outcomes.  
Pharmacological treatment 
The medical officer may prescribe one or two pharmacological options for opioid 




Evidence indicates that buprenorphine is the drug of choice for a significant number of 
people undergoing opioid withdrawal symptoms. Buprenorphine is available as 8mg, 2mg 
and 0.4mg tablets. Its trade name is Subutex®. Buprenorphine is also available in 
combination with naloxone as 2mg and 8mg tablets and film for sublingual or buccal 
mucosal use. Its trade name is Suboxone®.  In general this should be the formulation used 
except in pregnancy or where allergy to naloxone is documented.  
As a partial agonist, buprenorphine can offer advantages over methadone tapering 
because withdrawal distress may be less intense, and there are often fewer side effects 
than experienced with other medication such as clonidine. There can be problems with 
precipitated withdrawal with initial doses due to its partial agonist properties [93]. 
Buprenorphine is an opioid used either as a pain reliever or as a substitute for drugs such 
as morphine, heroin or methadone, or to medicate someone undergoing opiate 
withdrawal. As a partial agonist (sometimes called ‘mixed agonist/antagonist’) it cannot 
produce the same level of opioid effects as heroin or methadone. It also means that 
overdose may be less of a problem. 
Buprenorphine binds very tightly to opioid receptors and can displace other opioids. 
Consequently commencing someone who is opioid dependent on buprenorphine may 
precipitate withdrawal.  
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• First doses should be delayed for at least six hours after heroin use and 24 hours 
after methadone. Buprenorphine should not be administered until withdrawal is 
evident. 
• Dose titration may be required in the event of worsening withdrawal symptoms 
[93]. 
• Buprenorphine blood levels peak at about 90 minutes after sublingual absorption, 
with the onset of clinical effects at 30-60 minutes and peak clinical effects at one 
to four hours. 
• Duration of effect is eight to 12 hours at low dose (e.g. less than 4mg) but at higher 
doses (greater than 8mg per day) effects may last 24-72 hours because of the 
strong receptor binding. The therapeutic effect lasts from one to two days. It is 
eliminated mainly by hepatic metabolism. 
The role of buprenorphine in treating opioid withdrawal is to reduce symptoms and 
craving, but not necessarily remove all symptoms or intoxicate the person. It is important 
that people understand that high doses can result in increased rebound withdrawal, 
prolonged duration of symptoms and increased side effects. Ongoing cravings are not 
necessarily an indication of inadequate doses, and may relate to other cues to resume drug 
use, such as the other people they are with or sighting needles and syringes. However, too 
low a dose can result in unnecessary withdrawal symptoms and the person ceasing 
treatment early. 
For most people, buprenorphine withdrawal is not as uncomfortable as it is from heroin or 
methadone. Most withdrawal symptoms will begin one to three days after the last dose. 
Use of buprenorphine 
It is supplied as sublingual tablets that dissolve under the tongue in about five minutes, 
with the drug being absorbed through the lining of the mouth into the bloodstream. 
Crushing the tablets does not seem to have much impact on absorption, but lessens the 
likelihood of the person giving the drug to others or selling it on the black market. If it is 
swallowed, most of the drug will be metabolised by the liver before reaching the general 
circulation. 
Contraindications 
Buprenorphine should not be taken by people who: 
• are allergic to buprenorphine 
• are breastfeeding (it may reduce milk production, also it does get into breast milk 
and so may affect the baby) 
• have severe liver or kidney problems 
• have serious breathing problems 
• are children under 16 years 
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• are intoxicated with alcohol or in alcohol withdrawal. 
Precautions for women who are:  
• heavy alcohol drinkers 
• taking any other drugs especially CNS depressants 
• pregnant or are trying to get pregnant 
• Evidence regarding the safety of buprenorphine maintenance in pregnancy is 
accumulating however it is not yet considered definitive 
• Neonatal withdrawal syndrome may be less severe than in methadone exposed 
infants 
• are breastfeeding  
• It may reduce milk production; although buprenorphine passes into breast milk, it 
is poorly orally absorbed. 
Use caution if using other drugs 
• benzodiazepines 
• alcohol 
• antidepressants (especially monoamine oxidase inhibitors) 
• any other central nervous system depressants. 
Side effects 
• drowsiness, especially if taken 
with alcohol 
• headaches 





• fainting and dizziness 
(orthostatic hypotension) 
• respiratory depression. 
 
There is a possibility that it may cause hepatic necrosis and hepatitis with jaundice. Liver 
function tests should be performed at regular intervals for those people receiving long-




Using buprenorphine in opioid withdrawal—suggested dosing 
protocol 
Hospital setting 
Buprenorphine is well suited to this application as it alleviates symptoms of withdrawal 
without significantly prolonging the duration of symptoms. When buprenorphine is used 
for inpatient withdrawal an authority is not required for the prescription.  
However, with outpatients the withdrawal program will need to be managed by an 
accredited prescriber, and an authority for the prescription from the SA Drugs of 
Dependence unit will be required.  
There should be some ability to tailor doses to degree of withdrawal as assessed by the 
Clinical Opiate Withdrawal Scale (COWS). Buprenorphine should not be commenced until 
objective withdrawal is present to reduce the likelihood of precipitating worse withdrawal 
symptoms. 
Table 13: Daily buprenorphine dose 
Day Buprenorphine sublingual tablet regime Total daily dose 
1 4mg at onset of withdrawal and additional  
2-4mg as necessary (more than four hours later) 
4-8mg 
2 4mg in the morning, additional 2-4mg evening dose 
as necessary 
4-8mg 
3 4mg in the morning, additional 2mg evening dose as 
necessary 
4-6mg 
4 2mg in the morning, if necessary, 2mg evening dose 
as necessary 
0-4mg 
5 2mg prn 0-2mg 
6 no dose  
7 no dose  
 
Buprenorphine should not be administered if there are features of intoxication or sedation, 
otherwise it should be given on person request as per the above protocol (there is no need 
for objective withdrawal for subsequent doses, only for the first).  
Observations should include COWS scores at every observation occasion, and just prior to 
discharge (see Appendix 10 for COWS). 
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Withdrawal in a Community setting 
Buprenorphine has been used successfully in community settings and its long duration of 
action and relative safety makes it well-suited to this application. The objective is to cover 
the period of most intense withdrawal symptoms and discontinue buprenorphine quickly 
to minimise rebound withdrawal phenomena and limit duration of symptoms. As with 
admission and management, flexibility with individual tailoring of dose is ideal. 
Symptomatic medications 
Buprenorphine does not alleviate all withdrawal symptoms (although buprenorphine is 
more effective) and is used in conjunction with appropriate additional symptomatic 
medications as described in Table 14 (below). 
Table 14: Use with symptomatic medications 
Insomnia temazepam 10-20mg nocte prn for no more than three 
nights. 
Vomiting metoclopramide (Maxolon®) 10mg oral/or intramuscular, 
three times a day, as necessary (TDS, PRN) 
Stomach cramps hyoscine butylbromide 10 – 20 mg  four times a day as 
necessary (QID PRN) 
Diarrhoea loperamide (Imodium) 2mg orally as necessary (generally 
4mg initially then 2mg as necessary following passing 
unformed stools, to a max of 16mg per day). 
Headache and 
muscle and bone 
aches/pain 
paracetamol 500mg-1 gram oral four to six hourly as 
necessary or Norgesic™ one to two tablets orally four times 
a day as necessary and/or  naproxen 250mg oral three times 
a day as necessary. 
Anxiety/agitation relaxation exercises/therapy and/or  massage. If 
unsuccessful diazepam 5-10mg orally four times a day as 
necessary for four days. 
[3, 103] 
Note: 
• Caution is recommended in exceeding stated duration of benzodiazepine use to 
avoid substituting for heroin dependence. 
• Duration of treatment may need to be longer than stated above for withdrawal 
from long-acting opioid (e.g. methadone, Kapanol® etc). 
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Pharmacotherapy treatment for opioid dependence  
Introduction 
Pharmacotherapy medication in management of opioid dependence is known as 
‘replacement or substitution pharmacotherapy’ (e.g. methadone and buprenorphine).  
There is a range of pharmacological therapies that are effective in the treatment of 
alcohol, opioid and nicotine dependence in Australia. Evidence-based pharmacotherapy is 
yet to be developed for psycho-stimulant dependence. 
All nurses, midwives, medical officers and allied health professionals need to know about 
these treatments, the rationale and benefits of use and what is required when this client 
population are admitted to hospital. While some people can achieve abstinence without 
the use of medication, others require prescribed medication for weeks, months or years. 
Longer-term prescribing of specific medications in this domain is known as ‘replacement or 
maintenance pharmacotherapy’ (e.g. methadone for opioid dependence, naltrexone for 
alcohol dependence, nicotine patches for nicotine dependence). Pharmacotherapy 
requires extensive medical and psychosocial assessment, supervision, monitoring and 
regular review (at least three monthly for stable persons, more frequently for those at 
risk), and should be part of a broader program of general health care (including dental), 
counselling, management of comorbid conditions and social support. It may or may not be 
a treatment of first choice for a person presenting to a GP or specialist service for the first 
time, and where other options have not been explored.  
Importance of Contraceptive advice and support   
Women that enter treatment for opioid dependence are likely to show improvement in 
their health and fertility – and pregnancy may occur. It is a common misconception that 
amenorrhoea is synonymous with infertile cycles. Women should be cautioned that while 
they may experience irregular menses while on methadone maintenance treatment they 
can continue to ovulate.  
Improved fertility and contraception information/advice is needed by all women on entry 
to drug or other health programs [60]. 
Opioid pharmacotherapy 
Opioid maintenance pharmacotherapy (often referred to as ‘replacement or substitution 
therapy’) is very effective for a significant number of people who are dependent on opioids 
such as heroin and morphine. There are two drugs that are most commonly used in 
Australia, Buprenorphine (Subutex) and Buprenorphine with naloxone (Suboxone) and 
Methadone.  
Buprenorphine is slowly becoming the drug of choice in opioid pharmacotherapy although 
it will not suit many clients particularly those with very high tolerance at induction to 
treatment. 
Methadone remains the gold standard drug of choice for pregnant women.  
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Buprenorphine or Buprenorphine with naloxone hydrochloride 
Buprenorphine is available in two forms, as a single drug (Subutex®) and in a combination 
(Suboxone®) which contains buprenorphine and naloxone hydrochloride in a ratio of 4:1.  
Suboxone® is likely to be the choice of Buprenorphine treatment in the future due to the 
less abuse potential due to naloxone precipitating acute withdrawal symptoms if injected. 
It is also considered it will reduce abuse potential and therefore illicit diversion to non 
treatment populations [105]. 
Note: Suboxone® has until recently been administered as a dissolvable buccal tablet. 
However it is now available as a sublingual film preparation that adheres to the sublingual 
or buccal mucosa and cannot easily be removed. This is proving to be the preferred 
formulation if available.  
Buprenorphine is: 
• a partial agonist—an opioid analgesic with both partial agonist which has the effect 
of reduces the respiratory depression effect in overdose [105] and antagonist 
properties 
• a drug which has a wider safety margin and strong receptor binding leading to a 
long half-life which allows for alternate day (double) dosing which is a more 
convenient option for many people 
• effective in managing opioid withdrawal and as a long term opioid 
pharmacotherapy 
• as effective as methadone for people with moderate levels of dependence, and 
possibly for those with higher levels [106] 
• administered sublingually and reaches its peak effect after about 3 hours. 
There are two explanations for reduced withdrawal symptoms on cessation following long 
term dosing of buprenorphine compared to other opioid pharmacotherapy.  
These are: 
• The tightness of receptor binding and slow dissociation from receptor sites gives 
rise to lower level withdrawal symptoms [105] 
• As a partial agonist it induces lower level physical dependence than methadone so 
cessation is more comfortable [106]. 
Safety 
Buprenorphine is relatively safe; there have been no deaths in Australia attributed to 
buprenorphine alone when taken in a prescribed dose. There have been deaths associated 




Indications for pharmacotherapy use  
It is recognised that Buprenorphine is an effective treatment for opioid dependence within 
a framework of medical, social and psychological interventions.  
Administration: Sublingual or buccal film  
Tablet and film strength:  Two strengths – 2mg and 8mg.  
Suboxone® has added naloxone at ratio of 4 buprenorphine to 1 naloxone i.e. 2mg 
has 0.5mg naloxone and 8mg has 2mgs naloxone.  
Dose levels: Usually 12 - 24mg per day. Some people may be maintained on lower doses.   
Duration of action: Buprenorphine is long acting with a terminal half life of 24 – 37 hours. 
Peak effect is 1 – 4hrs post sublingual administration. Effects last up to 12 hrs for low doses 
(2mg) and up to 48-72 hrs for higher doses (16 or 32mg). 
Dosing frequency: Some people may be dosed every day whereas others, who meet 
specific criteria, may be receiving double doses (maximum dose of 32mg per day), every 
second day (four doses per week) and others on three doses per week depending on which 
regimen best suits the individual person and the prescribed dose.  
See the National clinical guidelines and procedures for the use of buprenorphine [107] on 
the following website:  
www.health.gov.au/internet/drugstrategy/publishing.nsf/Content/buprenorphine-guide 
Side effects 
The side effects of Buprenorphine are similar to those which occur with the use of other 
opioids. Some side effects have been reported, however these are relatively mild, occur 
early in commencing treatment and reduce over time. Side effects include: 
• constipation 
• insomnia 







During stabilisation or following dose increase, the person’s capacity to operate machinery 
or drive may be decreased until tolerance to the dose develops. 
Contraindications 
The contraindications for buprenorphine pharmacotherapy include: 
• known hypersensitivity 
• previous severe side effects 
• children less than 16 years of age 
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• pregnancy and breastfeeding 
• acute psychosis or severe depression – particularly if at moderate to high risk of 
suicide. 
Precautions 
Buprenorphine should be used with caution by client populations with: 
• concomitant prescription of CNS 
depressant drugs due to overdose 
risk or dependence on these drugs 
e.g. alcohol, benzodiazepines, 
antidepressants  
• increased intracranial pressure 
• chronic obstructive airways disease 
or corpulmonale 
• severe hepatic disease (may alter 
hepatic metabolism of 
buprenorphine) 
• severe hepatic insufficiency 
(Suboxone is metabolised by the 
liver and its activity may be 
increased or extended) 
• myxoedemaCYP3A4 inducers e.g. 
carbamazepine, phenolbarbital, 
phenytoin, rifampicin (potential 
interactions are not known) 
• recent head injury 
• abdominal conditions (can 
obscure diagnosis or clinical 
course) 
• pre-existing respiratory 
depression, hypoxia or 
hypercapnea 
• severe respiratory insufficiency 
• impaired renal function 
• hypothyroidism 
• adrenal cortical insufficiency e.g. 
Addison’s disease 
• delirium tremens 
• hypotension 
• biliary tract dysfunction 
• kyphoscoliosis 





Table 15:  Drug interactions with buprenorphine  





Additive sedative effects  Additive central nervous 
system (CNS) depression 
Amiodarone Clinically 
important 
May cause increased plasma 
concentration  
Inhibition of metabolism in 
the liver 






Erythromycin – may increase 
serum erythromycin levels and 
therefore increased risk of 
ventricular arrythmia and sudden 
death. 





 May cause increased plasma 
concentration  




 May cause increased plasma 
concentration  
Risk of serotonin syndrome due 
to serotonin toxicity with MAO 
inhibitor and for example, 
amitriptyline, doxepin 
Inhibition of metabolism in 
the liver 









 Additive sedative effects  Additive CNS and depression 
and fatal over dose risk 
particularly with high doses  
Carbamazepine  May cause increased clearance 
and lower serum levels 
Increased metabolism in the 
liver 
Cimetidine  Clinically 
important 
May cause increased plasma 
concentration  
Inhibition of metabolism in 
the liver 
Dispyramide  May cause increased plasma 
concentration  




use in conjunction 
with buprenorphine) 
 No evidence of effect – 
manufacturer contraindicates use 
of domperidone with CYP3A4 
inhibitors 





  Weak inhibition of 
metabolism 
Fluvoxamine  May cause raised serum levels  Inhibit metabolism 







May cause increased serum 
concentrations  
Ritonavir – sub clinical 
prolongation of QTc has been 
observed 




Table 15 cont: Drug interactions with buprenorphine 
Drug Degree of 
interaction 
Effect Mechanism 
HIV antiviral drugs 
e.g. Efavirenz, 
nevirapine 
 May cause increased clearance 
and lower serum levels 




May cause increased serum 
concentrations  
Inhibition of metabolism in 
the liver 
MAOI’s, Doxepin   Clinically 
important 
May cause serotonin toxicity and 
risk of serotonin syndrome  
May induce excessive intra-
synaptic serotonin 
Nefazodone  May cause increased plasma 
concentration  
Inhibition of metabolism in 
the liver 
Nifedipine   May cause increased plasma 
concentration  
Inhibition of metabolism in 
the liver 
Opioids  Additive sedative effects 
May induce withdrawal  
In overdose - high doses of 
naloxone may be needed to 
reverse effects  
Additive CNS depression  
May complicate the use of 
additional opoids for 
analgesia due to degree of 
blockade as Buprenorphine 
is a partial agonist 
Barbiturates e.g.  
phenytoin, 
phenobarbital 
 May cause increase experience of 
side effects when co-
administered with buprenorphine 
May cause increased clearance 
and lower serum levels 
Side effects 







May cause additive respiratory 
depression  
and serotonin toxicity  
Amitriptyline – additive CNS 
effects 
Additive CNS depression  
May induce excessive intra-
synaptic serotonin 
Sotalol  Increased sedative and or 
increase hypotensive effect.  
Additive effects in  
Spironolactone 
(aldactone)  
 May cause increased clearance 
and additivel hypotensive effect 
Increased metabolism in the 
liver 
Addtive effect on blood 
pressure 
St John’s Wart  May cause increased clearance 
and lower serum levels 




use in conjunction 
with buprenorphine) 
 Additive sedative effects  Additive or synergistic CNS 
effects 
Verapimil  May cause increased plasma 
concentration  





For further information regarding the range of drugs metabolised by Cytochrome P4503A4 
– see the National clinical guidelines and procedures for the use of Buprenorphine (2006, 
page 71) on the following website: 
www.health.gov.au/internet/drugstrategy/publishing.nsf/Content/buprenorphine-guide 
Ceasing treatment 
When deciding to cease Buprenorphine treatment, there is usually a gradual reduction in 
dose occurring over several weeks. For further information about tapering dose regimes go 
to the website above.  
Methadone 
Methadone is very cost effective for those being treated, as well as the service provider 
and government. 
Action and dispensing  
Methadone is a synthetic opioid (depressant) with a long half-life, e.g. longer acting than 
heroin. It is active orally as syrup. For the purposes of treating opioid dependence it can be 
administered once a day under medical or nursing supervision at a specialist clinic, or 
dispensed from a specified community pharmacy or hospital pharmacy. Methadone is 
administered as an oral syrup. 
The use of methadone maintenance has a strong evidence base particularly in areas of 
reducing criminal activity and illicit opioid injecting, thus reducing the cost to society and 
improving health and well being of individuals.  
Methadone for opioid dependence should be provided as one element of a personalised 
treatment  program that includes non-medical therapies, treatment for any comorbid 
physical or psychiatric disorder, and where counselling is available  
Doses range from 40mg to 120mg/day depending on individual health status and 
circumstances of each person. Methadone is more effective at higher doses (at least 60mg) 
as a maintenance therapy. Most people will experience few symptoms of withdrawal or 
craving for opioids once stabilised on their individualised methadone regime.  
There are criteria for admission to methadone maintenance programs and the person 
being treated registered with the relevant local authority such as the state health 
department. 
Should a lapse to  opioid use occur, high doses of prescribed methadone will ‘blunt’ the 
euphoric effects of other opioids. 
Note: Caution needs to be observed regarding people receiving high doses if there is 





Note: There is a significant risk of fatal overdose in the first few weeks of methadone 
treatment, due to rapid dose increases. Advice should be sought from a medical 
practitioner with experience in prescribing methadone prior to commencement.  
*An authority to prescribe methadone needs to be obtained from the relevant regulatory 
agency.  
Pain relief  
(See Section 3.1.3 on pain and analgesia for further information). 
If a person is being prescribed methadone as a maintenance pharmacotherapy for opioid 
dependence, even at high doses, they will require additional opioids over and above their 
daily methadone dose for effective pain relief due to tolerance and hyperalgesia (increased 
sensitivity to pain). Accident and emergency and other nursing and medical staff need to 
know that a person is taking methadone so that effective pain relief can be offered. 
Safety 
There is a risk of overdose if additional opioids are taken with methadone. Dose tolerance 
reduces with abstinence, so the person needs to be reassessed if they have not had 
methadone for more than three days. Methadone has no severe long-term effects on 
health, however, it is a drug of dependence and expert advice should be sought if there is 
abrupt cessation of use. Most people can remain in treatment over a long term with no ill 
effects on health. 
Administration: Oral syrup. 
Side effects 
Short term: (Related to the central nervous system depressant properties of opioids) 
• constipation 
• nausea/vomiting 
• drop in body temperature 




• weight gain 
• tooth decay due to decreased oral secretions. 
 
Contraindications: 
• kidney disease 




(See Table 14: Drug interactions with Opioids). 
Withdrawal 
Following the cessation of methadone (severity varies with the dose), withdrawal will 
occur one to three days after last dose, and may last two weeks or more. Abrupt cessation 
from doses above 20mgs per day is not recommended (See Section 3.1.2: Opioids). 
Use in pregnancy 
(See section 2.6: Managing withdrawal). 
Breastfeeding 
(See section 2.6: Managing withdrawal). 
Naltrexone 
Note: Research on effectiveness of long-term naltrexone pharmacotherapy for opioid 
abstinence maintenance indicates poor acceptance with high drop-out rates from 
treatment. This therapy may be selected for a person who is highly motivated, abstinent 
and psychologically stable ,not likely to cease naltrexone and  then relapse into opioid use 
– thus increasing  risk of overdose with use of an opioid, due to reduced opioid tolerance 
[93, 110]. 
Naltrexone is an opioid antagonist recently registered for use in relapse prevention in 
Australia. As an antagonist, naltrexone blocks both the euphoric and analgesic effects of 
opioids. It is long acting, with effects lasting between 24 and 72 hours. 
As a maintenance pharmacotherapy treatment for opioid dependence, naltrexone is 
prescribed for daily use for up to two years to help prevent relapse to opioid use, and is 
administered orally.  
It should always be used in conjunction with counselling and support and access to other 
psychotherapy. It has also been used in rapid detoxification (see below). There are 
particular issues for nurses in managing withdrawal from opioids precipitated by 





There is a high risk of death by opioid overdose if the person takes opioids after ceasing 
naltrexone due to reduced tolerance to opioids. 
Use of naltrexone while still opioid-dependent will bring on severe withdrawal symptoms. 
People must have completed opioid withdrawal prior to using naltrexone and have a low 
withdrawal score. 
As naltrexone use can be associated with psychological depression, medical staff should be 
informed of any history of depression. A referral to a psychologist or psychiatrist may be 
required. Naltrexone is not the pharmacotherapy of choice for people who have a pre-
existing depression. 
Pain relief  
If a person is using naltrexone, opioid-based analgesics (or codeine-based cough 
medicines) will be ineffective. Accident and emergency and other nursing and medical staff 
need to know if a person is taking naltrexone so that effective pain relief can be provided 
by using non-opioid analgesics in these situations. 
Side effects 
Naltrexone is generally well tolerated. Some of the side effects may be due to residual 
withdrawal symptoms associated with heroin or other opioid dependence. If depression 
occurs as a side effect or if the person is unable to tolerate Naltrexone, an alternative 
pharmacotherapy is often considered. Side effects may include: 
• depression 
• headaches 
• nausea and vomiting 
• constipation 
• anxiety 
• sleep disturbances 
• loss of energy 
• abdominal pain 
• loss of appetite. 
Withdrawal 
No withdrawal syndrome occurs when naltrexone treatment stops.  
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Nursing guidelines—maintenance pharmacotherapy in the acute 
hospital setting 
Rationale 
Effective nursing care includes appropriate management of a person receiving 
maintenance pharmacotherapy during their hospital stay. The continued provision of their 
maintenance pharmacotherapy is important as it will help maintain their comfort and 
safety, assist in planning pain management, and prevent the harms associated with poorly 
managed opioid withdrawal, thus reducing the risk of relapse and/or unplanned early 
discharge.  
General principles 
Nurses must consult with the ATOD specialist about the care of all people admitted to 
hospital who are receiving maintenance pharmacotherapy. Ensure that their methadone or 
buprenorphine dose is known and confirmed with prescriber, and that the dose is quoted 
in mg. 
Ensure that adequate pain relief is provided and that this is individually tailored to the 
person’s clinical presentation and expressed need. 
Methadone 
Procedural guidelines 
Take an alcohol, tobacco and other drug use history on admission. 
Assess the person for signs of alcohol and other drug intoxication, overdose or withdrawal 
and take appropriate action. (See Section 2.4: Managing intoxication, Section 2.5: 
Managing overdose and Section 2.6: Managing withdrawal). 
When a person reports that they are receiving maintenance pharmacotherapy, confirm the 
following: 
• name of their program/prescribing doctor 
• what medication regime they are on, e.g. methadone or buprenorphine 
• where they get their medication, e.g. at the drug clinic or  community pharmacy 
• dose (ensure doses are recorded in mg) 
• date and time of last dose (ensure methadone doses are recorded in mg) 
• dosage and number of take-away doses usually provided, e.g. three a week 
(ensure doses are recorded in mgs and mls for methadone) 
• whether the person has brought any take-away doses to hospital 
• confirm the person’s enrolment in a pharmacotherapy maintenance program by 
telephoning the usual prescriber or service provider 
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• contact the program or the dispenser to confirm the details given above, including 
take-away doses, and inform them of the person’s admission to hospital. If a 
person cannot supply telephone numbers, call an alcohol and drug information 
service for details of maintenance pharmacotherapy services, accredited doctors 
licensed to prescribe (e.g. GPs) 
• arrange for any take-away doses held by the person to be forwarded to the 
hospital pharmacy. Take-away doses must not be consumed in hospital and should 
not be returned to the person on discharge 
• particular care must be taken to notify the pharmacotherapy service (GP and/or 
chemist) of the person’s impending discharge from your hospital so that continuity 
of care, in particular the pharmacotherapy regime, can be maintained. The person 
must also be informed in a timely manner as to what they can expect and what has 
been planned 
• arrange for prescription of maintenance pharmacotherapy by the appropriate 
medical officer and dispensing by the hospital pharmacy. Ensure that methadone 
syrup and not physeptone tablets are used for people on methadone maintenance 
• where oral methadone is contraindicated (e.g. nil-by-mouth), an alternative opioid 
should be administered parenterally. Buprenorphine can still be given sublingually 
when on a nil-by-mouth order. If other medical contraindications occur, such as 
head injury, contact the senior medical officer and follow the appropriate local 
policy guidelines 
• monitor the potential for drug interactions with methadone. 
For people on a maintenance pharmacotherapy program who require pain relief: 
• Follow the procedures above 
• In addition to authorised methadone dose, provide the person with such opioid 
analgesics as are necessary to control pain. Such people often have altered 
tolerance to opioids and may require higher doses of analgesia than normal.
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Table 16: Drug interaction with opioids 
Opioid interaction Examples Opioids affected Mechanism Effect 
Other medicines (and 








All Increased CNS depression Additive effect – potentiation of 
respiratory depression 












Increased blood levels of 
methadone or 
buprenorphine by 
inhibition of the enzyme 
CYP3A4 
Dose of methadone or 
buprenorphine may need to be 
decreased to prevent toxicity or 
overdose AND may need to be 
increased to prevent withdrawal 
symptoms when the enzyme 
inhibitor is stopped 
Medicines that decrease 
opioid levels 
Anticonvulsants (e.g. barbiturates, 
carbamazepine, phenytoin) 




St John’s Wort 
Methadone  
Buprenorphine 
Decreased blood levels of 
methadone or 
buprenorphine by 
induction of enzyme 
CYP3A4 
Dose of methadone or 
buprenorphine may need to be 
increased to prevent withdrawal 
symptoms AND decreased to 
prevent overdose when the 






Table 16 cont: Drug interaction with opoids 
Opioid interaction Examples Opioids affected Mechanism Effect 
Opioids that act as partial 
agonists 




Other full agonists 
Buprenorphine is a partial 
agonist and displaces 
other opioids from 
receptor sites 
Can precipitate withdrawal 
symptoms – advise waiting until 
opioid is excreted (confirmed by 
presence of withdrawal symptoms) 
before taking buprenorphine 
Opioid antagonists Naltrexone (active orally) 
Naloxone (active by injection – IV, 
IM and SC) 
All Naltrexone and naloxone 
are full antagonists and 
displace other opioids 
from receptor sites 
Will precipitate withdrawal 
symptoms if taken when agonist or 
partial agonists have recently been 
taken 




Methadone Prolongation of QTc 
interval 
Can cause torsades de pointes. Use 
cautiously with methadone. 
Medicines affecting urine 
pH 
Vitamin C 
Sodium bicarbonate (antacids) 
Methadone Affects excretion of 
methadone – increased 
excretion of acidic urine, 
decreased excretion of 
alkaline urine 
Increased excretion may cause 
withdrawal 
Decreased excretion may cause 
toxicity 
[111]
Maternal and neonatal care 
(See section 2.6: Maternal and Neonatal Care). 
Midwives and nurses may experience considerable challenges in managing opioid use during 
pregnancy and post natal periods and in managing potential withdrawal in the neonate. 
Professional non-judgemental care such as respect, reassurance, support and reinforcement of 
positive behaviour will optimise outcomes.  
Attracting and maintaining women in specialist drug treatment and perinatal maternity 
services is vital for them and their babies [112]. Follow-up studies suggest that the long-term 
outcomes for women who undertake methadone treatment during pregnancy are better, 
including childbirth and their infant’s development in terms of their pregnancy, childbirth and 
infant development, irrespective of continuing illicit drug use. Continued drug use may reduce 
the protective effect of treatment [113, 114]. 
Treatment services that offer non-judgemental, strengths based holistic care based on realistic 
and non-punitive goal setting, counselling and psychosocial support promotes long term 
engagement [58]. 
Engaging the woman’s partner/family is an important aspect of enabling her to feel supported 
and to achieve progress and well-being at the earliest possible stage. 
The key aims in caring for the pregnant woman and her baby are to: 
• Ensure that she receives continuity of care and her family feel welcome and not judged 
by nurses, midwives and other staff, and that she knows her antenatal care and drug 
use can be managed effectively.  
• Encourage the woman to cease illicit opioid and other drug use and to access 
Methadone pharmacotherapy treatment and ensure her pharmacotherapy regime will 
be stable and comfortable (client and her partner should be given priority access) in 
order to help her cease illicit opiate and other drug use. 
• Provide effective coordination of services for her and her family care occurs between 
all relevant services (midwife /doctor and specialist A&OD team) and other parties. 
This will usually involve a planning meeting (with consent) around the 32nd week of 
the pregnancy or earlier as necessary for the wellbeing and safety of the woman and 
her baby (but not a formal case conference unless needed for specific reasons) with 
the woman and her partner. This meeting provides the opportunity to gain an 
understanding of the woman’s issues and perspectives and work with the woman and 
her partner. This is also a time to identify problems and solutions, plan for education, 
set goals and plan support and key networks and resources for the remaining prenatal 
period and following the birth. A decision to hold a formal case conference can be 
made at this meeting or subsequently, depending on circumstances and need. Case 
management should include relevant members of the multidisciplinary team and 
collaborating practitioners.  
• Provide psychosocial and refer for practical support.  
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• Monitor nutrition, risk of anaemia, dental health, complications from any infections 
arising from unsafe injecting drug use. 
The woman, and her partner, should be informed about all clinical meetings and invited to 
participate.  
Assessment – Opioid use and Pregnancy 
• type of opioid used e.g. codeine, morphine, heroin 
• pattern of opioid use & quantify amount/dose e.g. daily, occasional 
• time & date of last use/dose 
• risks e.g. sharing injecting equipment, unprotected sex, driving vehicle or operating 
machinery when intoxicated 
• medical or mental health conditions 
• other drug use including tobacco, alcohol, medicines or inhalants. 
Maternal health problems 
A number of health problems related to drug use that can occur during pregnancy that need to 
be discussed with the woman. The woman’s ongoing health should be managed, monitored 
and reviewed throughout her pregnancy, and include: 
• nutrition 
• risk of anaemia 
• dental health  
• bacterial or viral infections such as from unsafe injecting.  
These all contribute to the increased risk of complications in pregnancy, including premature 
delivery. 
Smoking tobacco during pregnancy increases the risk of complications in pregnancy and in the 
baby who has an increased risk of Sudden Infant Death Syndrome (SIDS) – see Nicotine in 
Psycho-stimulants below. 
There are therefore a range of issues that contribute to increased risk of obstetric 
complications and premature delivery for women who use opioids. A woman’s pregnancy is 
recognised as a special entry criterion for her access to methadone pharmacotherapy 
programs due to increased risk that withdrawal poses to the woman’s health and continuation 
of her pregnancy. 
Potential obstetric complications of non-medical opioid use during pregnancy 
Uncontrolled use of opioids during pregnancy can result in obstetric complications, including: 
• abrupto placentae, spontaneous abortion, and intrauterine death with the most 
common being intrauterine growth retardation with low birth weight, and premature 
labour, foetal distress, meconium aspiration and neonatal jaundice [89]. These 
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symptoms are likely to be caused by fluctuation in illicit opioid dose leading to 
repeated intoxication and withdrawal episodes, rather than due to the nature of the 
opioids themselves  
• blood-borne viral infections can be vertically transmitted by mother to her baby. 
Opioid Withdrawal in Pregnancy  
(See section 2.6: Managing Withdrawal). 
Opioid Withdrawal in pregnancy is associated with: 
• a high risk of relapse and generally should not be encouraged  
• increased risks to foetus e.g. serious risk of miscarriage or stillbirth, miscarriage or low 
birth weight for gestational age, particularly if withdrawal is sudden and not medically 
managed. 
If Methadone maintenance pharmacotherapy is refused and withdrawal is requested by a 
pregnant woman, advise her of: 
• the risks  
• methadone maintenance – preferred and safest option 
• conditions under which medically supervised withdrawal would need to occur to 
reduce risks. 
Conditions for supervised withdrawal are: 
• second trimester only (wks 14 – 32) 
• high level of medical supervision in obstetric inpatient unit – foetal monitoring 
• use tapering doses of methadone to ensure gradual withdrawal. 
The benefits of methadone maintenance should be continually reinforced and encouraged 
during the withdrawal period in order to prevent relapse to illicit drug use. 
Methadone treatment during pregnancy  
Methadone pharmacotherapy is the medication treatment of choice (may include gradual 
dose reduction) for pregnant women who are dependent on opioids. Methadone 
pharmacotherapy is known to improve their health and the chances of delivering a healthy 
full-term baby [89] Methadone treatment is not associated with adverse postnatal infant 
development. 
Research studies have shown that methadone pharmacotherapy is associated with: 
• improved outcomes,  maternal, foetal development and higher birth weight  
• reduced perinatal and infant mortality 
However, effectiveness is reduced if non-medical opioid and or other drug use 




For practical reasons, opioid-dependent partners of pregnant women seeking treatment 
should be accepted into treatment expediently so as to maximise their capacity to engage in 
and benefit from treatment. 
Where possible, referral to or advice from a specialist obstetric service for women with ‘at risk’ 
pregnancies should be sought in regards to combined obstetric care and treatment for drug 
dependence.  
Pregnant women who are opioid dependent should be advised of the benefits of receiving well 
coordinated care between their opioid pharmacotherapy prescriber and maternity service to 
ensure the best possible outcomes for herself and her baby. 
Many women may wish to decrease their methadone dose during their pregnancy but 
withdrawal during pregnancy or a return to non – medical opioid use are associated with 
serious risks. These aspects need to be discussed with the person and persons should be 
closely monitored. A methadone pharmacotherapy reduction regime can be implemented at 
any stage of pregnancy provided the dose reduction does not precipitate sudden withdrawal 
[115].  
Pregnancy alters methadone metabolism by the liver and therefore, a woman may need an 
increase in her doses and/or have divided doses. In general, a higher methadone dose is 
associated with better pregnancy outcomes for women who use more than one drug.  
Induction into methadone pharmacotherapy 
• A pregnant woman should have priority access (including partner as their use may 
increase risk of relapse). 
• May include admission to inpatient obstetric unit for stabilisation and rapid dose 
titration based on symptoms and respite from external environment. 
• Preventative planning and actions to prevent withdrawal due to the woman vomiting 
her dose or being nauseated and unable to take her oral dose as regularly as 
prescribed [60]. 
Adequate dosing 
• Doses are titrated to the level that blocks withdrawal and suppresses other opioid use. 
• Titrated to the woman’s symptoms – (not kept low) to try to reduce possible neonatal 
abstinence syndrome as there is no dose response relationship between methadone 
and the risk of neonatal abstinence syndrome. 
• Dose increases may be required in response to risk of or relapse to injecting heroin or 
other drug use. 
• Increased doses may be needed as pregnancy progresses due to increased rate of 





There is little evidence to suggest split dosing is preferable to single daily dosing. However, it: 
• May stabilize conditions within the uterus by reducing the difference in peak and 
trough concentrations of methadone in the woman’s blood. 
• May be considered a clinical option for women who experience withdrawal symptoms 
as pregnancy advances, particularly in the 3rd trimester.  
• Second dose – daily take away can be considered for women who are stable on 
pharmacotherapy as well as physically and psychologically. This requires approval from 
State Regulatory Authority (Drugs of Dependence Unit SA) [60]. 
Managing occasional vomiting 
• can be serious 
• can lead to withdrawal – mother and foetus – foetal distress 
• a protocol is required for management e.g. if dose vomited: 
• within 10 minutes of dosing – consider repeat dose 
• within 10 – 60 minutes of dosing – consider half a repeat dose 
• more than 60 minutes of dosing – consider giving half of repeat dose if   withdrawal 
symptoms occur 
Note: even if observed – it is unlikely all stomach contents expelled – unsure how much of 
dose has been absorbed: 
• if in doubt, reassessment by experienced clinician required  4-6 hrs after vomiting 
(methadone effects at peak) to determine if additional small dose is needed [60].  
Management of frequent and or continuing vomiting 
Women should be advised that: 
• they need to eat before taking their methadone dose 
• they need to sip the dose slowly 
• where the dose consistently causes or exacerbates vomiting –  consider splitting the 
dose or offering rectal prochlorperazine/metochlopramide 30 – 60 minutes before 
dosing 
• if the woman is experiencing constant vomiting not necessarily related to the 
methadone dose they need  to be assessed and treated according to obstetric 
protocols for hyper-emesis gravidarum: 
• assess degree of dehydration & ketosis (consider admission if urine ketones more than 
2+) 
• look for other causes e.g. UTI 
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• consider I/V re-hydration 
• consider medications e.g. rectal prochlorperazine (Stemetil®) or IM or IV ondansetron 
(Zofran®) 
• consider need for modified diet and, vitamin and iron supplements [60].  
On presentation of labour 
When a woman presents in labour, the following needs to be undertaken: 
• inform her methadone prescriber and dosing pharmacist of the admission & non 
ability to attend for dosing 
• ascertain time of her last dose and or provision expected possession of takeaway 
doses 
• ensure she receives her usual daily methadone dose as prescribed 
• obtain copies or confirmation of: 
• identity (her birth date and photo) 
• date, time and amount of last dose 
• current prescription (mg). 
Buprenorphine pharmacotherapy during pregnancy  
Buprenorphine is not the first drug of choice for opioid pharmacotherapy treatment during 
pregnancy. It is not currently TGA approved for this indication. This is due to relative lack of 
evidence so far regarding efficacy when compared to methadone, which has been first line 
therapy for over 30 years. There is however, increasing evidence that buprenorphine may be 
used safely in pregnancy and is as efficacious as methadone. 
Women who are already prescribed buprenorphine pharmacotherapy for opioid dependence 
prior to becoming pregnant may wish to continue during pregnancy and breastfeeding. 
Women should be fully informed with regard to the evidence to date re safety and TGA status.  
In addition experienced practitioners may offer buprenorphine as an option for 
commencement during pregnancy.  
If buprenorphine is prescribed during pregnancy, it should be in the Subutex formulation.  
The team needs to case manage as for Methadone pharmacotherapy e.g. 
• continue Buprenorphine during admission and care 
• give other analgesia and opioids (if indicated) to manage pain – (Pethidine may be less 
effective due to Buprenorphine pharmacology).  
Buprenorphine has partial agonist and antagonist opioid properties – analgesia may be 





Labour of a pregnant woman who is opioid tolerant (dependent) is similar to that of any other 
woman. However, there are particular issues of which to be aware of and prepared. There can 
be increasing placental insufficiency in pregnancies of opioid dependent women, leading to: 
• increased risk of intra-partum hypoxia 
• foetal distress 
• meconium staining. 
The opioid-dependent pregnant woman requires careful risk assessment and careful risk 
assessment, monitoring and management of withdrawal as required during labour. Seek 
specialist advice. 
It is important to encourage the woman to present for admission early in her labour so as to 
limit any need she may have to self- medicate with alcohol or other drugs, ensure monitoring 
of pain and analgesic requirements and adequacy of the regimen implemented. 
Pain management in labour  
The pain relief needs of women in labour who are also undergoing methadone 
pharmacotherapy are often under estimated.  Women with a history of opioid drug use can 
have increased analgesia requirements and due to heightened sensitivity to pain, doses should 
be titrated based on each individual woman’s response.  
Women on methadone and buprenorphine programs should be offered a review appointment 
with an anaesthetist, prior to term to discuss their pain relief options during labour, delivery 
and post natal period including post surgical pain   where caesarean delivery is required.  
The following may assist in pain management: 
• analgesia requires individualised assessment, medication options and attention. Pain 
must be assessed regularly and the dose of analgesia titrated to the individual’s 
response – keep in mind the dose may need to be higher due to opioid  tolerance  
• the woman must continue to receive her prescribed daily methadone dose(s) on time, 
in liquid form, not tablet – to prevent opioid withdrawal. This dose does not provide 
pain relief 
• all forms of pain relief including non pharmacological means should be considered and 
escalated as required. For example Paracetamol, Entonox® gas, TENS®, bath/shower, 
massage, breathing exercises  
• additional opioid pain relief at the typical dose may not be effective if opioid receptors 
are already saturated e.g. with methadone and hypersensitivity to pain has developed 
• if a woman is prescribed methadone or buprenorphine pharmacotherapy, her usual 
dose will not relieve labour pain 




Note: Pethidine may not be effective due to changes in opioid receptors. 
Management of intractable pain 
• When assessment indicates uncontrolled pain is not due to lowered pain threshold, 
further assessment for other obstetric or medical causes is essential e.g. 
pyelonephritis, abruption, sacro iliac abscess. 
• Assessment of potential birthing risk is essential e.g. foetal distress. 
• Careful monitoring and management for signs of opioid withdrawal or overdose. 
Late presentations 
Women who present for drug treatment the first time in their third trimester, or in labour, can 
have a high risk of complications due to inadequate antenatal care. Effective management 
includes: 
• admission to hospital (regardless of what type of drugs are used) 
• thorough assessment of opioid use is critical (to avoid risk of over or under estimating 
opioid tolerance, and to inform decisions about treatment). 
This should include: 
• time of last dose and amount (mg)  
• usual pattern of drug use and quantity e.g. daily , weekly) 
• onset of symptoms (to identify whether they may be due to withdrawal) 
• signs of withdrawal 
• urine drug screen 
• assessment of level of opioid tolerance and dependence as this will have immediate 
significance for managing analgesia during labour and predicting and managing 
neonatal withdrawal  
• development of a detailed management plan including liaison with general 
practitioner, community or mental health professionals as needed, and plans for 
discharge 
• initiate and refer with the woman’s consent for drug treatment 
• monitor withdrawal symptoms using reliable withdrawal scales – COWS (Clinical 
Opioid Withdrawal Scale). (See Appendix 10).  
• if not in labour and not receiving pharmacotherapy – encourage pharmacotherapy 
induction to e.g. Methadone is the current gold standard treatment in pregnancy) – 
seek advice from ATOD experienced medical clinician and if appropriate facilitate rapid 




If on Methadone contact prescriber and pharmacist to confirm: 
• current dose in mg 
• whether today’s dose has been given or date and time of last dose 
• receipt of any take away doses today for today or subsequent days. Some clients who 
are stable may be in possession of more than one take away dose [60]. 
Postnatal guidelines 
Post-natal care of mother and baby includes: 
• provide a low-stimulus environment for mother and her baby where possible. This will 
facilitate bonding and minimise any withdrawal symptoms and other stressors 
• provide support and care for mother in equal priority as for her baby  
• attend to mother’s needs particularly treating residual pain and opioid withdrawal as 
appropriate 
• pain after caesarean section, tubal ligation or vaginal birth can be difficult to control 
and should be assessed and managed in consultation with ATOD specialist.  
Informing mother (and father) about the likely NAS treatments and procedures including close 
monitoring, withdrawal scoring and medications (if required) is important, along with being 
non-judgemental and supportive. 
Explain that: 
• both mother and her baby will be monitored for signs of withdrawal (and treated as 
needed)  
o if on opioid pharmacotherapy (e.g. methadone)  monitoring of dose 
requirements and any necessary adjustments will be made 
• her methadone pharmacotherapy will continue according to her prescription and on 
advice from her ATOD specialist and or prescriber 
• if not on pharmacotherapy her own and her baby’s withdrawal symptoms (NAS) will be 
monitored and treatment will be provided as necessary 
• neonatal withdrawal can occur 1-4 days following delivery and up to 7 – 10 days if the 
mother has been taking methadone in conjunction with benzodiazepines 
• NAS treatment may require admission of her baby to the specialist neonatal unit 
• encourage both the mother and father questions 
• avoid separation of mother and baby wherever possible (reduces NAS symptoms) 
• Encourage breastfeeding if at all possible 
• assist with breast feeding as needed, and if not contraindicated (see breastfeeding) 
• ensure mother can manage her breastfeeding positions and techniques that can 
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prevent cracked nipples. A lactation consultant while she is in hospital or after 
discharge is likely to be needed to assist her during these early stages  
• if she is not breast feeding  educate her about the benefits of  frequent skin to skin 
contact with her baby and safe  bottle feeding positions. Also involve father in these 
discussions and help him to know what to do.  
Note: Hepatitis C is not a contraindication for breastfeeding 
• involve the mother and father in all of her baby’s care, including any neonatal 
abstinence syndrome (NAS) scoring and management. 
• assist mother in baby settling techniques e.g. dummy, relaxation, baths, massage 
Discharge planning needs to include frequent and close follow-up and support from key 
agencies. The following may be useful: 
• home visiting support as soon as possible following discharge 
• referral to a service specialising in supporting mothers and their babies  
• lactation support  
• parenting education, baby massage and care programs 
• ATOD specialist services support 
• post natal mental health services (where indicated)[60].  
Post-natal pharmacotherapy dose review 
The pharmacotherapy dose needs to be reviewed in the early days following birth and 
regularly thereafter as blood volume and metabolism change rapidly following delivery 
The focus of the review is on supporting the mother, enhancing and supporting stability on 
pharmacotherapy – taking into account any:  
• signs of withdrawal or sedation  
• risk of resuming non-medical opioid or other drug use [60].  
Post-natal transfer back to community prescriber 
• plan for timely transfer so as to ensure continuity of pharmacotherapy 
• prior to discharge the prescriber and pharmacist should be notified of date of 
discharge, and date, time and amount (mg) of last dose given. This is particularly 
important where the dose has been adjusted and different to the dose that was 
prescribed prior to admission. If discharge is to be on a weekend day, the prescriber 
may not be available and must be notified in advance 
Post natal Contraceptive advice  
• improved fertility and contraception education and or advice is needed by women on 
entry to pharmacotherapy programs or other ATOD treatment 
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• the health and fertility of women who enter treatment for opioid dependence is likely 
to improve – and further pregnancy may occur  
• women should be advised that they may experience irregular menses while on opioid 
pharmacotherapy while still continuing to ovulate. It is a common misconception that 
amenorrhoea is synonymous with infertile cycles [60]. 
Future pregnancy plans and contraception options should be discussed and implemented prior 
to discharge as appropriate. 
Neonatal Abstinence Syndrome NAS 
About 60% infants born to mothers on methadone will develop clinical features of withdrawal 
(NAS). Women and their partner/families should be well informed about NAS ante-natal stages  
and become familiar with monitoring and possible treatment of their baby. This can assist to 
reduce parental distress. 
Assessment and monitoring for onset of NAS: 
• All pregnant women with a recent history of ATOD use, including opioids, need to be 
assessed for their potential withdrawal and NAS in their newborn.  
Therefore: 
• determine  the woman’s recent pattern of ATOD use  
• identify the type of ATOD’s and the time and amount of last dose/s 
• risk of NAS and maternal withdrawal 
• if mother is receiving pharmacotherapy for opioid dependence (methadone or 
buprenorphine – and type Suboxone® or Subutex®). 
If the mother has been opioid dependent and is breastfeeding, she may require opioid levels 
to be maintained with methadone pharmacotherapy to prevent neonatal abstinence 
syndrome (NAS) in her newborn. 
Assess possibility of neonatal abstinence syndrome by documenting signs and symptoms on 
the Neonatal Abstinence Syndrome Scoring Chart (See Appendix 14) from two hours post 
delivery. Score the infant one hour after a feed. 
Do not administer naloxone (Narcan®) to the infant if mother is receiving methadone or other 
opioids and has had opioid pain relief. If respiratory difficulties occur, supportive management 
(including artificial ventilation) is indicated. 
Onset 
Symptoms usually start about 72 hours after delivery, but can occur sooner. It may be delayed 
for up to two weeks of age due to the long half-life of methadone.  
There is no clear relationship between maternal methadone dose and the incidence, severity 
or duration of NAS [115].  
There are no adverse long-term sequelae if diagnosed early and effectively managed [89, 115]. 
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The mother and father must be reassured of this.  
Signs of NAS opioid withdrawal 
Signs of opioid withdrawal: 
• tend to occur 24-72 hours after delivery 
• can be vague and multiple 
• spectrum of symptoms e.g. high-pitched cry, rapid breathing, hungry but ineffective 
sucking, and excessive wakefulness 
• hyper-tonicity and convulsions can occur but these are not common 
• can be delayed for up to 7-10 days if the woman has been taking methadone in 
conjunction with benzodiazepines. 
Concomitant benzodiazepine use causes more prolonged NAS symptoms, including respiratory 
problems and depression.  
Regularly observe and document signs and symptoms on the Neonatal Abstinence Syndrome 
Scoring Chart (See Appendix 14) from two hours post delivery.  
Note: Do not administer Narcan® to the neonate. 
Score the infant every four hours or prior to feeds unless more frequent scoring is indicated. 
Observe regularly between scoring to identify any escalation of symptoms, and act 
accordingly.  
Medical management of neonatal abstinence syndrome (NAS) 
The diagnosis of NAS should be made in consultation with a neonatologist. 
Due to opioid exposure in utero, medication of neonate should be initiated when the Finnegan 
or modified Finnegan score (see Appendix 14).  
• score averages 8 or more on three consecutive assessments or  
• 12 or more on 2 consecutive assessments when assessed by an experienced scorer 
[60].  
The choice of opioid for NAS withdrawal is usually morphine, as it is less likely to require 
treatment with another agent or cause seizures and may reduce the duration of required 
treatment. If unclear what the starting dose should be a starting dose of 0.5mg per kg per day 
is often recommended. Doses are titrated according to NAS withdrawal scores to control 
withdrawal symptoms [60]. 
Caution: Where the neonate has respiratory difficulties, supportive management (including 
artificial ventilation) may be indicated. 
For comprehensive information see Neonatal Abstinence Syndrome Clinical Practice Guideline 




Breastfeeding and opioids 
• opioids are present in breast milk 
• breastfeeding is recommended for women who are stable and maintained on a 
pharmacotherapy program 
• breastfeeding is not recommended if methadone is being used in combination with 
other drugs. If use is occasional (recreational) encourage mother to express and 
dispose of contaminated milk for 24 hours before resuming feeding  
• if the woman’s opioid use is un stable, and short acting opioids are being used – she 
should be encouraged  not to breastfeed - it is important to focus on her bonding and 
feeding skills, and supporting and stabilising her drug use and lifestyle 
• contra-indicated if HIV +, Not contraindicated in HCV except temporarily if nipples 
actively bleeding, mother should be assisted to express and dispose until bleeding 
resolved). 
Note: Breastfeeding should be interrupted for 24 hours after using heroin, owing to the 
uncertain composition of street heroin.  
Unstable drug use may raise child protection concerns. 
• Women should wean their infant over at least a one-week period to prevent any risk 
of methadone withdrawal in the infant. 
• Mothers should be informed that research evidence on the effects of high doses of 
methadone through breastfeeding is unclear; breastfeeding should be discussed with 
her by the medical practitioner. 
• Buprenorphine safety in breastfeeding is as yet not established, however although 
buprenorphine passes into breast milk, it is not well orally absorbed. If a woman 
wishes to breastfeed while taking buprenorphine she needs to be informed that there 
may be risks, and support her decision [60].  
Breastfeeding & Blood Borne virus infection 
Women with HIV, hepatitis B or C should be advised on the best available evidence related to 
transmission of these viruses through breast milk. The current recommendations are: 
HIV 
HIV positive mothers should not breastfeed as it increases the risk of transmission – especially 
in the first 6 months. It is important to inform mothers of the importance of skin to skin 
contact [60 pg 21], and to provide reassurance that in Australia bottle feeding is a safe 
alternative. 
Hepatitis C (HCV) 
There is no evidence that breastfeeding increases the risk of transmission from mother to 
infant. The mother should discard her breast milk if there is a possibility of blood 
contamination e.g. cracked, infected, abraded or bleeding nipples. 
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Women need to be educated that: 
• HCV does appear in breast milk 
• HCV transmission may depend on viral load 
• in absence of HIV co-infection that can increase HCV viral load, risk of HCV 
transmission appears small 
• HCV transmission is blood- borne – not via gastrointestinal tract [60].  
Hepatitis C has been found in breast milk, but the levels of virus are not thought to be high 
enough to pose a transmission risk.  
Because the health benefits of breastfeeding far outweigh the low risk of hepatitis C 
transmission, women with hepatitis C are encouraged to breastfeed.  
Women with hepatitis C who have cracked or bleeding nipples are advised to express and 
discard milk from that breast until lesions are healed as blood may be present in the breast 
milk. 
Breastfeeding & Hep B 
There is no evidence that breastfeeding increases risk of transmission from mother to infant.  
To protect against transmission it is important for all infants of Hep B positive mothers to 
receive active and passive immunisation within 12 hours of birth [60].  
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3.1.3 Pain and analgesia  
Pain management in the general population 
One of the biggest challenges facing nurses and other health care professionals is providing 
adequate pain relief for people experiencing acute and/or chronic pain. 
 It is generally accepted that pain is poorly treated in the general population for which there 
are a number of reasons.  
The key factor in effective pain management is adequate assessment of the: 
• pain and its aetiology 
• any treatment the person is receiving, including drug kinetics 
• appropriate management response, which may include analgesia. 
People receiving prescribed opioids either for treatment of opioid dependence or chronic pain, 
or those with acute pain caused by injury or illness are a particular clinical challenge [116].  
Pain management in this population may involve consideration of the: 
•  nature of the person’s acute and/or chronic pain. 
• pain relief needs of the person’s  acute and/or chronic pain who has been exposed to 
regular opioid analgesia will require higher doses of opioid or an alternative analgesia 
regime  
• risk of hyperalgesia where prolonged use of opioids causes a paradoxical effect of 
greater neural sensitivity. 
Note: People receiving opioid pharmacotherapy during their drug treatment are physically 
more sensitive to pain than those who are opioid ‘naive’ [117]. 
Pain management for people receiving opioid pharmacotherapy  
A person who is currently receiving opioid medication for their chronic pain or opioid 
dependence has specific pain relief needs which need to be considered in the acute care 
setting. For further information go to ‘Specific pain management guidelines for opioid tolerant 
people’.     
Latrogenic dependence 
Iatrogenic dependence is where a person has been treated with opioid analgesia for a pain 
condition and subsequently becomes opioid dependent with associated behaviours.  
The differentiation between psychological dependence and pseudo- psychological dependence 
can be difficult for the clinician. The key factor is adequate pain management.  
With adequate pain management any unhelpful behaviours should. If adequate pain 
management is provided and the behaviours do not cease it may mean the person is 
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psychologically dependent, making it sometimes difficult to ascertain if adequate pain 
management had been achieved  [117]. Failure to provide adequate pain management may 
increase the risk of psychological dependence developing  (iatrogenic dependence)  [118]. 
Tolerance 
Physical tolerance occurs when progressively larger amounts of the psychoactive drug are 
required to get the same effect. Or if the amount of drug consumed remains constant, the 
effect of the drug diminishes. The development of physical tolerance by people on long-term 
opioid therapy is the central problem for effective pain management for this population.  
In spite of being maintained on relatively large amounts of opioids, this population require 
even larger amounts of opioids for analgesic effect. Effective pain management starts by 
administering the dose usually required for an opioid naive individual, and then titrating doses 
upwards until adequate pain relief is achieved. Analgesics should not be withheld unless the 
person is becoming over-sedated. 
Cross-tolerance  
Tolerance to one opioid makes a person cross-tolerant to another opioid. It is the mechanism 
by which opioid substitution works. People are given long acting methadone or buprenorphine 
because it stops the withdrawal syndrome associated with a shorter acting opioid such as 
heroin. Similarly benzodiazepines are administered to alcohol dependent people to prevent 
them going into withdrawal (alcohol and benzodiazepines act at the same receptors and cross-
tolerance occurs). 
Hyperalgesia 
Pain is an important human function as it signals to the brain that there is injury or illness. 
During opioid therapy the relatively large dose required is circulated and providing analgesia. 
The brain, in order to maintain homeostasis thus becomes more sensitive to pain – ‘counter 
balances’ the usual analgesic effect of the opioid.  
Unfortunately, it commonly sensitizes more than required and people maintained on opioids 
become more sensitive to pain, even those with high plasma opioid concentrations, compared 
to opioid naïve people.  
This may contribute to the development of opioid tolerance. As the body becomes more 
sensitive to pain it requires more opioid to achieve a pain free state.  As stated, it is the 
primary complicating factor in the pain management of opioid dependent people. 
Effective pain management  
It is crucial that nurses have a sound understanding of the general pharmacological principles 
of effective pain management for the person who is opioid tolerant (dependent). This includes 
the person who is receiving opioid pharmacotherapy treatment for their opioid dependence, 
or is using regular doses of opioids for other reasons such as chronic pain.  
Factors impeding opioid analgesia include: 
• tolerance due to regular exposure to opioid analgesia  
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• hyperalgesia to the above 
• receiving opioid replacement therapy – for opioid dependence e.g. methadone and 
buprenorphine  
• opioid pharmacotherapy for dependence – methadone and buprenorphine – are 
administered according to the half life of the drug. This is every 24 hours for 
methadone and every 24 - 48 hours for buprenorphine. This is to prevent opioid 
withdrawal and not provide analgesia 
• tolerance develops very rapidly to opioid exposure and any analgesic effects while 
receiving pharmacotherapy diminish over time 
• the person becomes tolerant not only to their methadone or buprenorphine but also 
cross-tolerant to the analgesic effects of other opioids [117]. 
Additional doses of opioids do not necessarily cause respiratory and CNS depression as 
tolerance to the respiratory and CNS depression effects develops quickly. For example, as the 
pain increases for people with carcinomas and opioid doses are increased as a consequence, 
there is generally no increase in respiratory and CNS depression in doses adequate to achieve 
pain control.  
Note: Pain is a natural antagonist to opioid induced respiratory and CNS depression.  
Seeking medication relief from pain is not the same as ‘drug seeking’ 
A careful clinical assessment for the objective evidence of pain will decrease the chance of 
manipulation by a drug-seeking person and also support the administration of opioid 
analgesics in a person with a history of drug dependence. Clinicians often perceive opioid 
dependent people with pain issues to be demanding and manipulative. In turn, opioid 
dependent people, often due to a history of discrimination and inadequate pain relief, may:  
• become distrustful of the medical community and concerned about being stigmatized 
• fear that their pain will be under treated or that their opioid maintenance dose will be 
altered or discontinued 
• act very inappropriately to get opioids but actually suffering from unrelieved pain 
(pseudo-psychological dependence) 
• have good pain relief but be very fearful of the re-emergence of pain 
• fear withdrawal symptoms should their pain relief be discontinued 
• fear a reduction in the current effective doses of opioid analgesics. 
Major health effects of unrelieved pain 
There are major health implications associated with unmanaged pain. These include physical 
stasis, decubitus ulcers, foot droop etc), prolonged post-operative recovery, clinical 
depression, cardiovascular stress, increased tumour growth and relapse or exacerbation of 
dependence issues. It is critical for pain to be managed to achieve optimal overall health. 
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The dangers associated with unrestricted opioid dosing 
However, the answer is not as simple as dosing without restriction in an effort to produce pain 
relief. While there are dangers with unmanaged pain, there are dangers with unrestricted 
opioid dosing.  
While opioids theoretically have no maximum analgesic ceiling, hyperalgesia (as stated), 
neuro-endocrinological (hormone) dysfunction and possibly immune-suppression (decreased 
functioning of the immune system) may occur at high doses. Respiratory depression can 
present difficulties in spite of tolerance (especially if the person is on other medication or 
consumes alcohol or another central nervous system depressant).  
Sedation can interfere with daily function and the processes of driving and safety around the 
home. The care of dependents may also be affected with lethal consequences if sedated. It has 
also been suggested that repeated dose escalations lack incremental benefit at higher doses 
(e.g. more than 200 mg of morphine daily or equivalent) [119]. 
Factors affecting the pain experience 
The pain experience of people maintained on opioids with chronic pain is not simply 
augmented by opioid induced hyperalgesia. It is also exacerbated by subtle withdrawal 
syndromes. It may also be influenced by intoxication with related sympathetic arousal and 
muscle tension. Sleep disturbance, mood changes and functional changes (associated with a 
comorbid condition such as hepatitis C) may also affect the pain experience [117, 120]. 
Identifying and treating co-occurring conditions which impact upon the perception of pain and 
therefore the successful management of the pain is of paramount importance. Important 
examples of frequently co-morbid conditions are depression and anxiety. Both may 
significantly complicate the treatment of pain, and dependence, but may be responsive to a 
range of treatments. 
Specific pain management guidelines for opioid tolerant people 
Those with active dependency 
• build trust 
• openly acknowledge history of dependency, and allow people to discuss fears about 
how this may affect pain management and treatment by staff 
• reassure people that their history of dependency problems will not prevent adequate 
pain management 
• respect and believe the person’s report of pain 
• reassure the person that staff are committed to assertively providing effective pain 
relief 
• treat acute pain aggressively 




• educate staff  
• prescription of opioids to a person with a known dependency problem for the 
management of pain is not illegal or unethical 
• people with a dependency problem may be relatively pain intolerant 
• detoxification is an ineffective short-term treatment for a dependency problem and 
inappropriate in the presence of pain. 
• broaden the treatment plan 
• with the person, develop a treatment contract for opioid analgesia 
• request consultation from an addiction medicine specialist 
• carefully document treatment plan, including analgesic use, response and regular 
reviews of efficacy of current plan 
• knowledgeably administer opioids 
• utilize non-pharmacologic and non-opioid analgesic alternatives 
• consider client-controlled analgesia which may decrease total opioid requirements and 
the drug seeking behaviours 
• choose long-acting opioids with gradual onset of action and lower street value, 
administered under continuous scheduled dosing orders (e.g. 4 times a day-QID) 
rather than as-needed orders (PRN) 
• opioid cross-tolerance and the person’s increased pain sensitivity will often necessitate 
higher opioid analgesic doses administered at shorter intervals 
• if physically maintained on an agonist (e.g. methadone), do not administer a mixed 
opioid agonist/antagonist (e.g. buprenorphine) as withdrawal may be precipitated 
[117].  
Those on opioid maintenance therapy 
• continue the usual dose of methadone or buprenorphine (or equivalent) 
• use short-acting opioid analgesics and titrate to effect 
• contact methadone or buprenorphine maintenance clinic  
• notify them of admission, discharge and confirm the time and amount of last 
maintenance dose 
• notify them of any medications such as opioids or benzodiazepines given to the person 
during hospitalization because they may show up on routine urine drug screening 




People currently abstinent from opioids  
Building trust 
• openly acknowledge history of dependence, and allow person and staff to discuss 
fears of re-activation of dependency 
• explain any intent to use opioids or other psychoactive medications 
• respect person’s right to decide whether or not to be administered opioids.  
Education 
• explain health risks associated with unrelieved pain, including risk of relapse 
• explain that the known risk for re-activation of dependency to opioids in the context of 
pain is small 
• ensure that the person understands differences between psychological and physical 
dependence. 
Minimising withdrawal following procedure or treatment  
• taper opioid analgesics slowly to minimize emergence of withdrawal symptoms 
• assess for presence of withdrawal symptoms at least QID during analgesic taper; treat 
symptomatically 
• offer non-pharmacological and non-opioid analgesic alternatives. 
Supporting abstinence 
• encourage the person to increase contact with family and/or significant other 
supports.  Reassure person that it is acceptable to take medications for medical 
reasons. Offer to educate/reassure significant others if required 
• request consultation from addiction medicine specialist 
• request consultation from allied health professionals to devise pain management plans 
to support and minimise analgesic requirements 
• identify and treat all co-morbid conditions or make appropriate referrals 
• include family in plan of pain care 
• if relapse occurs, intensify abstinence efforts; do not terminate pain care [117]. 
Those receiving naltrexone for alcohol or opioid dependence 
• cease naltrexone prior to pain-producing procedures if possible. Encourage the client 
to seek additional support as required to maintain abstinence during this period. (3-5 
days) and caution opioid dependent individuals about the risk of relapse  
• in the initial 24 hour period as the naltrexone begins to wear off, multimodal analgesic 
regimes (e.g. non-steroidal anti-inflammatories (e.g. ibuprofen), paracetomol, 
ketamine, tramadol and regional nerve blocks/anaesthetics) are recommended. 
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o caution is needed – there is experimental evidence of opioid receptor up-
regulation following naltrexone/opioid antagonist withdrawal. Therefore 
abrupt discontinuation of naltrexone may lead to increased opioid sensitivity 
and a possibility of opioid toxicity with opioid administration. Increased 
supervision and monitoring is necessary during this time.  
• continued administration of naltrexone will prevent the analgesic effects of regularly 
used doses of opioid based analgesia 
• if unable to decrease naltrexone prior (e.g. in the Emergency Department or for an 
emergency surgical procedure) multimodal analgesic regimes (e.g. non-steroidal anti-
inflammatories (ibuprofen®), paracetomol, ketamine, tramadol and regional nerve 
blocks/anaesthetics) are recommended. 
Note: If pain is not effectively managed the person should (if at all possible) be transferred to a 
High Dependency Unit, and opioids titrated.  
• very high doses in combination with opioid adjuvants may be needed (e.g. non-
steroidal anti-inflammatories (ibuprofen), paracetomol, ketamine, tramadol, regional 
nerve blocks -  the opioids will override antagonist effects of naltrexone offering relief 
• the therapeutic window may be narrow, necessitating careful monitoring for 
precipitous respiratory and CNS depression [117]. 
Those with chronic pain and dependence 
• complicated by the need to take opioids on a regular basis for the treatment of pain 
• complicated by the lack of clear pathology underlying the pain experience 
• complicated in that complete analgesia is not the practical goal of opioid treatment. 
Treatment  
• address dependency issues 
• use specific treatment contracts which should detail frequency of review, dispensing 
agreements and any specific monitoring 
• define and manage physical and emotional elements of pain. There are various 
interventions that can be helpful, and particularly important if the painful condition 
causes significant life challenges and consequent grief and loss issues 
• identify and treat co-morbid conditions as indicated 
• holistic care including the use of physiotherapy and occupational therapy as required 
addressing pain management and functional capacity. Interventions may include 
acupuncture, exercise plans, anxiety management and mindfulness training. 
Monitor assess and document 
• pain severity and quality 
• level of function 
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• presence of adverse events 
• opioid analgesic use 
• evidence of opioid misuse 
• evaluation and plan  
• progress toward therapeutic goals [121] . 
Therapeutic goals 
Includes the functional restoration of: 
• physical capabilities 
• psychological intactness 
• family and social interactions 
• degree of health care utilization 
• drug use for symptom control [117]. 
Preparing for discharge 
• If they have become dependent (tolerant) to opioids and are at risk of withdrawal 
ensure withdrawal is assessed and a management plan is activated prior to their 
discharge, and that their aftercare strategy is in place.  
• If they are already physically dependent to opioids, initiate long acting, 
pharmacotherapy and overall treatment plan  
• If withdrawal has occurred prior to discharge being  agreed on, taper opioids slowly to 
minimise the emergence of withdrawal symptoms 
• Monitor for emergence of withdrawal symptoms at least QID, and treat aggressively 
and symptomatically. 
If the person will be discharged on opioid analgesics with limited maintenance: 
• choose a single, long-acting formulation with low street value 
• write prescriptions for decreasing quantities of opioids for short periods of time with 
no repeats. Specify frequent dispensing. Clearly communicate discharge plans and 
medications to all community clinicians 
• specify dosing times (not ‘PRN’) 
• assess person’s level of motivation for drug treatment and encourage entry into 
treatment [117]. 
Acute pain and opioid-dependence   
People who use opioids regularly will have increased tolerance to opioid analgesics. 
Recognising the significant impact of opioid tolerance on achieving effective analgesia for 
acute pain is crucial. 
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Ensure an adequate ATOD history has been taken to determine whether the person is likely to 
be opioid or other drug tolerant. 
The person requires an individualised regime of appropriate analgesics for their medical 
condition and alleviation of drug withdrawal. Because of their neurological tolerance, they may 
require higher doses of opioids or other analgesics than people who are not opioid dependent, 
particularly if they are receiving daily methadone as pharmacotherapy for opioid dependence. 
A person likely to have opioid tolerance is someone who: 
• has had regular prescribed opiate medications for long periods—they may have 
iatrogenic dependence 
• is currently receiving opioid pharmacotherapy treatment for their drug dependence or 
who is currently dependent on opioids such as long acting morphine, codeine or 
heroin  
• regularly takes liver enzyme-inducing drugs (e.g. alcohol, phenytoin, Dilantin®, 
Interferon® or Rifampicin®). 
Indication of opioid tolerance is decreased duration or minimal analgesic effect of the opioid 
medication – this is an involuntary physiological response. 
Nursing care  
Nurses need to regularly assess pain and provide effective analgesia for this person. Being non-
judgemental, observing and believing the person’s reported level of pain and responding 
accordingly will minimise fear and agitation. This approach can go a long way to enhance the 
person’s individualised medication and non medical pain management regime once in place. 
Discussing with the person about any changes in their medications can help to reassure them, 
and lessen any anxiety they may feel about being under-medicated and remaining in pain.  
Note: providing opioid and any other suitable analgesia will not make the person more drug 
dependent, exacerbate the existing drug problems or precipitate relapse. 
Pain relief  
• intravenous or intramuscular administration may be needed initially 
• as analgesia need lessens change to oral medication of equivalent strength. 
• a patient-controlled analgesic (PCA) system may assist in achieving rapid relief of pain 
• this person is just as likely to do well as the non opioid tolerant person with PCA  
• change from PRN medication (as necessary) to set times if possible. 
• adjuvant medication may be helpful, particularly if prolonged use of analgesics is 
required. Adjuvant medications include: 
• tricyclic antidepressants 




• should analgesic needs be prolonged (weeks), it is appropriate to change from short-
acting to long-acting medication to achieve more constant pain relief throughout the 
day (e.g. MS Contin®, Kapanol® or Physeptone®) 
• offer additional pain relief through e.g. heat, bathe, massage, music etc.  
Note: It is critical that analgesia is given as prescribed and is withheld unless medically 
indicated. 
People taking prescribed methadone for drug treatment  
• if the person is taking methadone their usual daily dose must be continued—as this 
will not provide pain relief. They will need additional analgesia prescribed 
• buprenorphine has a partial antagonist effect and therefore partially blocks opioid 
action at the CNS neural pathways level  
• effective pain management starts with the dose usually required for an opioid naive 
person, and then titrating doses upwards until adequate pain relief is achieved 
• analgesics should not be withheld unless the person is becoming over-sedated. 
In a ‘nutshell’: 
• allay any fears the person has about not having adequate  pain relief  
• discuss with them any management plan. 
Other supportive methods of pain relief can be useful in acute or chronic pain states. They 
include: 
• trans-cutaneous electrical nerve stimulation (TENS®) machine 
• relaxation techniques and meditation 
• diversion techniques 
• massage 
• hydrotherapy 
• consult a pain management specialist or appropriate clinical advisory service. 
One of the biggest challenges facing nurses and other health care professionals is  providing 
adequate pain relief for people experiencing acute and/or chronic pain. 
 It is generally accepted that pain is poorly treated in the general population for which there 





Benzodiazepines belong to the sedative-hypnotic group of drugs. They have a general central 
nervous system depressant effect which is dose dependent; as the dose increases there is 
progression from sedation through hypnosis to stupor. 
Benzodiazepines cause respiratory depression, but this effect is minimal unless other central 
nervous system depressants are taken (e.g. alcohol and opioids). A synergistic action may 
occur when alcohol or opioids are used in conjunction with benzodiazepines. This may result in 
respiratory depression that may be life-threatening. 
People who use large amounts of benzodiazepines may experience withdrawal seizures on 
cessation of use or severe reduction in dose. Benzodiazepine use should not cease abruptly. A 
dose reduction regime should always be used. 
Uncomplicated benzodiazepine withdrawal can be accomplished at home with a gradual 
diazepam reduction regime. However, anyone who presents already exhibiting symptoms of 
withdrawal (e.g. agitation, confusion, convulsions, and delirium) should be admitted for 
assessment and treatment. The following guidelines focus on inpatient withdrawal and 
management. 
Criteria for in-hospital management 
People may need admission because: 
• they present in withdrawal 
• they have an illness or injury which warrants admission and withdrawal becomes an 
additional clinical issue 
• they are unable to take responsibility for the self-administration of their medication in 
the home. 
Assessment and quantification 
Record the name of the drug, the dose (in milligrams) and duration of use, frequency, time of 
last use, positives and negatives and goals related to use. There are two main patterns of 
benzodiazepine dependence, the most common being low dose dependency over many years, 
particularly among women and elderly people. High dose dependence, often in the context of 
poly drug use, can also occur. 
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Table 17: Absorption rates, half-life, and equivalent daily doses of common benzodiazepines  





30-90 min 32 hours 5mg 
Triazolam Halcion™ 1 hour 2 hours 0.25mg 
Alprazolam Kalmar™ 
Xanax™ 
1 hour 14 hours 0.5-1.0mg 
Bromazepam Lexotan™  12 hours 3-6mg 
Clonazepam Paxam™ 
Rivotril™ 
2-3 hours 22-54 hours 0.5mg 
Chlordiazepoxide Librium™  15 hours 15-20mg 
Flunitrazepam Hypnodorm™ 
Rohypnol™ 
1-2 hours  
20-30 hours  
1mg 
Chlorazepate Tranxene™  60 hours 7.5mg 
Lorazepam Ativan™ 2 hours 12 hours 1-2mg 
Flurazepam* Dalmane™  70 hours 20mg 
Nitrazepam Alodorm™ Mogadon™ 2 hours 28 hours 5mg 
Clobazam Frisium™  18 hours 15mg 
Oxazepam Murelax ™  Alepam™   Serepax™ 2-3 hours 8 hours 15-30mg 
Temazepam Euhypnos™ Normison™ Nomapam™ 
Temaze™  Temtabs™ 
30-60 min 10 hours 20mg 
*  Based on manufacturer’s product information.  
** Elimination half-life: time for the plasma drug concentration to decease by 50%  





People who use benzodiazepines on a regular basis may develop tolerance to the sedative 
effect. In some people benzodiazepines produce a paradoxical reaction of violence and 
disinhibited behaviour. (See Section 2.4: Managing intoxication). 
Effects of benzodiazepines 
• decreased anxiety 
• hypnotic effects (sleepiness) 
• sedation 
• anti-convulsant effects. 
Side effects 
• poor motor coordination 
• slurred speech 
• blurred vision 
• poor memory recall 
• drowsiness 
• in rare cases, agitation, hostility, 







The use of therapeutic doses of benzodiazepines, for as little as six weeks, can result in neuro-
adaption and withdrawal syndrome (that lasts from one to six weeks) on cessation. If a 
therapeutic dose is prescribed, and continued for longer than six weeks, physical dependence 
and symptoms of withdrawal will affect 15-50% of people (studies vary). Not everyone will 
experience symptoms, and of those who do, the symptoms are not always disabling. This 
information can be reassuring when discussing the need for withdrawal.  
Longer-term use may result in withdrawal symptoms that can last from six months to one year, 
with gradual diminishing intensity of symptoms. Withdrawal from short-acting benzodiazepines 
generally occurs earlier and is more severe than withdrawal from longer-acting 
benzodiazepines. Onset of withdrawal depends on the half-life of the particular benzodiazepine 
used by the person.  
Abrupt withdrawal from high doses use (greater than 50mg diazepam or equivalent per day) 
without withdrawal symptoms has been observed clinically, but the incidence is unknown. Use 
of higher doses is more likely to produce a withdrawal syndrome with more severe symptoms. 
Many people who are using high doses of benzodiazepine, and who also use opioids, report 
that benzodiazepine withdrawal is worse than opioid withdrawal, commenting that 
benzodiazepine withdrawal is ‘mentally’ worse. Withdrawal symptoms may be more severe for 
people who use more than one kind of benzodiazepine, perhaps because of the unpredictable 
effects of withdrawal from drugs with varying half-lives. 
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The person’s expectations 
The number of symptoms experienced, and their magnitude, will vary with the severity of 
withdrawal. If the person is receiving a long-term prescription of methadone or buprenorphine 
for concomitant opiate dependency, the dose should be kept stable throughout the 
benzodiazepine reduction period. Concurrent withdrawal of both drugs is not recommended 
without specialist support and medical supervision in an inpatient setting. 
Signs and symptoms of benzodiazepine withdrawal 
Subjective symptoms with few observable signs of withdrawal are a feature, particularly of low 
dose withdrawal. Individuals may report feeling extremely mentally distressed (as though they 
are ‘going mad’), although they may not have any obvious signs of physical discomfort. This 





• poor memory 




• poor concentration 
• depression 
• aches and twitching. 
Less frequent symptoms 
• nightmares 
• feelings of unreality 
• panic attacks 
• dry retching 
• decreased appetite 
• sweating 
• increased sensory perception 
(e.g. metallic taste) 
• headaches 
• tremor 
• raised body temperature 





• weight loss 
• lethargy 
• aches and pains 
• palpitations 
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• persistent tinnitus 
• paranoia   
• seizures (more common with concurrent alcohol withdrawal) 
• confusion. 
Major complications 
• progression to severe withdrawal 
• risk of injury (to self or others) or self-destructive behaviour due to altered mental state 
• risk of dehydration or electrolyte imbalance 
• potential for seizures 
• presence of concurrent illness which masks or mimics withdrawal 
• accidents due to orthostatic hypotension.  
Course of withdrawal from short-acting and long-acting benzodiazepines 
Withdrawal from short-acting benzodiazepines (e.g. oxazepam, temazepam, alprazolam, and 
lorazepam) typically produces a faster and more severe onset of symptoms than withdrawal 
from long-acting benzodiazepines (e.g. diazepam, nitrazepam), and may be more difficult to 
undergo and complete. Some people who use benzodiazepines, particularly at low-doses, do 
not experience any withdrawal symptoms. 















Nursing management  
(See Section 2.6: Withdrawal Management). 
Undertake nursing observations to identify and manage withdrawal symptoms and prevent the 
progression to severe withdrawal. 
There is no validated tool for recording benzodiazepine withdrawal symptoms in an inpatient 
setting. There is a tool currently being trialled by the Drug and Alcohol Services, South Australia.  
(See Appendix 12: Benzodiazepine Withdrawal Assessment Scale).  
In particular offer: 
• reassurance regarding distorted sensory stimuli 
• heat and massage for muscle aches 
• symptomatic management to reduce the severity of symptoms. 
Pharmacological treatment 
The availability of nursing and medical supervision in a hospital setting enables a more rapid 
reduction of the diazepam dose than in a community setting (e.g. at home). The 
pharmacological management of benzodiazepine withdrawal usually occurs by converting the 
average daily dose (e.g. Serepax) to the equivalent diazepam dose (maximum 80mgs per day), 
and implementing a gradual or rapid diazepam reduction regime. 
The usual tapered dose is for an inpatient to reduce the dose from 80mg per day by 10mg daily 
until 40mg per day is achieved, and then reduce by 5mg per day until zero is achieved.  
The reductions from 40mg per day may be undertaken as an outpatient with daily, second daily 
or twice per week dispensing by a community pharmacist. Reductions as an outpatient can be 
more gradual over several weeks or even months in some instances.  
The optimal dosage should reduce severity of withdrawal symptoms without over-sedating, and 
this requires monitoring of the person and individualising the regime accordingly. 
• Mild to moderate withdrawal is usually adequately controlled by administration of oral 
diazepam.  
• The person may need assistance with emergent anxiety symptoms as doses are slowly 
tapered. 
• Severe withdrawal may require administration of intravenous diazepam. Beware of the 
possibility of apnoea during the first few minutes of administration.  
Note: Caution is required. Diazepam needs to be used with extreme caution and may even be 
contraindicated in certain conditions (e.g. respiratory failure, liver disease). In some cases, use 




Maternal and Neonatal care 
Regular consumption of benzodiazepines is contraindicated in pregnancy.  There is an increased 
risk of congenital malformations (see above*), regular use can also be associated with neonatal 
withdrawal and use immediately prior to delivery may result in neonatal hypotonia, 
hypothermia, sedation and respiratory depression. 
Women who are pregnant and dependent on benzodiazepines should not abruptly cease using 
the drug. A slow gradual reduction regime, using long acting benzodiazepine under close 
medical supervision, is essential. 
Withdrawal Management 
Withdrawal is usually managed with a diazepam reducing regime.  The preferred approach is 
one of slow reduction and the protocol for managing benzodiazepine withdrawal may be 
followed (commencing in inpatients then completed as an outpatient).   
If there are no reasonable options for managing the withdrawal slowly, the reduction may be 
completed as an inpatient over a 2-week period. 
Neonates 
Neonatal withdrawal 
Newborns can have shown a variety of symptoms related to benzodiazepine intoxication or 
withdrawal such as: 
• respiratory distress secondary to 
hypoventilation 
• hypotonia or hypertonia 
• poor temperature regulation 
• disturbed sleep 
• diarrhoea 




Neonatal Abstinence Syndrome may be delayed onset – usually 1-10 days after delivery and can 
last 7-28 days. It can persist for several weeks. 
• nursing withdrawal observations – 
Finnegan scale is used 
• provide supportive treatment as 
primary management of baby 
• observe and monitor baby in hospital 
for one week in hospital 
• weekly review for first month of life 
as outpatient 
• educate parents to observe and seek 
assistance for withdrawal in the 
newborn 
• pharmacological treatment may not be 
needed if it is indicated the usual drug 
of choice is phenobarbitone 






• safety of benzodiazepines in breast milk is unknown 
• women using higher than therapeutic doses should not breastfeed 
• it is essential that benzodiazepines are not stopped abruptly. The woman needs to be 
advised of this necessary. She will need close supervision and support for her gradual 
and safe reduction of her particular benzodiazepine medication (preferably during 
pregnancy) 
• if breast feeding avoid feeding baby for 1 - 2 hours after taking benzodiazepine tablet 
(peak plasma period) to prevent maternal drowsiness /sleep and potential dropping/ 
smothering of infant and infant drowsiness 
• monitor baby’s condition & cease that feed if baby seems sedated. 
Sedative drugs & sleeping accidents 
There is a risk with any CNS depressant that the person becomes sedated - women who use 
these drugs should therefore be advised: 
• not to have baby sleep with her 
• that if she is heavily sedated she may not wake for baby’s feed or if baby becomes 
distressed 
• consider a safety plan i.e. have another responsible adult to care for baby if she decides 
to use ATOD. 
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3.1.5 Gamma hydroxybutyrate (GHB)  
Introduction 
Gamma hydroxybutyrate (GHB) is known as fantasy, grievous bodily harm, GBH, liquid E, liquid 
ecstasy, and liquid X.  
GHB is a central nervous system depressant with similar action to benzodiazepines. Its effects 
are known to be highly dose dependent. 
GHB is used mainly for its euphoric effect. In high doses, profound sedation and seizures can 
occur [122].  
Drug combinations and interactions  
Poly drug use is common. It is known that many people who use drugs use more than one at a 
time e.g. combining alcohol with amphetamine, heroin or benzodiazepines or hallucinogens. 
The effect of any drug cannot be assured. Effects of using different drugs in combination are 
unpredictable.  The effects of combined drugs can be exaggerated e.g. severe depression, 
anxiety or other. These  may last for weeks instead hours or days [123]. 
Drugs may interact thus increasing the effects of each other with an increased potential for 
toxicity and overdose e.g. GHB and heroin; GHB and alcohol; and GHB and any other CNS 
depressant [123]. 
The effects of drugs when combined are unpredictable and have synergistic effects  
Assessment and quantification 
(See Section 2.2: Assessment). 
Particular attention needs to be paid to the types of drugs the person may have used in 
combination with GHB. Where other CNS depressants (particularly alcohol, opioids) have been 
used, the person may need close monitoring to identify risks related to CNS depression. 
GHB intoxication 




• decreased inhibition 
• nausea 
• placidity 
• blurred vision 
 
• hot/cold flushes 
• relaxation and tranquillity 
• drowsiness 
• increased sociability 
• enhanced sense of touch 
• increased confidence 




Short-term effects (high doses) include: 
• rapid onset intense drowsiness 
• impaired movement and speech 
• disorientation/confusion 
• vomiting and nausea 
• muscle stiffness 
• coma of short duration 
• aggression if stimulated despite near 
respiratory apnoea 
• uncontrollable twitching 
• agitation 
• hallucinations 
• seizures (myoclonic) 
• respiratory collapse/arrest/death. 
Long-term use 
Little is known of the consequences of long-term use. There is high potential for abuse, as well 
as for physical and psychological dependence. 
Nursing management of GHB intoxication 
(See Section 2.4: Managing intoxication). 
Nursing interventions are the management of symptoms arising from the drug and its effects 
and/or the effects of the use of more than one drug. 
Harm minimisation information: 
• do not mix drugs including prescribed medication, alcohol, herbal preparation, caffeine 
and antidepressants 
• poly drug use to control the effects of one or another drug is dangerous and can place 
the person at greater risk of toxic overdose and intensify the ‘come-down’ period 
• do not mix GHB with HIV medications as effects are increased 
• avoid using caffeine, e.g. guarana, caffeine-based drinks due to risk of dehydration 
• avoid using alcohol with GHB due to the potentiation of CNS depressant properties. 
GHB overdose 
Concurrent use of alcohol or other CNS depressants is common in GHB overdose. People 
typically regain consciousness spontaneously within five hours of ingestion.  
GHB overdose should be considered in any case of unexplained sudden coma, i.e. without any 





• decreased level of 
consciousness/coma 
• severe respiratory depression 
• respiratory acidosis 
• hypotension (occasionally) 




Nursing management of GHB overdose 
(See Section 2.5: Managing overdose). 
Medical management of GHB overdose 
• Generally presents with sedation similar to alcohol.  
• No specific antidote.  
• Management is supportive with attention to airway management and cardio-
respiratory support if necessary 
GHB withdrawal 
(See Section 2.6: Managing withdrawal). 
Drink Spiking  
It is important to know that in most instances of drink spiking it is additional alcohol that has 
been put in the person’s drink. Drink spiking is also known to occur with GHB and while GHB 
has been implicated in some cases of date rape but is very rare. 
If someone believes their drink has been spiked, a urine screen undertaken as soon as possible 
can assist in gaining evidence for the person’s suspicions and may also assist police in any 
investigations that may need to occur. 
Because of these CNS depressant effects and possibility of poly drug use, combined GHB use 
with opioids or other depressant (e.g. alcohol and benzodiazepines) is highly dangerous and can 
result in toxicity, overdose and death. 
Note: A person who presents to the hospital as confused, or their companion reports that they 
have had a recent period of unconsciousness or no memory of what has happened (amnesia), 
consider that they may have been raped or assaulted. The person needs to be carefully 
assessed for signs of injury and/or rape, as well as GHB intoxication, and adverse effects of 




Preventing drink spiking 
The following strategies can be given to people to assist them to prevent their drinks from 
being spiked: 
• party with a trusted companion who is not drinking or drink considerably less and 
watch out for each other  
• buy your own drinks 
• watch your drink being poured or pour your own 
• never accept a drink from a stranger 
• never leave your drink unattended 
• don’t drink your drink if it tastes funny, different or more bitter than usual 
• avoid getting drunk, remain in control and be aware of what is happening around you 
• drink sensibly, stay safe. 
An early sign of spiking is feeling intoxicated to a level that is not in keeping with the amount of 
alcohol consumed. If the person believes that they or their friend’s drink has been spiked they 
need to: 
• stay with their friend 
• alert bar staff or other responsible person 
• seek medical help as required 
• notify police of the incident 
• notify nursing and medical staff if at hospital or clinic. 
Maternal and neonatal care 





3.2 Cannabis  
Introduction 
 It is difficult to classify cannabis due to its mixture of mood, cognitive, motor and perceptual 
effects. It therefore does not clearly belong to any other drug class and has therefore been 
presented here separately [125]. 
Cannabis is the generic name given to the psychoactive substances found in the marijuana plant 
Cannabis sativa. The main active constituent is Delta 9-tetra-hydrocannabinol (THC). The 
psychoactive effects of cannabis are caused by THC. These include: 
• perceptual changes which may in some cases be frank hallucinations 
• psychomotor changes with slowed reaction time, distance judgement and impaired 
coordination 
• cognitive impairment with sedation, slowed thinking, difficulty concentrating and 
impaired memory. 
Note:  Psychosis may be triggered by the use of cannabis in prone individuals. 
Assessment and quantification 
Nurses must record the duration of use, frequency, quantity, date and time of last use, 
positives and negatives and the person’s goals related to their use. 
Cannabis is difficult to quantify. In Australia it is usually smoked either on its own or mixed with 
tobacco. It can be smoked as a cigarette (joint or spliff), or with a water pipe (bong). People 
who use cannabis usually talk about cones which refers to the small combustion chamber of the 
water pipe. One cone = about 0.1g. therefore the clinician could ask how many cones the 
person uses a month, a week, a day etc.  
To estimate actual quantity used over a period of time it can be useful to ask the person how 
much money they spend on cannabis per week (e.g. money bag a week; an ounce or gram a 
week, divided by the number of days they use). 
Long-term health effects 
As with tobacco smoking, cannabis smoking holds an increased risk of respiratory disease (e.g. 
cancer, asthma, chronic bronchitis and emphysema). There may be problems related to 
attention, concentration and memory and motivation. 
Cannabis intoxication 
Time of onset and duration of effects 
When smoked, THC is delivered rapidly into the bloodstream with plasma peaks at end of 
smoking, and falling to low levels within two hours, lasting for up to four hours. The effect of 
one bong/joint may last 3-5 hours. 
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Cannabis urine or blood testing 
It is the presence of the cannabis metabolite, 11-nor-THC-9 carboxylic acid that is measured in 
blood or urine tests. The metabolite is inactive. This means that testing merely confirms the 
person has used cannabis at some time recently (e.g. usually in last few weeks), and neither 
confirms or refutes intoxication.  
THC is lipophilic and rapidly taken up by body lipids resulting in slow elimination of metabolites. 
Where a person has used cannabis in high amounts over long periods of time, the person may 
show traces of the metabolite in their urine for up to a few weeks to a few months.  
Tolerance and neuro-adaption occur with prolonged regular use of cannabis, resulting in 
dependence. Withdrawal will occur on cessation and symptoms include relatively weak effects 
on cardiovascular, respiratory and thermo-regulatory systems. These usually only result in a 
slight increase in heart rate to about 20bpm above base line. 
Acute effects include: 
• euphoria 
• sleepiness  
• feeling of wellbeing 
• impaired memory, cognition and task 
performance even though person 
feels creative and confident  
• relaxation 
• hunger (munchies)  
• perceptual distortions (e.g. sharpened 
senses and altered sense of time) 
• depersonalisation. 
Physical effects include: 
• raised pulse (increase by approx 
20bpm above baseline) 
• orthostatic hypotension 
• bronchodilatation 
• muscle relaxant 
• anticonvulsant effects 
• vasodilation (especially conjunctiva—
red eyes) 
• reduced intra-ocular pressure 
• anti-emetic 
• analgesia. 
Acute toxicity can result in: 
• anxiety 
• panic attacks 
• visual hallucinations 
• impaired short term memory and 
attention 
• confusion  
• persecutory delusions 
• overt psychotic reactions in 
vulnerable people 
• impaired motor skills, reaction time, 





A short-lived psychotic state can occur associated with use of high doses (e.g. hydroponically 
grown cannabis). This generally resolves within a week after cessation of cannabis. Cannabis-
induced psychosis can be difficult to distinguish from precipitation of a psychosis in those with a 
predisposition to mental illness [125]. 
Management of cannabis intoxication 
(See Section 2.4: Managing intoxication). 
Cannabis withdrawal 
(See Section 2.6: Managing withdrawal). 
Cannabis withdrawal is now considered a clinical entity, with considerable individual variation 
in severity and duration.   
It has been estimated that some may experience withdrawal after only three weeks of smoking 
two cones per day while others may smoke daily for several years with no evidence of 
withdrawal on cessation. Overall the likelihood of symptomatic THC withdrawal increases with 
duration and frequency of use. 
Withdrawal symptoms 
The withdrawal syndrome may be relatively mild or severe, but it is not life-threatening.  In 
general, inpatient admission for withdrawal is usually scheduled for 5 days; however people 
with severe dependence may require a longer admission.  
The most common symptoms are: 
• anxiety 
• weight loss 
• sleep disturbances (e.g. insomnia) 
• mild depressive features 
• vivid dreams or nightmares 
• anorexia 
• mood swings (e.g. sudden 
depression or anger outbursts) 
• abdominal pain  
• tremor 
• increased body temperature 
• restlessness 
• panic attacks 
• headaches 
• irritability (may persist for several 
weeks to months) 
• salivation [126]. 
 
Withdrawal observations 
There is currently no validated assessment tool for monitoring the severity of cannabis 
withdrawal. Withdrawal severity is monitored using a cannabis withdrawal chart developed by 





(See Section 2.6: Managing withdrawal). 
Nursing management includes: 
• withdrawal monitoring and observations 4 hourly  
• reassurance  
• medications as ordered and on time 
• drug information and self-help materials provided as appropriate [126]. 
Some people may use cannabis while in hospital to control withdrawal, anxiety, nausea or pain. 
Non-punitive management of the person can assist in clarifying what they are experiencing and 
preventing difficult behaviours. 
Pharmacological management of cannabis withdrawal 
There are no specific pharmacological treatment regimes at this time. Symptoms are treated 
with similar medications used for stimulant withdrawal. Timely administration of symptomatic 
medication is critical to reduce withdrawal discomfort.  
Ordered medications may include: 
• diazepam 5-10mg qid prn - may be useful, particularly with severe agitation and 
aggression or insomnia 
• olanzepine: 2.5mg-5mg BD prn (for severe agitation/racing thoughts not relieved by 
diazepam) (Other atypical anti-psychotic may be used if appropriate) 
• metoclopramide 10mg oral or IM tds prn for nausea 
• temazepam 10-20mg oral nocte prn for sleep 
• paracetamol 500 - 1000mg oral qid prn + naproxen 250mg tds prn [126]. 
On discharge 
For some people, withdrawal symptoms may persist following discharge. A medical officer may 
offer discharge medications to cover any residual withdrawal symptoms for up to 3 days 
maximum following discharge using an internal pharmacy script depending on the symptoms 
still being experienced on discharge. 
For example: Diazepam 5mg qid prn and or Olanzapine: 2.5mg-5mg BD prn [126]. 
It is recommended that medications should not continue beyond a total of 7-10 days [126]. 
Depending on the person’s needs and decisions their discharge care plan should involve a 
planned referral to specialist drug and alcohol services, and their local GP or health service for 
general health support. If they have been combining tobacco with cannabis, and they wish to 




Maternal and neonatal care 
Cannabis use in Pregnancy  
Smoking cannabis during pregnancy is not recommended due to effects on foetus and mother 
(similar to tobacco) [60] (Refer to Section 3.6: Tobacco).  
The use of cannabis in pregnancy is associated with neonatal withdrawal.  There is controversy 
about other effects on foetal growth and development, and a possible link has been found with 
childhood leukaemia and transient developmental delay in the neonate’s visual system. 
There is little published literature about the effects of the active chemical THC and stimulant 
withdrawal in pregnancy, however it is reasonable to assume that substantial physical and 
psychological distress are best avoided.  Nursing care should focus on the provision of a safe 
and comfortable environment with the provision of support and reassurance.  
Possible health  effects 
The health effects of cannabis on the developing foetus are not clearly established. There is 
controversy about other effects on foetal growth and development. A possible link has been 
found with childhood leukaemia and transient developmental delay in the neonate’s visual 
system and there have been reports of developmental problems in children born to cannabis-
dependent parents. 
Effects on the mother may include respiratory effects similar to tobacco, mood disturbances, 
financial, social and psychological problems. 
Management 
Women and their families should be advised of the physical, psychological and social 
implications for themselves and their baby from regular cannabis use. In particular mothers 
should be advised that heavy exposure to cannabis in utero may influence newborn infant 
behaviours in first weeks of life. 
Nursing care should focus on the provision of a safe and comfortable environment with the 
provision of support and reassurance.  
If a woman identifies herself as a regular cannabis user, she should be encouraged and 
supported to cease use. She needs to be offered the range of interventions to assist her to 
cease. This should include: 
• support & non judgmental care 
• information 
• brief intervention 
• counselling  




Cannabis withdrawal in pregnancy 
Medical management may include minimal use of medications as the preferred option but if 
required the following may be used: 
• Metoclopramide 
• Diazepam  
• Paracetamol 
• Pericyazine (is used only where diazepam is unsuccessful, use small doses ie ≤5mg tds 
and avoid in last trimester as during late pregnancy, high doses have caused prolonged 
neurological disturbances in the newborn. 
Neonatal withdrawal 
The use of cannabis in pregnancy is associated with neonatal withdrawal. 
• There is low evidence of mild neonatal abstinence syndrome solely from cannabis use – 
not apparent until second week of life 
• Unlikely to require care in neonatal nursery [60]. 
Breastfeeding 
Potential risks should be weighed against the benefits of breast feeding when the mother is 
using amphetamines. Women should be supported in their decision to breastfeed.  
THC is found in the breast milk of mothers who use cannabis, but effects on baby are not 
known. There is not enough information to make recommendations about cannabis and 
breastfeeding. As cannabis is a long acting drug, advice to breastfeed before drug use is not 
helpful. 
Advice to mothers should be as for tobacco which is to: 
• never smoke while feeding baby  





In this chapter: 
3.3.1  Nicotine 






Tobacco is the major cause of drug-related deaths in Australia. There are over 4000 chemicals 
in tobacco smoke, many of which are poisonous, and 43 that have been proven to be 
carcinogens. These chemicals include nicotine, tar and carbon monoxide. 
Nicotine 
Nicotine is the short-acting psychoactive drug in tobacco that causes addiction among smokers. 
The strength of addiction is said to be as powerful as or more so than that of heroin. Nicotine is 
a poison. Swallowing one drop of pure nicotine can kill an adult.  
Tar 
When a cigarette burns, tar is released. Tar is the main cause of lung and throat cancer in 
smokers.  
Carbon monoxide 
Carbon monoxide is a colourless, odourless and very toxic gas, which is taken up more readily 
by the lungs than oxygen. High levels of carbon monoxide in the blood is typical of smokers and, 
together with nicotine, increases the risk of heart disease, hardening of the arteries and other 
circulatory problems.  
Assessment and quantification 
All smokers need assessment, information and education about the risks of smoking. All 
smokers should be encouraged to cease smoking, or at least greatly reduce their intake. A 
person who is dependent on nicotine will experience withdrawal symptoms when they cut 
down or stop smoking. These can include increased nervousness and tension, agitation, loss of 
concentration, changes to sleep patterns, headaches and cravings. 
Assessment 
Tobacco consumption is measured by the actual number of cigarettes smoked per day (not the 
number of packets). The strength of cigarettes (i.e. the tar content and nicotine level) is also 
important to record. Record the duration of use, frequency, quantity, date and time of last use, 
positives and negatives and the person’s goals related to their tobacco use.  
These questions are useful in identifying nicotine dependence. Does the person: 
• Smoke 10-15 or more cigarettes a day? 
• Smoke their first cigarette within 30 minutes of rising? 
• Experience craving or withdrawal symptoms when trying to give up? 
A yes answer to any of the above has been reliable in identifying nicotine dependence [127]. A 




This test is relevant for any smokers admitted to hospital – to raise the issue and discuss their 
potential for giving up. Supports may be needed to help them manage being prohibited from 
smoking during admission.  
This tool is easily administered, identifies the severity of dependence and can be used to 
determine the dose and types of nicotine replacement therapy that might be offered to the 
person whilst they are in hospital. This information is useful for the medical officer considering 
prescribing nicotine replacement therapy.  
Table 18: Fagerstrom Test Score - level of NRT according to level of dependence  
Dependence level  NRT Dosage – combination therapy  
Refer to Nurse Initiated medication Formulary  
High  Patches 21mg/24hr   
and/or 
Lozenge or Gum 4mg/1hr to maximum of 10 per day in total  
or Varenicline (Champix®) 
Moderate  Patches 21mg/24hr  
Lozenge or Gum 4mg/1hr to maximum of 10 per day in total  
Low to Moderate  Patches 14mg/24hr  
Lozenge or Gum 2mg/1hr to maximum of 10 per day in total  
Low  May not need NRT  
Monitor for withdrawal symptoms  
[128] 
See below for contraindications and precautions in the use of nicotine replacement therapy. 
Clients’ previous attempts to stop smoking may also provide assistance in identifying which 
products may be suitable.  
Effects of cigarette smoking 
The effects of smoking will vary from person to person and depend on such things as: 
• a person’s susceptibility to chemicals in tobacco smoke 
• the number of cigarettes smoked per day 
• the age when the person began smoking  




Immediate effects of cigarette smoking 
• smoking one cigarette immediately 
raises a person’s blood pressure and 
heart rate and decreases the blood 
flow to body extremities 
• a smoker may also experience 
dizziness, nausea, watery eyes and 
acid in the stomach  
• paralysed cilia in lungs and airways 
• brain and the nervous system activity 
is stimulated for a short time and 
then reduced 
• appetite, taste and smell are 
weakened 
• kidneys produce less urine. 
Long term effects of cigarette smoking 
• smokers typically experience 
shortness of breath, persistent 
coughs, reduced fitness, yellow stains 
on fingers and teeth and decreased 
sense of taste and smell  
• smoking can cause impotence in men, 
while women who smoke are less 
fertile than non-smokers 
• respiratory infections such as 
pneumonia and chronic bronchitis 
• heart attack and coronary disease 
• stomach ulcers  
• narrowing/hardening of blood vessels, 
particularly heart / lungs 
• smokers have more colds and flu 
than non-smokers and find it harder 
to recover from minor illnesses 
• people who smoke tend to have 
facial wrinkles appearing much 
earlier and, in general, look older 
than non-smokers of the same age 
• emphysema, a progressive and 
potentially fatal lung disease 
• cancer of the lung, throat, mouth, 
bladder, kidney, pancreas, cervix, 
stomach 
• peripheral vascular disease due to 
decreased blood flow to the legs 
• may inhibit some symptoms of 
Parkinson’s disease. 
Other risks of cigarette smoking 
• smoking during pregnancy can affect the unborn child and babies are more likely to be 
born underweight, premature or stillborn 
• passive smoking, where a person is subject to breathing in the cigarette smoke of 
others, can cause lung damage, including cancer and heart disease 
• 50 Australians die every day from smoking compared to 10 who die from alcohol-




Benefits of smoking cessation 
There are immediate benefits at any age. For example: 
Within a week: 
• nicotine and carbon monoxide out of the system 
• lungs working more efficiently 
• taste buds functioning better 
• sense of smell improves 
• breath, hair, fingers, teeth, clothes cleaner.  
Within three months: 
• blood flow to the hands and feet improves. 
After twelve months: 
• the risk of cancer and heart disease is reduced [129]. 
Abstinence rates from nicotine replacement therapy (pharmacotherapy) are much higher for 
hospital clients, community volunteers, and people attending smoking clinics than others in the 
general community [130]. Nurses and midwives have a critical role in assessing and assisting 
their clients and other persons wishing to stop smoking with the help of nicotine replacement.  
For support and information contact QUIT (131 848) for free self-help materials—books, videos, 
courses and a telephone counselling service. 
Early/brief intervention 
(See Section 2.3: Early and brief intervention) 
Although people may tell health professionals that they do not want to stop smoking, it is still 
important to offer brief intervention. This may be limited to raising concern for their health, 
linking smoking to their current admission (e.g. respiratory or heart disease, or other health 
issues. Providing information about harms from smoking is needed, tobacco related harms.  
Where the person is concerned about their smoking and is thinking about change, discussion 
about times, places and other triggers for smoking can help identify the cues to smoke and 
enable the smoker to start developing strategies to overcome these and begin self 
management, cessation and relapse prevention. Discussion of the costs of smoking and the 
benefits of quitting can assist the person to make decisions to quit. 
The following strategies can be used to combat craving when giving up smoking: 
• delaying the next cigarette by 20 minutes 
• deep breathing instead of lighting a cigarette 
• distracting oneself at ‘trigger’ times—for example, going for a walk instead of coffee 
with friends who smoke, changing what you usually drink when smoking (e.g. 
substituting tea with juice) 
• drinking a glass of water when a craving starts. 
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Nicotine replacement therapy using patches, gum and or lozenges is a very useful adjunct to 
behavioural self management strategies such as those listed above. 
While giving up is the only effective strategy against tobacco-related harm, there are some 
measures that can encourage the person to begin the process of quitting even if the person is 
not yet ready to stop. These include smoking fewer cigarettes and having the first cigarette 
later in the day as a way of cutting down. 
The Quitline is a 24-hour national service and provides ongoing support and self-help 
information phone. 
Nicotine withdrawal 
(See Section 2.6: Managing Withdrawal). 
Nicotine withdrawal occurs when the dependent smoker reduces intake or stops smoking.  
Signs and symptoms 
Nicotine withdrawal starts a few hours after last intake and peaks at between 24 - 72 hours. 
While not life-threatening, it is characterised by a set of symptoms including: 
• increased nervousness 
• tension, agitation 
• changed sleep pattern 
• bowel disturbance  
• changes in taste buds 
• irritability  
• loss of concentration 
• headache 
• stomach upsets 
• muscle spasm  
• craving. 
Management of nicotine withdrawal 
Provide support and self-help information. The person may wish to use patches, lozenges or 
gum as pharmacological assistance in managing withdrawal through gradual cessation. Where a 
person has severe dependence, concurrent use of more than one form of nicotine replacement 
therapy may be required. (See Table 17: Fagerstrom Test Score - level of NRT according to level 
of dependence). 
Pharmacological management  
Nicotine replacement therapy (NRT) 
NRT comes in various forms, e.g. nicotine patches, nasal spray, nasal inhaler, lozenges and gum. 
NRT is useful for people who are dependent on nicotine, motivated to reduce and cease use 
and are free from medical contraindications.  




Possible side effects of NRT 
The most common side effects are skin reactions (transient itching, burning and tingling), 
occurring in up to half of nicotine replacement therapy users. These are usually minor and 
relieved by rotating the patch site on the skin. 
• Some skin reactions can be more serious, e.g. dermatitis or skin sensitisation—and may 
require cortisone or cessation of nicotine replacement therapy 
• Most skin reactions tend to occur after three to four weeks of use 
Most common systemic side effects are disturbed sleep and vivid dreams, however these do 
not occur using the 16-hour patch. 
The 24-hour patch can be removed at bed time, or a lower strength patch can also be used to 
reduce sleep difficulties. 
NOTE: Where a 16 hour patch is used, people should be advised that it takes a couple of hours 
to absorb through the skin. This is important as cravings are usually strongest in the morning. 
To avoid this high risk time, people using NRT should be advices to place the patch as soon as 
possible on wakening and to use another form of NRT vas required over the first two hours e.g. 
gum, lozenges. 
Absolute contraindications to NRT 
• recent myocardial infarction 
• unstable angina pectoris 
• severe cardiac arrhythmia 
• recent cardiovascular accident 
• pregnancy and lactation. 
Relative contraindications to NRT 
• stable ischaemic heart disease, peripheral vascular disease or cerebrovascular disease 
• psoriasis, eczema, urticaria 
• hyperthyroidism, insulin dependent diabetes mellitus, phaeochromocytoma 
• liver or renal disease 
• peptic ulcer. 
Zyban® (Bupropion Hydrochloride) 
Non-nicotine based therapy: an atypical antidepressant known as bupropion (Zyban®).  
Zyban® is used as a short term adjunct in the treatment of nicotine dependence in people over 
the age of 18 years, within a comprehensive treatment program where the goal is abstinence. 
Combination NRT such as patches supplemented with bupropion (Zyban®) or nicotine gum can 
relieve intermittent craving. The combination of patch and gum decreases withdrawal 
symptoms more than either alone [127]. 
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Absolute contraindications for bupropion (Zyban®) 
• history of seizures 
• central nervous system tumour 
• abrupt alcohol or benzodiazepine withdrawal 
• bulimia or anorexia nervosa 
• concurrent use of monoamine oxidise inhibitors (MAOIs). 
Relative contraindications for bupropion (Zyban®) 
• lowered seizure threshold 
• renal impairment 
• hepatic impairment 
• bipolar disorder 
• latent psychosis 
• concurrent nicotine replacement therapy 
• elderly or children 
• pregnancy or lactation. 






• gastrointestinal upset  
• rash  
• taste disorders 
• flushing 
• hypertension 
• impaired concentration 
• depression 
• anorexia 
• dry mouth 
• fever 
Varenicline tartrate (Champix®) 
Varenicline tartrate is non-nicotine oral therapy for smoking cessation. It is approved as a 
nicotinic receptor partial agonist. It has been shown to be efficacious and well-tolerated 
smoking cessation pharmacotherapy  in most people. It is superior to placebo and bupropion in 
helping maintain long-term abstinence. 
Interactions with other drugs may be minimal. However,  safety of the combination of 
varenicline tartrate and bupropion is not established. The combination of varenicline tartrate 
and NRT has caused the discontinuation of treatment due to side effects such as nausea, 
headache, vomiting, dizziness dyspepsia and fatigue and should not be used. 
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Side effects of varenicline tartrate 
The most common side effect of varenicline tartrate is nausea. This has been described as mild 
to moderate and often transient. Other adverse effects which occurred more frequently with 
varenicline tartrate than placebo include vomiting, constipation, abnormal dreams and 
insomnia. In addition there have been post-marketing reports of mood and behavioural 
changes.  
Contraindications to varenicline tartrate 
Varenicline tartrate is contraindicated, or its use needs be taken under strict consideration, in 
the following situations: 
• renal disease 
• pregnant or breast-feeding women. 
For full prescribing information on varenicline, please visit: www.pbs.gov.au/pbs/ 
Maternal and neonatal care 
There are significant risks from smoking to maternal health generally (as for any smoker) and 
particularly during pregnancy. There are also significant risks to the foetus and newborn. Any 
woman smoking during pregnancy should be encouraged to quit and offered support. 
Smoking contributes to increased rates of low birth weight, incidence of spontaneous abortion, 
prematurity and sudden infant death syndrome [131], and a higher rate of ectopic pregnancy 
[132]. 
Possible adverse effects to mother and baby  
• pregnancy complications, including 
ectopic pregnancy, miscarriages, 
stillbirth, placental problems, bleeding 
during pregnancy and premature birth 
• increased foetal heart rate, decreased 
foetal movements 
• respiratory complications 
• asthma, possibly related to passive 
smoking effects 
• low birth weight 
• impaired ‘rehearsal breathing’ in the 
foetus 
• middle ear infections in the baby’s first 
weeks 
• sudden infant death syndrome (‘cot 
death’) [60].  
Mental Health 
If a pregnant woman is prescribed anti psychotic medicines, and wants to quit smoking, her 
prescribing psychiatrist must be consulted to adjust her doses as necessary. 
Women with history of depression should be monitored following tobacco cessation for: 
• increasing symptoms of depression 
• new episode of depression 




• Tobacco smoking reduces breast milk supply. Nicotine is present in breast milk which 
can cause gastric irritation in the baby.  
• Research suggests that breast-feeding is still safer for both mother and baby.  
• Smoking is best avoided prior to and during feeds and around a feeding infant. 
Following a cigarette, at least 20 minutes should elapse before feeding [60]. 
Women should be informed that: 
• breast feeding is safest option 
• nicotine reduces breast milk supply 
• nicotine is present in breast milk – but there is minimal absorption from the gut 
• mothers who smoke are less likely to start breast feeding than mothers who don’t 
smoke and are more likely to breastfeed for a shorter period of time 
• avoid smoking at least 20 minutes before feeds, and never smoke during feeds 
• do not smoke inside house or car,  or near baby & other children [60]. 
Nicotine Replacement Therapy (NRT) in Pregnancy 
• neither bupropion or varenicline tartrate are suitable for use in pregnancy or whilst 
breastfeeding. 
• lack of safety evidence of NRT use in pregnancy  
However NRT is recommended in specific circumstances e.g.: 
• if the woman is otherwise unable to quit and benefits of cessation outweigh her risks of 
NRT and continued smoking. 
Guidelines 
• therapy should begin and be completed earlier in pregnancy rather than close to 
delivery 
• dose should be the lowest possible 
• intermittent dose from gum and inhalants are preferred over patches which deliver 
constant dose 
• monitor for smoking relapse following therapy completion [60]. 
Breastfeeding and NRT 
Women on NRT should be advised to breastfeed first and then as soon as possible after 
breastfeeding use one of the intermittent NRT delivery methods (e.g. inhaler, gum) to maximise 





Amphetamine type stimulants (ATS) belong to a drug group known as ‘psychostimulants’. These 
are a diverse range of central nervous system (CNS) stimulants e.g. nicotine, caffeine, pseudo- 
ephedrine, amphetamine (speed) and cocaine (coke, snow), methamphetamine (crystal meth, 
speed, ice), methylphenidate (Ritalin®), and methylene dioxy-methamphetamine (MDMA) – 
ecstasy. Nicotine is also a psychoactive stimulant (See Section 3.6).  
As a psycho-stimulant, amphetamines action on the CNS to raise and sustain neurotransmitters, 
particularly dopamine, that are responsible for memory attention, purposeful behaviour and 
feelings of pleasure [133]. 
Stimulants also have peripheral sympathomimetic action. They are often used for effects such 
as euphoria, increased sense of well-being, energy, confidence or over-confidence, improved 
cognitive and psychomotor performance, suppression of appetite and to remain awake [134]. 
Over time and with repeated use, neurotransmitters become depleted leading to poor 
concentration, depressed mood, lethargy, fatigue, sleep disturbance and amotivation [133]. 
Assessment and quantification 
Next to cannabis use, amphetamines are the most commonly-used group of illicit drugs used 
amongst young Australian women and men, usually commencing during late adolescence with 
significant rate of injecting use. Therefore it is very important when taking the ATOD history to 
include amphetamine and other psychostimulant use.  
Quantification of illicit drugs used, including amphetamines, can be difficult as they are 
commonly  ‘cut’ – mixed – with other substances including other drugs, glucose and sucrose 
meaning that the actual dose is always unknown. Try to find out and record: 
• usual pattern of use (e.g. occasional vs. bingeing over several days and if this time is 
different)  
• type of amphetamine used (e.g. MDMA, methamphetamine) 
• last dose/use (date and time) 
• route/s of administration (injecting, snorting, swallowing) 
• quantity and frequency (e.g. number of tablets/per time, frequency of use – daily, 
weekly, binges/runs) 
• dollar cost of the drug/’deal’ (at least estimated ‘street’ weight in grams) 
• form (powder, paste, crystal or tablet) 
• risk of dependence and withdrawal  
• other medical problems e.g. hepatitis from sharing injecting equipment,  
• any psychiatric comorbidity (may be causally related or coincidental) [135]. 
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Also record what other drugs (legal, medicinal and illicit) taken in association with their 
amphetamine use (poly drug use) and efforts to self-medicate for unwanted effects of 
amphetamines. E.g. use of major tranquilisers such as olanzepine to soften the come down 
from stimulant effects. 
If appropriate, and depending on the mental and physical state of the person, try to determine 
and record why the person uses this drug—what does it do for them (e.g. performance-
enhancing) and any harm they believe it has caused.  
Amphetamine intoxication 
Onset of action when taken orally is about 30-60 minutes, with peak cardiovascular effect at 60 
minutes and CNS effects about two hours. Duration of effect is about 4-6 hours. Intranasal 
(snorting) produces effects within a few minutes; smoking and intravenous use produces even 
faster effects. 
The signs and symptoms of intoxication vary depending on the type and amount (dose) of 
amphetamine used, and whether any other  drug has also been used [133]. 
Signs of intoxication include: 
• increased blood pressure, pulse, 
respiration, temperature 
• suppression of appetite 
• talkative, rapid or pressured speech 
• euphoria and or exhilaration 
• stereotypical, repetitious movement 
or behaviour 
• teeth grinding 
• wakefulness and inability to sleep 
• increased libido 
• anger, aggression, hostility, 
impulsivity and or recklessness 
• dry mouth 
• increased alertness and activity—
constant movement, fidgety or 
restlessness 
• enhanced self-confidence 
• mood swings 
• clenched jaw  
• panic 
• pupils may be enlarged 
• suspiciousness or paranoia 
• in rare cases dysphoria and delirium. 
With higher doses, in addition to the above, the following may be evident: 
• agitation, tension, irritability or loss of 
behavioural control or aggression 
• tremors 
• anxiety or panic 
• paranoia 
• increased respiration 
• hallucinations e.g. visual or auditory 
• sweating 








In addition to tolerance and psychological dependence, long term effects of regular 
amphetamine use may include: 
• weight loss 
• poor appetite or malnutrition 
• mood swings including depression, 
anxiety or paranoia, thought and 
emotional disturbances  
• psychosis including hallucinations 
and delusions  
• dehydration 
• kidney problems 
• chronic sleep disturbance 
• irregular menses or amenorrhoea 
[133].  
Potential harms 
As well as the harms from using an unknown dose, actual chemical nature of the drug and other 
ingredients, unsafe injecting practices of amphetamines carry a high risk of contracting 
bacterial infections causing  endocarditis and septicaemia, and blood borne viruses such HIV, 
hepatitis B or hepatitis  C).  
Any amphetamine use, whether injected or not,  is associated with an increased risk of: 
• cardiomyopathy,  myocardial infarction 
• CVA, burst aneurysm 
• poor oral health e.g. gingivitis, caries (due to dry mouth) damaged teeth from  grinding 
and jaw clenching 
• formication leading to compulsive picking at skin (face and arms). 
Acute toxicity 
Acute toxic effects of amphetamines are ‘an extension of the pharmacological properties of the 
drugs, and are determined by the dose, route of administration, mental state and personality of 
the user’ [134]. The person’s environment at the time of use is also relevant [1]. 
Manufacture of these illegal drugs involves poor quality control resulting in extreme variability 
the quality and chemical composition of these drugs. These factors place anyone who uses 
amphetamines  at risk of being exposed to adulterants, unknown doses, questionable 
ingredients, unpredictable side effects and toxicity [134]. 
Note: The possibility of psycho-stimulant use should be considered in a young person 
presenting with seizures or cerebrovascular accident. This is not dependent on length of time 
used, as it can occur with once off or occasional use.  
Constellation of serious symptoms includes: 
• Skin: Sweating and hyperpyrexia, hot and cold flushes 
• CNS: Tremor, restlessness,  agitation, muscle twitching, repetitive behaviour 
• Neuropsychiatric: Manifestations include paranoia, hallucinations, delusions, hyper-
arousal, and bizarre, violent and erratic behaviours 
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• Cardiovascular: Chest pain, hypertension, tachycardia, dysrhythmias, arrhythmias, 
myocardial infarction, cerebral vascular accident and sudden death 
• Respiratory: Shortness of breath 
• Neurological: Seizures 
• Muscular-skeletal: Muscle rigidity 
• Infection: Bacterial endocarditis may result from intravenous use   
• Gastro-intestinal system: Severe abdominal pain, bloody stools, bowel ischaemia and 
infarction.  
• Severe headache [133, 134]. 
Chronic toxicity 
Chronic toxicity is manifested by: 
• Nutritional: weight loss. 
• Neuropsychiatric complications: poor concentration and attention, memory 
impairment, sleep disturbances, hallucinations, depression, anxiety, and panic attacks. 
Suicidal ideation has also been reported.  
Chronic and/or excessive amphetamine use can lead to  a person having an acute psychotic 
episode resembling paranoid schizophrenia [134]. Shorter binges or ‘runs’ of multiple daily 
doses over several can also result in psychosis similar to acute schizophrenia characterised by: 
• severe agitation 
• restlessness 
• hallucinations—predominantly visual 
but can be auditory or tactile 
• hostility and violence 
• anxiety 
• paranoid delusions 
• repetitive stereotypical behaviours 
• loosening of association and ideas in 
a setting of clear consciousness. 
Psychotic symptoms generally subside soon after the drug use ceases some people may 
experience persistent symptoms for weeks or months [134]. 
Nursing management of amphetamine intoxication 
(Also See Section 2.4: Managing Intoxication). 
Nurse the person by: 
• maintaining a non judgemental, respectful approach [133] 
• listen and respond to needs or requests as timely [133] 
• clear, concise communication [133]  
• ensure the person has extra personal space [133] 
• regularly checking vital signs, physical and psychological status 
• interpreting drug screening urinalysis 
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• being calm and supportive 
• ensuring a calm, soothing environment—reducing environmental stimuli 
• offering reassurance 
• explaining what is happening and that it will pass 
• avoiding confrontation and arguments 
• creating a sense of security and confidence that the situation is under control 
• providing food and fluids to maintain nutritional status and fluid balance 
• administer adequate doses of diazepam to control agitation and anxiety as ordered 
• administer medications to treat psychotic episodes where sedation is insufficient 
• undertake brief intervention and provide person with information about 
amphetamines, and harms that are associated with use, and services.   
Always be alert for the possibility of complications or presence of medical illnesses/ injuries 
that are either related or coincidental to the person’s presentation. 
Provide harm reduction strategies and information 
Once intoxication has diminished and/or if the person indicates they do not wish to stop 
amphetamine use, provide them with relevant harm reduction information and where to 
access clean needle programs. (See Section 1.2 for general harm reduction strategies; and 
information relating to amphetamines). 
Encourage the person to: 
• maintain hydration with frequent sips of water to avoid dehydration 
• maintain good nutrition and provide health diet information 
• ensure adequate rest and sleep 
• regular amphetamine free days  
• do not inject  
• maintain good dental and oral hygiene 
• use less than 1/2/ gram per day. 
Inform the person about amphetamines toxicity (overdose) and when to call an ambulance, and 
risks that may not be able to be avoided e.g. cardiovascular effects, mental health effects:  
• encourage them to cut down and consider cessation of use 
• advise them to avoid other risky behaviours such as combining alcohol, amphetamines 
and driving [Adapted from 133] 
• provide them with information about potential drug interactions with prescribed 
medication, illicit drugs and alcohol 
• See [133] on the following website: www.nationaldrugstrategy.gov.au    
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Medical Management of Amphetamine Intoxication and complications 
Guidelines for the Management of Psychostimulant Toxicity, can be sourced from the National 
Drug Strategy website [136]:  
www.health.gov.au/internet/drugstrategy/publishing.nsf/Content/9DFC79ECB850641ECA2571
F40016229F/$File/emergency-book.pdf   
• Acute agitation should be managed in a low stimulus environment, with some 
continuity of staffing.  
• Staff safety is of utmost importance. It is important to ensure that adequate health and 
security staff are available to be used if needed, but on the other it is important to 
minimize the number of clinicians and others interacting with the patient.    
Acute agitation 
Use of the Level of Agitation Scale will assist in identifying the severity of agitation, and 
response required. (See Appendix 12C).  
Acute agitation can be managed using an oral diazepam regime or if required an intravenous 
diazepam regime. No sedation protocol is 100% safe.  
Clinical response to sedation falls along a continuum with controlled and acceptable behaviour 
at one end and rousable drowsiness (not unconsciousness) at the other. Health care providers 
who administer sedation, regardless of practice setting, should have access to advanced airway 
assessment and management skills so that successful ‘rescue’ of patients can be made should 
an adverse sedation event occur. The most common adverse events of sedation include: 
1. airway obstruction 
2. respiratory depression including apnoea 
3. aspiration 
4. significant hypotension 
5. laryngo-spasm (particularly in the context of antipsychotic medication 
6. administration) [136].  
Oral diazepam is the preferred approach as below: 
Oral diazepam:  
• initial dose of 10-20mgs of diazepam should be administered orally  
• if rousable within 30 minutes of  first dose, no more sedation required 
• if no clinical response or insufficient clinical response is made at 30 minutes, an 
additional 10 mgs of diazepam should be administered 
• repeat this regime until the person is rousable or a total dose of 60mgs of diazepam has 
been administered  
• only exceed 60mg if no obvious signs of respiratory depression are evident. Do not 
exceed 120 mgs in a 24-hour period) [136].   
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Alternatively an intravenous protocol should be used if oral medication is not possible. 
Intravenous diazepam: 
• initial dose of 2.5-5mgs of diazepam* should be administered intravenously (IV)  
• if person is rousable within 10 minutes of  first dose, no more sedation is required  
• if no clinical response at 10 minutes, additional higher 5-10mg boluses of diazepam 
should be administered 
• repeat this regime until the person is rousable or 60mg of diazepam has been 
administered (Do not exceed 120 mgs in a 24-hour period) 
• if no response consider alternate class agent [136].   
Paranoia and possible ATS induced or related psychosis  
Agitation related to acute toxicity usually settles within a few hours. If there is ongoing paranoia 
then consider the use of an anti-psychotic such as olanzepine.  
An initial dose of 10mg orally or IM if oral refused. This can be repeated in 1 hour if required. 
ATS related psychosis may take some time to resolve and treatment should be guided by 
persistent symptomatology [76].  
Cardiovascular and cerebrovascular complications of acute toxicity  
ATS toxicity can lead to myocardial and cerebral ischaemia due to their positive inotropic 
effects and to some degree their vasospastic effects. These latter effects are much more 
intense if cocaine is involved. Hypertension can also lead to cerebral haemorrhage.  
Specialist advice should be sought about specific complications.  
Serotonin syndrome  
This can arise from ATS toxicity. Some ATSs are more likely to cause this problem [e.g. MDMA]. 
Its features include: 
• autonomic signs, tachycardia, hypertension, hyperthermia, sweating 
• neuromuscular changes 
o  tremor 
o clonus 
o hyper-reflexia 
• altered mental status  
• delirium 
Treatment is largely symptomatic and includes sedation, at times paralysis and ventilation, 
active cooling measures, intravenous fluids, specific treatment of cardiac arrhythmias and 
seizures. However specific serotonin antagonists such as cyproheptadine may also be indicated 




Repeated and prolonged use of amphetamine leads to marked tolerance, neuro-adaptation and 
dependence, and withdrawal on cessation. Withdrawal from amphetamines emerges between 
8-20 hours after the last dose. 
Duration of acute withdrawal symptoms is associated with the type of amphetamine used and 
its half-life, and duration of excessive use (up to about three weeks for amphetamines). 
Withdrawal from amphetamines is not life-threatening, but depression resulting from 
withdrawal can lead to suicidal ideation, self-harm and possibly death. 
Cessation results in what is often referred to as the immediate phase—‘crash’—whereby the 
person will experience a range of intense CNS depressant-like symptoms with craving for sleep 
and feelings of exhaustion replacing craving for the drug [110]. 
Withdrawal is characterised by three phases: crash, withdrawal and extinction. 
Phase I—Crash 
The ‘crash’ (hangover) follows cessation of amphetamines use and lasts one to two days. This 
may be associated with a binge and may or may not progress to withdrawal.  
Crash symptoms include: 
• extreme lethargy 
• hunger 
• formication (feeling of crawling 
insects on skin) 
• headache 
• anxiety 
• hypersomnia (excessive sleep) 
• irritability 
• agitation  
• aggression 
• confusion 




Phase II—Withdrawal  
If neuro-adaptation and dependence have developed the crash will be followed by the second 
phase—withdrawal. This will be associated with a period of normal moods, little craving for the 
drug, and normal sleep pattern for one to four days. Withdrawal symptoms reduce in a linear 
fashion over 7 to 10 days. However then dysphoria and craving for the drug start to increase 
again in conjunction with: 
• flattened mood or depression-related symptoms including inactivity, lack of energy  
• poor concentration, fatigue, anhedonia, and dysphoria 
• suicidal ideation may also be evident 
• mood swings 
• vivid unpleasant dreams peaking at day 5 (~11 hours per night) and declining by day 9  
• taking longer to fall asleep, awakening while sleep, being unclear on awakening 
• increased daytime sleeping 
• agitation - aggressive outbursts, irritability,  tension may recur  
• anxiety 
• psychotic symptoms may recur 
• craving for the drug can be intense 
• increased appetite [135]. 
Phase III—Extinction (prolonged withdrawal) 
This phase lasts at least 2 weeks and is evidenced by: 
• depression-related symptoms largely resolved 
• continuation of increased sleep (9 hours per night) with reduced quality and depth 
• increased appetite but milder than above 
• paranoia and suicidal ideation may persist 
• bradycardia (not clinically significant). 
‘Extinction’ of withdrawal is characterised by gradual diminishing of the acute symptoms, and 
may last for weeks or several months. There can be episodic craving in response to 
environmental stimuli (cues) to use, and a feeling of anhedonia (inability to respond to pleasant 
events). The frequency of craving and the anhedonia does decrease over time, but likelihood of 




Nursing management of withdrawal 
To date there is little reliable evidence of a particular medication regime that is most effective 
for psycho-stimulant (including amphetamine) withdrawal management.  
Sound symptomatic medical treatment and good nursing are required which include:  
• Provide supportive care and safe environment. 
• Nursing observations—four hourly.  
• Observation and monitoring  according to  The validated Observer Rated Amphetamine 
Cessation Symptom Assessment  tool currently used in South Australia (see Appendix 
12) [138].   
• Provide withdrawal medications as ordered and on time. 
• Provide self-help information (e.g. booklet titled: Getting through amphetamine 
withdrawal, Turning Point, Victoria. In SA you can call ADIS on 1300 13 1340 (24hr/7 
days week) to ask how to access this and other useful resources. 
• Monitor the stages of withdrawal and adapt nursing care to changing needs for sleep, 
food intake and mood changes (e.g. allow for sleeping during the day). 
• Ensure adequate food and fluid intake, allow for hunger and increased appetite. 
• Support during angry outbursts can assist the person to complete withdrawal. 
• Monitor depressed mood to identify and prevent risk of self-harm. 
• Educate the person about ways of coping with craving e.g. delay (delay decision to use 
for a designated period of time), distract (individual engages in activity of interest to 
distract from craving), decide (once craving has subsided, individual reviews list of pros 
and cons of reducing use, reinforcing own reasons to reduce and then makes decision 
about using) [135]. 
• Give tips for coping with cravings, to improve sleep, relaxation, coping with mood 
swings, aches and pains, nutrition and strange thoughts focussing on the present. 
• Identify high-risk situations and assist person to develop strategies to prevent relapse. 
• Provide harm reduction information and strategies (e.g. safe injecting drugs, nutrition 
and managing hydration). 
• Ensure effective referral for after care and support post discharge. 




Medical Management - Amphetamine Withdrawal 
Simple uncomplicated withdrawal from amphetamine type substances can be undertaken at 
home, as long as there is available nursing and medical back-up, and a supportive home 
environment.  There are still no established pharmacological treatments based on rigorous 
evidence for ATS withdrawals.  
After the initial neuroamine-depletion driven “crash” patients may develop varying levels of 
agitation, sleep disturbance and intense cravings.  
Pharmacological approaches are largely symptom driven.  
Antipsychotics have not been demonstrated in published studies to have efficacy in alleviating 
amphetamine withdrawal symptoms. However, they are indicated for amphetamine-induced 
agitation or psychosis complicating withdrawal if control of these symptoms is not achieved 
with a long-acting benzodiazepine such as diazepam.  
Olanzepine, a sedating antipsychotic, is likely to be a first choice for control of marked agitation 
usually low doses and (in combination with a benzodiazepine regime) [135]. 
Medication regimes may include the following: 
• Diazepam: 5 - 10 mg oral QID prn (for anxiety, agitation, insomnia) in inpatients for 10 - 
14 days. Preferably should be stopped before discharge but, if it is considered 
necessary, decrease to 5 mg TDS prn (total inpatient + outpatient diazepam should be 
no more than 14 days). 
• Olanzepine: 5-10 mg per day prn (for severe agitation/racing thoughts not relieved by 
diazepam) (other atypical anti-psychotic may be used if appropriate). 
Note: Category B3 – insufficient data on risks of use in pregnancy. 
Other symptomatic medications may also be useful, for example: 
• Paracetamol + naproxen for headaches  
• Metoclopramide for nausea 
• Temazepam for night-time sedation. 
Note: These doses are for oral medications.  Be aware that concomitant administration of IM 
olanzepine and parenteral benzodiazepines may increase the risk of death. It is recommended 
to delay administration of a benzodiazepine for 1 ½ to 2 hours after IM olanzepine 
administration. 
Antidepressants are clinically indicated based on the patient’s history of depression or current 
presentation. The choice of antidepressant should be based on the same criteria that would be 
applied with any depressed individual. Where the client is already on an antidepressant, this 




Maternal and neonatal care 
Effect of Amphetamine use in Pregnancy 
The health risks of amphetamine use in pregnancy have not been clearly established.  
A history of intravenous use is a marker of high risk pregnancy. 
The use of stimulants in pregnancy may be associated with hypoxia as a result of 
vasoconstriction and hypertension caused by the drugs’ action – may be associated with an 
increased risk of miscarriage, premature labour and IUGR.  
Use of amphetamines is associated with mental health problems and the mother’s general 
health (especially nutrition) and mental health must be closely monitored. 
Management 
Pregnant women using amphetamines should: 
• be advised of the health risks to herself and her baby 
• if seeking further support be provided with counselling 
• receive care within a multidisciplinary framework 
• be encouraged and motivated to cease amphetamine use e.g. build on the pregnant 
woman’s goals to do what is best for the baby 
• be monitored for mental illness due to the link between amphetamine use and mental 
illness [60] 
• be encouraged to have regular, supportive antenatal care to improve outcomes for her 
and her baby [133] 
• be encouraged to avoid poly drug use [133]. 
Always seek specialist advice for pregnant women and mothers and their babies who are at risk 
because of amphetamine use. 
Neonates 
If amphetamines are used close to the birth, the baby may be born intoxicated. Signs of 
intoxication can include hyperactivity and agitation including seizures. Babies may show 
behavioural disturbances such as: 
• increased startle response 
• abnormal sleep patterns 
• withdrawal symptoms in the first few weeks after birth can include sleepiness and lack 
of responsiveness [60]. 
There is no conclusive evidence that stimulant use by the mother causes specific malformations 
in the foetus. 
Breastfeeding 
Methamphetamine use reduces breast milk production and is excreted in breast milk. Breastfed 
274 
 
infants of methamphetamine using mothers may become irritable, agitated, cry and have poor 
sleep patterns [133]. 
Potential risks should be weighed against the benefits of breastfeeding when the mother is 
using amphetamines. Women should be supported in their decision to breastfeed.  
Breastfeeding is not recommended if mother has regular and unstable use of amphetamines or 
other drugs. Breastfeeding mothers who use amphetamines rarely or in binges must be: 
• informed of the risks 
• educated in how to avoid harmful effects to the baby by: 
o breastfeeding being ceased for 24 hrs after cocaine/amphetamines use 
mothers  
• planning for supplementary feeding when intending to use 





Cocaine is a CNS stimulant similar to naturally occurring adrenaline. It has local anaesthetic 
effects and is a vasoconstrictor [139]. It is derived from leaves of the coca bush. It was first 
extracted from coca leaves as an isolated substance in its pure form by the German chemist 
Albert Niemann, ands he named it cocaine in 1860. Cocaine was an original ingredient of the 
soft drink Coca Cola® from 1886 to 1903. 
In Australia cocaine is usually taken as a white powder, which can be rubbed on gums, 
swallowed, snorted through a straw or similar object or dissolved in water and injected. This 
form of cocaine is destroyed at high temperatures and is therefore not smoked [140].  
Cocaine can be available as freebase or crack cocaine (sold as crystals or rocks) which is 
smoked, however ‘crack’ use is rare in Australia [139]. It is commonly referred to on ‘the street’ 
as coke, Charlie, snow, blow, toot, C, crack, cola, nose candy and white dust [140]. 
Effects 
• very short acting with effects lasting up to 30 minutes 
• readily absorbed via mucous membranes - rate of absorption limited by local 
vasoconstriction 
• blocks fast sodium channels causing local anaesthetic and pro-arrhythmic effects [141]. 
Cocaine can be used occasionally or in high-dose ‘binges’ over several days. Binges are often 
followed by similar effects to those of an amphetamine binge which is the “crash” in which the 
person experiences feelings of intense depression, lethargy and hunger [140]. 
Effects from small doses of cocaine include: 
• feeling of well being, increased self 
confidence and euphoria 
• diminished fatigue  
• taking risks  
• reduced appetite  
• increased heart rate  
• moving more quickly than usual  
• increased talkativeness or overly 
quiet contemplation and rapture   
• increased energy, feeling more 
awake and alert, reduced need for 
sleep  
• increased energy, alertness, and 
mental clarity 
• becoming excitable 
• feeling aggressive or easily upset  
• increased body temperature  
• increased blood pressure 
• reduced appetite 
• increased libido  
• indifference to pain and localised 




High doses may give rise to: 
• headache  
• violence or aggression  
• chest pain, cardiac arrhythmias and 
myocardial infarction  
• delirium 
• psychotic symptoms (e.g. auditory or 
visual hallucinations or paranoia) 
• dizziness 
• feelings of restlessness and difficulties 
with concentration  
• hyperthermia (risk of rhabdomyolysis) 
• tremor, muscular twitching, 
overactive reflexes or poor 
coordination may be present [128, 
139, 140, 142]. 
Note: High doses of cocaine can result in convulsions, cerebrovascular accidents - subarachnoid 
haemorrhage, cerebral haemorrhage, cerebral infarction, coma, and death [134].  
Long-term effects may be related to the method of using cocaine and may include: 
• insomnia  
• depression, anxiety, paranoia and psychosis (can resemble paranoid schizophrenia), 
hallucinations, some people may experience formication (feelings of insects crawling 
under the skin)  
• eating disorder and weight loss  
• sexual dysfunction  
• dependence  
• sensitivity to light and sound  
• impaired thinking 
• seizures 
• cerebral atrophy, CVA 
• hypertension and irregular heartbeat. 
Problems due to route of administration can include: 
• damaged nasal mucosa, nosebleeds, nasal sores, sinus problems, damage to the inside 
of the nose including nasal perforation may occur arising from snorting   
• bronchitis, tracheal inflammation with persistent cough form inhalation of hot cocaine 
vapours from smoking freebase 
• injection site abscesses, endocarditis, and blood borne infections such as hepatitis B, C 
or HIV 
• collapsed veins are associated with cocaine injection 
• subcutaneous injection can cause severe vasoconstriction and prevent blood flowing to 




Smoking freebase or crack cocaine can cause: 
• breathing difficulties  
• long-term cough  
• chest pain  
• lung damage [128]. 
Health effects 
Short-term health effects include: 
Cardiovascular 
• Hypertension, tachycardia, dysrhythmias, arrhythmias, and sudden death  
• myocardial oxygen demand and enhanced platelet aggregation, mesentery artery 
constriction, and thrombus formation, peripheral ischaemia, gangrene of extremities, 
arthritis, and vasculitis 
Infection (risk of injecting) 
• Bacterial endocarditis 
• Septicaemia 
• Cellulitis 
• blood borne viral infection 
Respiratory tract 
• Inhalation of cocaine leading to asthma, gas exchange abnormalities, non-specific 
pulmonary oedema, pulmonary haemorrhage, and haemoptysis, due to 
vasoconstriction  
• Pneumothorax, pneumopericardium and pneumomediastinum may occur after free 
base smoking with deep, forced and prolonged inhalation. Sudden death can result 
from cardiac arrest. 
Liver 
Cocaine and MDMA have been associated with: 
• hepatic ischaemia 
• acute hepatitis 
• hepatic necrosis 
• and with MDMA - liver failure [134]. 
Chronic toxicity 
Effects of chronic toxicity include: 
Nutritional 




• poor concentration and attention 
• memory impairment 
• sleep disturbance 
• hallucinations 
• flashbacks (vivid sense of reliving the past drug use experience) 
• depression, anxiety, and panic attacks 
• suicidal ideate - has  been reported 
Nasal tract 
• rhinorrhoea, nasal ulcers, epistaxis, sinusitis 
• perforation of  nasal-septal from chronic intranasal cocaine use. 
Dependence  
Cocaine is addictive, inducing tolerance with frequent use over a relatively short time of weeks 
or months depending on the individual. Tolerance causes the person to need more of the drug 
to achieve the same effects previously achieved with smaller amounts.  
Dependence means that cocaine becomes central to the person’s life, and they find it difficult 
to abstain or cut down. Some people may develop ‘reverse tolerance’, where adverse effects of 
cocaine can be experienced more intensely [140]. 
Poly Drug Use and Concomitant drug use 
People who use cocaine sometimes also use other drugs to cope with some of the effects of 
cocaine (e.g. tranquillisers, alcohol, marijuana or heroin) to help them sleep. This could lead to 
dependence on several drugs or leading to serious physical and psychological problems and 
increasing the risk of overdose. One such risk arises from ‘speedballing’ which involves mixing 
cocaine with heroin which is taken at the same time. 
Likewise, there is a risk of interactions among over the counter and prescribed medications, for 
example serotonin toxicity may occur with concomitant use of amphetamines, MDMA or 




Assessment and quantification  
(See Section 2: Assessment). 
Undertake and record general observations: 
• temperature, blood pressure and pulse (particularly abnormalities which may mean risk 
of overdose or complications e.g. arrhythmias, CVA or MI)  
• signs of potential complications 
Undertake and record the recent cocaine history as well as ATOD history including concomitant 
cocaine use with other drugs (polydrug use): 
• dose, quantity and frequency 
• usual pattern of use and if this time is different (e.g. number of tablets/per time, 
frequency of use - daily, weekly, binges/runs) 
• last dose/use (date and time) 
• asking the person about the cost of their last dose will also give an estimation of the 
most recent amount taken   
• any difference in the last dose (more or less) than usual - may be critical for early 
identification of risk for overdose or other complications 
• asking about how much is usually spent over what time period gives an estimation of 
the usual dose taken 
• route/s of administration e.g. injecting, snorting, swallowing 
• form (powder that is dissolved and injected, single or multiple tablets) 
• risk of dependence and withdrawal  
• drugs usually taken with cocaine -legal, medicinal and illicit (due to concerns about 
potentiation and drug interactions) Also ask about what prescription or over the 
counter medicines or other substances they take to self medicate for unwanted cocaine 
effects or “come down” [141] 
• risk of complications from acute or chronic toxicity. 
As well as asking about and recording all drugs used – legal, medicinal and illicit – in association 
with cocaine (polydrug use) ask if the person if they use any of these to self-medicate any 
unwanted effects of cocaine.  
Absorption 
Cocaine is readily absorbed through the mucous membranes such as in the nasal passage, with 
the rate of absorption being limited by localised vasoconstriction.  
Time of onset and duration of effects 
Cocaine is highly fat soluble resulting in rapid crossing of the blood-brain barrier and onset of 




Onset of action according to route of administration, when: 
• snorted - within minutes 
• inhaled or intravenous - within seconds  
Effects: 
• immediate and marked ‘rush’ 
• highly pleasurable with heightened cognitive awareness, energy and euphoria lasting 
for about 30 minutes 
• rapidly diminish due to short half-life 
• rapidly metabolised by the liver [134]. 
As an adrenergic stimulant cocaine use results in a short lived ‘rush’ characterised by euphoria, 
energy and alertness. However these desired effects quickly merge into intoxication 
characterised by: 
• CNS effects: agitation, increasing levels of anxiety, paranoia and thought disorder, as 
well as seizures 
• Motor effects: such as teeth-grinding, repetitive movements and tremor 
• Noradrenergic effects: tachycardia and hypertension. These may result in myocardial 
ischaemia, or stroke 
• Hyperthermia and metabolic disturbance 
• Having a fairly short half life, these effects will generally subside rapidly after ingestion. 
Managing intoxication and complications  
(See Section 2.4: Managing intoxication; Section 3.4 Amphetamines - managing intoxication). 
Complications 
Acute toxic complications from cocaine use are rare. However, they can occur at any time and 
are not necessarily dose related. 
Some people may only need general monitoring and nursing care. Others will need 
interventions for specific complication [141].   
The term ‘overdose’ from cocaine relates to the acute toxicity that can arise. Small amounts 
(doses) can cause overdose in people who are especially sensitive [141]. 
Safe management relies on: 
• regular observation and monitoring 
• prevention and early detection of complications  
• ensuring safety 
• some people may only need general monitoring and nursing care. Others will require 
medical intervention for specific complications [141]. 
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Signs and symptoms of complications 
Early signs include: 
• sudden rise in body temperature 
• chest pain 
• flushed face 
• hot skin with no sweating 
• muscle cramps 
• stiffness in arms or legs [142, 143]. 
And: 
• tachycardia, irregular or weak heart beat 
• breathing problems 
• heart failure, cardiac arrest, myocardial infarction 
• seizures 
• cerebral haemorrhage (CVA) 
• death 
• cardiac ischaemia 
• hyperthermia  
• rhabdomyolysis [141]. 
Complications can be characterised by: 
CNS effects 
• agitation 
• increasing anxiety 
• paranoia  
• thought disorder 
• seizures 
• cocaine induced psychosis 
Motor effects 
• teeth-grinding 






• tachycardia and hypertension – can result in myocardial ischaemia; stroke 
• hyperthermia 
• metabolic disturbance. 
Cocaine induced psychosis  
Cocaine psychosis usually occurs following a binge of several days whereby the person has not 
slept or eaten properly. Symptoms are similar to other acute psychotic conditions and include: 
• suspicion and paranoia 
• paranoid delusions 
• auditory and visual hallucinations 
• formication ‘coke bugs’ resulting in scratching and sores  
• high risk behaviour such as driving a car, jumping from heights, excessive drinking  
• aggressive or violent behaviour [139, 140]. 
Nursing Management 
Nursing management includes: 
• nurse the person in a safe, cool, quiet and low stimulus environment and approach 
them calmly and with quiet confidence 
• assist person to remove any warm, heavy or restrictive clothing to avoid overheating 
• provide support and reassurance 
• avoid confrontation or arguments 
• encourage normal fluid intake 
• provide timely medications as prescribed 
• undertake usual nursing assessment and monitoring of vital signs especially TPR & BP 
• monitor for signs of overheating, cardiovascular or cerebral complications 
• encourage or offer to contact family/friend to sit quietly with them 
• allow the person to talk (effect of the drug) and actively listen to them so as to reassure 
them that they are being cared for and listened to 
• cocaine psychosis and other symptoms can occur – usually resolve as effects wear off 
• reassess symptoms during the ‘come down’ period 
• provide nursing care as for any other psychotic event.  




People who use cocaine may seek high calorie sweet foods during the come down period.  
People who use cocaine may be nutritionally compromised making them vulnerable to 
Wernicke’s encephalopathy.  Implement the Wernicke’s encephalopathy prevention thiamine 
regime prior to glucose loading. 
Following initial administration of thiamine offer and provide frequent tasty, easy to swallow 
low acidic snacks and high calorie foods such as ice-cream and custard. 
In a ‘nutshell’: 
• reassurance and supportive care in a quiet calm environment 
• observation and maintenance of airway, breathing and circulation 
• assessment of any evidence of injury or illness 
• obtaining specimens for investigations 
• ensuring all medications are given as prescribed on time. 
Medical management of intoxication and complications 
Medical management is symptomatic and should NOT be based on urine or blood toxicology. 
Treat the patient, not the test. General approaches include: 
• stabilisation and maintenance of vital signs including temperature, oxygen, IV access 
and cardiac and pulse oximetry monitoring 
• monitoring and early intervention for hyperthermia 
• administering intravenous Thiamine, glucose, and naloxone in the confused or 
unconscious person in the event that Wernicke’s encephalopathy, hypoglycaemia or 
opioid overdose may be causing or confusing the presentation. 
Note: Ensure safety and offer reassurance at all times. 
General medical approaches 
Monitor until the person is: 
• no longer tachycardic and hypertensive 
• calm and cooperative. 
Medical management of Toxicity 
People with cocaine toxicity need initial evaluation and stabilisation including attention to:  
• removing any residual cocaine from nostrils 
• ABCs 
• oxygen 
• intravenous access 




Temperature and glucose levels 
• temperature may reach critical level – close monitoring and early intervention indicated 
• temperature of a hyperthermic person can keep rising secondary to agitation and 
continuous attempts to remove any physical restraints 
• monitor for hypoglycaemia which can present as any neuropsychiatric abnormality. 
Restraint 
• avoid physical restraints if possible 
• benzodiazepines are an effective and safe pharmacologic restraint if required. 
Pregnancy 
Prevalence of unrecognised (unknown) pregnancy is about 6% in females presenting to ED 
affected by cocaine. Therefore: 
• perform routine pregnancy testing as physiologic changes in pregnancy may increase 
cocaine toxicity 
• cocaine may induce miscarriage, premature labour, or foetal toxicity 
• modifications may be necessary for acute management [144]. 
 Table 19: Commonly prescribed medications to manage complications 
Agitation Benzodiazepines preferred (due to the added benefit of reducing risk of 
seizures and control of hypertension and arrhythmias) where sedation is 
required to manage e.g. risk of self harm, agitation or aggression. 
Severe psychosis Antipsychotics for severe psychosis (monitor for respiratory compromise or 
hypotension). Caution is required where the person is intoxicated with 
psychostimulants as some antipsychotic medications e.g. haloperidol or 
pericyazine may lower the seizure threshold. 
Seizures Benzodiazepines initially and then phenobarbitone if persistent or recurrent. 
NOTE: Phenytoin Sodium is generally not used in drug-induced seizures. 
Severe hypertension Vasodilators, benzodiazepines are also used as they minimise the CNS effect 
of cocaine on the CNS. 
Hypotension Parenteral fluids and if refractory to fluids, pressor agents may be prescribed. 
Arrythmias Oxygen, benzodiazepines, and anti-arrythmics as required. 
Chest pain Aspirin, oxygen and vasodilator such as nitroglycerin and benzodiazepines 
may be ordered as a first-line response, usually in association with 
monitoring cardiac enzymes and ECG’s and cardiac imaging.  
Phentolamine Mesylate may be used as a second line response (corrects 
vasoconstriction effect of cocaine). 
Concomitant heroin 
use 
With respiratory depression – may require administration of naloxone which 
can increase cocaine toxicity and remove the moderating effect on 
unopposed cocaine effects. 
Cardiac arrest Vasopressin is commonly used as it increases coronary blood flow and 





The following investigations can be useful: 
• blood and toxicological screening to confirm or refute diagnosis and reveal the 
presence of any other drugs used 
• CT scans and lumbar puncture in the confused, unconscious, or otherwise 
neurologically impaired cocaine user [145].  
• severe headache, seizures, localising signs or ongoing confusion may also warrant CT 
scanning to exclude haemorrhagic or non-haemorrhagic stroke and traumatic injury 
secondary to the confused state 
• electrocardiogram (ECG) 
• serum electrolytes 
• liver function tests  
• creatinine kinase concentration 
• urine drug screen to confirm exposure to particular drugs [141]. 
Note: Beta blockers are contraindicated as unopposed alpha-receptor stimulation can worsen 
vasoconstriction and increase blood pressure. Phenytoin has no role in the treatment of drug-
induced seizures. 
Note: for management of acute complications consult ED physician or intensivist.   
Serotonin Syndrome 
Serotonin syndrome is a drug induced dose related range of symptoms attributable to 
increasing serotonin concentrations in the central nervous system which cause a toxic state. 
Symptoms can vary from mild to life threatening. Concomitant use of cocaine, MDMA, 
amphetamines, MAOI, ir SSRI antidepressants can induce serotonin syndrome. Mild to 
moderate syndrome usually resolves in 24 – 72 hours [146].  
Serotonin syndrome can also occur due to psycho-stimulant (e.g. cocaine) toxicity and higher 
dose tramadol. 
This syndrome is characterised by: 
• clonus 
o  symmetrical and more dramatic in lower limbs 
o inducible/spontaneous/ocular 










• hyperthermia and excessive sweating 




• teeth-grinding,  
• dehydration,  
• metabolic problems e.g. electrolyte disturbance and metabolic acidosis [146].  
Nursing Management: 
• monitoring for symptoms, early identification and intervention 
• supportive care 
• monitoring vital signs (temperature, pulse , respiration, blood pressure, urine output) 
• aggressive cooling techniques for hyperthermia such as cool water sprays, ice packs 
• administration of prescribed medications and symptomatic relief as ordered 
Medical management may require: 
• intravenous hydration 
• withdrawal of the implicated drug(s)  
• aggressive supportive care 
• administration of serotonin antagonist drugs such as cyproheptadine (periactin) 
• review of treatment for the condition for which the seratonergic drugs were prescribed 
• specific interventions for the hyperthermia – may require paralysis and ventilation  
artificial cooling procedures 
• benzodiazepines may be used to control seizures and muscle hyperactivity [146]. 
Note: In severe cases, people require intensive care if there are complications such as severe 






(See Section 2.6: Managing Withdrawal, and Section 3.2.2: Managing Amphetamine 
Withdrawal). 
Cocaine withdrawal is similar to amphetamine withdrawal. This involves a ‘crash’ period from 
well established dependence (tolerance), often involving prolonged or shorter sleep periods, 
and difficulty sleeping at night [147]. 
Withdrawal occurs due to cessation or rapid reduction in the regular amount used.  
Withdrawal from cocaine is not life threatening but mood swings and depression can arise and 
lead to suicidal ideation, self harm and possibly death. Suicidal ideation should be managed as 
per organisational procedures [147].  
Withdrawal symptoms 
Phase 1 - Crash (period immediately prior to withdrawal) 
Onset - 1 to 4 days after last dose. The crash is characterised by: 
• agitation and restlessness (arising from neuroamine depletion) 
• depression, low mood and/or anxiety 
• feelings of intense hunger 
• intense craving 
• insomia or prolonged, disturbed sleep 
• extreme fatigue and exhaustion [140].  
Phase 2 – Acute withdrawal 
These symptoms emerge after the crash phase and are usually short lived (4-5 days). Some 
symptoms are longer lasting e.g. cravings can persist over several weeks. 
• intense cravings 
• nausea and or vomiting 
• tremor 
• anxiety 
• deep depression with suicidal thoughts or anhedonia or (no enjoyment in any activities) 
• angry outbursts 
• hunger 
• lethargy , lack of energy, feeling weak, 
• muscle pain 




Phase 3 – Extinction 
On completion of Phase 2 the person may experience the following symptoms which may 
persist for some months: 
• intense cravings 
• anhedonia  
• depressed mood  
• inability to make decisions  
• short term memory problems [140]. 
Nursing Management 
• ongoing monitoring for symptoms related to the ‘crash’ or ‘extinction’ phases 
• monitor for hypertension 
• monitor temperature – observe sweating or feeling hot and cold 
• timely provision of prescribed medications e.g. to manage physical or mental health 
symptoms, sleep etc. 
• monitor for signs of serotonin syndrome particularly if taking MAOI or SSRI 
antidepressants 
• reassess any mental health symptoms e.g. anxiety, depression and paranoia after 48 
hours 
• closely monitor for depression and suicidal ideation 
• if present, respond immediately and manage accordingly 
• assess and reassess memory and concentration as this can be compromised 
• repeat any conversation or instructions as needed 
• person may need reassurance that this may persist for some time, but will resolve over 
time if they are drug free 
• if person has been snorting, monitor for (severe) sinus or nose pain 
• seek medical assessment for pain management 
• nasal tissue is slow to heal. 
Monitor intensity of cravings for drug. Discuss with the person the nature of cravings (due to 
changes to the brains biochemistry whilst the brain is trying to readjust to normal function)   
and subsequent risk of using other drugs (including those not previously used or preferred), 
particularly during the first few weeks following acute withdrawal as this can drive relapse. 
• encourage healthy, low acidic, light,  tasty and easily digestible foods e.g. custard and 
ice-cream 
• person may have gastric upset or indigestion (particularly if they have been snorting), 
may crave high calorie sweet foods.  
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Discuss the risk of using other drugs (including those that are not previously used nor preferred) 
during the first few weeks after withdrawal. This is an insidious effect arising from the brain 
wanting to be intoxicated. Assist person to establish supports to help and assist them maintain 
abstinence and lifestyle change after discharge. 
Assist the person to help develop an achievable post discharge plan, including: 
• strategies for relapse prevention 
• offer advice about the need to be drug free to give their brain a rest 
• referral to specialist ATOD service, GP or other relevant agency. Advise the person to 
see a specialist ATOD professional prior to using cocaine again and if they would like 
assistance to cease use 
• discuss cravings and how to manage them 
• discuss cues and triggers that could lead to relapse and strategies to manage them 
[147] 
• where to obtain information (ADIS 24 hr phone line 1300 13 1340).  
Risk reduction information 
The person should be provided with a clear message that it is always safer not to use drugs, but 
there are ways to reduce the risk. These include: 
• it is safer not to inject cocaine 
if injecting, be aware of the risk of : 
• blood-borne viruses such as Hepatitis B & C, HIV  
• other infections due to injecting such as e.g. bacterial endocarditis, abscesses  
• blocked or inflamed blood vessels  
• use clean equipment (e.g. needles & syringes, spoons, water, swabs, filters etc). 
Never: 
• drive or undertake dangerous activities while using cocaine  
• use when you are on your own  
• use while pregnant - can affect the unborn child  
• use large amounts  





Medical management is symptomatic and may include: 
• Benzodiazepines for agitation -beware of using these beyond three to four days due to 
the risk of development of tolerance and physical dependence. 
• Antipsychotic medication for symptoms of psychosis e.g. paranoia, delusions, 
hallucinations. Psychiatric consultation is recommended where symptoms of psychosis 
are severe or do not resolve within days of cessation of use.  
• Antidepressants for depression that persists following withdrawal. Specialist 
assessment and a treatment plan combining counselling (e.g. cognitive behavioural 
therapy) and antidepressant medication may be considered. The side effect profile may 
be important in choosing an antidepressant. 
• Aspirin or paracetamol may be ordered for headache. 
Maternal and Neonatal Care 
Effect of Cocaine on pregnancy  
There are adverse effects due to drug impurity, unknown dose & presence of other drugs. 
A history of intravenous use is an indicator of high risk pregnancy. 
Increased risk (may also be due to concurrent tobacco/cannabis use. 
Complications 
• vasoconstriction & hypertension – foetal hypoxia 
• miscarriage 
• pre-term labour- e.g. rupture of membranes 
• low birth weight 
• growth retardation 
• abrupto placentae  
• still birth 
• genitourinary malformations [60]. 
Management 
Women using cocaine should: 
• be advised of the health risks to herself and her baby 





If cocaine is used close to the birth, the baby may be born intoxicated. Signs of intoxication can 
include hyperactivity and agitation including seizures. Babies may show behavioural 
disturbances such as: 
• increased startle response 
• abnormal sleep patterns 
• withdrawal symptoms in the first few weeks after birth can include sleepiness and lack 
of responsiveness 
• an increased risk of genito-urinary malformations in the foetus with cocaine [60]. 
Neonatal Withdrawal - Cocaine 
Exposure to regular cocaine use by the mother places the neonate at risk of Neonatal 
Abstinence Syndrome (NAS)  
NAS symptoms may be mild and not require medication. However more severe symptoms 
could require medication and supportive care [60]. 
Breastfeeding 
Cocaine use while breastfeeding has induced intoxication and seizures in infants. 
Breastfeeding should stop for seven days after cocaine use. Breast milk should be expressed 
and discarded for this period [60]. 
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3.4. Other Drugs  
In this chapter: 
3.4.1  Hallucinogens 
3.4.2 LSD 
3.4.3 Psilocybin (magic mushrooms) 
3.4.4 Phencyclidine (PCP) 






Hallucinogens (also known as psychedelics) include naturally occurring compounds and 
synthetic chemicals. They produce distortion in thoughts, mood and perceptions - typically 
inducing illusions or hallucinations. They are most commonly used ‘once off’ or recreationally in 
social settings such as homes, dance parties, rave parties, clubs and pubs. These drugs are not 
usually associated with dependence arising from long-term, high-level use.  
There are a number of drugs that come into this category. They include lysergic acid 
diethylamide (LSD), phencyclidine (PCP), psylocibin (magic mushrooms).  
Note: MDMA (ecstasy) and methylene dioxy-amphetamine (MDA) are psychostimulants that 
also have hallucinogenic properties. 
Assessment and quantification 
Quantification of hallucinogens is difficult because purity and actual ingredients are uncertain.  
In assessing hallucinogen use, ask about and record: 
• how often the person uses the substance  
• what they think the substance is  
• the dollar cost of the drug  
• how much extract, fibre (e.g. mushrooms ), or how many tabs are used  
• duration of use 
• frequency 
• quantity 
• date and time of last use 
• positives and negatives  
• goals related to their use 





Signs of intoxication: 
• altered perception, thought, emotions 
• unusual and vivid perception of shapes, colours, sounds 
• blurred boundary between self and surroundings 





In some cases users can experience pronounced mood swings—detachment may alternate with 
fear, paranoia, distress and panic. The nurse will need to provide reassurance and supportive 
care so such people do not injure themselves or others during a panic episode (this episode 
usually ends when the drug wears off). 
Hallucinogen overdose 
Overdose from hallucinogens is rarely seen. However, death due to overdose in animal studies 
resulted from respiratory failure and hyperthermia. 
Hallucinogen withdrawal 
There is no evidence of a withdrawal syndrome from hallucinogens even after abrupt cessation 
or substantial reduction in their use. 
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3.4.2 LSD  
LSD Intoxication 
Subjective effects of LSD typically peak several hours after ingestion. While pleasant, it can 
induce dysphoric experiences. LSD: 
• generally taken as a ’ticket’ which is a piece of paper that has been soaked in the dilute 
LSD solution and dried  
• is absorbed orally and difficult to detect in the  blood 
• highly potent, so the usual dose is small 
• causes high level tolerance to behavioural effects after three to four daily doses but this 
dissipates with abstinence 
• involves less tolerance to cardiovascular effects 
• has cross-tolerance between  mescaline and psilocybin; but none with amphetamines 
or its derivatives, anticholinergics, ketamine or phencyclidine (PCP). 
Acute toxicity 
Somatic effects—sympathomimetic: 




• increased body temperature 
• increased blood pressure 
• hyper-reflexia 
• nausea 







• emotional lability. 
Chronic toxicity (largely unknown) 
• flashbacks (like drug effects, sometime after use of drug); may persist for years after 
use depending on the number of magnitude of doses the person has taken over the 
previous months or years 
• flashbacks are precipitated by a number of factors including cannabis use, anxiety and 
fatigue 
• may cause reduced capacity for abstract thinking with repeated use [75].  
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3.4.3 Psilocybin (magic mushrooms)  
Psilocybin Intoxication  
Effects from an oral dose (e.g. 0.2mg/kg) develop in 30 minutes after eating mushrooms or five 
minutes after drinking extract. These last for 4-8 hours and are followed by drowsiness and 
sleep. The effects can produce symptoms that resemble psychosis. 
Acute toxicity 
Active ingredients in these mushrooms cause CNS and cardiac toxicity.   
Common effects of lower dose: 
• agitation 




As magic mushrooms are seasonal and not usually taken on a regular long-term basis, chronic 




3.4.4 Phencyclidine (PCP) 
PCP was briefly used as a dissociative anaesthetic but delirium and hallucinations during 
recovery were troublesome [75]. 
There are sporadic reports of PCP use in Australia. 
Intoxication 
PCP can be smoked, swallowed, snorted or injected.  
Onset of effects varies in relation to method of use. Effects depend on dose taken.  
Typical duration of action is 4-6 hours but may be much longer following high doses. The half-
life for PCP is 7-16 hours. 
Acute effects 
Common effects of lower dose: 
• may resemble alcohol intoxication 
• slurred speech 
• numbness of extremities 




• depersonalisation and a sense of 
detachment from one’s body. 
Prominent symptoms of higher dose:  
• distorted sensory processing 
• drowsiness 
• hostile and bizarre behaviour  




• respiratory depression 
• disorganised thinking 
• apathy 
• marked anaesthesia and catatonic-





Note: PCP is an acid seeking drug, lowering urinary Ph (acidification) speeds up excretion. 
• Other symptoms reported have been sinus tachycardia, arrhythmias, hypotension, and 
bradycardia 
• Altered pupils, nystagmus, decreased pupillary light reflexes, absent corneal reflexes, 
and bilateral ptosis may occur at any level, and are usually accompanied by cholinergic 
symptoms such as dilated pupils, hyper-salivation, sweating and flushing.  
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Chronic toxicity  
Chronic effects are not well known. There is some evidence of adverse changes such as chronic 
psychotic sequelae in the form of organic brain dysfunction and/or behavioural effects that may 
manifest as: 
• personality changes 
• persistent difficulties with memory, speech and thinking 
• “flashbacks” have been reported following cessation [75].  
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3.4.5 Methylene dioxy-methamphetamine 
(Ecstasy) and other amphetamine types  
These drugs are related to amphetamines and have hallucinatory and stimulant properties. 
They cause pleasant emotional effects, euphoria and increased energy. 
Ecstasy—MDMA: Onset of action when taken orally is 30-60 minutes with peak effect at 90 
minutes. Duration of effect is about 4-6 hours. 
Autonomic effects are: 
• hypertension 
• tachycardia 
• hyperthermia   
• possible toxicity to serotonergic neurones [75]. 
Intoxication 
Acute complications from MDMA use is unpredictable. The management of these symptoms is 
a medical emergency.  
Toxicity may present as follows: 
• cardiovascular complications with hypertension, tachyarrhythmia and ischaemia  
• CNS complications with haemorrhagic and non-haemorrhagic stroke, seizures and 
vasculitis 




o Acute renal failure secondary to Rhabdomyolysis 
• Psychiatric presentations with 
o Acute psychosis with agitation 
o Anxiety 
o Delirium 
The possibility of amphetamine use should be considered in a  young adult presenting with 
seizures or a cerebrovascular accident [133] [134]. 
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Toxicity is much more likely with concurrent use of anti-depressant monoamine oxidase 
inhibitors such as moclobamide.  
Nursing management 
(See Section 2.4: Managing intoxication, Section 3.2.2: Amphetamines for further information 
and ‘Management’). 
Medical Management 
The medical management of acute MDMA intoxication is ‘… as for amphetamines and cocaine, 
with treatment of the symptom complexities as they emerge’[145]. 
MDMA and other amphetamine type substances have many features in common due to their 
overlapping pharmacological effects.  
Treatment is targeted at symptoms and supportive, rather than specific to type of substance.  
Initial assessment should include: 
• recent ATOD drug history  
• what and when last dose/use 
• any cardio- and cerebro- vascular symptoms e.g. 
o chest pain, headache, neck stiffness or photophobia 
Observations to include: 
• pulse, BP, temperature, respiratory rate,  
• airway security 
• pupil size,  
• mental state, level of agitation [76] 
• signs of injury or other illness. 
Investigations to include:  
• electrolytes, liver function tests, blood count, glucose, CPK, ECG. 
• urine drug screen if available but not essential as treatment is symptomatic 




• hypertension  
• acute agitation and or psychosis  
• cardiovascular complications such as stroke and myocardial ischaemia 
• metabolic problems e.g. hyponatremia, rhabdomyolysis 
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For a more detailed discussion of the above recommendations, as well as dosage, indications 
and contraindications of specific medications (e.g. as listed above), seek latest evidence by 
going to www.dassa.sa.gov.au and refer to Wickes encephalopathy [148].   
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3.5 Other drugs 
In this chapter: 
3.5.1 Ketamine 
3.5.2 Inhalants (solvents) 
3.5.3 Anabolic androgenic steroids (AAS) 
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3.5.1  Ketamine 
Introduction 
Ketamine is often called K, or Special K. The effects of ketamine appear subjective depending on 
individual characteristics of the user and setting in which it is used.  
Ketamine is a drug with multiple mechanisms of action, but the degree to which each 
contributes to the different effects experienced through the use of ketamine is not clear [149].  
Ketamine is a dissociative anaesthetic with stimulant properties in low doses. It is commonly 
swallowed, snorted, smoked or injected. Ketamine is used mainly for its euphoric effect. 
Drug combinations and interactions 
The effects of a drug can never be predictable, and when combinations of drugs are used their 
effects can be more extreme and unpredictable. Mixing drugs may result in a “come-down” 
period being more severe and feelings of depression and anxiety may last for weeks instead of 
a few days [123]. 
Ketamine and alcohol can act together, increasing the effect of both each other and the 
potential for drug related toxicity and overdose [123]. 
Drugs that appear to have opposite actions, e.g. stimulants and depressants, seem to cancel 
each other out. However, drug combinations place stress on a body that is trying to maintain a 
functional balance [123]. 
Assessment and quantification 
(See Section 2.2: Assessment). 
Ketamine intoxication 
Acute Effects 
Peak effects depend on route of administration, and occur from 30 seconds (IV) to 20 minutes 
(oral) after usage. Duration of effect is typically 1-3 hours. The half-life is three hours [75]. 
Potential dangers of ketamine use are drug-induced psychosis, violence, accidents and marked 
psychomotor and cognitive impairment [149]. 
Use of ketamine can produce a range of schizophrenic-like symptoms, including: 
• flattened affect 
• thought disorders 
• depersonalisation 




Short term effects at low doses produce a state resembling alcohol intoxication with: 
• ataxia  
• euphoria 
• slurred speech 
• nystagmus  
• numbness of extremities 
• cardiovascular and respiratory stimulation. 





• muscle rigidity 
• risk of respiratory collapse and failure 
• hostile and bizarre behaviour 
• disorganised thoughts  
• hallucinations (distorted sensory 
processing)  




• blurred vision  
• dissociative ‘out of body’ sensations 
(flying or floating)—detachment from 
immediate environment 
• reduced response to pain 
• feelings of aggression 
• stimulation 
• temporary paralysis 
• euphoria 
• confusion and disorientation. 
Longer term effects: 
• weight loss 
• loss of appetite 
• flashbacks 
• possible memory, attention and vision impairment 
• possible psychological dependence 
• possible development of tolerance to some behavioural and toxic effects [75] 




Nursing management of ketamine intoxication 
(See Section 2.4: Managing intoxication). 
Nursing interventions are the management of symptoms arising from the drug and its effects 
and/or the effects of the use of more than one drug. 
Harm reduction information: 
• Do not mix drugs including prescribed medication, alcohol, herbal preparation, caffeine 
and antidepressants. 
• Trying to counterbalance one drug with another does not work, and taking more drugs 
to try and do this is likely to place the person at greater risk of toxic overdose and 
intensify the ‘come-down’ period. 
• Avoid using caffeine, such as guarana and other caffeine-based drinks due to risk of 
dehydration. 
Ketamine overdose 
Possible symptoms of ketamine overdose 
Respiratory depression may occur where there has been rapid intravenous administration, but 
can occur in slower administration hyperthermia seizures may occur in people with known 
seizure disorders (literature reports that ketamine use may induce or terminate seizures) [149]. 
Nursing management of ketamine overdose 
(See Section 2.5: Managing overdose). 
Ketamine withdrawal 
(See Section 2.6: Managing withdrawal). 
Abrupt withdrawal can occur after cessation of long-term daily use [75]. 
Withdrawal from ketamine has not been accurately characterised.  
Maternal and neonatal care 
Little is known of the effect of ketamine during pregnancy.  The use of ketamine during 
pregnancy is not recommended. 
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3.5.2  Inhalants (solvents)  
Introduction 
Inhalants, also known as ‘solvents’ or ‘volatile substances’ include gases and other volatile 
compounds or mixtures of compounds such as petrol, sealants, ‘super glue’, paint - ‘chroming’, 
glues, aerosol propellants, acetone and paint thinners. These products vaporise, and when 
inhaled cause the person to rapidly become intoxicated. Commonly used terms for inhalant use 
include ‘sniffing’; ‘bagging’, ‘huffing’ or ‘petrol-sniffing’.  
These substances are inhaled through the nose or mouth. They are usually sprayed into and 
inhaled from a plastic bag, soaked rag or sleeve, or inhaled from the product container or 
empty drink or other containers. 
Inhalants: 
• are not classified medically as drugs  
• are chemicals that when exposed to air change from liquid or semisolid states to 
vapour  
• can contain CNS depressants; slowing and altering brain activity 
• can contain nitrites which are stimulants that speed up brain activity. 
Why people inhale 
(See Section 1.4: Understanding ATOD problems). 
Reasons are individual, varied, and complex, with no single reason for people’s decision to use 
inhalants, as with all other drug use [1].  
Inhalant use can occur amongst people from any social, demographic, economic, cultural 
background, and always serves a purpose. Commonly people who use inhalants are children, 
adolescents and young adults. Reasons for inhalant use include:  
• low cost 
• easily accessible  
• experimentation 
• pleasure, excitement, fun  
• connection with peers 
• increased confidence  
• relief from boredom 
• relief from hunger - appetite suppressant 
• escape from bad memories, grief, pain or trauma 
• coping with fear, anxiety, unwanted thoughts, bad experiences and situations [151]. 
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Patterns of inhalant use:  
• Once off 
• Occasional (irregular)  
• Opportunistic 
• Chronic use daily or almost daily – dependent use [151]. 
For further information go to: 
www.nhmrc@nhmrc.gov.au  
NHMRC reference code: CP136. 
Health effects   
While some people may experience minimal harm to their health from inhalant use others 
develop serious problems. These include injuries, physical tolerance and dependence, chronic 
health problems including, lowered immunity, nerve and organ damage and cognitive disability. 
For some individuals serious mental health problems may also co-exist including psychosis, 
mood disorders, self-harm and suicidal ideation. Other harms include interrupted physical, 
mental, emotional, educational, social, cultural and overall development, and worsening social 
and emotional capacity.  
Recovery from the short-term physical effects of inhalant use tends to be rapid. Prognosis is 
generally good for people who only use inhalants occasionally and do not inhale an excessive 
amount when using [151].  
Acute effects  
The acute effects of inhalant user are unpredictable and range from mild to serious, and acute 
and longer term health problems. 
Intoxication in itself has associated life threatening risks from injury or complications from 
inhaling.  There can be milder adverse effects such as nausea or headache or serious effects 
such as seizures, organ damage, neurological deficits, and cognitive impairment.  
Signs and symptoms of adverse effects include: 




• poor appetite 
• bronchio-spasm 
• asthma 
• muscles/joint pain 
Note: Sudden death has been reported in people with no previous history of volatile substance 
use. It unpredictable and can occur from ‘once off’ use. It is caused by the direct toxic effects, 





• euphoria  
• light-headedness – dizziness   
• headache  
• blurred or double vision 
• ataxia 
• red conjunctivae  
• nystagmus 
• cough  
• slurred speech 
• excess salivation 
• abdominal cramps 
• nausea, vomiting, diarrhoea 
Serious complications:  
• injury  
• tachycardia,  arrhythmia,  
dysrhythmias, cardiac arrest 
• seizures 
• stroke 
• brain damage 
• psycho-motor retardation 
• increasing drowsiness to unconscious 
• unstable mood  
• bizarre or reckless behaviour  
• hallucinations 
• impaired cognitive function  
• respiratory distress 
• pneumonia 
• suffocation  
• dehydration and electrolyte 
imbalance  
• sudden death [151]. 
Sudden Sniffing Death Syndrome (SSDS) 
SSDS is unpredictable and can occur with first time use or episode of repeated use. 
A person who is inhaling is at increased risk of SSDS if startled, emotionally stressed or engaging 
in extreme physical activity (e.g. running) while intoxicated. This is due to release adrenaline 
(for fight - flight response) with increased blood pressure, heart rate and cardiac output. Death 
can also occur due to the chemicals in some inhalants sensitising the heart to adrenaline.  
Note: Any sudden surge of extra adrenaline to heart leading to disturbances in cardiac rhythm 
can be fatal (ventricular fibrillation). 
Longer term effects 
There is a range of longer term, often serious, health conditions associated with inhalant use. 
These are:  
• chronic headaches 
• chronic fatigue 
• recurrent tinnitus 
• poor balance and co-ordination – 
ataxia 
• weight loss and malnutrition 
• anaemia craving 
• liver damage 
• kidney damage   
• immune deficiencies 
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• nasal bleeding  and mucosa erosion 
• sinus problems 
• gastrointestinal disorders 
• cardiac complications 
• respiratory disease 
• poor muscle tone 
• chronic infections 
• depression 
• anxiety 
• poor cognitive function 
• brain damage [151].  
Table 20: Various inhalants and their affects in the body 
Toluene Can cause damage to the brain that can result in: impaired 
coordination, loss of hearing and blurred vision. Impaired cognition, 
liver and kidney damage. Spasms to limbs. 
Benzene Suppression of bone marrow, increased risk of leukaemia, 
suppression of immune system. 
Trichlorethylene Cirrhosis of the liver, loss of hearing and vision, Sudden sniffing death 
syndrome. 
Butane Burns, SSD 
Nitrous Oxide Limb spasms, depression of heart muscle, altered perception, 
reduces oxygen to brain which can result in brain damage or death. 
Altered motor coordination, blackouts. 
Altered blood pressure. 
Amyl & Butyl Nitrite Suppressed immune system, damage to blood cells which effects 
oxygen supply to vital tissues and organs. 
Freon Obstruction to airway and injury to airways, SSD, liver damage. 
Lead (Petrol) 
 
Affects all systems of the 
body – large number of 
health issues can arise 
from exposure.  
Effects - dose related. Can cause death. 
Brain damage - cognitive impairment, reduced visual & motor skills 
deficits, reduced reaction time.  
Psychological impairment - reduced IQ, anxiety, learning difficulties, 
attention deficit disorders, behavioural problems. Physical e.g 
stunted growth, impaired hearing, kidney damage, loss of appetite, 
vomiting, high blood pressure, reduced Vitamin D & calcium 
metabolism, abdominal cramps. 
Foetal effects - e.g. miscarriage, neonatal death, premature birth, 
reduced birth weight. 
Reproductive effects - e.g. altered testicular functioning, erectile 
dysfunction, decreased libido, and fertility problems. 




Absorption, metabolism and excretion  
As the inhalant enters the bloodstream the chemicals are rapidly distributed via the lungs to 
the brain, liver, kidneys and bone marrow.  Inhalants are metabolised by the liver. 
Many inhalant chemicals are excreted by the kidneys. Others are eliminated unchanged from 
the body, primarily through the lungs. As most inhalant chemicals are fat-soluble, complete 
elimination can take some time as these are released from fatty tissue into the blood. 
Not all inhalant chemicals can be excreted e.g. some metals such as lead and vinyl chloride may 
accumulate permanently in the brain and other organs, and causing permanent damage and 
chronic illness. 
Onset and time-frame of effects 
Onset is rapid from about 1 to 5 minutes from start of inhalation or after between 15 to 20 
inhalations.  After the person has become intoxicated the acute effects will continue to for 
several minutes after inhalation has stopped. If they continue to inhale the substance acute 
intoxication will be extended and may persist for hours after cessation. This is due to the 
generally longer half-lives and time of elimination of inhaled substances, which vary widely. 
Therefore the actual time that a particular chemical remains in the body is not easily predicted.  
Trajectory of effect:  
• Initial stage – excitement, dizziness, exhilaration, nausea, visual and auditory 
hallucinations 
• Early CNS depression – dullness, disorientation, loss of self control and blurred vision 
• Medium CNS depression – drowsiness, lack of muscular co-ordination and slurred 
speech 
• Late CNS depression – Stupor, delirium, epileptic type seizures. 
Assessment and quantification  
Inhalant assessment is needed to determine the pattern of use, type/s and effects of inhalant 
used and clinical symptoms. The main areas to cover are: 
• type of inhalant/s they have recently used 
• amount  of inhalant recently used (can be difficult to quantify) 
o If the person has the inhalant with them you could ask them to show you how 
much remains so as to make an estimate of amount used 
• pattern of inhaling 
• frequency of inhaling during a session  
• method of inhaling  (bagging, sniffing). 
Advise not to use:  
• explain links of inhaling with current problems e.g. illness, injuries, impact on family, 




• provide holistic health care and offer ongoing support through to services on discharge 
e.g. specialist ATOD agency 
• offer ‘shared’ care with other key services  
• offer referral for support and counselling to family.  
You may decide to seek specialist consultation Where appropriate  you can suggest a referral or 
support from a specialist Drug &Alcohol nurse or service to assist the person.  
Before undertaking this assessment it is important to:  
• explain reasons and purpose of assessment 
• explain that this is standard procedure. 
Assessment should include (if possible): 
• risk assessment  - injury, self-harm, suicide 
• medical - physical examination  
• drug use history including all inhalants, alcohol, drugs or other substances 
• laboratory investigations e.g. full blood screen, urine drug screen, ECG if possible 
• psycho-social history 
• brief cognitive assessment e.g. Mini-Mental State Examination 
• further investigations as indicated [151].  
Based on their assessment it can be useful to provide the person feedback, and reassure them 
you are there to assist. Considering their physical and psycho-social needs is important and will 
provide important information that needs to be incorporated into their immediate and after 
care plan.  
 
An integrated team approach will be effective in planning and implementing future support and 
intervention – including the clinical team, Aboriginal workers (if person is Aboriginal), social 
workers and community groups.  Education, harm reduction strategies will also be necessary. 
 
Note: It is important to attend to any statutory obligations concerning the welfare of children 




Table 21: Key domains of clinical assessment of inhalant use 
Type (s) of substance (glue, spray paint (colour), 
petrol, deodorants, cooking spray). Gather 
information about all substances inhaled. 
Method of administration (bagging, sniffing). 
Quantity (if they can – ask in bags, cans, puffs, 
volume or container size if petrol). 
Frequency (daily, number of times per day, 
weekly). 
Pattern (time of day, binge, week-ends). Duration (first use, most recent use, periods of 
abstinence). 
With Whom (alone or in group). Where (at home, the beach). 
Desired effects (what they want from use – not 
same as what they get). 
Effects experienced.  
Unwanted effects experienced (from use, 
include behaviour, how long effects last), 
outcomes of inhaling substances. 
Adverse effects – If yes, is it likely to happen again, 
and if so how and when? 
Recovery Time (how long it take for effect to 
wear off, how long before reusing). 
Other drugs used (list in order of preferences. This 
may include drugs such as cannabis, are they using 
together). 
Changes in use or patterns of use (more then 
when first started / less). 
Symptoms Experienced (if cease or significantly 
reduce use, time frame e.g. 24-48 hours after last 
use). 
Seizures or Passing out (while using or after use, 
ask if using in a group what others may have 
witnessed). 
Accidents while intoxicated (head injuries). 
History of inhaling (first use, any treatment or 
interventions, supported or not supported when 
ceased use, reason for resuming use, or change 
of substance, what helped and what did not). 
Appearance (gait, dress, groom, facial expressions). 
Behaviour (agitation, panicky, eye contact, 
relaxed). 
Speech (rate, volume, rhythm, pressured, 
stammering). 
Mood (how they are feeling – any changes, 
difference when using alone or in group). 
Affect (as observed by you). 
Perception (hallucinations, auditory, tactile, 
gustatory or olfactory. Does this occur when 
using or not using, before use or after starting). 
Concentration, Attention, Orientation (time, place, 
person, span). 
Memory (short and long term). Sleep (continuous, broken, time frame) 
Pro’s and Con’s of Use (this can identify if use is 
for e.g. emotional or physical pain, enjoyment, 
boredom). 
Appetite (increased, decreased, weight loss or gain, 
deliberate or not). 
Energy and Motivation (low, high, too much too 
little). 
Insight (ability to understand their situation). 
Risks (to self, others, from others). What they would like to do about use (stop, cut 
down, continue use, motivation to change) 
Note: Reports of coordination problems in the absence of intoxication, poor memory/problem 




In a ‘nutshell’: 
Inhalant intoxication involves: 
• rapid onset - within seconds 
• time frame of action with 15 –20 breaths with intoxication lasting up to 6 hours 
• resembles alcohol intoxication 
• unpredictable effects  
Note: Consider inhalant use  - if asthma, allergies, hay fever do not  improve with treatment 
and good compliance with medications [152].  
Inhalant intoxication 
(See Section 2.4: Managing intoxication). 
Inhalant intoxication can resemble alcohol intoxication. While individual components of 
compounds can differ in their psycho-active effects, the overall action of most is depression of 
the central nervous system (CNS).   
Initial feelings of exhilaration and euphoria are commonly followed by: 
• tinnitus 




• perceptual dysfunction 
The effects and signs of inhalant intoxication are influenced by the: 
• type of inhalant/s used (variable half-life) 
• dose and time frame of inhalant used  e.g. number of consecutive inhalations and 
length of time inhaling during the episode) 
• method of inhalation 
• age and gender of person 
• physical fitness and general health of person  
• person’s previous experience 
• where they were when inhaling  e.g. alone; with friends; inside or outside a building; in 
a safe place/unsafe place etc). 
Note: If polydrug use has occurred involving alcohol, medicines or other drugs the time to 
recover from acute intoxication can be lengthened. There is also serious risk of drug 




Signs of recent inhalant use:  
• possession of inhalant items e.g. 
aerosol container, cloth, plastic 
bag, balloon   
• dilated pupils 
• odour of inhalant on clothing or 
person  
• tremor  
• slurred speech  
• ataxia 
• poor concentration  
• unstable mood 
• not ‘themselves
Safety issues during acute intoxication   
If a person is still inhaling at this time  
• remain calm – ensure you are safe 
• approach the person slowly and calmly 
• adjust pace of your movements to the person’s 
• stand to their side at a distance  
• speak slowly, quietly using short simple sentences -  in reassuring manner  
• ensure good ventilation e.g. stay outside, open doors and windows 
• do not remove the container  
• ask for matches and or lighters  
• once safe to do so, help person to a safe, low stimulus environment  to avoid over-
stimulation, shock, hallucinations, SSDS 
• keep the person still and quiet –offer small amounts of fluids 
• assess and obtain medical assistance if required  
o arrange transport to medical aid or safe place 
o report their very recent inhalant use, and if possible time of last use 
• if medically safe – wait until person is settled and more at ease then gently persuade 
them to give you the container - do not remove if person is agitated or aggressive 
• remain with the person to ensure their safety and well being 






 (See Section 2.5: Managing overdose). 
Inhalant overdose is rare providing no other solvents, alcohol or drugs have also been used 
(polydrug use).  
Toxicity varies greatly, depending on the substance. Generally, signs are cardiac arrhythmias, 
hypoxia, and neurological impairment. 
Note: Immediate first aid is required. Family and associated should be trained and encouraged 
in recognising and giving emergency care and cardiopulmonary resuscitation wherever possible. 
Inhalant withdrawal  
(See Section 2.6: Nursing management of withdrawal). 
A person who inhales regularly can develop tolerance and become physically dependent [151]. 
As a result Inhalant withdrawal can occur on rapid reduction or cessation of regular use. 
Physical tolerance will decrease after a short period of abstinence (See Glossary for definitions 
of tolerance and dependence). 
Symptoms of inhalant withdrawal:  
• runny eyes or noses  
• rapid heart beat 
• tremor/trembling 
• twitching 




• poor concentration 
• lethargy 
• poor sleep  
• anxiety 
• depression 
• hallucinations [145].  
As there  is no validated scale for measuring inhalant withdrawal symptoms or standardised 
prescribed medication regime,  clinical practice suggests that sound clinical observation, 
monitoring and judgement are required [153]. 
Observations and monitoring inhalant withdrawal require particular attention to: 




• oxygen saturation 
• dehydration 
Arrange immediate medical assessment for:
• toxicity 
• head or other injury  
• infection e.g. pneumonia 
• difficulty breathing   
• unusual behaviours 
• worsening of physical symptoms 
• increasing agitation or anxiety 
• diminishing consciousness  
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• panic [151]. 
Symptomatic medications  
It is also important to provide medications for symptoms such as  headache, muscle pain 
nausea and fever. If pain is not easily relieved seek medical assessment [154]. 
If the person is experiencing anxiety, panic, or is agitated they may be prescribed a 
benzodiazepine providing their medical assessment deems this to be safe.  
Screening and medical investigations  
Particular screening may be required, and  include:  
• cognitive function  
•  nutritional status  
•  mental health status  
Various  medical investigations may be ordered depending on the substance(s) inhaled. These 
may include: 




• CT scan head 
• Blood Urea Nitrogen (BUN) 
• liver function 
• other tests as necessary  
• heavy metal screening 
• drug screen 
• chest x-ray 
• electrolytes 
• MRI head 
• creatinine level 
• anion gap measurement. 
Note: With investigation for serum levels of Nitrous Oxide Vitamin B12 deficiency using the 
Schillings test results are almost always normal. It is suggested that further tests include 
Homocysteine levels which seem more sensitive in detecting vitamin B12 deficiency 
Other interventions 
(See Section 2.3: Early and brief intervention). 
Inhalant Harm Reduction Strategies  
Inform the person who may continue using inhalants to never: 
• inhale in unsafe places e.g.  near water, roads or high places 
•  inhale alone – stay with friends or someone who can offer first aid if something goes 
wrong 
• use inhalants with alcohol  or other drugs 
•  inhale when near flames e.g. near cigarette lighters, lit  matches or candles or open  
campfire  - risk of burns and explosions 
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• spray aerosols directly into the mouth as this can freeze the airways  to lungs, or cause 
choking and asphyxiation 
• inhale from plastic bags over the head – risk of suffocation  
• smoke tobacco or cannabis during or immediately after inhaling – danger of burns 
• drive, ride or operate machinery while intoxicated  
Inform the person who may continue using inhalants to: 
• always inhale outside or in well ventilated areas e.g. near open window/door 
• inhale from paper, cloth bags, rag, or soft drink bottle to help prevent suffocation 
• if ‘chroming’ (inhaling aerosol paint)  – turn can upside down to reduce spilling  residue  
chemicals  on body or clothes  
• take frequent breaks  from inhaling – give time for body and brain  to recover 
• drink plenty of water or non-alcoholic fluids – to prevent dehydration 
• have emergency numbers in pocket or nearby  to get help if needed 
• know how to give first aid to others with you  
If the person comes to the  emergency department it is important to determine what produce 
they have inhaled and the time of last episode. Dangerous drug interactions can occur between 
prescribed medications  that may be required and the inhalant they have used.Maternal 
and Neonatal Care 
Mother and baby at risk from: 
• sudden death 
• organ damage 
• low birth weight for gestational age 
• birth defects  
• intoxication  
• weight loss & poor nutrition  
• miscarriage or death of foetus  
Neo-natal withdrawal  
Withdrawal syndrome is characterised by typical odour (from pulmonary excretion of the 
inhalant), excessive high pitched cry, sleeplessness, hyperactive moro-reflex, tremor, 
Hypotonia, poor feeding [60]. 
Inhalants and Breastfeeding  
• many inhalants can be detected in breast milk e.g. lead, acetone and benzene 
• most inhalants are lipophilic (fat stored), excreted in breast milk and ingested by breast 
fed babies 
• chronic exposure to petrol may decrease breast milk production [60] 
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3.5.3  Anabolic androgenic steroids (AAS) 
Introduction 
Steroids are available illegally on the “black” market and are commonly veterinary 
preparations.  
People who use of anabolic steroid may not consider themselves as illicit drug users and are 
generally older than other illicit drug users.  
Many steroid users are health conscious, some to the point of obsession, and use of other illicit 
drugs is low. Some groups may also use amphetamines or other psychostimulants.  
Steroid users tend not to access health programs and do not receive messages aimed at illicit 
drug users, e.g. harm reduction information related to injecting drugs, even though this group is 
at risk [155]. 
Counterfeit steroids (AASs) are sold from time-to-time, with variable dose, constituents, quality 
and safety. 
Steroid users may have a distorted ‘body image’, often described as a reverse anorexia, where 
they see themselves as underweight [156]. 
Steroid users may use AASs in combination with other medical drugs, e.g. growth hormones, 
reproductive hormones, diuretics, beta two agonists, thyroxin, insulin, creatinine monohydrate. 
Oestrogen antagonists may be used to reduce unwanted side effects, and medical indications 
for the use of AAS are limited [155]. 
Definition 
AASs are synthetically modified derivatives of testosterone available in oral or parenteral form. 
Anabolic substances are those that have the ability to synthesise body tissue and increase 
muscle mass and/or strength. Androgenic substances promote the development of male sexual 
characteristics.  
Purpose for use 
Steroids may be used to enhance performance in sport, enhance physique in various 
occupations, or enhance body image. People use steroids for many reasons. These include: 
• pursuit of body excellence 
• improved athletic performance  
• capacity to train at high levels—high intensity workouts with rapid recovery, diminished 
fatigue 
• increased strength 
• lean muscle mass 
• heightened libido 
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• greater self confidence 
• a sense of well being 
• sexual arousal 
• social acceptability amongst peers [106, 157, 158]. 
Population groups identified as possibly using steroids include:  
• body builders and power lifters 
• track and field athletes and swimmers 
• martial arts athletes 
• motorcyclists  
• actors, models 
• male sex workers  
• manual labourers  
• adolescent males 
• gymnasium users 
• footballers and other sportsmen and 
women 
• occupational groups (e.g. 
security/crowd controllers, firemen, 
army personnel, police) 
• amphetamine or heroin users wishing 
to regain weight loss as a result of 
their other A&OD use [151, 155, 156]. 
Forms of anabolic steroids 
Pharmaceutical steroids are prepared for human use and are only available on prescription. 
Steroids with high anabolic effects are preferred, and steroids with androgenic effects should 
be avoided. 
Water based, e.g. Stanazol 
The water and steroid is rapidly absorbed and more rapidly excreted then oil-based steroids, 
may have to be administered twice a week, and is often used with a 23-gauge or 21-gauge 
needle, as the powder in the suspension can clog a narrower needle. 
Oil based, e.g. Deca 50 
Oil-based preparations take longer to be absorbed and take effect, and can be effective for 
longer than water-based steroids, e.g. two to three weeks. Some people may use them more 
frequently than every two to three weeks. Oil-based steroids are usually used with a 25-gauge 
needle. 
Tablets, e.g. Anapolon® 50 
The effects of this form of steroid are short-acting, and are often taken twice a day.  
Tablets are generally associated with more adverse side effects due to the pharmacokinetics of 
this drug the ‘first pass’ is through the digestive system, where the steroid may lose some of its 
potency, and can cause liver damage.  
Some steroid tablets have a coating that is designed to prevent it from being destroyed by 
acidity in the stomach, and these are categorised as C-17 alphalkylated and the coating used is 
toxic to the liver.  
Anapolon® may be more toxic than injectable steroids but this is as yet unclear. 
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Administration of AAS  
There is a common practice amongst steroid users of drawing up the drug from the same vial, 
thus increasing their exposure to blood-borne viruses. This occurs in a context of disbelief 
amongst this group who tend to perceive themselves as different from other groups of drug 
users and therefore ‘immune’ [106]. 
There is no scientific evidence demonstrating the superiority in effect or safety of one form of 
administration over another, such as oral versus injectable. The ‘evidence’ that exists appears 
to be anecdotal in origin. 
Common terms relating to patterns of AAS use 
Cycling: Steroids are commonly used in time cycles of between six to 12 weeks, often with a 
break of an equal period of time in between each cycle.  
Fast tapering: Starting on a mid-range dosage and reducing to nothing over four to six weeks. A 
break of four to six weeks is usually taken before the cycle is repeated. 
Long increasing cycle: Commencing with one third (1/3) of the dose, the person plans to finish 
the cycle with, then they increase the dose slowly over 10-14 weeks. This longer cycle is 
claimed to produce large muscle mass gains, but some users report that it produces the most 
unwanted side effects. 
Plateauing: This is similar to the tolerance phenomena where the CNS has adapted and  larger 
doses are required to achieve the same results/drug effect. 
Pyramid cycle: Increasing the dose over four to five weeks, then decreasing over the next four 
to five weeks. Having eight weeks rest before repeating the cycle. 
Shot-gunning: Using one off doses. 
Stacking: Using more than one type of steroid at a time.  
Tapering: Initiating a high dose followed by gradual reduction. 
Therapeutic uses of AAS 
AASs facilitate the development and repair of muscle tissue and the androgenic effects relate to 
the development of male sexual characteristics [159]. 
There are a number of steroidal drugs that are scheduled S4 for prescription for medical use. 
These include: 
• treatment of male gonadal failure, proven gonadotrophin deficiency and hypogonadism 
• androgen therapy for refractory anaemia’s, wasting as a result of malignancies 
(including radiation therapy), or other illnesses (e.g. AIDS, burns, major trauma, chronic 





Effects of AAS use 
Risks associated with AAS use 
Risks may increase with the type of steroid used, dose, duration of use, route of administration, 
and the number and types of steroids and other drugs used simultaneously. The physical and 
psychological status of person is also influential. There are a number of direct risks associated 
with the use of anabolic steroids. These include: 
• the range of physiological responses to abnormal hormone levels 
• the risks related to the route of administration (e.g. exposure to blood-borne viruses, 
and bacterial infections resulting in abscesses at the injection site, cellulitis and 
endocarditis due to unsafe injecting practices) 
• unsafe intramuscular injection techniques 
• problems arising from using supplies for veterinary use only and the unknown effects 
on the human male or female body 
• unreliable labelling and accuracy, purity, dose, ingredients and sterility of the drug 
• not checking drug expiry dates 
• combining anabolic steroids with other drugs (e.g. psychostimulants, diuretics or other 
performance-enhancing drugs) 
• not practicing safe sex (condoms). 
Wanted effects of AAS use 
All drug use is functional as there are always reasons why people take drugs, including AAS [1]. 
These can include wanting to: 
• look better (increase self image) 
• increase muscle bulk and strength 
• alter mental state to feel more powerful/assertive 
• prevent muscle breakdown related to increase training or need to be more competitive 
• increase appetite [161]. 
Unwanted/adverse effects of AAS use 
Adverse effects may be exaggerated by those wanting to deter people from using AAS. Care 
should be taken to avoid this when discussing the possible adverse effects with people [156]. 
However it is important that people have current research-based information from which to 




These factors need attention: 
Musculo-skeletal 
• premature closing of the epiphysis of the long bones resulting in stunted growth in 
adolescents 
• tendon or ligament damage. 
Reproductive 
• reduction in testosterone and sperm production 
• adenocarcinoma of the prostate 
• adenocarcinoma of the colon 
• Wilm’s tumour 
• decreased breast size and altered fat distribution in women 
• hairline recession in men 
• male pattern baldness in women—irreversible 
• transient infertility 
• increased libido (at least initially, or a reduction in libido) 
• impotence in men (usually reversible) 
• involuntary and long-lasting erection (can be days) 
• testicular atrophy (usually reversible) 
• hirsutism in men and women 
• gynaecomastia in men 
• irregularities or cessation of menstrual periods, infertility (usually reversible) 
• clitoral enlargement (usually permanent and not reversible) 
• deepening voice in women (permanent). 
Cardiovascular 
• hypokalaemic-induced arrhythmia due to concomitant diuretic use 
• hypertension 
• oedema 
• salt and fluid retention with bloating of face and elsewhere 
• increased low density lipid proteins and decreased high density lipid proteins, which 




Psychological and behavioural  
• Causality is unclear but the following effects have been described: 
• increased aggressiveness 
• increased irritability 




• psychological dependence 
• increased confidence in some, and depression and lowered mood in others [158, 160, 
162].  
Endocrine 
• insulin resistance or impaired glucose tolerance 
• diabetes. 
Liver 
• liver damage, e.g. jaundice, cirrhosis, tumours 
• reversible liver function test abnormalities. 
Other 
• immunological changes 
• male characteristics in unborn female foetus 
• sleeping difficulties 
• abscesses—bacterial infection from unsafe injecting or if too short a needle is used 
• acne—permanent scarring possible 
• more frequent colds 
• foetal abnormalities. 
Uncertain or debated harmful effects include: 
• aggression ‘roid rage’ 
• cancer of the liver, kidneys, prostate 
• hypertension 




Possible social effects 
• breakdown of relationships or legal problems due to aggression, moodiness, sexual 
dysfunction, obsession with body building affecting the partner 
• legal issues arising from using/dealing/supplying illicit drugs  
• loss of career if a sportsperson or employed in particular profession/job. 
Myths and misinformation 
A number of myths exist regarding AAS use, and the methods of administration that apparently 
work better, none of which are based on scientific evidence. 
Research evidence on the best approach to taking anabolic steroids for positive effects is scant. 
There are a range of issues and perspectives that appear to guide people in their choice of 
steroid, dosing regime, and route of administration. Others may claim that: 
• there is an effective dose that is below that which causes unwanted side effects 
• if there are no side effects there will be no primary or long term effects, e.g. anabolic 
gains 
• that a ‘flat’ dosing regime, accompanied by abrupt cessation, causes the least 
disruption to normal body function, and allows a return to normality more rapidly 
• the pyramid cycle is the safest as the gradual increase in dose allows the body to adjust 
to increasing doses, and the tapering dose in the second half of the cycle allows the 
body to readjust gently thus avoiding a cessation reaction. It should be noted that many 
steroids are metabolised and eliminated slowly from the body so there is an inbuilt 
taper in blood levels even if administration of the substance is suddenly ceased 
• higher doses work better 
• using more than one anabolic steroid is better 
• using  steroids will prolong life 
• injecting into muscle rather than a vein reduces the likelihood of contracting a blood-
borne virus infection 
• one six week cycle will achieve the goal [159]. 
AAS and other drug interactions 
The concomitant use of steroids with other drugs is not recommended. These are examples of 
AAS polydrug interactions. 
Stimulant effects are similar to those caused by steroids—although physiological processes are 
different. When combined there may be: 
• increased heart rate 




These may be dangerous and can be fatal. 
Cocaine causes similar effects to amphetamines although for a shorter period of time.  
When combined there may be: 
• increased heart rate, blood pressure and body temperature 
• euphoria.  
When used together steroids and cocaine can: 
• mask pain 
• increased pressure on the heart leading to convulsions and cardiac arrest  
• provoke feelings of aggressiveness and competitiveness 
• increase libido. 
Psychological depression may occur when ceasing combined use of cocaine with steroids. 
CNS depressant drugs 
Use of CNS depressants e.g. benzodiazepines, opiates, alcohol can: 
• reduce responsiveness to pain that can cause athletes to rupture muscles and damage 
the skeletal system. 
Use of steroids with diuretics can: 
• alter the sodium/potassium balance in the body. This may cause, exhaustion, kidney 
damage, muscle weakness, cardiac arrest and death 
• increase sodium levels and cause fluid retention.  
Nolviadex (Tamoxifen): An anti-oestrogen drug that is used concurrently with AAS to prevent 
the effects of oestrogen metabolites which result in steroids being aromatised. It may not be 
reliably effective in preventing gynaecomastia because there may be a number of physiological 
mechanisms that cause this disorder. Women using Nolviadex with steroids can experience 
menopausal symptoms. 
Clonidine: If used in combination with AAS there is an increased risk of kidney and liver disease 
and impotence. 
Insulin: Does not assist in an increase in muscle mass and definition. There have been reports 
of several insulin-related deaths in Australia and other parts of the world due to the ill informed 
belief that insulin, when used in combination with AAS, will increase muscle mass and definition 
[160]. 
Dependence 
Generally physical dependence (neuro-adaption) does not appear to occur with steroid use. 
There are some reports of cases of psychological dependence, but this is so far controversial 
[158]. There is some evidence that particular people may become dependent on steroids, as 




For example, those users whose: 
• continued use has become more important than family, friends, health or work 
• fear prevents them from stopping due to a need to maintain strength or size gains 
despite obvious harmful consequences [160].  
Assessment and quantification 
• Ask the person about type of 
steroid/s—include multiple steroid 
use  
• type of AAS—number and type taken 
simultaneously 
• doses used 
• administration regime (e.g. tablets or 
injecting—ask size of needle)  
• periods of abstinence or ‘spells’  
• adverse effects 
• time of last dose 
• when first commenced or 
recommenced steroid use  
• beliefs about use  
• pattern and duration of use (e.g. 
cycling) 
• wanted effects (reason for using) 
• risk factors (e.g. unsafe injecting 
techniques such as sharing of steroid 
solution and injecting equipment, 
skin hygiene, poly drug use such as 
multiple AAS and/or other drugs). 
Nursing management of AAS use 
• nursing observations for drug effects and side effects 
• provide supportive care (psychological effects) 
• provide supportive nursing care in relation to minimising and relieving unwanted 
physical side effects 
• attend to psychological issues 
• management of behavioural issues (e.g. aggression)  
• provide harm reduction information and strategies. 
Harm reduction information AAS use 
Avoid sensationalism and provide factual and practical information. Advise the person that: 
• AAS use cannot be considered risk-free for anyone 
• it is best not to ever use/to cease use 
• there can be temporary and permanent adverse effects 
• seek advice on specific training regimes and diet as alternatives to steroid use is 
available 
• never purchase products as counterfeit steroids are sold. Authentic steroids are sealed 
in the original packaging with a clear ‘use by date’. If the seal is damaged or removed, 
or there is no label or the label may be a photocopy, this is likely not authentic 
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• contents may be contaminated or replaced with other substances 
• monitor health in consultation with a general practitioner 
• use of steroids in high doses is dangerous. Supervision and advice from a medical 
doctor may assist in reducing AAS risks and harms 
• safety and effectiveness of oral versus injectable steroids is questionable due to liver 
metabolism 
• there is  information about AAS  effects and possible adverse effects 
• non-prescribed use of steroids is not recommended, risky and illegal. 
• it is wise to avoid use of AAS with other drugs can result in drug interactions  
• to have blood tests prior to an AAS cycle and on completion of AAS cycle to screen for 
liver, kidneys and heart function. Other pathology tests may be useful, e.g. serum 
electrolytes, cholesterol, blood pressure, oedema, and blood-borne viruses (if at risk). 
The person needs careful pre-test and post-test counselling 
Note: pathology tests of doubtful benefits include full blood count—except where specifically 
indicated by clinical history, and gonadotrophin, oestrogen and testosterone levels 
• they need to always use new needles and syringes and other injecting equipment such 
as swabs 
• they should to never share steroid solution—use your own 
• they should  never share any injecting equipment 
• using safe injecting techniques is safest —never inject a steroid into a vein or artery 
(intramuscular injection should be used) as oil-based steroids can cause clots if injected 
into an artery 
• using steroids in combination with diuretics ‘water pills’ is risky. This can be fatal due to 
marked electrolyte disturbances 
• avoiding use of higher doses as these are unlikely to achieve greater 
performance/appearance or other enhancing effects due to saturation of steroid 
receptors—dose should be kept to a minimum 
• if side effects are experienced, cease use immediately and do not treat the effects with 
other drugs, seek medical advice 
• using any tablet or substance that you cannot confidently identify is very risky [156, 




The person must be advised not to use insulin. However, if they are determined to use insulin 
give them the following advice to reduce the risks: 
• consider using a natural method of raising the blood insulin levels during workouts (e.g. 
consuming glucose containing fluids at intervals during exercise) which may have a 
protein sparing effect, help maintain blood glucose and insulin levels 
• always use insulin in the presence of another person (who will stay for the time of 
insulin effect not only at the time of injection) who knows the risks of insulin use and 
can administer first aid 
• always use clean injecting equipment and technique—inject subcutaneously into the 
abdomen or outer thigh 
• rotate injecting sites to protect tissues 
• always use short-acting insulin 
• use human insulin not animal insulin 
• take care in measuring the dose of insulin as it is very concentrated 
• do not believe that more insulin is better 
• only use once a day, immediately before breakfast 
• consult an experienced professional sports nutritionist to discuss the use of insulin 
• use low glycaemic index foods at regular intervals throughout the day [156, 157, 160]. 
Cycle completion 
There is a period at the completion of an AAS cycle when steroid users experience a temporary 
‘shut down’, where synthetic testosterone is no longer available and their own body is not yet 
producing testosterone (or is doing so at a greatly reduced rate).  
This results in loss of muscle size and weight, reduced strength, loss of lean muscle, and gain in 
body fat. As steroids relieve joint pain, joint pain may be experienced. The person may feel 
small, fat, weak, mentally depressed and have general aches and pains.  
These factors and negative comments from others may encourage the person to recommence 
use.  
Ceasing AAS use 
Most wanted and unwanted effects are reversible with cessation of use. 
There is no need to taper dose to cease use, however idiosyncratic symptoms due to cessation 
can arise (e.g. mood swings and depression) which should be monitored and if necessary 
treated. 
As with people who use other drugs, AAS users may find it difficult to cease their use. They 
need to be educated and supported in using as safely as possible, and encouraged to consider 




Signs and symptoms of cessation of AAS use 
Some users report that length of time they have been using steroids and doses used affects 
how they feel when they cease use. 
There is evidence that if a person has been using steroids for a long time at high doses, it takes 
up to four months or more for the body’s natural testosterone production to return to normal. 
However the precise relationship between dose, duration of use and symptoms on cessation 
remains unclear. When a steroid cycle is completed the effects of abnormally low testosterone 
levels may be experienced.  
These include: 
• mood swings 
• rage 
• lethargy 
• weight loss 
• decrease in libido [156, 160] 
• violent behaviour 
• depression and suicidal ideation 
• decreased appetite 
• decrease in physical strength. 
Some people who use steroids may have damage to testosterone production and need 
hormone replacement therapy [163]. 
Maternal and neonatal care 
Steroids can be teratogenic and masculinise female foetuses. Women should be advised not to 
use before, during or after pregnancy or while breastfeeding. 
For further information on steroid use go to:  
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Appendix 1: Alcohol Use Disorders Identification Test (AUDIT) 
  
D0718 - 8/03 - P1 of 2
The guide above contains examples of one standard drink.
Introduction
Because alcohol use can affect health and interfere with certain medications and treatments, it is important that we ask you some questions about your use
of alcohol.  Your answers will remain confidential, so please be as accurate as possible.  Try to answer the questions in terms of ‘standard drinks’.  Please
ask for clarification if required.
Please tick the response that best fits your drinking.
1. How often do you have a drink containing alcohol?
Never Monthly orless
2 - 4 times a
month




2. How many standard drinks do you have on a typical
day when you are drinking?
3. How often do you have six or more standard drinks
on one occasion ?
4. How often during the last year have you found that




1 or 2 3 or 4 5 or 6 7 to 9 10 or more
Never Less thanmonthly Monthly Weekly
Daily or
almost daily
5. How often during the last year have you failed to do
what was normally expected of you because of
drinking?
6. How often during the last year have you needed a
first drink in the morning to get yourself going after
a heavy drinking session?
7. How often during the last year have you had a feeling
of guilt or remorse after drinking?
8. How often during the last year have you been unable
to remember what happened the night before because
you had been drinking?
No Yes, but not in thelast year
Yes, during the last
year
9. Have you or someone else been injured because of
your drinking?
10. Has a relative, friend, doctor, or other health care
worker been concerned about your drinking or
suggested you cut down?
Do you think you presently have a problem with drinking?
No ProbablyNot Unsure Possibly Definitely
In the next 3 months, how difficult would you find it to
cut down or stop drinking?



























A full strength can or stubbie contains one and a half standard drinks.
AUDIT Questions
D0718 - 8/03 - P2 of 2
How to score and interpret the AUDIT
The World Health Organization’s Alcohol Use Disorders Identification Test (AUDIT) is a very reliable and simple screening tool which is sensitive to early
detection of risky and high risk (or hazardous and harmful) drinking.  It has three questions on alcohol consumption (1 to 3), three questions on drinking
behaviour and dependence (4 to 6) and four questions on the consequences or problems related to drinking (7 to 10).
The Supplementary Questions do not belong to the AUDIT and are not scored.  They provide useful clinical information associated with the client’s
perception of whether they have an alcohol problem and their confidence that change is possible in the short-term.  They act as an indication of the degree
of intervention required and provide a link to counselling or brief intervention following feedback of the AUDIT score to the client.
Scoring the AUDIT
• The columns in the AUDIT are scored from left to right.
• Questions 1 to 8 are scored on a five-point scale from 0, 1, 2, 3, and 4.
• Questions 9 & 10 are scored on a three -point scale from 0, 2 and 4.
• Record the score for each question in the “score” column on the right, including a zero for questions 2 to 8 if ‘skipped’.
• Record a total score in the “TOTAL” box at the bottom of the column.  The maximum score is 40.
Consumption score
Add up questions 1 to 3 and place this sub-score in the adjacent single box in the far right column (maximum score possible = 12).  A score of 6 or 7
may indicate a risk of alcohol-related harm, even if this is also the total score for the AUDIT (e.g. consumption could be over the recommended weekly intake
of 28 for men and 14 for females in the absence of scoring on any other questions).  Drinking may also take place in dangerous situations (e.g. driving,
fishing/boating).  Scores of 6 to 7 may also indicate potential harm for those groups more susceptible to the effects of alcohol, such as young people, women,
the elderly, people with mental health problems and people on medication.  Further inquiry may reveal the necessity for harm reduction advice.
Dependence score
Add up questions 4 to 6 and place this sub-score in the adjacent single box in the far right column (maximum score possible = 12).  In addition to the
total AUDIT score, a secondary ‘dependence’ score of 4 or more as a subtotal of questions 4 to 6, suggests the possibility of alcohol dependence (and
therefore the need for more intensive intervention if further assessment confirms dependence).
Alcohol-related problems score
Any scoring on questions 7 to 10 warrants further investigation to determine whether the problem is of current concern and requires intervention.
AUDIT Total score Dependence score Risk level Possible Interventions
0 - 7 below 4 Low-risk
8 - 15 below 4 Risky or hazardous level.
Moderate risk of harm.  May include
some clients currently experiencing
harm (especially those who have
minimised their reported intake and
problems).
• Brief Intervention
- feedback of AUDIT and harm reduction advice may be 
sufficient
Ideally also:
- setting goals and limits
- a motivational interview
- self-monitoring of drinking
- use of “The Right Mix” self-help guide
• Counselling may be required.4 or more Assess for dependency
16 - 19 below 4 High-risk or harmful level.
Drinking that will eventually result
in harm, if not already doing so.
May be dependent.
• Brief Intervention (all components) is a minimum requirement.
• Assessment for more intensive intervention.
• Counselling using CBT principles and motivational interviewing
in individual sessions and/or in groups.
• Follow-up and referral where necessary.
4 or more Assess for dependence
20 or more below 4 High-risk
Definite harm, also likely to be
alcohol dependent.  Assess for
dependence.
• Further assessement preferably including family and significant
others.
• More intensive counselling and/or group program.
• Consider referral to medical or specialist services for withdrawal
management.
• Pharmacotherapy to manage cravings.
• Relapse prevention, longer-term follow-up and support.
4 or more Almost certainly dependent.
Assess for dependency.
• Use ‘Right Mix’ materials to reinforce low-risk drinking, 
particularly for those who previously had alcohol problems 
or whose circumstances may change.
• Harm reduction advice may be appropriate for those in 
susceptible groups (see ‘Consumption Score’ above).
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Appendix 2A: The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)  
  
  HO6: Clinical Form 
WHO-ASSIST V3.1 for health professionals Aust   March 2010 
WHO  -  ASSIST V3.1  
 
 
CLINICIAN ID    CLINIC  
 
CLIENT ID OR NAME   DATE       
 
INTRODUCTION (Please read to client.  Can be adapted for local circumstances ) 
 
The following questions ask about your experience of using alcohol, tobacco products and other 
drugs across your lifetime and in the past three months.  These substances can be smoked, 
swallowed, snorted, inhaled, injected or taken in the form of pills (show response card). 
Some of the substances listed might have been prescribed to you by a doctor (such as sedatives, 
pain medications or amphetamine-based products).  For this interview, medications that are used 
as prescribed by your doctor are not recorded.  However, if you have taken such medications for 
reasons other than prescription, or taken them more frequently, or at higher doses than 
prescribed, please let me know.   
While some of the questions that will be asked are about your use of drugs other than alcohol or 
tobacco, please be assured that information on such use will be treated as strictly confidential. 
 
NOTE: BEFORE ASKING QUESTIONS, GIVE ASSIST RESPONSE CARD TO CLIENT 
 
Question 1 (please circle the response for each category of substance)· 
In your life, which of the following substances have you 
ever used?  (NON-MEDICAL USE ONLY)   
a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) No Yes 
b.  Alcoholic beverages (beer, wine, spirits, etc.) No Yes 
c.  Cannabis (marijuana, pot, grass, hash, etc.) No Yes 
d.  Cocaine (coke, crack, etc.) No Yes 
e. Amphetamine type stimulants (speed, meth, ecstasy, ice etc.) No Yes 
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) No Yes 
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, 
Temazepam, Normison, Stilnox, etc.) No Yes 
h.  Hallucinogens (LSD, acid, mushrooms, trips, Ketamine, etc.) No Yes 
i.  Opioids (heroin, morphine, methadone, opium, 
Buprenorphine, codeine, etc.) No Yes 
j.  Other - specify: No Yes 
 
Probe if all answers are negative: 
“Not even when you were in school?” 
If "No" to all items, stop interview. 
If "Yes" to any of these items, ask 
Question 2 for each substance ever used. 
 
  HO6: Clinical Form 
WHO-ASSIST V3.1 for health professionals Aust   March 2010 
 
Question 2 
In the past three months, how often have you used 
the substances you mentioned (FIRST DRUG, 






































a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 2 3 4 6 
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 2 3 4 6 
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 2 3 4 6 
d.  Cocaine (coke, crack, etc.) 0 2 3 4 6 
e. Amphetamine type stimulants (speed, meth, ecstasy, ice etc.) 0 2 3 4 6 
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 2 3 4 6 
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, 
Temazepam, Normison, Stilnox, etc.) 0 2 3 4 6 
h.  Hallucinogens (LSD, acid, mushrooms, trips, Ketamine, etc.) 0 2 3 4 6 
i.  Opioids (heroin, morphine, methadone, opium, 
Buprenorphine, codeine, etc.) 0 2 3 4 6 
j.  Other - specify: 0 2 3 4 6 
 
 
If "Never" to all items in Question 2, skip to Question 6. 
 
If any substances in Question 2 were used in the previous three months, continue with 





During the past three months, how often have you 
had a strong desire or urge to use (FIRST DRUG, 






































a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 3 4 5 6 
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 3 4 5 6 
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 3 4 5 6 
d.  Cocaine (coke, crack, etc.) 0 3 4 5 6 
e. Amphetamine type stimulants (speed, meth, ecstasy, ice etc.) 0 3 4 5 6 
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 3 4 5 6 
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, 
Temazepam, Normison, Stilnox, etc.) 0 3 4 5 6 
h.  Hallucinogens (LSD, acid, mushrooms, trips, Ketamine, etc.) 0 3 4 5 6 
i.  Opioids (heroin, morphine, methadone, opium, 
Buprenorphine, codeine, etc.) 0 3 4 5 6 
j.  Other - specify: 0 3 4 5 6 
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Question 4 
During the past three months, how often has your 
use of (FIRST DRUG, SECOND DRUG, ETC) 






































a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 4 5 6 7 
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 4 5 6 7 
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 4 5 6 7 
d.  Cocaine (coke, crack, etc.) 0 4 5 6 7 
e. Amphetamine type stimulants (speed, meth, ecstasy, ice etc.) 0 4 5 6 7 
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 4 5 6 7 
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, 
Temazepam, Normison, Stilnox, etc.) 0 4 5 6 7 
h.  Hallucinogens (LSD, acid, mushrooms, trips, Ketamine, etc.) 0 4 5 6 7 
i.  Opioids (heroin, morphine, methadone, opium, 
Buprenorphine, codeine, etc.) 0 4 5 6 7 





During the past three months, how often have you failed 
to do what was normally expected of you because of 






































a.  Tobacco products      
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 5 6 7 8 
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 5 6 7 8 
d.  Cocaine (coke, crack, etc.) 0 5 6 7 8 
e. Amphetamine type stimulants (speed, meth, ecstasy, ice etc.) 0 5 6 7 8 
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 5 6 7 8 
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, 
Temazepam, Normison, Stilnox, etc.) 0 5 6 7 8 
h.  Hallucinogens (LSD, acid, mushrooms, trips, Ketamine, etc.) 0 5 6 7 8 
i.  Opioids (heroin, morphine, methadone, opium, 
Buprenorphine, codeine, etc.) 0 5 6 7 8 
j.  Other - specify: 0 5 6 7 8 
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Ask Questions 6 & 7 for all substances ever used  (i.e. those endorsed in Question 1) 
 
Question 6 
Has a friend or relative or anyone else ever 
expressed concern about your use of 











































a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 6 3 
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 6 3 
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 6 3 
d.  Cocaine (coke, crack, etc.) 0 6 3 
e. Amphetamine type stimulants (speed, meth, ecstasy, ice etc.) 0 6 3 
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 6 3 
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, 
Temazepam, Normison, Stilnox, etc.) 0 6 3 
h.  Hallucinogens (LSD, acid, mushrooms, trips, Ketamine, etc.) 0 6 3 
i.  Opioids (heroin, morphine, methadone, opium, 
Buprenorphine, codeine, etc.) 0 6 3 





Have you ever tried to cut down on using (FIRST DRUG, 











































a.  Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 0 6 3 
b.  Alcoholic beverages (beer, wine, spirits, etc.) 0 6 3 
c.  Cannabis (marijuana, pot, grass, hash, etc.) 0 6 3 
d.  Cocaine (coke, crack, etc.) 0 6 3 
e. Amphetamine type stimulants (speed, meth, ecstasy, ice etc.) 0 6 3 
f.  Inhalants (nitrous, glue, petrol, paint thinner, etc.) 0 6 3 
g.  Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, 
Temazepam, Normison, Stilnox, etc.) 0 6 3 
h.  Hallucinogens (LSD, acid, mushrooms, trips, Ketamine, etc.) 0 6 3 
i.  Opioids (heroin, morphine, methadone, opium, Buprenorphine, 
codeine, etc.) 0 6 3 
j.  Other – specify: 0 6 3 
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Have you ever used any drug by injection? 
(NON-MEDICAL USE ONLY) * * * 
 
IMPORTANT NOTE: 
Clients who have injected drugs in the last 3 months should be asked about their pattern of 
injecting during this period, to determine their risk levels and the best course of intervention. 
PATTERN OF INJECTING  INTERVENTION GUIDELINES 
4 days per month, on average, over 
the last 3 months (or less) 
 
Brief Intervention including the “Risks 
of Injecting” card 
    
More than 4 days per month, on 
average, over the last 3 months 
 
Further assessment and more 
intensive treatment*  
 
HOW TO CALCULATE A SPECIFIC SUBSTANCE INVOLVEMENT SCORE. 
 
For each substance (labelled a. to j.) add up the scores received for questions 2 through 7 inclusive.  Do not 
include the results from either Q1 or Q8 in this score.  For example, a score for cannabis would be calculated 
as: Q2c + Q3c + Q4c + Q5c + Q6c + Q7c 
 
Note that Q5 for tobacco is not coded, and is calculated as: Q2a + Q3a + Q4a + Q6a + Q7a 
 











a. tobacco  0 - 3 4 - 26 27+ 
b. alcohol  0 - 10 11 - 26 27+ 
c. cannabis  0 - 3 4 - 26 27+ 
d. cocaine  0 - 3 4 - 26 27+ 
e. amphetamines   0 - 3 4 - 26 27+ 
f. inhalants  0 - 3 4 - 26 27+ 
g. sedatives  0 - 3 4 - 26 27+ 
h. hallucinogens  0 - 3 4 - 26 27+ 
i. opioids  0 - 3 4 - 26 27+ 
j. other drugs  0 - 3 4 - 26 27+ 
 
Now use ASSIST FEEDBACK REPORT CARD to give client feedback about their 
risk scores as part of the brief intervention. 
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Appendix 2B: (ASSIST) Response Card for Client 
  
HO7: Clinical Form 
Australian version March 2010 
WHO ASSIST V3.0/3.1   RESPONSE CARD (FOR CLIENT) 
 
SUBSTANCES 
a. Tobacco products (cigarettes, chewing tobacco, cigars, etc.) 
b. Alcoholic beverages (beer, wine, spirits, etc.) 
c. Cannabis (marijuana, dope, pot, grass, hash, etc.) 
d. Cocaine (coke, crack, etc.) 
e. Amphetamine-type stimulants (speed, ecstasy, meth, ice, paste, crystal, base,       
diet pills, etc.) 
f. Inhalants (nitrous, NOS, glue, petrol, sprays, paint thinner, amyl, etc.) 
g. Sedatives or Sleeping Pills (Valium, Serepax, Rohypnol, Normison, diazepam, 
temazepam, etc.) 
h. Hallucinogens (LSD, acid, mushrooms, trips, Ketamine, etc.) 
i. Opioids (heroin, opium, morphine, methadone, codeine, etc.) 
j. Other - specify: 
 
 
Response Card (ASSIST Questions 2 – 5) 
 
Never: not used in the last 3 months. 
 
Once or twice: 1 to 2 times in the last 3 months. 
 
Monthly: average of 1 to 3 times per month over the last 3 months. 
 
Weekly: 1 to 4 times per week. 
 
Daily or almost daily: 5 to 7 days per week. 
 




Yes, but not in the past 3 months 
 




Appendix 2C: (ASSIST) Feedback Report Card for Client   
HO8: Clinical Form 
WHO ASSIST V3.0/3.1 Feedback Report Card Aust                          March 2010 
 
WHO ASSIST V3.0/3.1 Feedback Report Card (for Clients) 
 
 




Substance Score Risk Level 
 
a. Tobacco products  
 0-3 Low  
4-26 Moderate  
27+ High 
 
b. Alcoholic Beverages  




c. Cannabis  
 0-3 Low  
4-26    Moderate  
27+ High 
 
d. Cocaine  
 0-3 Low  
4-26    Moderate  
27+ High 
 
e. Amphetamine type stimulants  
 0-3 Low  
4-26    Moderate  
27+ High 
 
f. Inhalants  
 0-3 Low  
4-26    Moderate  
27+ High 
 
g. Sedatives or Sleeping Pills  
 0-3 Low  
4-26    Moderate  
27+ High 
 
h. Hallucinogens  
 0-3 Low  
4-26    Moderate  
27+ High 
 
i. Opioids  
 0-3 Low  
4-26    Moderate  
27+ High 
 
j. Other - specify 
 0-3 Low  
4-26    Moderate  
27+ High 
 
What do your scores mean? 
Low: You are at low risk of health and other problems from your current pattern of use. 
 
Moderate: You are at risk of health and other problems from your current pattern of substance 
use, both now and also in the future if you continue the same pattern of use. 
 
High: You are at high risk of experiencing severe problems (health, social, financial, legal, 
relationship) as a result of your current pattern of use and could be dependent. 
Are you concerned about your substance use? 
HO8: Clinical Form 





Your risk of experiencing these harms is:……… 
 
Regular tobacco smoking is associated with: 
Low     Moderate     High 
 (tick one) 
 
 Premature ageing, wrinkling of the skin 
 Respiratory infections and asthma 
 High blood pressure, diabetes 
 Respiratory infections, allergies and asthma in children of smokers 
 Miscarriage, premature labour and low birth weight babies for pregnant women 
 Kidney disease 
 Chronic obstructive airways disease 
 Heart disease, stroke, vascular disease 






Your risk of experiencing these harms is:……… 
 
Regular excessive alcohol use is associated with: 
Low     Moderate     High 
 (tick one) 
 Hangovers,  aggressive and violent behaviour,  accidents and injury 
 Reduced sexual performance,  premature ageing 
 Digestive problems,  ulcers,  inflammation of the pancreas,  high blood pressure 
 Anxiety and depression,  relationship difficulties,  financial and work problems 
 Difficulty remembering things and solving problems 
 Deformities and brain damage in babies of pregnant women 
 Stroke,  permanent brain injury,  muscle and nerve damage 
 Liver disease,  pancreas disease 






Your risk of experiencing these harms is:…… 
 
Regular use of cannabis is associated with: 
Low     Moderate     High 
 (tick one) 
 Problems with attention and motivation  
 Anxiety, paranoia, panic, depression 
 Decreased memory and problem solving ability 
 High blood pressure 
 Asthma, bronchitis 
 Psychosis in those with a personal or family history of schizophrenia 
 Heart disease and chronic obstructive airways disease 
 Cancers 
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Your risk of experiencing these harms is:…. 
 
Regular use of cocaine is associated with: 
Low     Moderate     High 
 (tick one) 
 Difficulty sleeping,  heart racing,  headaches,  weight loss 
 Numbness,  tingling,  clammy skin, skin scratching or picking 
 Accidents and injury,  financial problems 
 Irrational thoughts 
 Mood swings - anxiety, depression, mania 
 Aggression and paranoia 
 Intense craving, stress from the lifestyle 
 Psychosis after repeated use of high doses 







Your risk of experiencing these harms is:……. 
 
Regular use of amphetamine type stimulants is 
associated with: 
Low     Moderate     High 
 (tick one) 
 Difficulty sleeping,  loss of appetite and weight loss,  dehydration 
 jaw clenching,  headaches,  muscle pain 
 Mood swings –anxiety,  depression,  agitation,  mania,  panic,  paranoia 
 Tremors,  irregular heartbeat,  shortness of breath 
 Aggressive and violent behaviour 
 Psychosis after repeated use of high doses 
 Permanent damage to brain cells 






Your risk of experiencing these harms is:….……. 
 
Regular use of inhalants is associated with: 
Low     Moderate     High 
 (tick one) 
 Dizziness and hallucinations,  drowsiness,  disorientation,  blurred vision 
 Flu like symptoms,  sinusitis,  nosebleeds 
 Indigestion,  stomach ulcers 
 Accidents and injury 
 Memory loss,  confusion,  depression,  aggression 
 Coordination difficulties,  slowed reactions,  hypoxia 
 Delirium,  seizures,  coma,  organ damage (heart,  lungs,  liver,  kidneys) 
 Death from heart failure 
HO8: Clinical Form 




Your risk of experiencing these harms is: 
 
Regular use of sedatives is associated with: 
Low     Moderate     High 
 (tick one) 
 Drowsiness, dizziness and confusion 
 Difficulty concentrating and remembering things 
 Nausea,  headaches,  unsteady gait 
 Sleeping problems 
 Anxiety and depression 
 Tolerance and dependence after a short period of use. 
 Severe withdrawal symptoms 






Your risk of experiencing these harms is:……….. 
 
Regular use of hallucinogens is associated with: 
Low     Moderate     High 
 (tick one) 
 Hallucinations (pleasant or unpleasant) – visual, auditory, tactile, olfactory 
 Difficulty sleeping 
 Nausea and vomiting 
 Increased heart rate and blood pressure 
 Mood swings 
 Anxiety,  panic,  paranoia 
 Flash-backs 






Your risk of experiencing these harms is: 
 
Regular use of opioids is associated with: 
Low     Moderate     High 
 (tick one) 
 Itching,  nausea and vomiting 
 Drowsiness, constipation,  tooth decay 
 Difficulty concentrating and remembering things 
 Emotional problems and social problems 
 Reduced sexual desire and sexual performance 
 Relationship difficulties 
 Financial and work problems, violations of law 
 Tolerance and dependence,  withdrawal symptoms 





Appendix 3: IRIS 
Indigenous risk impact screen (IRIS) and brief intervention 
 
The Indigenous Risk Impact Screen and Brief Intervention program provides a culturally secure 
and validated screening instrument and brief intervention designed to meet the specific needs 
of Aboriginal and Torres Strait Islander communities in Queensland and across Australia. 
The Indigenous Risk Impact Screen (IRIS) is a two factor screening instrument that assesses risk 
for alcohol and other drug use and associated mental health issues in a culturally appropriate 
and timely manner. 









Taking a Drinking History (Example 1) 
It is useful to ask the person to fill in this form. You may need to assist them. 
Over the next ______ weeks, please write down how you drink. Fill out the sheet each night 
before going to bed. 
Look at column number one. 
Write down what day it is today. 
How many drinks have you had all day today? Record number of standard drinks for each type 
of drink. If you did not have any beer today, put a dash in that square. If you drank beer write 
down the number of standard drinks you had. 
Use the guide below to calculate how many standard drinks are in each type of beverage 
STANDARD DRINKS 
A standard drink contains 10 grams of alcohol. Beer, wine and spirits vary in the amount of 





Light beer  
(425ml) 







Beverage Day of the week 
 ___day ___day ___day ___day ___day ___day ___day 
Beer        
Table Wine        
Spirits        
Fortified Wine        
Other        
[Adapted from 165] 
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ATOD Assessment Form - Drinking History (Example 2) 
The alcohol assessment process should be incorporated into the nursing assessment form. The 
suggestions that follow assume the usual nursing assessment includes general nursing 
observations, medical and social and mental health history, contact with other services or 
agencies including alcohol and other drug services. 
Recent drinking (last three months, in particular last two weeks) 
Alcohol 
type 
How much (gms 
per day) 









      
      
      
      
• Other relevant information (include person’s concerns, pros and cons of use, purpose 
of use and need it fulfils, wanting to reduce or stop). 
Last use Date: Comments  
 Time:  
 Amount:  
 BAC on admission:  









Note: Place on CIWA-Ar if: 
• Adult male consuming eight standard drinks (80gms) or more on a regular basis 
• Adult female consuming six standard drinks (60gms) or more on a regular basis 
• Previous alcohol withdrawal history  
If score reaches 8 on CIWA-Ar contact medical officer. 
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(Prescribed, over the counter and herbal/complementary medicines, tobacco and illicit 
substances including inhalants) 




























       
       
       
       
       
 
Other relevant information (include pros and cons of use, purpose of use and need it fulfils, 
concerns want to reduce or cease use). 









Note: Place on appropriate Drug Withdrawal Assessment Scale if there is suspicion of 
emergence of drug withdrawal or if there is a past history of withdrawal symptoms and recent 
use has not decreased. 
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FAGERSTROM TEST for NICOTINE DEPENDENCE  
This tool is used to score a clients level of nicotine dependence once they have been identified 
as a current or recent smoker. 
Please Tick one box for each question 
 
How soon after waking do you smoke your first 
cigarette? 
Within 5 minutes 
5-30 minutes 
31-60 minutes 
   3 
   2 
   1 
Do you find it difficult to abstain from smoking in 




   1 
   0 
What cigarette would you hate to give up? 
The first one in the 
morning 
Any other 
   1 
   0 
How many cigarettes a day do you smoke? 
10 or less 
11 to 20 
21 to 30 
31 or more 
   0 
   1 
   2 
   3 
Do you smoke more frequently in the morning?  
Yes 
No 
   1 
   0 




   1 
   0 
Add total score  
SCORE 
1-2 = Low dependence 
3-4 = Low to moderate dependence 
5-7 = Moderate dependence 




























Eyes open spontaneously 4
Eye opening to verbal stimuli  3
Eye opening to pain 2














Withdrawal from pain 4
Abnormal flexion to pain 3
Abnormal extension to pain 2






































Record reaction to light as
‘+’ if normal
‘S’ if sluggish
‘-’  if none















Record ‘C’ if no response
possible due to bilateral







Determining Best Motor Response
Withdrawal from pain of
the limb by flexion at the
elbow and external rotation
at the shoulder joint.
Abnormal flexion to pain
of the elbow and wrist
(usually both arms) with
internal rotation of the
shoulder and simultaneous
extension of the legs. This
is also known as
‘decorticate response’.
Abnormal extension to
pain of (usually both) arms
and legs. This is also
known as ‘decerebrate
response’).
Rub one of the superior
orbital margins (eyebrow)
while applying firm pressure.
Patients able to localize
pain will respond by moving
a hand above the chin.
NB: Avoid asking patient
just to squeeze your hand











NB: Rubbing the sternum is
not a good way to determine
best motor response as it
may not help to distinguish
between ‘localizing pain’ and
‘abnormal flexion’. It may
also leave bruise marks.
If appropriate response is not seen, go to next step
Step 1
NB: Intoxicated patients will often require considerable and sustained stimuli.
If appropriate response is not seen, go to next step.
Ask the patient to ‘obey a
command’ that requires a
specific response, such as














Apply firm pressure to a
fingernail bed and look for








 Appendix 9: CIWA-Ar 
  
















Headache, fullness in head
Orientation and clouding of sensorium
Total score
Nursing Management: •  Nurse in a quiet, evenly lit environment
 • Provide reassurance and explanation
 • Re-orientate the person if confused




Nausea and vomiting 
 Ask “Do you feel sick in the stomach? Have you vomited?”  Observation 
 
0  No nausea and no vomiting 
1  Mild nausea with no vomiting 
2 
3 
4  Intermittent nausea, with dry retching 
5 
6 
7  Constant nausea, frequent dry retching and vomiting
 
Tremor 
 Arms extended, elbows slightly flexed and fingers spread. Observation 
 
0  No tremor 
1  Not visible, but can be felt fingertip to fingertip 
2 
3 
4  Moderate 
5 
6 





0  No sweat visible 
1  Barely perceptible sweating, palms moist 
2 
3 
4  Beads of sweat obvious on forehead 
5 
6 





 Ask “Do you feel nervous?” Observation 
 
0  No anxiety, at ease 
1  Mildly anxious 
2 
3 
4  Moderately anxious or guarded so anxiety is inferred 
5 
6 
7  Equivalent to acute panic states as seen in severe delirium or acute 





0  Normal activity 
1  Somewhat more than normal activity 
2 
3 
4  Moderately fidgety and restless 
5 
6 
7  Paces back and forth during most of the interview or constantly  
 thrashes about
Tactile disturbances 
 Ask “Have you any itching, pins and needles sensations, any burning, 
any numbness or do you feel bugs crawling on or under your skin?” 
Observation 
 
0  None 
1  Very mild itching, pins and needles, burning or numbness 
2  Mild itching, pins and needles, burning or numbness 
3  Moderate itching, pins and needles, burning or numbness 
4  Moderately severe hallucinations 
5  Severe hallucinations 
6  Extremely severe hallucinations 
7  Continuous hallucinations 
 
Auditory disturbances 
 Ask “Are you more aware of sounds around you? Are they harsh? Do they 
frighten you? Are you hearing anything that is disturbing to you? Are you 
hearing things you know are not there?” Observation 
 
0  Not present 
1  Very mild sensitivity 
2  Mild sensitivity 
3  Moderate sensitivity 
4  Moderately severe hallucinations 
5  Severe hallucinations 
6  Extremely severe hallucinations 
7  Continuous hallucinations 
 
Visual disturbances 
 Ask “Does the light appear to be too bright? Is its colour different? 
Does it hurt your eyes? Are you seeing things you know are not there?”  
Observation 
 
0  Not present 
1  Very mild sensitivity 
2  Mild sensitivity 
3  Moderate sensitivity 
4  Moderately severe hallucinations 
5  Severe hallucinations 
6  Extremely severe hallucinations 
7  Continuous hallucinations 
 
Headache, fullness in the head 
 Ask “Does your head feel different? Does it feel as though there is a 
band around your head?” Do not rate for dizziness or light headedness. 
Otherwise rate severity. 
 
0  Not present 
1  Very mild 
2  Mild 
3  Moderate 
4  Moderately severe 
5  Severe 
6  Very severe 
7  Extremely severe
 
Orientation and clouding of sensorium 
 Ask “What day is this? Where are you? Who am I?” Observation 
 
0  Orientated and can do serial additions 
    Ask person to perform serial addition of 3s up to 30 eg 3,6,9..... 
1  Cannot do serial addition or is uncertain about date 
2  Disorientated by date by no more than 2 calendar days 
3  Disorientated for date by more than 2 calendar days 
4  Disorientated for place and/or person 
  
ALCOHOL WITHDRAWAL ASSESSMENT SCALE




Guide to scoring risk of alcohol withdrawal in general hospital setting: 
Severity    CIWA-Ar score    Action 
Mild  Less than 10  Under 8  
Offer symptomatic 
medications as needed e.g. 
for headache and nausea  
8 or over notify MO 
immediately  
Diazepam protocol + 
symptomatic medications 
unless contraindicated 
Moderate  10 – 20  Diazepam protocol + 
symptomatic medications 
unless contraindicated   
Severe  20+  As above  
 
Maximum possible score = 67
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Appendix 10: Clinical Opiate Withdrawal Scale (COWS) 
  
 79 
Clinical Opiate Withdrawal Scale 
(Wesson & Ling 2003) 
 
For each item, circle the number that best describes the patient’s signs or symptoms. Rate on just the apparent 
relationship to opiate withdrawal. For example, if heart rate is increased because the patient was jogging just prior to 
assessment, the increased pulse rate would not add to the score. 
Patient’s Name Date and Time 
Reason for this assessment 
Resting Pulse Rate          …………………beats/minute 
Measured after patient is sitting or lying for one minute 
0 pulse rate 80 or below 
1 pulse rate 81-100 
2 pulse rate 101-120 
4 pulse rate greater than 120 
GI Upset: over last ½ hour 
0 no GI symptoms 
1 stomach cramps 
2 nausea or loose stool 
3 vomiting or diarrhea 
5 multiple episodes of diarrhea or vomiting 
Sweating: over past ½ hour not accounted for by room 
temperature or patient activity 
0 no report of chills or flushing 
1 subjective report of chills or flushing 
2 flushed or observable moistness on face 
3 beads of sweat on brow or face 
4 sweat streaming off face 
Tremor: observation of outstretched hands 
0 no tremor 
1 tremor can be felt, but not observed 
2 slight tremor observable 
4 gross tremor or muscle twitching 
Restlessness: Observation during assessment 
0 able to sit still 
1 reports difficulty stilling still, but is able to do so 
3 frequent shifting or extraneous movements of 
legs/arms 
5 unable to sit still for more than a few seconds 
Yawning: Observation during assessment 
0 no yawning 
1 yawning once or twice during assessment 
2 yawning three or more times during assessment 
4 yawning several times/minute 
Pupil size 
0 pupils pinned or normal size for room light 
1 pupils possibly larger than normal for room light 
2 pupils moderately dilated 
5 pupils so dilated that only the rim of the iris is visible 
Anxiety or Irritability 
0 none 
1 patients reports increasing irritability or anxiousness 
2 patient obviously irritable or anxious 
4 patient so irritable and anxious that participation in the 
assessment is difficult 
Bone or Joint aches: If patient was having pain 
previously, only the additional component attributed to 
opiate withdrawal is scored 
0 not present 
1 mild diffuse discomfort 
2 patient reports severe diffuse aching of joints/muscles 
4 patient is rubbing joints or muscles and is unable to sit 
still because of discomfort 
Gooseflesh skin 
0 skin is smooth 
3 piloerection of skin can be felt or hairs standing up on 
arms 
5 prominent piloerection 
Runny nose or tearing: Not accounted for by cold 
symptoms or allergies 
0 not present 
1 nasal stuffiness or unusually moist eyes 
2 nose running or tearing 





The total score is the sum of all 11 items 
 
Initials of person  
completing assessment          ……………………………… 
Score: 5-12 = mild; 13-24 = moderately severe; more than 36 = severe withdrawal 
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Benzodiazepine Withdrawal Assessment Scale 
Vital signs to be taken daily—otherwise at the discretion of clinical staff. 
Note: Total Score is indicative of increasing of decreasing severity of withdrawal. Scores are not 
directly linked to pharmacological management as occurs with alcohol scores based on the 
CIWA-Ar. 
Surname:  Given name:  
Date  UR No.  
 
Date              
Time              
Blood pressure              
Temperature              
Pulse              
Respiration rate              
Benzodiazepine assessment score—Range 0, 1, 4 or 7 (see next page) 
1 Anxiety              
2 Restlessness/agitation              
3 Palpitations              
4 Headache              
5 Concentration              
6 Appetite              
 TOTAL              
 
 Sleep (0700) 
Staff  observation  
             
 Sleep (0800) 
Client observation 
             
 Other symptoms 
 




These questions refer to how the person is feeling right now, at the present moment. 
1. Anxiety 
Ask ‘Do you feel nervous?’ 
4. Headache 
Ask ‘Do you have a headache or 






No anxiety—at ease 
Mild 
Moderately anxious or guarded so 
anxiety is inferred 
Equivalent to acute panic states as 










2. Restlessness/Agitation- Observation 
Ask ‘Do you feel more restless or 
agitated than you are normally? 
5. Concentration 







Somewhat more than normal 
activity 
Moderately fidgety or restless 










Ask ‘Are you aware of your heart racing 
in your chest?’ 
6. Appetite 








Moderate awareness of heartbeat 





No loss of appetite 
Slight loss 
Moderate loss 
Complete loss of appetite, unable 
to eat at all 
  7. Sleep 
(0800 observations only—not to be 
included in total score) 
Ask ‘How did you sleep last night?’ 










Appendix 12A:  Amphetamine Cessation Symptom Assessment Observer rated (DASSA, 2010) 
  
Withdrawal Services No.16 - Front Desk\Red Folder\06-03 Amphetamine Cessation Assessment  
8/11/2011 
 
AMPHETAMINE CESSATION SYMPTOM ASSESSMENT 




GIVEN NAMES: ………………………………………….. 
 
DOB:  ……… /………./ ……….. 
 
REG NO:    ………………………. 
 
Date:                  
Time:                  
Temperature                  
Pulse                  
Respirations                  
Blood Pressure                  
Weight                  
OBSERVE THE CLIENT FOR FIVE MINUTES THEN USE THE KEYS BELOW AS A GUIDE TO YOUR CLINICAL ASSESSMENT (SCORE RANGE 0 - 4) 
1 Tension                  
2 Depression                  
3 Agitation                  
4 Irritability                  
TOTAL                  
 
1: TENSION 2: DEPRESSION 3: AGITATION 4: IRRITABILITY 
0. Not at all tense 
1. A Little 
2. Moderately 
3. Quite a lot 
4. Extremely 
0. No sadness or depression 
1. Affect a little blunted 
2. Moderately blunted but reactive 
3. Affect flat but reactive 
4. Withdrawn, unresponsive 
0. Not at all agitated 
1. A little 
2. Moderately 
3. Quite a lot 
4. Extremely agitated 
0. Not at all irritable 
1. A little 
2. Moderately 
3. Quite a lot 
4. Extremely irritable 
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Appendix 12b:  Amphetamine Cessation Symptom Assessment Subjective(DASSA, 2010) 
  
Withdrawal Services No.16 - Front Desk\Red Folder\06-03 Amphetamine Cessation Assessment  
8/11/2011 
 







DOB:  ……… /………./ ……….. 
 
REG NO:    ………………………. 
PLEASE SCORE EACH ITEM BELOW ACCORDING TO HOW YOU FEEL NOW 0 = NOT AT ALL : 1 = A LITTLE 2 = MODERATELY 3 = QUITE A LOT 4 = EXTREMELY 
Date:                  
Time:                  
1 Do you have difficulty concentrating?                  
2 Are you sleeping (or wanting to sleep) a lot?                  
3 Are you feeling tense?                  
4 Have you had vivid, unpleasant dreams?                  
5 Do you feel irritable?                  
6 Do you feel tired?                  
7 Do you feel agitated?                  
8 Do you feel that life is not worth living?                  
9  How active are you compared to your usual level of activity?                  
10 Do you feel anxious?                  
11 Have you lost interest in things, or no longer take pleasure in them?                  
12 Is it difficult for you to trust other people?                  
13 Do you feel sad?                  
14 Do you feel as if your movements are slow?                  
15 In the past 24 hours, how much of the time   have you been craving for amphetamines?                 
16 How strong   is your craving for amphetamines?                 








Level of Agitation Scale (Amphetamine withdrawal) 
Score from 1 – 5 by circling the relevant number in the score column. 
Item Score 
Patient is asleep.  1 
Patient is awake but calm, without verbal aggression or agitation.  2 
Patient is angry, but this is primarily focused on the situation, and requests are 
not delivered in an obviously threatening or aggressive manner 
3 
Patient is awake and agitated with some verbal outbursts but no physical 
aggression 
4 





Appendix 13: Cannabis Withdrawal Scale (CWS) (DASSA, 2010) 
  
DRAFT  January 2005 











Cannabis Withdrawal Scale (CWS) 
BD OBSERVATIONS 
Date               
Time               
Temperature               
Pulse               
Respiration Rate               
Blood Pressure               
Pupil Size and Reaction               
Sclera (red Y/N)               
Weight (daily) - Morning               
 
1 Shakiness/Tremulousness               
2 Depressed Mood               
3 Decreased Appetite               
4 Nausea               
5 Irritability               
6 Sleep Difficulty               
7 Sweating               
8  Craving to Smoke Marijuana               
9 Restlessness               
10  Nervousness/Anxiety               
11 Increased Aggression               
12 Headaches               
13 Stomach Pains               
14 Strange/Wild Dreams               
15 Increased Anger               
16 Other (list)               
                





GIVEN NAMES: …………………………………………….. 
 
DOB:  ……… /………./ ………..      SEX    M   F 
 





PLEASE SCORE EACH ITEM BELOW ACCORDING TO HOW YOU FEEL NOW 
 
0=NONE     1=MILD     2=MODERATE     3=SEVERE  
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DATE AND TIME IN HOURS 





























Continuous High-Pitched Cry 
2 
3 
         
Sleeps <1 hour after feeding 
Sleeps <2 hours after feeding 




         
Mild Tremors Disturbed 
Mod-Severe Tremors Disturbed 
1 
2 
         
Mild Tremors Undisturbed 
Mod-Sever Tremors Undisturbed 
3 
4 
         
Increased Muscle Tone 2          
Excoriation (Specify area) 1          
Myocionic Jerks 3          





























Fever (37.3°C – 38.3°C) 
Fever (38.4°C and higher) 
1 
2 
         
Frequent Yawning (>3-4 times) 1          
Nasal Stuffiness 1          
Sneezing (>3-4 times) 1          
Nasal Flaring 2          
Respiratory Rate >60/min 
























Excessive Sucking 1          










         
 Max Score: 
41 
TOTAL SCORE           




Neonatal Abstinence Syndrome Scoring Chart (Finnegan) 
Guidelines for Neonatal Abstinence Syndrome (NAS) Scoring 
Score 1 for each of the following (except 1). 
1. High-pitched cry: Score 2 if a cry is high-pitched at its peak, score 3 if a cry is high-pitched 
throughout. 
2. Sleep: Consider total amount of time baby was asleep between feeds. 
3. Tremors: This is a scale of increasing severity, and only one score should be made from the 
four categories. Undisturbed sleep means when the baby is asleep or at rest in a cot. 
4. Increased muscle tone: Score if the baby has a generalised muscle tone greater than the 
upper limit of normal. 
5. Excoriation: Score if excoriation occurs more than three to four times in 30 minutes. 
6. Nasal flaring: Score if nasal flaring is present without other evidence of airways disease. 
7. Respiratory rate: Score if respiratory rate of greater than 60 per minute is present without 
other evidence of airways disease. 
8. Excessive sucking: Score if the baby sucks more than average. 
9. Poor feeding: Score if the baby is very slow to feed or takes inadequate amounts. 
10. Regurgitation: Score only if the baby regurgitates more frequently than usual in newborn 
infants. 
Modifications for prematurity are mainly necessary in the sections on sleeping, e.g. a baby who 
needs three-hourly feeds can only sleep at most 2.5 hours between them. Scoring should be one if 
baby sleeps less than two hours, 2 if sleeps less than one hour, and 3 if the baby does not sleep 
between feeds. Many premature babies require tube feeding. Babies should not be scored for poor 
feeding if tube feeding is customary for their period of gestation. 
If the baby has three consecutive scores averaging more than eight (8), the child should be treated 
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